

NATIONALE VERSORGUNGS LEITLINIEN

Nationale VersorgungsLeitlinie

Chronische KHK

Recherchedokumentation
+ Evidenztabellen



Version 7
AWMF-Register-Nr. nvl-004

Träger:

Bundesärztekammer

Kassenärztliche Bundesvereinigung

Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften

© 2024 NVL-Programm



Inhaltsverzeichnis

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1 | Recherche zu KHK – Themenübergreifende Recherche | 4 |
| 1.1 | PICO-Frage | 4 |
| 1.2 | Recherchestrategien | 4 |
| 1.3 | Screening | 7 |
| 1.4 | Flowchart..... | 8 |
| 2 | Recherche zu KHK – Themenübergreifende Recherche: Ergänzung | 9 |
| 2.1 | PICO-Frage | 9 |
| 2.2 | Recherchen | 9 |
| 3 | Recherche zu KHK – Gezielte Recherche: Quell- und Referenzleitlinien | 17 |
| 3.1 | Gezielte Recherche (28.05.2014–16.05.2023)..... | 17 |
| 4 | Recherche zu KHK – Gezielte Recherche: Epidemiologie | 19 |
| 4.1 | Gezielte Recherche Epidemiologie (29.09.2023) | 19 |
| 5 | Recherche Statine mittlere Dosis vs. Hohe Dosis (AkdÄ – Recherchefrage 3/4)..... | 20 |
| 5.1 | PICO-Frage | 20 |
| 5.2 | Recherchestrategien | 20 |
| 5.3 | Flowchart..... | 25 |
| 6 | Recherche Statine Zielwert vs. feste Dosis (AkdÄ - Recherchefrage5/6)..... | 26 |
| 6.1 | PICO-Frage | 26 |
| 6.2 | Recherchestrategien | 26 |
| 6.3 | Flowchart..... | 30 |
| 7 | Recherche zu Bempedoinsäure bei maximal verträglicher Statintherapie (AkdÄ – Recherchefrage 25)..... | 31 |
| 7.1 | PICO-Frage | 31 |
| 7.2 | Recherchestrategien | 31 |
| 7.3 | Flowchart..... | 34 |
| 8 | Recherche zu Anhang 8.1.1 der 5. Auflage 2019 (S. 123ff) Stabile KHK: Keine Indikation zur Antikoagulation (Empfehlung 7-1 und Empfehlung 7-3) | 35 |
| 8.1 | PICO-Frage | 35 |
| 8.2 | Recherchestrategien | 35 |
| 8.3 | Flowchart..... | 38 |
| 9 | Recherche zu Protonenpumpeninhibitoren..... | 39 |
| 9.1 | PICO-Frage | 39 |
| 9.2 | Recherchestrategien | 39 |
| 9.3 | Flowchart..... | 42 |
| 10 | Recherche zu Anhang 8.1.4, 8.1.5 und 8.1.6 der 5. Auflage 2019 (S. 124ff) Z.n. elektiver PCI bei stabiler KHK: Clopidogrel oder Prasugrel oder Ticagrelor plus ASS nach elektiver PCI (Empfehlung 7-5) bzw. nach akutem Koronarsyndrom (Kapitel 7.1.4)..... | 43 |
| 10.1 | PICO-Frage | 43 |
| 10.2 | Recherchestrategien | 43 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 10.3 | Flowchart..... | 47 |
| 11 | Recherche zu Anhang 8.1.7 der 5. Auflage 2019 (S. 124ff) Z.n. elektiver PCI bei stabiler KHK: Elektive PCI und Indikation zur OAK (Empfehlung 7-6 und Empfehlung 7-7)..... | 48 |
| 11.1 | PICO-Frage..... | 48 |
| 11.2 | Recherchestrategien..... | 48 |
| 11.3 | Flowchart..... | 52 |
| 12 | Evidenztabelle..... | 53 |
| 12.1 | Kapitel Epidemiologie..... | 53 |
| 12.2 | Kapitel Diagnostik..... | 69 |
| 12.3 | Kapitel Therapieplanung und gemeinsame Entscheidungsfindung..... | 105 |
| 12.4 | Kapitel medikamentöse Therapie - Lipidsenker..... | 114 |
| 12.5 | Kapitel medikamentöse Therapie – Thrombozytenaggregationshemmer..... | 178 |
| 12.6 | Versorgungskoordination..... | 284 |
| | Literatur..... | 292 |

1 Recherche zu KHK – Themenübergreifende Recherche

1.1 PICO-Frage

- P** erwachsene Patient*innen mit chronischer KHK
I jegliche diagnostische, medikamentöse, nicht medikamentöse Intervention
C jeglicher diagnostische, medikamentöse, nicht medikamentöse Vergleich
O muss in Auftaktsitzung priorisiert werden
S systematische Übersichtsarbeiten, HTA
Z ab 01.01.2020

Version 6.0 der NVL Chronische KHK wurde im September 2022 veröffentlicht (Gültigkeit bis 15. September 2027), Letzte Recherchen wurden im Dezember 2019 umgesetzt

1.2 Recherchestrategien

1.2.1 Datenbanken der Cochrane Library (23.11.2022)

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------------------------------------------|--------|
| #9 | #1 OR #2 OR #6 OR #7 in Cochrane Protocols; Publication date from 01/01/2020 | 9 |
| #8 | #1 OR #2 OR #6 OR #7 in Cochrane Reviews; Publication date from 01/01/2020 | 44 |
| #7 | ((coronary heart diseas* OR CHD OR coronary artery diseas* OR CAD OR angina pectoris OR stable angina)):ti,ab,kw | 45138 |
| #6 | #3 AND #4 AND #5 | 7489 |
| #5 | (stable OR chronic):ti,ab,kw | 215409 |
| #4 | (heart disease OR coronar* OR myocard*):ti,ab,kw | 117284 |
| #3 | (ischemi* OR ischaemi* OR atheroscleros* OR arterioscleros* OR stenosis* OR occlusion):ti,ab,kw | 80042 |
| #2 | MeSH descriptor: [Angina Pectoris] explode all trees | 4687 |
| #1 | MeSH descriptor: [Coronary Disease] explode all trees | 14779 |

| Cochrane Reviews | |
|------------------|----|
| • Review | 44 |
| • Protocol | 9 |

1.2.2 NICE (03.11.2022)

| Nr. | Suchfrage |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | coronary heart disease chronic ischaemic heart disease coronary syndrome* |
| Suchzeitraum | seit 2020 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 1 + 0 + 0 |

| Nr. | Suchfrage |
|-------------------------|-----------------------|
| Eingeschlossene Treffer | 1 |
| 2. Filter | NICE advice, evidence |
| Treffer | 0 |
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Quellen:

<https://www.nice.org.uk/guidance/ipg732/evidence/overview-final-pdf-11186291773> - Bioresorbable stent implantation to treat coronary artery disease Interventional procedures guidance [IPG732] Published: 03 August 2022 (Rapid Review to 11-08-2021)

1.2.3 IQWiG (03.11.2022)

| Nr. | Suchfrage |
|-----------------------------------------------------------------------------------|--------------------------|
| Filter | Projekte, Ergebnisse |
| Suchzeitraum | seit 01.01.2020 |
| Suchbegriff: koronare Herzkrankheit | |
| Treffer | 6 |
| Eingeschlossene Treffer | 6 |
| Filter | ThemencheckMedizin - HTA |
| Suchzeitraum | seit 01.01.2020 |
| Suchbegriffe: ...koronare Herzkrankheit, KHK, Koronarsyndrom (Einzelsuche) | |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |

Quellen:

[GA20-01] CT- oder MRT-Diagnostik bei Verdacht auf chronische koronare Herzkrankheit: eine Evidenzkartierung - <https://www.iqwig.de/projekte/ga20-01.html> 2020

[D06-01L] Positronen-Emissions-Tomographie (PET) bei koronarer Herzerkrankung - <https://www.iqwig.de/projekte/d06-01l.html> (vorläufiger Bericht) 2020 – Auftrag zurück genommen

[H20-07] Koronare Lithoplastie bei koronarer Herzkrankheit- Bewertung gemäß §137h SGB V - <https://www.iqwig.de/projekte/h20-07.html> 2021

[H21-06] Koronare Lithoplastie bei koronarer Herzkrankheit - Addendum zum Auftrag H20-07 - <https://www.iqwig.de/projekte/h21-06.html> 2021

[D22-01] Computertomographie-Koronarangiographie zur Diagnosestellung bei Patientinnen und Patienten mit Verdacht auf eine chronische koronare Herzkrankheit - <https://www.iqwig.de/projekte/d22-01.html> 2022 (Berichtsplan, Abschlussbericht geplant für 2023)

[V22-04] Leitliniensynopse für die Aktualisierung des DMP koronare Herzkrankheit <https://www.iqwig.de/projekte/v22-04.html> 2022 (Berichtsplan, Abschlussbericht geplant für 2023)

1.2.4 AHRQ (03.11.2022)

| Kategorien | Suchbegriffe/ Filter (Keine Einschränkung des Zeitraums) | Treffer | Eingeschlossene Treffer |
|--------------------|-------------------------------------------------------------|---------|-------------------------|
| EPC Evidence-based | coronary heart disease coronary syndrome* seit 2020 | 12 0 | 6 0 |

| Kategorien | Suchbegriffe/ Filter (Keine Einschränkung des Zeitraums) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|-------------------------------------------------------------|---------|----------------------------|
| Technology Assessment Program (completed) | allgemein/ abgeschlossen im Prozess, seit 2020 | 0 | 0 |

Quellen:

[Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force](#)

Date: August 2022 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Pacific Northwest EPC—Oregon Health & Science University, Report Status: Final

[Behavioral Counseling to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive Services Task Force](#)

Date: July 2022 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Kaiser Permanente Research Affiliates, Report Status: Final

[Vitamin, Mineral, and Multivitamin Supplementation for the Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force](#)

Date: June 2022 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Kaiser Permanente Research Affiliates, Report Status: Final

[Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force](#)

Date: April 2022 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Kaiser Permanente Research Affiliates, Report Status: Final

[Screening for Asymptomatic Carotid Artery Stenosis in the General Population: An Evidence Update for the U.S. Preventive Services Task Force](#)

Date: February 2021 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Kaiser Permanente Research Affiliates, Report Status: Final

[Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Updated Systematic Review for the U.S. Preventive Services Task Force](#)

Date: November 2020 - Report Type: U.S. Preventive Services Task Force Evidence Syntheses

Affiliation: Kaiser Permanente Research Affiliates, Report Status: Final

1.2.5 Übersicht der eingeschlossenen Treffer

| Aggregierte Evidenz | Anzahl |
|----------------------|--------|
| Cochrane Datenbanken | 49 |
| NICE | 2 |
| IQWiG | 6 |
| AHRQ | 6 |

1.2.6 Zusatzinformationen Epidemiologie etc.:

1.2.6.1 www.gbe-bund.de (0 neue Treffer seit 2020)

Quellen:

<https://www.gbe-bund.de/pdf/gesber2015.pdf> Gesundheit in Deutschland (Bericht) [Gesundheit in Deutschland, 2015] Robert Koch-Institut (Hrsg) (2015) Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. RKI, Berlin + Gesundheitsbericht. Gemeinsam getragen von RKI und Destatis. (bereits zitiert)

1.2.6.2 www.degs-studie.de (0 neue Treffer seit 2020)

Quellen:

<https://edoc.rki.de/bitstream/handle/176904/1490/28vWvi57DzAA.pdf?sequence=1&isAllowed=y> - Prävalenz von Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl 2013 · 56:650–655 DOI 10.1007/s00103-013-1666-9 Online publiziert: 27. Mai 2013 (bereits zitiert)

1.2.6.3 <https://covid-19.cochrane.org/> (03.11.2022)

| Kategorien | Suchbegriffe/ Filter (Keine Einschränkung des Zeitraums) | Treffer | Eingeschlossene Treffer |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------|
| in 179.472 studies with 191.992 references | (coronary and heart and disease) OR (chronic and ischaemic and heart and disease) and german* Filter: 01.01.2020-03.11.2022 Filter: Journal Article Study aim: Epidemiology | 4 matching studies with 7 references | 2* |

*Quellen:

<https://covid-19.cochrane.org/studies/crs-15513321> - CORONA Germany - Clinical Outcome and Risk in Hospitalized COVID-19 Patients - A Registry From Germany

- Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients-Results from the CORONA Germany Study (<https://pubmed.ncbi.nlm.nih.gov/34501427>)

<https://covid-19.cochrane.org/studies/crs-16693366> - Preventing SARS-CoV-2 In-Hospital Infections in Cardiovascular Patients and Medical Staff: an Observational Study From the German Heart Center Berlin (<https://pubmed.ncbi.nlm.nih.gov/33614675>)

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:

A1 (Dubletten):

A2 (nicht englisch/deutsch):


A3 (Conference Abstracts):

1.3 Screening

| | |
|-----------|--------------------|
| E | PICO erfüllt |
| P | Protokoll |
| Aa | PICO nicht erfüllt |

Eingeschlossene Treffer insgesamt nach Ausschlüssen:

1.4 Flowchart



2 Recherche zu KHK – Themenübergreifende Recherche: Ergänzung

2.1 PICO-Frage

- P** erwachsene Patient*innen mit chronischer KHK (ggf. auch ergänzende Themen)
I jegliche diagnostische, medikamentöse, nicht medikamentöse Intervention
C jegliche
O muss in Auftaktsitzung priorisiert werden
S Ergebnisberichte (GBA Innovationsausschuss)

2.2 Recherchen

2.2.1 GBA Innovationsausschuss – Projekte / neue Versorgungsformen

strukturierte Recherche: Ergänzung 23.01.2023, aktualisiert 30.10.2023

<https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/> (Treffer: 210 gesamt/ n=27 relevant für KHK)

| Nr. | Suchfrage |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ABSCHaLoM Projekt laufend | Altern in Bewegung für Menschen im ländlichen Raum https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/abschalom-altern-in-bewegung-fuer-menschen-im-laendlichen-raum.500 |
| AdAM Beschlussdatum: 23.02.2023 Beschlusstext (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) | Anwendung digital-gestütztes Arzneimitteltherapie- und Versorgungs-Management https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/adam-anwendung-digital-gestuetztes-arzneimitteltherapie-und-versorgungs-management.71 <ul style="list-style-type: none"> - Ergebnisse sollen aufgrund der aus Teilergebnissen erkennbaren positiven Tendenzen an das BMG und die gematik weitergeleitet werden - Erkenntnisse sollen geprüft werden zur Verbesserung der digitalen Unterstützung der Arzneimitteltherapiesicherheit in ärztlichen Praxen, insbesondere zu den identifizierten Hürden (z. B. bislang fehlende technische Interoperabilität von Systemen zur Arzneimitteltherapie-sicherheit und Primärsystemen der Leistungserbringer) - entwickelt wurde ergänzend eine S2k-Leitlinie |
| BlenCon Projekt laufend | Blended Consultation – Berufsgruppenübergreifende und telemedizinische Versorgung von Pflegeheimbewohnern mit kardiologischen Erkrankungen https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/blecon-blended-consultation-berufsgruppenuebergreifende-und-telemedizinische-versorgung-von-pflegeheimbewohnern-mit-kardiologischen-erkrankungen.566 |
| Cardiolotse Bericht in Erstellung | Entwicklung eines Versorgungsmodells zur Verbesserung der poststationären Weiterbehandlung am Beispiel kardiologischer Erkrankungen https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/cardioltse-entwicklung-eines-versorgungsmodells-zur-verbesserung-der-poststationaeren-weiterbehandlung-am-beispiel-kardiologischer-erkrankungen.181 <ul style="list-style-type: none"> - Versorgungsform wird als Selektivvertrag fortgeführt bis die Auswertung der begleitenden Studie durch die Technische Universität München abgeschlossen ist und der Projektträger eine Transferentscheidung getroffen hat (vermutlich Ende des Jahres 2023) |

| Nr. | Suchfrage |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CoCare | coordinated medical care – Erweiterte koordinierte ärztliche Pflegeheimversorgung |
| Beschlussdatum: 12.05.2022 Beschluss text (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) | https://innovationsfonds.g-ba.de/beschluesse/cocare-coordinated-medical-care-erweiterte-koordinierte-aerztliche-pflegeheimversorgung.73 - GBA empfiehlt Weiterleitung an das BMG zur Prüfung der Ergebnisse mit denen themenverwandter Projekte zur Implementierung in Gesetzgebungsverfahren |
| Comm4Care SAN | Versorgung Pflegebedürftiger unter Optimierung der interprofessionellen Kommunikation |
| Bericht in Erstellung | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/comm4care-san-versorgung-pflegebeduerftiger-unter-optimierung-der-interprofessionellen-kommunikation.350 |
| DIKOM | Diagnostik und Konsil im Pflegeheim mittels Mobiler Geriatrie-Unit |
| Projekt laufend | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/dikom-diagnostik-und-konsil-im-pflegeheim-mittels-mobiler-geriatrie-unit.494 |
| EliPfad | Personalisierter, interdisziplinärer Patientenpfad zur sektorenübergreifenden Versorgung multimorbider Patienten mit telemedizinischem Monitoring |
| Projekt laufend | (RCT) https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/elipfad-personalisierter-interdisziplinärer-patientenpfad-zur-sektorenebergreifenden-versorgung-multimorbider-patienten-mit-telemedizinischem-monitoring.507 |
| ERIC | Enhanced Recovery after Intensive Care |
| Beschlussdatum: 21.01.2022 Beschluss text (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) Dokumentation der Rückmeldungen (PDF) | https://innovationsfonds.g-ba.de/beschluesse/eric-enhanced-recovery-after-intensive-care.55 - GBA empfiehlt Weiterleitung an die Gesundheitsministerien der Länder zu Prüfung einer Adaption im Bereich Intensivmedizin im jeweiligen Bundesland - Ergebnisse zur Bedarfsplanung im GBA sowie der Deutschen Krankenhausgesellschaft (DKG), GKV-Spitzenverband, InEK - sowie Weiterleitung an spezifische Fachgesellschaften |
| eRIKA | eRezept als Element interprofessioneller Versorgungspfade für kontinuierliche AMTS |
| Projekt laufend | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/erika-erezept-als-element-interprofessioneller-versorgungspfade-fuer-kontinuierliche-amts.503 |
| ErwiN | Erweiterte Übertragung von arztentlastenden Tätigkeiten in ArztNetzen |
| Projekt laufend | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/erwin-erweiterte-uebertragung-von-arztentlastenden-taetigkeiten-in-arztnetzen.564 |
| FAMOUS | Fallbezogene Versorgung multimorbider Patientinnen und Patienten in der Hausarztpraxis durch Advanced Practice Nurses (APN) |
| Projekt laufend | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/famous-fallbezogene-versorgung-multimorbider-patientinnen-und-patienten-in-der-hausarztpraxis-durch-advanced-practice-nurses-apn.361 |
| GeRas | Geriatrische Rehabilitationserfolge nachhaltig sichern |
| Projekt laufend | https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/geras-geriatri-sche-rehabilitationserfolge-nachhaltig-sichern.430 |

| Nr. | Suchfrage |
|------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GerinoVe Bericht in Erstellung | Regionales Geriatrisches Notfall-Versorgungszentrum https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/gerinove-regionales-geriatrisches-notfall-versorgungszentrum.110 |
| GerNe Bericht in Erstellung | E-Health-basierte, sektorenübergreifende geriatrische Versorgung / Geriatrisches Netzwerk GerNe https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/gerne-e-health-basierte-sektoreuebergreifende-geriatrische-versorgung-geriatrisches-netzwerk-gerne.175 |
| HandinHand Bericht in Erstellung | Hausarzt und Pflegeexperte Hand in Hand – ANP Center zur Zukunftssicherung der medizinischen Basisversorgung in der Region https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/handinhand-hausarzt-und-pflegeexperte-hand-in-hand-anp-center-zur-zukunftssicherung-der-medizinischen-basisversorgung-in-der-region.192 |
| HerzEffektMV Beschlussdatum: 24.01.2023 Beschlusstext (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) | Entwicklung und spezifischer Aufbau eines sektorenübergreifenden Care-Centers zur Versorgungsoptimierung chronischer Herzerkrankungen in MV https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/herzeffekt-mv-entwicklung-und-spezifischer-aufbau-eines-sektoreuebergreifenden-care-centers-zur-versorgungsoptimierung-chronischer-herzerkrankungen-in-mv.82 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| LeIKD Beschlussdatum: 20.09.2022 Beschlusstext (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) | Lebensstil-Intervention bei Koronarer Herzkrankheit und Diabetes https://innovationsfonds.g-ba.de/beschluesse/leikd-lebensstil-intervention-bei-koronarer-herzkrankheit-und-diabetes.105 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| MAMBO Beschlussdatum: 16.12.2022 Beschlusstext (PDF) Ergebnisbericht (PDF) Anlage 48, 49 (Excel) Evaluationsbericht (PDF) | Multimorbide Menschen in der ambulanten Betreuung: Patientenzentriertes, Bedarfsorientiertes Versorgungsmanagement https://innovationsfonds.g-ba.de/beschluesse/mambo-multimorbide-menschen-in-der-ambulanten-betreuung-patientenzentriertes-bedarfsorientiertes-versorgungsmanagement.121 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| OAV Beschlussdatum: 12.05.2023 Beschlusstext (PDF) Ergebnisbericht (PDF) Evaluationsbericht (PDF) | Optimierte Arzneimittelversorgung für pflegebedürftige geriatrische Patienten https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/oav-optimierte-arzneimittelversorgung-fuer-pflegebeduerftige-geriatrische-patienten.111 - GBA spricht keine Empfehlung aus (Abschlussbericht verfügbar) - aufgrund positiver Tendenzen Weiterleitung der Ergebnisse zur Information an den Deutschen Hausärzterverband e. V., die Deutsche Gesellschaft für Geriatrie e. V., die Bundesvereinigung Deutscher Apothekerverbände e. V., den Deutschen Pflegerat e. V., die Bundesarbeitsgemeinschaft der Freien Wohlfahrtspflege e. V. und den Bundesverband privater Anbieter sozialer Dienste e. V. |

| Nr. | Suchfrage |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>PASTA</p> <p>Beschlussdatum: 21.01.2022</p> <p>Beschlusstext (PDF)</p> <p>Ergebnisbericht (PDF)</p> <p>Evaluationsbericht (PDF)</p> <p>Dokumentation der Rückmeldungen (PDF)</p> | <p>Patientenbriefe nach stationären Aufenthalten</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/pasta-patientenbriefe-nach-stationaeren-aufenthalten.113</p> <ul style="list-style-type: none"> - Empfehlung zur Überführung in die Regelversorgung - Weiterleitung an den GKV-Spitzenverband, die Kassenärztliche Bundesvereinigung, die Deutsche Krankenhausgesellschaft (Rahmenvertrag Entlassmanagement) - Ziel: automatisiert erstellte, laienverständliche Patienteninformationen als einen weiteren Baustein der routinemäßigen Dokumentation im Entlassmanagement zu etablieren (sowie weitere) |
| <p>pAVK</p> <p>Beschlussdatum: 24.01.2023</p> <p>Beschlusstext (PDF)</p> <p>Ergebnisbericht (PDF)</p> <p>Evaluationsbericht (PDF)</p> | <p>TeGeCoach – Periphere arterielle Verschlusskrankheit (pAVK): Gesundheitscoaching und telemetrisch unterstütztes Gehtraining zur Steigerung der Lebensqualität</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/pavk-tegecoach-periphere-arterielle-verschlusskrankheit-pavk-gesundheitscoaching-und-telemetrisch-unterstuetztes-gehtraining-zur-steigerung-der-lebensqualitaet.99</p> <ul style="list-style-type: none"> - Empfehlung zur Überführung in die Regelversorgung - Weiterleitung an die Verbände der Kranken- und Pflegekassen auf Bundesebene und an die kassenärztlichen Vereinigungen (Prüfung der Umsetzung als neue Versorgungsform) |
| <p>PRECOVERY</p> <p>Projekt laufend</p> | <p>Prehabilitation „Karl-Heinz“ mit Schwerpunkt auf kardiale und kognitive Funktionen vor Eingriffen am Herzen: eine Analyse des Gesundheitszustands</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/precovery-prehabilitation-karl-heinz-mit-schwerpunkt-auf-cardiale-und-kognitive-funktionen-vor-eingriffen-am-herzen-eine-analyse-des-gesundheitszustands.502</p> |
| <p>PromeTheus</p> <p>Projekt laufend</p> | <p>Prävention für mehr Teilhabe im Alter</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/prometheus-praevention-fuer-mehr-teilhabe-im-alter.369</p> |
| <p>QT-Life</p> <p>Bericht in Erstellung</p> | <p>Apothekenbasierte Früherkennung der unerwünschten Arzneimittelwirkung QT-Streckenverlängerung</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/qt-life-apothekenbasierte-frueherkennung-der-unerwuenschten-arzneimittelwirkung-qt-streckenverlaengerung.373</p> |
| <p>USER</p> <p>Bericht in Erstellung</p> | <p>Umsetzung eines strukturierten Entlassmanagements mit Routinedaten</p> <p>https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/user-umsetzung-eines-strukturierten-entlassmanagements-mit-routinedaten.263</p> |
| <p>VESPEERA</p> <p>Beschlussdatum: 20.08.2021</p> <p>Beschlusstext (PDF)</p> <p>Ergebnisbericht (PDF)</p> <p>Evaluationsbericht (PDF)</p> | <p>Versorgungskontinuität sichern – Patientenorientiertes Einweisungs- und Entlassmanagement in Hausarztpraxen und Krankenhäusern</p> <p>https://innovationsfonds.g-ba.de/beschluesse/vespeera-versorgungskontinuitaet-sichern-patientenorientiertes-einweisungs-und-entlassmanagement-in-hausarztpraxen-und-krankenhaeusern.37</p> <ul style="list-style-type: none"> - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |

2.2.2 GBA Innovationsausschuss – Projekte / Versorgungsforschung

strukturierte Recherche: Ergänzung 23.01.2023

<https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/> (Treffer: 411 gesamt/ n=29 relevant für KHK)

| Nr. | Suchfrage |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| arriba-PPI Beschlussdatum: 16.08.2023 Beschlusstext (PDF) Ergebnisbericht (PDF) Dokumentation der Rückmel- dungen (PDF) | Evaluation einer patientenorientierten Absatzstrategie zur Reduktion der Überversorgung mit Protonenpumpenhemmern (PPI) / arriba-PPI https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/arriba-ppi-evaluation-einer-patientenorientierten-absetzstrategie-zur-reduktion-der-ueberversorgung-mit-protonenpumpenhemmern-ppi-arriba-ppi.142 - Ergebnisse werden weitergeleitet zur Information an die kassenärztlichen Vereinigungen und an die Verbände der Kranken- und Pflegekassen auf Bundesebene; ebenso an den Deutschen Hausärzterverband sowie die DE-GAM |
| BEVOR Bericht in Erstellung | Patienten-relevante Auswirkungen von Behandlung im Voraus planen: cluster-randomisierte Interventionsstudie in Seniorenpflegeeinrichtungen https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/bevor-patienten-relevante-auswirkungen-von-behandlung-im-voraus-planen-cluster-randomisierte-interventionsstudie-in-seniorenpflegeeinrichtungen.204 |
| BURDEN 2020 Beschlussdatum: 01.03.2023 Beschlusstext (PDF) Ergebnisbericht (PDF) | Die Krankheitslast in Deutschland und seinen Regionen. Grundlagen einer umfassenden Planung im Gesundheitswesen https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/burden-2020-die-krankheitslast-in-deutschland-und-seinen-regionen-grundlagen-einer-umfassenden-planung-im-gesundheitswesen.124 - Ergebnisse werden weitergeleitet an das BMG (Ziel: dauerhafte Etablierung einer nationalen Krankheitslaststudie); zudem an den Unterausschuss Bedarfsplanung des GBA (räumliche Verteilung) sowie an die Gesundheitsministerkonferenz der Länder (GMK) |
| CareTrans Projekt laufend | Care in Transition – Pflegeteams im Spannungsfeld von Migration und Akademisierung am Beispiel von Krankenhaus und Pflegeheim https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/caretrans-care-in-transition-pflegeteams-im-spannungsfeld-von-migration-und-akademisierung-am-beispiel-von-krankenhaus-und-pflegeheim.381 |
| ChroMO Projekt laufend | Monitoring-Routinen bei Menschen mit chronischen Erkrankungen: Bestandsaufnahme und Fahrplan für die Zukunft https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/chromo-monitoring-routinen-bei-menschen-mit-chronischen-erkrankungen-bestandsaufnahme-und-fahrplan-fuer-die-zukunft.556 |
| DASi Projekt laufend | Digital assistierte Informationserfassung vor der Sprechstunde https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/dasi-digital-assistierte-informationserfassung-vor-der-sprechstunde.338 |
| DECADE Projekt laufend | Förderung des Selbstmanagements in der hausärztlichen Versorgung zur Prävention von Herz-Kreislauf-Erkrankungen https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/decade-foerderung-des-selbstmanagements-in-der-hausaerztlichen-versorgung-zur-praevention-von-herz-kreislauf-erkrankungen.312 |

| Nr. | Suchfrage |
|----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DEMAND Bericht in Erstellung | Implementierung einer standardisierten Ersteinschätzung als Basis eines Demand Managements in der ambulanten Notfallversorgung https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/demand-implementation-einer-standardisierten-ersteinschaetzung-als-basis-eines-demand-managements-in-der-ambulanten-notfallversorgung.136 |
| Der nahtlose Patient - Projekt laufend | Von der präoperativen Vorbereitung zur postoperativen Rehabilitation https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/der-nahtlose-patient-von-der-praeoperativen-vorbereitung-zur-postoperativen-rehabilitation.454 |
| EMSE Beschlussdatum: 03.04.2020 Beschlusstext (PDF) Ergebnisbericht (PDF + Anlagen) | Entwicklung von Methoden zur Nutzung von Routinedaten für ein sektorenübergreifendes Entlassmanagement https://innovationsfonds.g-ba.de/beschluesse/emse-entwicklung-von-methoden-zur-nutzung-von-routinedaten-fuer-ein-sektoreuebergreifendes-entlassmanagement.3 <ul style="list-style-type: none"> - Vorprojekt zu USER (s.o.), GBA empfiehlt auf Basis der Ergebnisse zum Prozessmodell weitere Erprobung sowie als informative Ressource für Vertragsverhandlungen zwischen GKV-Spitzenverband, KBV und DKG |
| ENLIGHT-KHK Bericht in Erstellung | Erfassung und Optimierung der Leitlinienadhärenz im Indikationsstellungsprozess zur Koronarangiographie bei stabiler Koronarer Herzerkrankung https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/enlight-khk-erfassung-und-optimierung-der-leitlinienadhaerenz-im-indikationsstellungsprozess-zur-koronarangiographie-bei-stabiler-koronarer-herzerkrankung.128 |
| ENQUIRE Bericht in Erstellung | Evaluierung der Qualitätsindikatoren von Notaufnahmen auf Outcome-Relevanz für den Patienten https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/enquire-evaluierung-der-qualitaetsindikatoren-von-notaufnahmen-auf-outcome-relevanz-fuer-den-patienten.122 |
| ESC+ Beschlussdatum: 21.01.2022 Beschlusstext (PDF) Ergebnisbericht (PDF) | Evaluation des bestehenden Selektivvertrages nach § 140a SGB V – careplus https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/esc-evaluation-des-bestehenden-selektivvertrages-nach-140a-sgb-v-careplus.118 <ul style="list-style-type: none"> - der GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| EVITA Beschlussdatum: 12.05.2022 Beschlusstext (PDF) Ergebnisbericht (PDF) Dokumentation der Rückmeldungen (PDF) | Evidenzbasiertes Multimedikations-Programm mit Implementierung in die Versorgungspraxis https://innovationsfonds.g-ba.de/beschluesse/evita-evidenzbasiertes-multimedikations-programm-mit-implementierung-in-die-versorgungspraxis.77 <ul style="list-style-type: none"> - GBA empfiehlt Weiterleitung an Verbände der Kranken- und Pflegekassen auf Bundesebene, die Bundesvereinigung Deutscher Apothekerverbände e. V. (ABDA) und den Deutschen Hausärzterverband e. V. - Zudem Hinweis auf die Veröffentlichung der im Projekt weiterentwickelten „S3-Hausärztliche Leitlinie Multimedikation“ - basierend auf den Erkenntnissen des Projekts soll geprüft werden, ob weitergehende Ansätze des Projekts genutzt werden können |
| GenderVasc Bericht in Erstellung | Geschlechtsspezifische reale Versorgungssituation von Patienten mit arteriosklerotischen kardiovaskulären Erkrankungen in Deutschland |

| Nr. | Suchfrage |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/gendervasc-geschlechtsspezifische-reale-versorgungssituation-von-patienten-mit-arteriosclerotischen-kardiovaskulaeren-erkrankungen-in-deutschland.246 |
| HeartGap Projekt laufend | Gender Health Gaps in der leitlinienorientierten stationären kardiologischen Versorgung und Implementierungsstrategien zu deren Reduktion https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/heartgap-gender-health-gaps-in-der-leitlinienorientierten-stationaeren-kardiologischen-versorgung-und-implementierungsstrategien-zu-deren-reduktion.540 |
| INTEGRAL Beschlussdatum: 18.12.2020 Beschluss text (PDF) Ergebnisbericht (PDF) | 10-Jahres-Evaluation der populationsbezogenen integrierten Versorgung Gesundes Kinzigtal in Aufbau- und Konsolidierungsphase https://innovationsfonds.g-ba.de/beschluesse/integral-10-jahres-evaluation-der-populationsbezogenen-integrierten-versorgung-gesundes-kinzigtal-in-aufbau-und-konsolidierungsphase.10 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| ISAR-IQ Bericht in Erstellung | Integration und räumliche Analyse von regionalen, standortspezifischen und patientenindividuellen Faktoren zur Verbesserung der Versorgungsqualität bei Revaskularisation der Arteria carotis https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/isar-iq-integration-und-raeumliche-analyse-von-regionalen-standortspezifischen-und-patientenindividuellen-faktoren-zur-verbesserung-der-versorgungsqualitaet-bei-revaskularisation-der-arteria-carotis.311 |
| KARDIO-Studie Beschlussdatum: 12.05.2022 Beschluss text (PDF) Ergebnisbericht (PDF) Dokumentation der Rückmeldungen (PDF) | Linksherzkatheter bei Brustschmerzen und KHK: Analyse regionaler Variationen und Behandlungspfade zur Verbesserung der Indikationsqualität https://innovationsfonds.g-ba.de/beschluesse/kardio-studie-linksherzkatheter-bei-brustschmerzen-und-khk-analyse-regionaler-variationen-und-behandlungspfade-zur-verbesserung-der-indikationsqualitaet.78 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| Kardiologie-Vertrag Beschlussdatum: 25.06.2020 Beschluss text (PDF) Ergebnisbericht (PDF) | Evaluation Kardiologie-Vertrag – Evaluation des Vertrages zur Versorgung im Fachgebiet der Kardiologie in Baden-Württemberg gemäß § 73 c SGB V (Kardiologie-Vertrag) https://innovationsfonds.g-ba.de/beschluesse/evaluation-kardiologie-vertrag-evaluation-des-vertrages-zur-versorgung-im-fachgebiet-der-kardiologie-in-baden-wuerttemberg-gemaess-73-c-sgb-v-kardiologie-vertrag.4 - GBA spricht keine Empfehlung aus (Abschlussbericht vorhanden) |
| LLKVP Projekt laufend | S3-Leitlinie Hausärztliche Risikoberatung zur kardiovaskulären Prävention https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/llkvp-s3-leitlinie-hausaerztliche-risikoberatung-zur-kardiovaskulaeren-praevention.522 |
| MIDAS-Studie Bericht in Erstellung | Einfluss eines Clinical Decision Support (CDS) Systems auf Quantität und Qualität indizierter medizinischer Bildgebung https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/midas-studie-einfluss-eines-clinical-decision-support-cds-systems-auf-quantitaet-und-qualitaet-indizierter-medizinischer-bildgebung.208 |
| Mo2Regio Projekt laufend | Sektorenübergreifendes Monitoring und Modellierung der regionalen Gesundheitsversorgung |

| Nr. | Suchfrage |
|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/mo2regio-sektorenebergreifendes-monitoring-und-modellierung-der-regionalen-gesundheitsversorgung.547 |
| PARTNER Projekt laufend | Interprofessioneller Behandlungspfad zum PATientenzentrierTeN dEpRescribing potentiell inadäquater Medikation bei älteren Patienten mit Multimedikation https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/partner-interprofessioneller-behandlungspfad-zum-patientenzentrierten-deprescribing-potentiell-inadaequater-medikation-bei-aelteren-patienten-mit-multimedikation.456 |
| REVASK Bericht in Erstellung | Versorgungsanalyse zur myokardialen Revaskularisationstherapie bei chronischer KHK https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/revask-versorgungsanalyse-zur-myokardialen-revaskularisationstherapie-bei-chronischer-khk.210 |
| SELMA Bericht in Erstellung | Verbesserte Versorgungsstruktur für Menschen mit chronischen Herzerkrankungen mit implantierter Herzunterstützung durch curriculares Selbstmanagement https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/selma-verbesserte-versorgungsstruktur-fuer-menschen-mit-chronischen-herzerkrankungen-mit-implantierter-herzunterstuetzung-durch-curriculares-selbstmanagement.212 |
| Together4Trans Projekt laufend | S3-Leitlinie zur interdisziplinären, integrierten Gesundheitsversorgung für trans*, transsexuelle und nichtbinäre Menschen https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/together4trans-s3-leitlinie-zur-interdisziplinaren-integrierten-gesundheitsversorgung-fuer-trans-transsexuelle-und-nichtbinaere-menschen.586 |
| WEGE Projekt laufend | Analysen von Versorgungsverläufen bei älteren AOK Versicherten im Vorfeld einer Pflegebedürftigkeit https://innovationsfonds.g-ba.de/projekte/versorgungsforschung/wege-analysen-von-versorgungsverlaeufen-bei-aelteren-aok-versicherten-im-vorfeld-einer-pflegebeduerftigkeit.557 |
| ZWEIT Beschlussdatum: 16.10.2023 Beschluss text (PDF) Ergebnisbericht (PDF) | Bestandsaufnahme und Bedarfsanalyse von medizinischen Zweitmeinungsverfahren in Deutschland https://innovationsfonds.g-ba.de/beschluesse/zweit-bestandsaufnahme-und-bedarfsanalyse-von-medizinischen-zweitmeinungsverfahren-in-deutschland.171 - Ergebnisse werden an den Unterausschuss Qualitätssicherung des GBA weitergeleitet (u. a. aktuelle Versorgung und Inanspruchnahme von Zweitmeinungen) |

2.2.3 Übersicht der eingeschlossenen Treffer

Ergebnisse GBA Innovationsausschuss

- | | |
|--------------------------|---------------------------------|
| • Neue Versorgungsformen | n=27 (n=10 Berichte vorliegend) |
| • Versorgungsforschung | n=29 (n=9 Berichte vorliegend) |

3 Recherche zu KHK – Gezielte Recherche: Quell- und Referenzleitlinien

Die allgemeine systematische Recherche von 2014 zu Bildgebenden Verfahren schloss n = 41 Arbeiten ein, n = 31 zur Diagnostik sowie n = 10 zur Prognose (vgl. Anhang 2.1 des Leitlinienreports der Version 5.0 der NVL Chronische KHK); zur Koronarangiografie erfolgte eine Leitlinienrecherche (2010-2015), wobei n = 9 Leitlinien berücksichtigt wurden (vgl. Anhang 2.2 S. 44f des Leitlinienreports der Version 5.0 der NVL)

3.1 Gezielte Recherche (28.05.2014–16.05.2023)

Relevante Leitlinien (v. a. mit Evidenzaufbereitungen)

ESC

www.escardio.org/Guidelines

Topic: Coronary Artery Disease (Chronic)

- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2020) 41, 407/477 doi:10.1093/eurheartj/ehz425 <https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Chronic-Coronary-Syndromes>
 - <https://academic.oup.com/eurheartj/article/41/3/407/5556137?login=true>

AWMF

www.awmf.org/leitlinien/leitlinien-suche.html

S3, Langfassung Leitlinie; Schlagworte: koronare Herzkrankheit, KHK, Angina pectoris, Brustschmerz

- S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung, in Überarbeitung, geplante Fertigstellung: 30.09.2023: <https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung>

DGK

leitlinien.dgk.org/leitlinien

Suchwort: koronare Herzkrankheit, KHK, Angina pectoris, Brustschmerz

- Rolf, A., Schmermund, A., Hell, M., et al. Positionspapier Erbringung kardialer CT-Leistungen Kardiologie 2023 · 17:81–94. <https://doi.org/10.1007/s12181-023-00599-z>,
 - <https://leitlinien.dgk.org/2023/positionspapier-qualitaetskriterien-fuer-die-erbringung-kardialer-ct-leistungen/>
- Perings, S., Smetak, N., Kelm, M. et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. für „Brustschmerz-Ambulanzen“. Kardiologie (2016) 10: 301. doi:10.1007/s12181-016-0074-4
 - <https://leitlinien.dgk.org/2016/kriterien-der-deutschen-gesellschaft-fuer-kardiologie-herz-und-kreislaufforschung-e-v-fuer-brustschmerz-ambulanzen-update-2016/>
- Update 2020: Giannitsis, E., Post, F., Haerer, W. et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung für „Chest Pain Units“. Kardiologie (2020). <https://doi.org/10.1007/s12181-020-00417-w>
 - <https://leitlinien.dgk.org/2020/kriterien-der-deutschen-gesellschaft-fuer-kardiologie-herz-und-kreislaufforschung-fuer-chest-pain-units-2/>

- H. Reinecke, M. Braun, L. Frankenstein et al. (2015) Kriterien für die Notwendigkeit und Dauer von Krankenhausbehandlungen bei Koronarangiografien und –Interventionen Kardiologe 2015 · 9:295–302
 - <https://leitlinien.dgk.org/2015/kriterien-fuer-die-notwendigkeit-und-dauer-von-krankenhausbehandlungen-bei-koronarangiografien-und-interventionen/>

DEGAM

<https://www.degam.de/leitlinien>

geplante und aktuelle Leitlinien

- S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung, in Überarbeitung, geplante Fertigstellung: 30.09.2023
- S3-Leitlinie Hausärztliche Risikoberatung zur kardiovaskulären Prävention, in Überarbeitung, geplante Fertigstellung: 06.2024. www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-024_Risikoberatung%20kardiovaskul.%20Praevention/oeffentlich/053-024|_Hausa%CC%88rtliche_Risikoberatung_kardivaskula%CC%88re_Praevention_29-08-2018.pdf

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|--------------------------------------------------------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 05.2014 – 16.05.2023 |
| Suchbegriff: koronare Herzkrankheit, KHK, Angina pectoris, Brustschmerz | |
| Treffer | 29 |
| Eingeschlossene Treffer | 6 |

- [D22-01] Computertomographie-Koronarangiographie zur Diagnosestellung bei Patientinnen und Patienten mit Verdacht auf eine chronische koronare Herzkrankheit, Letzte Aktualisierung 17.02.2023.
- [V22-04] Leitliniensynopse für die Aktualisierung des DMP koronare Herzkrankheit, Letzte Aktualisierung 16.05.2023. <https://www.iqwig.de/projekte/v22-04.html>
- [GA20-01] CT- oder MRT-Diagnostik bei Verdacht auf chronische koronare Herzkrankheit: eine Evidenzkartierung, Letzte Aktualisierung 30.06.2020. https://www.iqwig.de/download/ga20-01_herz-ct-oder-mrt-bei-verdacht-auf-khk_arbeitspapier_v1-0.pdf
- [V16-03] Leitlinienrecherche zur Aktualisierung des DMP KHK, Letzte Aktualisierung 28.03.2018. <https://www.iqwig.de/projekte/v16-03.html>
- [D15-02] Messung der myokardialen fraktionellen Flussreserve (FFR-Messung) bei koronarer Herzkrankheit, Letzte Aktualisierung 09.01.2017. <https://www.iqwig.de/projekte/d15-02.html>
- [V15-01] Orientierende Prüfung des Überarbeitungsbedarfs des DMP koronare Herzkrankheit - Rapid Report, Letzte Aktualisierung 17.03.2016. <https://www.iqwig.de/projekte/v15-01.html>

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | coronary angiography, cardiac imaging, diagnostic imaging, coronary disease |
| Suchzeitraum | from 2014 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Eingeschlossene Treffer | 0 |

Zusatzinformation:

- DG43-QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography. published: 17 March 2021. <https://www.nice.org.uk/guidance/dg43>

- MTG32- HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography. Published: 13 February 2017. Review Decision April 2021. <https://www.nice.org.uk/guidance/mtg32/evidence/review-decision-april-2021-pdf-9076795165>

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab November 2017 bis 10.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|--------------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

4 Recherche zu KHK – Gezielte Recherche: Epidemiologie

4.1 Gezielte Recherche Epidemiologie (29.09.2023)

Die themenübergreifende ergänzende Recherche zur NVL Chronische KHK vom 23.01.2023 bzw. aktualisiert vom 30.10.2023 ermittelte u. a. aus dem Innovationsausschuss des GBA (Projekte / Versorgungsforschung; Kapitel 2.2.2 GBA Innovationsausschuss – Projekte / Versorgungsforschung) den Projektbericht des Projektes BURDEN 2020 (Details siehe dort).

Der Projektbericht enthielt u. a. den Verweis auf Primärpublikationen, in denen weitere Verweise u. a. auf die Ergebnisse des Projektes BURDEN 2020 in einem Gesundheitsinformationssystem (www.daly.rki.de) sowie die Ursprungsquellen für die epidemiologischen Kennzahlen (www.krankheitslagedeutschland.de) zu finden waren.

Aus den ergänzenden Quellen (Projekthomepage) sowie der bereits zuvor durchgeführten themenbezogenen Recherche gingen weitere Quellen hervor (siehe auch dort, Kapitel 2 Recherche zu KHK – Themenübergreifende Recherche: Ergänzung).

Gezielt ausgewählt wurden (Details siehe separate Evidenztabelle):

| Gezielte Recherche – Epidemiologie: ermittelte Quellen |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Porst M, Lippe Ev, Leddin J, et al. The Burden of Disease in Germany at the National and Regional Level Results in Terms of Disability-Adjusted Life Years (DALY) from the BURDEN 2020 Study. Dtsch Arztebl Int 2022; 119(46):785-792. DOI: 10.3238/arztebl.m2022.0314. http://www.ncbi.nlm.nih.gov/pubmed/36350160 . |
| Robert Koch-Institut (2022): Ergebnisdatensatz BURDEN 2020 – Krankheitslast in Deutschland und seinen Regionen, Berlin:Zenodo. DOI: 10.5281/zenodo.7323766 www.daly.rki.de/map |
| Robert Koch-Institut (RKI). Gesundheitliche Lage der erwachsenen Bevölkerung in Deutschland – Ergebnisse der Studie GEDA 2019/2020- EHIS. J Health Monit 2021; 6(3). |
| Robert Koch-Institut, editor. Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. Berlin: RKI; 2015. www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtd/gesundheit_in_deutschland_2015.pdf (bereits zitiert in der Version 6.0 der NVL Chronische KHK) |
| Wissenschaftlichen Instituts der AOK (WIdO). KrankheitslageDeutschland.de www.krankheitslage-deutschland.de |
| Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland (Zi). Versorgungsatlas – Dashboard häufige chronische Krankheiten www.versorgungsatlas.de/dashboard/#/evaluation/1005 |

5 Recherche Statine mittlere Dosis vs. Hohe Dosis (AkdÄ – Recherchefrage 3/4)

5.1 PICO-Frage

- P Patient*innen mit stabiler KHK
I Statine mittlere Dosis
C Statine hohe Dosis
O Effektivität und Sicherheit

Studientyp: systematische Reviews, Metaanalysen, RCT

Sprache: englisch, deutsch

5.2 Recherchestrategien

Hinweis: Recherchefrage 3/4 (Statine hohe Dosis vs. niedrig-moderat) des Leitfadens der AkdÄ.

PICO-3/4: Effektivität und Sicherheit von Statinen in Hochdosis in der Primär- und Sekundärprävention (SR)

Suchzeitraum: 2012 bis 15.12.2021

Suchbegriffe: #1 AND #1A AND #1B AND #8 AND #10

#1 Statine

"hmg-coa reductase inhibitors" OR "hmg-coa reductase inhibitor" OR statin OR statins OR simvastatin OR pravastatin OR atorvastatin OR fluvastatin OR rosuvastatin OR lovastatin OR pitavastatin OR cerivastatin

#1A Moderate bis geringe Dosis

"low-dose" OR "low dose" OR "low intens*" OR "low-intens*" OR "low intensity" OR "low-intensity" OR "moderate-dose" OR "moderate dose" OR "moderate intens*" OR "moderate-intens*" OR "moderate intensity" OR "moderate-intensity" OR "mediumdose" OR "medium dose" OR "medium intens*" OR "medium-intens*" OR "medium intensity" OR "medium-intensity" OR "middle-dose" OR "middle dose" OR "middle intens*" OR "middle-intens*" OR "middle intensity" OR "middle-intensity" OR "less statin"

#1B Hochdosis

"high-dose" OR "high dose" OR "high intensity" OR "high-intensity" OR "high intens*" OR "high-intens*" OR "more statin"

#8 Klinische Endpunkte

death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR resuscitation OR bypass

#10 SR

"systematic review" OR metaanalys* OR meta-analys* OR "pooled analys*" OR network

Eingeschlossene Volltexte: n = 4 (Primärprävention, SR) sowie n = 4 (Sekundärprävention, SR)

PICO-3/4: Effektivität und Sicherheit von Statinen in Hochdosis in der Primär- und Sekundärprävention (RCT)

Suchzeitraum: 2012 bis 15.12.2021

Suchbegriffe: ##1 AND #1A AND #1B AND #8 AND #9

#1 Statine

"hmg-coa reductase inhibitors" OR "hmg-coa reductase inhibitor" OR statin OR statins OR simvastatin OR pravastatin OR atorvastatin OR fluvastatin OR rosuvastatin OR lovastatin OR pitavastatin OR cerivastatin

#1A Moderate bis geringe Dosis

"low-dose" OR "low dose" OR "low intens*" OR "low-intens*" OR "low intensity" OR "low-intensity" OR "moderate-dose" OR "moderate dose" OR "moderate intens*" OR "moderate-intens*" OR "moderate intensity" OR "moderate-intensity" OR "mediumdose" OR "medium dose" OR "medium intens*" OR "medium-intens*" OR "medium intensity" OR "medium-intensity" OR "middle-dose" OR "middle dose" OR "middle intens*" OR "middle-intens*" OR "middle intensity" OR "middle-intensity" OR "less statin"

#1B Hochdosis

"high-dose" OR "high dose" OR "high intensity" OR "high-intensity" OR "high intens*" OR "high-intens*" OR "more statin"

#8 Klinische Endpunkte

death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR resuscitation OR bypass

#9 RCT

randomized OR randomised OR "at random" OR randomly

Eingeschlossene Volltexte: n = 0 (Primärprävention, RCT) sowie n = 6 (Sekundärprävention, RCT)

Rechercheauftrag für die NVL Chronische KHK Version 7.0: Aktualisierung der Suche **ab 15.12.2021**

Hinweis: s. a. Methodenreport der Version 5.0: Anhang 8.2.5

5.2.1 Strukturierte Suche (Dezember 2021 – 11.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|-----------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 12.2021 – 11.05.2023 |
| Suchbegriff: Statine | |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | statin, low-density lipoprotein cholesterol, LDL, coronary artery disease, lipid modification |
| Suchzeitraum | from Dez 2021 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE advice |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE quality standard |

| Nr. | Suchfrage |
|---------|-----------|
| Treffer | 0 + 1* |

*im Mai 2023 veröffentlicht: <https://www.nice.org.uk/guidance/cg181/evidence/c-risk-assessment-and-reduction-including-lipid-modification-pdf-13065827440>

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab Dez 2021 bis 11.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|---------------------------------------------------------------|---------|----------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

Zusatzinformation (ältere Version berücksichtigt in der Evidenzaufbereitung des Leitfadens der AkdÄ):

- AHRQ. Final Evidence Review. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. August 23, 2022. <https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-review/statin-use-in-adults-preventive-medication> (Primärprävention)

5.2.2 Medline via Pubmed (www.pubmed.gov) (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #12 | Search: (#6 AND #9) NOT (#10 OR #11) | 15 |
| #11 | Search: (#6 AND #8) NOT #10 | 19 |
| #10 | Search: #6 AND #7 | 8 |
| #9 | Search: cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] | 3,311,804 |
| #8 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,543,149 |
| #7 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta] OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] | 656,883 |

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | |
| #6 | Search: #1 AND #2 AND #3 AND #4 Filters: from 2021/12/15 - 3000/12/12 | 54 |
| #5 | Search: #1 AND #2 AND #3 AND #4 | 295 |
| #4 | Search: death[tw] OR infarction[tw] OR stroke[tw] OR "coronary syndrome"[tw] OR revascularisat*[tw] OR "cardiovascular event"*[tw] OR "coronary event"*[tw] OR "cerebrovascular event"*[tw] OR "unstable angina"[tw] OR resuscitation[tw] OR bypass[tw] | 1,794,826 |
| #3 | Search: "high-dose"[tw] OR "high dose"[tw] OR "high intensity"[tw] OR "high-intensity"[tw] OR "high intens"*[tw] OR "high-intens"*[tw] OR "more statin"[tiab:~0] | 157,430 |
| #2 | Search: "low-dose"[tw] OR "low dose"[tw] OR "low intens"*[tw] OR "low-intens"*[tw] OR "low intensity"[tw] OR "low-intensity"[tw] OR "moderate-dose"[tw] OR "moderate dose"[tw] OR "moderate intens"*[tw] OR "moderate-intens"*[tw] OR "moderate intensity"[tw] OR "moderate-intensity"[tw] OR "mediumdose"[tw] OR "medium dose"[tw] OR "medium intens"*[tw] OR "medium-intens"*[tw] OR "medium intensity"[tw] OR "medium-intensity"[tw] OR "middle-dose"[tw] OR "middle dose"[tw] OR "middle intens"*[tw] OR "middle-intens"*[tw] OR "middle intensity"[tw] OR "middle-intensity"[tw] OR "less statin"[tiab:~0] | 149,411 |
| #1 | Search: "hmg-coa reductase inhibitors"[tw] OR "hmg-coa reductase inhibitor"[tw] OR statin[tw] OR statins[tw] OR simvastatin[tw] OR pravastatin[tw] OR atorvastatin[tw] OR fluvastatin[tw] OR rosuvastatin[tw] OR lovastatin[tw] OR pitavastatin[tw] OR cerivastatin[tw] | 66,905 |

5.2.3 Datenbanken der Cochrane Library (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #6 | (#1 AND #2 AND #3 AND #4) NOT (conference proceeding):pt in Trials, Year first published: from 2021 | 31 |
| #5 | (#1 AND #2 AND #3 AND #4) NOT (conference proceeding):pt in Cochrane Reviews, Cochrane Protocols | 0 |
| #4 | (death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR (cardiovascular NEXT event*) OR (coronary NEXT event*) OR (cerebrovascular NEXT event*) OR "unstable angina" OR resuscitation OR bypass):ti,ab,kw | 188453 |
| #3 | ("high-dose" OR "high dose" OR "high intensity" OR "high-intensity" OR (high NEXT intens*) OR high-intens* OR "more statin"):ti,ab,kw | 36286 |
| #2 | ("low-dose" OR "low dose" OR (low NEXT intens*) OR low-intens* OR "low intensity" OR "low-intensity" OR "moderate-dose" OR "moderate dose" OR (moderate NEXT intens*) OR moderate-intens* OR "moderate intensity" OR "moderate-intensity" OR "mediumdose" OR "medium dose" OR (medium NEXT intens*) OR medium-intens* OR "medium intensity" OR "medium-intensity" OR "middle-dose" OR "middle dose" OR (middle NEXT intens*) OR middle-intens* OR "middle intensity" OR "middle-intensity" OR "less statin"):ti,ab,kw | 42583 |
| #1 | ("hmg-coa reductase inhibitors" OR "hmg-coa reductase inhibitor" OR statin OR statins OR simvastatin OR pravastatin OR atorvastatin OR fluvastatin OR rosuvastatin OR lovastatin OR pitavastatin OR cerivastatin):ti,ab,kw | 18854 |

5.2.4 Epistemonikos (www.epistemonikos.org) (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | ("hmg-coa reductase inhibitors" OR "hmg-coa reductase inhibitor" OR statin OR statins OR simvastatin OR pravastatin OR atorvastatin OR fluvastatin OR rosuvastatin OR lovastatin OR pitavastatin OR cerivastatin) AND ("low-dose" OR "low dose" OR "low intens*" OR "low-intens*" OR "low intensity" OR "low-intensity" OR "moderate-dose" OR "moderate dose" OR "moderate intens*" OR "moderate-intens*" OR "moderate intensity" OR "moderate-intensity" OR "mediumdose" OR "medium dose" OR "medium intens*" OR "medium-intens*" OR "medium intensity" OR "medium-intensity" OR "middle-dose" OR "middle dose" OR "middle intens*" OR "middle-intens*" OR "middle intensity" OR "middle-intensity" OR "less statin") AND ("high-dose" OR "high dose" OR "high intensity" OR "high-intensity" OR "high intens*" OR "high-intens*" OR "more statin") AND (death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR resuscitation OR bypass) Filter: Publication type: Systematic Review; Publication year: 2021-2023 | 10 |

5.2.5 Übersicht der eingeschlossenen Treffer

| | strukturiert | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|--------------|-----------|-----------|---------------|-----------|
| Aggregierte Evidenz | | 8 | 0 | 10 | |
| RCTs | | 19 | 31 | - | |
| Sonstige Primär | | 15 | - | - | |
| GESAMT | | 42 | 31 | 10 | 83 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:


A1 (Dubletten): 23

A2 (nicht englisch/deutsch): -

A3 (Conference Abstracts): -

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 60

5.3 Flowchart



Legende

Aa Thema nicht passend (PICO)

Ap Studientyp nicht passend

6 Recherche Statine Zielwert vs. feste Dosis (AkdÄ - Recherche- frage5/6)

6.1 PICO-Frage

- P Patient*innen mit stabiler KHK
I Statine zielwertgesteuert
C Statine in fester Dosis
O Effektivität und Sicherheit

Studientyp: systematische Reviews, Metaanalysen, RCT

Sprache: englisch, deutsch

6.2 Recherchestrategien

Hinweis: Recherchefrage 5/6 (Statine, Zielwert vs. feste Dosis) des Leitfadens der AkdÄ.

PICO-5/6: Effektivität einer Zielwert-Strategie in der Primär- und Sekundärprävention (SR)

Suchzeitraum: 2017 bis 15.12.2021

Suchbegriffe: #3A AND #3B AND #8 AND #10

#3A Zielwert

target OR targeted OR targets OR targeting OR goal OR goals OR "goal-directed"

#3B LDL

„low density lipoprotein cholesterol“ OR ldl-c OR ldl OR „LDL cholesterol“

#8 Klinische Endpunkte

death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR "cardiovascular event*" OR „coro-
nary event*" OR „cerebrovascular event*" OR "unstable angina" OR resuscitation OR bypass

#10 SR

„systematic review“ OR metaanalys* OR meta-analys* OR „pooled analys*" OR network

Eingeschlossene Volltexte: n = 0 (Sekundärprävention, SR) sowie n = 2 (Primärprävention, SR)

PICO-5/6: Effektivität einer LDL-Zielwert-Strategie in der Primär- und Sekundärprävention (RCT)

Suchzeitraum: 2017 bis 15.12.2021

Suchbegriffe: #3A AND #3B AND #8 AND #9

#3A Zielwert

target OR targeted OR targets OR targeting OR goal OR goals OR "goal-directed"

#3B LDL

„low density lipoprotein cholesterol“ OR ldl-c OR ldl OR „LDL cholesterol“

#8 Klinische Endpunkte

death OR infarction OR stroke OR "coronary syndrome" OR revascularisat* OR "cardiovascular event*" OR „coro-
nary event*" OR „cerebrovascular event*" OR "unstable angina" OR resuscitation OR bypass

#9 RCT

randomized OR randomised OR „at random“ OR randomly

Eingeschlossene Volltexte: n = 3 (Sekundärprävention, RCT) sowie n = 1 (Primärprävention, RCT)

Rechercheauftrag für die NVL Chronische KHK Version 7.0: Aktualisierung der Suche **ab 15.12.2021**

Hinweis: s. a. Methodenreport der Version 5.0: Anhang 8.2.5 Strategien der Lipidsenkung: Strategie der festen Dosis (Empfehlung 7-13); Anhang 8.2.6 Strategien der Lipidsenkung: Zielwertstrategie (Empfehlung 7-14) (Expertenkonsens ohne strukturierte oder systematische Recherche)

6.2.1 Strukturierte Suche (Dezember 2021 – 11.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|----------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 12.2021 – 11.05.2023 |
| Suchbegriff: Statine, LDL | |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | statin, low-density lipoprotein cholesterol, LDL, treat-to-target, coronary artery disease |
| Suchzeitraum | from Dez 2021 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE advice |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Zusatzinformation:

- Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. Technology appraisal guidance [TA805] Published: 13 July 2022. <https://www.nice.org.uk/guidance/ta805/evidence>

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab Dez 2021 bis 11.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|---------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

Zusatzinformation (ältere Version berücksichtigt in der Evidenzaufbereitung des Leitfadens der AkdÄ):

- AHRQ. Final Evidence Review. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. August 23, 2022. <https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-review/statin-use-in-adults-preventive-medication> (Primärprävention)

6.2.2 Medline via Pubmed (www.pubmed.gov) (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #12 | Search: (#6 AND #9) NOT (#10 OR #11) | 78 |
| #11 | Search: (#6 AND #8) NOT #10 | 40 |
| #10 | Search: #6 AND #7 | 25 |
| #9 | Search: cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] | 3,311,804 |
| #8 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,543,149 |
| #7 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta] OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | 656,883 |
| #6 | Search: #3 AND #4 Filters: from 2021/12/15 - 3000/12/12 | 368 |
| #5 | Search: #3 AND #4 | 3,100 |
| #4 | Search: "death"[tw] OR "infarction"[tw] OR "stroke"[tw] OR "coronary syndrome"[tw] OR "revascularisat*"[tw] OR "cardiovascular event*"[tw] OR "coronary event*"[tw] OR "cerebrovascular event*"[tw] OR "unstable angina"[tw] OR "resuscitation"[tw] OR "bypass"[tw] | 1,794,826 |
| #3 | Search: #1 AND #2 | 13,743 |
| #2 | Search: "target"[tw] OR "trageted"[tw] OR "targets"[tw] OR "targeting"[tw] OR "goal"[tw] OR "goals"[tw] OR "goal-directed"[tw] | 2,080,433 |
| #1 | Search: "low density lipoprotein cholesterol"[tw] OR "ldl-c"[tw] OR "ldl"[tw] OR "LDL cholesterol"[tw] | 126,828 |

6.2.3 Datenbanken der Cochrane Library (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #7 | #5 NOT (conference proceeding):pt in Trials; Year first published: from 2021 | 103 |
| #6 | #5 NOT (conference proceeding):pt in Cochrane Reviews, Cochrane Protocols, Publication date: from 2021-12-15 | 0 |
| #5 | #3 AND #4 | 954 |
| #4 | ("death" OR "infarction" OR "stroke" OR "coronary syndrome" OR revascularisat* OR (cardiovascular NEXT event*) OR (coronary NEXT event*) OR (cerebrovascular NEXT event*) OR "unstable angina" OR "resuscitation" OR "bypass"):ti,ab,kw | 188454 |
| #3 | #1 AND #2 | 3273 |
| #2 | ((("target" OR "trageted" OR "targets" OR "targeting" OR "goal" OR "goals" OR "goal-di-rected")):ti,ab,kw | 128084 |
| #1 | ((("low density lipoprotein cholesterol" OR "ldl-c" OR "ldl" OR "LDL cholesterol")):ti,ab,kw | 27874 |

Zusatzinformation (vor dem Recherchezeitraum):

- Schmidt et al. 2020. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review). <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011748.pub3/epdf/full>
- Zhan et al. 2018. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review). <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/epdf/full>
- Taylor et al. 2013 Statins for the primary prevention of cardiovascular disease (Review). <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004816.pub5/full>

6.2.4 Epistemonikos (www.epistemonikos.org) (19. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | (title:(("low density lipoprotein cholesterol" OR "ldl-c" OR "ldl" OR "LDL cholesterol"))) OR abstract:(("low density lipoprotein cholesterol" OR "ldl-c" OR "ldl" OR "LDL cholesterol")) AND (title:(("target" OR "trageted" OR "targets" OR "targeting" OR "goal" OR "goals" OR "goal-directed")) OR abstract:(("target" OR "trageted" OR "targets" OR "targeting" OR "goal" OR "goals" OR "goal-directed"))) AND (title:(("death" OR "infarction" OR "stroke" OR "coronary syndrome" OR "revascularisat*" OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR "resuscitation" OR "bypass")) OR abstract:(("death" OR "infarction" OR "stroke" OR "coronary syndrome" OR "revascularisat*" OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR "resuscitation" OR "bypass")))) OR abstract:(("title:(("low density lipoprotein cholesterol" OR "ldl-c" OR "ldl" OR "LDL cholesterol")) OR abstract:(("low density lipoprotein cholesterol" OR "ldl-c" OR "ldl" OR "LDL cholesterol")) AND (title:(("target" OR "trageted" OR "targets" OR "targeting" OR "goal" OR "goals" OR "goal-directed")) OR abstract:(("target" OR "trageted" OR "targets" OR "targeting" OR "goal" OR "goals" OR "goal-directed"))) AND (title:(("death" OR "infarction" OR "stroke" OR "coronary syndrome" OR "revascularisat*" OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR "resuscitation" OR "bypass")) OR abstract:(("death" OR "infarction" OR "stroke" OR "coronary syndrome" OR "revascularisat*" OR "cardiovascular event*" OR "coronary event*" OR "cerebrovascular event*" OR "unstable angina" OR "resuscitation" OR "bypass")))))))) Filter: Publication type: Systematic review; Publication year: 2021-2023 | 14 |

6.2.5 Übersicht der eingeschlossenen Treffer

| | strukturiert | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|--------------|---------|----------|---------------|------------|
| Aggregierte Evidenz | | 25 | - | 14 | 39 |
| RCTs | | 40 | 103 | - | 143 |
| Sonstige Primär | | 78 | - | - | 78 |
| GESAMT | | | | | 260 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:


A1 (Dubletten): 32

A2 (nicht englisch/deutsch): 4

A3 (Conference Abstracts): -

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 224

6.3 Flowchart



Legende

Aa Thema nicht passend (PICO)

Ap Studientyp nicht passend

7 Recherche zu Bempedoinsäure bei maximal verträglicher Statintherapie (AkdÄ – Recherchefrage 25)

7.1 PICO-Frage

- P** Patient*innen mit stabiler KHK nach invasivem Verfahren oder akutem Koronarsyndrom bzw. akutem kardiovaskulärem Ereignis und Indikation zur Lipidsenkung
- I** Bempedoinsäure bei maximal verträglicher Statintherapie
- C** Placebo oder Standardtherapie
- O** Effektivität und Sicherheit

Studientyp: systematische Reviews, Metaanalysen, RCT

Sprache: englisch, deutsch

7.2 Recherchestrategien

Hinweis: Recherchefragen 25 (Bempedoinsäure) des Leitfadens der AkdÄ. (AkdÄ)¹

PICO-25: Effektivität und Sicherheit von Bempedoinsäure bei maximal verträglicher Statintherapie in der Sekundärprävention (RCT)

Suchzeitraum: 2017 bis 15.12.2021

Suchbegriffe: #7 AND #9

#7 Bempedoinsäure

"(ATP)-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002

#9 RCT

randomized OR randomised OR „at random“ OR randomly

Eingeschlossene Volltexte: n = 5

Rechercheauftrag für die NVL Chronische KHK Version 7.0: Aktualisierung der Suche **ab 15.12.2021**

7.2.1 Strukturierte Suche (Dezember 2021 – 11.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|------------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 12.2021 – 11.05.2023 |
| Suchbegriff: Bempedoinsäure | |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |

Zusatzinformation (berücksichtigt im Recherchezeitraum in der Evidenzaufbereitung des Leitfadens der AkdÄ):

- A20-92: Version 1.0 28.01.2021. IQWiG-Berichte – Nr. 1033. Bempedoinsäure (primäre Hypercholesterinämie und gemischte Dyslipidämie) – Nutzenbewertung gemäß § 35a SGB V
https://www.iqwig.de/download/a20-92_bempedoinsaeure_nutzenbewertung-35a-sgb-v_v1-0.pdf

¹ Evidenzaktualisierung des Leitfadens Medikamentöse Cholesterinsenkung zur Vorbeugung kardiovaskulärer Ereignisse der Bundesärztekammer / Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) – Version 1.0 März 2023 www.akdae.de/arsneimitteltherapie/lf/cholesterinsenkung

- A20-91: Version 1.0 28.01.2021. IQWiG-Berichte – Nr. 1031. Bempedoinsäure/Ezetimib (primäre Hypercholesterinämie und gemischte Dyslipidämie) – Nutzenbewertung gemäß § 35a SGB V
https://www.iqwig.de/download/a20-91_bempedoinsaeure-ezetimib_nutzenbewertung-35a-sgb-v_v1-0.pdf

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | Bempedoic acid |
| Suchzeitraum | from Dez 2021 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE advice |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Zusatzinformation (berücksichtigt im Recherchezeitraum in der Evidenzaufbereitung des Leitfadens der AkdÄ):

- Single Technology Appraisal Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515] Committee Papers. <https://www.nice.org.uk/guidance/ta694/evidence/appraisal-consultation-committee-papers-pdf-9082103581>
- Single Technology Appraisal Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515] Committee Papers: <https://www.nice.org.uk/guidance/ta694/evidence/final-appraisal-determination-committee-papers-pdf-9082103582>
- NICE Guidance: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia <https://www.nice.org.uk/guidance/ta694/resources/bempedoic-acid-with-ezetimibe-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-pdf-82609440519877>

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab Dez 2021 bis 11.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|---------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

7.2.2 Medline via Pubmed (www.pubmed.gov) (16. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------|--------|
| #10 | Search: (#4 AND #7) NOT (#8 OR #9) | 7 |
| #9 | Search: (#4 AND #6) NOT #8 | 23 |
| #8 | Search: #4 AND #5 | 13 |

| Nr. | Suchfrage | Anzahl |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #7 | Search: cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] | 3,311,046 |
| #6 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,542,811 |
| #5 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | 656,605 |
| #4 | Search: #1 OR #2 Filters: from 2021/12/15 - 3000/12/12 | 130 |
| #3 | Search: #1 OR #2 | 323 |
| #2 | Search: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [Supplementary Concept] | 166 |
| #1 | Search: "ATP:citrate lyase inhibitor"[Text Word] OR "ATP:citrate lyase inhibitor"[Text Word] OR "bempedoic"[Text Word] OR "ETC-1002"[Text Word] | 306 |

Hinweis: PubMed Medline Entry Terms: bempedoic acid, nilemdo, nexletol, ETC-1002, ESP55016, ESP-55016

7.2.3 Datenbanken der Cochrane Library (16. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #2 | "(ATP)-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002 in Trials, ;from 2021 | 42 |
| #1 | ("(ATP)-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002):ti,ab,kw in Cochrane Reviews, Cochrane Protocols | 0 |

7.2.4 Epistemonikos (www.epistemonikos.org) (16. Juni 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | (title:(title:("ATP-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002) OR abstract:("ATP-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002))) OR abstract:(title:("ATP-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002) OR abstract:("ATP-citrate lyase inhibitor" OR "ATP:citrate lyase inhibitor" OR bempedoic OR ETC-1002))) Filter: Publication type: Systematic review; Publication year: 2021-2023 | 12 |

7.2.5 Übersicht der eingeschlossenen Treffer

| | Strukturiert | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|--------------|---------|----------|---------------|-----------|
| Aggregierte Evidenz | | 13 | - | 12 | 25 |
| RCTs | | 23 | 42 | - | 65 |
| Sonstige Primär | | 7 | - | - | 7 |
| GESAMT | | | | | 97 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:


A1 (Dubletten): 22

A2 (nicht englisch/deutsch): 1

A3 (Conference Abstracts): 12

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 62

7.3 Flowchart



Legende

Aa Thema nicht passend (PICO)

Ap Studientyp nicht passend

8 Recherche zu Anhang 8.1.1 der 5. Auflage 2019 (S. 123ff) Stabile KHK: Keine Indikation zur Antikoagulation (Empfehlung 7-1 und Empfehlung 7-3)

8.1 PICO-Frage

- P** Patient*innen mit stabiler KHK
I Clopidogrel
C ASS oder Standardmedikation
O Gesamtmortalität, kardiovaskuläre Mortalität, Myokardinfarkt, unerwünschte Wirkungen

Studientyp: systematische Reviews, Metaanalysen

Sprache: englisch, deutsch

8.2 Recherchestrategien

Strukturierte Suche nach aggregierter Evidenz (21.11.2017 – 10.05.2023)

Hinweis: bis November 2017 n = 2 Treffer (n = 1 IQWiG Bericht (ASS vs. Clopidogrel), n = 1 Treffer NICE (ASS vs. Placebo))

- Der NICE-Review bezieht sich ausschließlich auf Patienten ohne zurückliegenden Myokardinfarkt. Zur Sekundärprävention nach Myokardinfarkt liegt zwar eine Empfehlung einer NICE-Guideline vor, bezüglich dieser Empfehlung wird jedoch keine systematische Suche berichtet. Als Evidenzgrundlage wird eine Übersichtsarbeit der Antithrombotic Trialists' (ATT) Collaboration zitiert. Wir fanden eine aktuellere Übersichtsarbeit der ATT-Collaboration, die keine neuen relevanten Studien identifiziert, jedoch ergänzende Informationen beispielsweise zu Patientencharakteristika bereitstellt. Beide Reviews der ATT-Collaboration wurden von uns methodisch bewertet und extrahiert. Da sie keine qualitative Bewertung der eingeschlossenen Studien berichten, erfolgte außerdem eine Extraktion und methodische Bewertung der Primärstudien.
- Im Rahmen der Konsultationsphase wurde die aktuell diskutierte Metaanalyse von Rothwell et al. zur Dosierung von ASS eingebracht.

bis Mai 2023 **n = 0 Treffer** (*Hinweis:* eine Zusatzinformation zur Prävention mit ASS ist weiter unten aufgeführt (AHRQ))

Systematische Suche nach aggregierter Evidenz und RCT (21.11.2017 – heute) s. u.

8.2.1 Strukturierte Suche (21. November 2017 – 10.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|---------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 11.2017 – 10.05.2023 |
| Suchbegriff: Clopidogrel | |
| Treffer | 4 |
| Eingeschlossene Treffer | 0 |

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|--------------|--------------------|
| Suchbegriffe | Clopidogrel |
| Suchzeitraum | from November 2017 |

| Nr. | Suchfrage |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE advice |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab November 2017 bis 10.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|--------------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

Zusatzinformation (nicht eingeschlossen)

Final Evidence Review. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication. April 26, 2022
<https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-review/aspirin-to-prevent-cardiovascular-disease-preventive-medication>

8.2.2 Medline via Pubmed (www.pubmed.gov) (6. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| #12 | Search: (#8 AND #10) NOT #11 | 345 |
| #11 | Search: #8 AND #9 | 198 |
| #10 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,546,908 |
| #9 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] | 660,331 |

| Nr. | Suchfrage | Anzahl |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| | OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | |
| #8 | Search: #5 AND #6 Filters: from 2017/11/21 - 3000/12/12 | 1,693 |
| #7 | Search: #5 AND #6 | 6,678 |
| #6 | Search: Clopidogrel*[tw] | 16,571 |
| #5 | Search: #1 OR #2 OR #3 OR #4 | 318,733 |
| #4 | Search: "Coronary Thrombosis"[Mesh] | 8,347 |
| #3 | Search: "Coronary Occlusion"[Mesh] | 4,352 |
| #2 | Search: "Angina Pectoris"[Mesh] | 44,667 |
| #1 | Search: coronary[tiab] AND (syndrome*[tiab] OR occlusion*[tiab] OR thrombosis*[tiab] OR disease*[tiab] OR (heart[tiab] AND disease*[tiab])) | 285,623 |

Hinweis: stufenweises Vorgehen: nach Einschluss der SR, ggf. zeitliche Begrenzung der RCT

8.2.3 Datenbanken der Cochrane Library (6. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|--------------------------------------------------------------------------------------------------------------|--------|
| #9 | #7 NOT (conference proceeding):pt in Trials; Year first published: from 2017 | 762 |
| #8 | #7 NOT (conference proceeding):pt in Cochrane Reviews, Cochrane Protocols; Publication date: from 2017-11-21 | 3 |
| #7 | #5 AND #6 | 3335 |
| #6 | ("clopidogrel"):ti,ab,kw | 6162 |
| #5 | #1 OR #2 OR #3 OR #4 | 51571 |
| #4 | MeSH descriptor: [Coronary Thrombosis] explode all trees | 565 |
| #3 | MeSH descriptor: [Coronary Occlusion] explode all trees | 510 |
| #2 | MeSH descriptor: [Angina Pectoris] explode all trees | 5570 |
| #1 | ((coronary AND (syndrome* OR occlusion* OR thrombosis* OR disease* OR (heart AND disease*)))):ti,ab,kw | 48766 |

8.2.4 Epistemonikos (www.epistemonikos.org) (6. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| | (advanced_title_en:(coronary) OR advanced_abstract_en:(coronary)) AND (advanced_title_en:(syndrome* OR occlusion* OR thrombosis* OR disease* OR (heart AND disease*)) OR advanced_abstract_en:(syndrome* OR occlusion* OR thrombosis* OR disease* OR (heart AND disease*))) AND (advanced_title_en:(clopidogrel) OR advanced_abstract_en:(clopidogrel)) [Filters: classification=systematic-review, protocol=no, min_year=2017, max_year=2023] | 180 |

8.2.5 Übersicht der eingeschlossenen Treffer

| | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|---------|----------|---------------|-------------|
| Aggregierte Evidenz | 198 | 3 | 180 | 381 |
| RCTs | 345 | 762 | | 1107 |
| GESAMT | | | | 1488 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:

A1 (Dubletten): 461

A2 (nicht englisch/deutsch): 20


A3 (Conference Abstracts):

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 1007 + n = 1 SR (strukturierte Suche)

Stufenweises Vorgehen:

- n = 204 Studienregisterpublikationen ausgeschlossen, n = 804 (SR: n = 222 +, RCT: n = 582)
- **e: n = 222 SR + n = 253 RCT (eingeschränktes RCT Screening, s. u.)**

8.3 Flowchart



Hinweis: das Screening der aggregierten Evidenz ergab u.a. eine systematische Übersichtsarbeit aus dem Jahr 2020 (Suche im Dec 2019), die der betrachteten Fragestellung entspricht, daher wurde das Screening der weiteren Evidenz (RCT) auf den Zeitraum ab 2020 eingeschränkt (n = 253), s.o. (e = eingeschränkt)

9 Recherche zu Protonenpumpeninhibitoren

9.1 PICO-Frage

Wirksamkeit und Sicherheit von Kombinationstherapien aus NSAR+PPI bei Patient*innen mit Schmerzen.

- P Patient*innen mit Schmerzen (alle)
 I NSAR+PPI
 C alle
 O Reduktion gastrointestinaler Nebenwirkungen
 alle sicherheitsrelevanten Endpunkte (AE, SAE)

Sprache: englisch, deutsch

Studientyp: SR über RCT

Zeitraum: keine Einschränkung

Hinweis: die AG medikamentöse Therapie der NVL Chronische KHK entschied in 2023, die Recherche der NVL Kreuzschmerz aus 2022 zu verwenden, um eine erweiterte Evidenzbasis für eine Empfehlung der NVL Chronische KHK nutzbar zu machen; die TiAb-Screeningtable wurde in Bezug auf möglicherweise ergänzend relevante Evidenz überprüft und die Ergebnisse der NVL Kreuzschmerz übernommen, die Aktualität und Gültigkeit der Recherche wurde als gegeben gesehen (Stand: 14.12.2023)

9.2 Recherchestrategien

9.2.1 Medline via Pubmed (www.pubmed.gov) (01. August 2022)

| Nr. | Suchfrage | Anzahl |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| #9 | Search: #7 AND #8 | 185 |
| #8 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta] OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | 597,106 |
| #7 | Search: #3 AND #6 | 2,877 |
| #6 | Search: #4 OR #5 | 49,23 |

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| #5 | Search: "PPI"[Title/Abstract] OR "PPIs"[Title/Abstract] OR "proton pump inhibitor*"[Title/Abstract] OR "omeprazole"[Title/Abstract] OR "esomeprazole"[Title/Abstract] OR "pantoprazole"[Title/Abstract] OR "lansoprazole"[Title/Abstract] OR "dexlansoprazole"[Title/Abstract] | 45,796 |
| #4 | Search: "proton pump inhibitors/adverse effects"[MeSH Terms] OR "proton pump inhibitors/therapeutic use"[MeSH Terms] OR "omeprazole"[MeSH Terms] OR "esomeprazole"[MeSH Terms] OR "pantoprazole"[MeSH Terms] OR "dexlansoprazole"[MeSH Terms] OR "lansoprazole"[MeSH Terms] | 17,580 |
| #3 | Search: #1 OR #2 | 188,339 |
| #2 | Search: "nsaid*"[Title/Abstract] OR "non steroidal anti inflammatory drug*"[Title/Abstract] OR "nonsteroidal anti inflammatory drug*"[Title/Abstract] OR "nonsteroidal antiinflammatory drug*"[Title/Abstract] OR "non steroidal antiinflammatory drug*"[Title/Abstract] OR "non steroidal anti inflammatory agent*"[Title/Abstract] OR "nonsteroidal anti inflammatory agent*"[Title/Abstract] OR "nonsteroidal antiinflammatory agent*"[Title/Abstract] OR "non steroidal antiinflammatory agent*"[Title/Abstract] OR "Aceclofenac"[Title/Abstract] OR "Acetaminophen"[Title/Abstract] OR "Celecoxib"[Title/Abstract] OR "Diclofenac"[Title/Abstract] OR "Ibuprofen"[Title/Abstract] OR "Indomethacin"[Title/Abstract] OR "Ketoprofen"[Title/Abstract] OR "Ketorolac"[Title/Abstract] OR "Meloxicam"[Title/Abstract] OR "Metamizole"[Title/Abstract] OR "Naproxen"[Title/Abstract] OR "Piroxicam"[Title/Abstract] OR "Pyrazolones"[Title/Abstract] | 129,392 |
| #1 | Search: "anti inflammatory agents, non steroidal/adverse effects"[MeSH Terms] OR "anti inflammatory agents, non steroidal/therapeutic use"[MeSH Terms] OR "cyclooxygenase inhibitors/adverse effects"[MeSH Terms] OR "cyclooxygenase inhibitors/therapeutic use"[MeSH Terms] OR "Acetaminophen"[MeSH Terms] OR "Celecoxib"[MeSH Terms] OR "Diclofenac"[MeSH Terms] OR "Etoricoxib"[MeSH Terms] OR "Ibuprofen"[MeSH Terms] OR "Indomethacin"[MeSH Terms] OR "Ketoprofen"[MeSH Terms] OR "Ketorolac"[MeSH Terms] OR "Meloxicam"[MeSH Terms] OR "Naproxen"[MeSH Terms] OR "Piroxicam"[MeSH Terms] OR "Pyrazolones"[MeSH Terms] | 134,169 |

9.2.2 Datenbanken der Cochrane Library (01. August 2022)

| Nr. | Suchfrage | Anzahl |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #22 | #16 AND #21 in Cochrane Reviews, Cochrane Protocols | 12 |
| #21 | #17 OR #18 OR #19 OR #20 | 17318 |
| #20 | (PPI OR PPIs OR proton pump inhibitor* OR omeprazole OR esomeprazole OR pantoprazole OR lansoprazole OR dexlansoprazole):ti,ab,kw (Word variations have been searched) | 10793 |
| #19 | MeSH descriptor: [Omeprazole] explode all trees | 3121 |
| #18 | MeSH descriptor: [Gastrointestinal Agents] explode all trees | 8329 |
| #17 | MeSH descriptor: [Proton Pump Inhibitors] explode all trees | 1563 |
| #16 | #1 OR #14 OR #15 | 36435 |
| #15 | ("nsaid*" OR "non steroidal anti inflammatory drug*" OR "nonsteroidal anti inflammatory drug*" OR "nonsteroidal antiinflammatory drug*" OR "nonsteroidal anti inflammatory agent*" OR "nonsteroidal anti inflammatory agent*" OR "nonsteroidal antiinflammatory agent*" OR "non steroidal antiinflammatory agent*" OR Aceclofenac OR Acetaminophen OR Celecoxib OR Diclofenac OR Etoricoxib OR Ibuprofen OR Indomethacin OR Ketoprofen OR Ketorolac OR Meloxicam OR Metamizole OR Naproxen OR Piroxicam):ti,ab,kw (Word variations have been searched) | 33505 |
| #14 | #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 | 12653 |

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------|--------|
| #13 | MeSH descriptor: [Pyrazolones] explode all trees | 861 |
| #12 | MeSH descriptor: [Piroxicam] explode all trees | 663 |
| #11 | MeSH descriptor: [Naproxen] explode all trees | 1180 |
| #10 | MeSH descriptor: [Meloxicam] explode all trees | 245 |
| #9 | MeSH descriptor: [Ketorolac] explode all trees | 964 |
| #8 | MeSH descriptor: [Ketoprofen] explode all trees | 583 |
| #7 | MeSH descriptor: [Indomethacin] explode all trees | 2753 |
| #6 | MeSH descriptor: [Ibuprofen] explode all trees | 2142 |
| #5 | MeSH descriptor: [Etoricoxib] explode all trees | 242 |
| #4 | MeSH descriptor: [Diclofenac] explode all trees | 2002 |
| #3 | MeSH descriptor: [Celecoxib] explode all trees | 1015 |
| #2 | MeSH descriptor: [Acetaminophen] explode all trees | 3482 |
| #1 | MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees | 7923 |

9.2.3 Epistemonikos (www.epistemonikos.org) (01. August 2022)

| Nr. | Suchfrage | Anzahl |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | [Title/Abstract]: ((NSAID*) OR (non steroidal anti inflammatory drug*) OR (nonsteroidal antiinflammatory drug*) OR (nonsteroidal anti inflammatory drug*) OR (nonsteroidal anti inflammatory drug*) OR (Acetaminophen) OR (Celecoxib) OR (Diclofenac) OR (Etoricoxib) OR (Ibuprofen) OR (Indomethacin) OR (Ketoprofen) OR (Ketorolac) OR (Meloxicam) OR (Metamizole) OR (Naproxen) OR (Piroxicam)) AND ((proton pump inhibitor*) OR (PPI*) OR omeprazole OR esomeprazole OR pantoprazole OR lansoprazole OR dexlansoprazole) (Publication type: Systematic review) | 66 |

9.2.4 Übersicht der eingeschlossenen Treffer

| | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|---------|----------|---------------|-------|
| Aggregierte Evidenz | 185 | 12 | 66 | 263 |


Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:

A1 (Dubletten): 51

A2 (nicht englisch/deutsch): 21

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 191

9.3 Flowchart



*n = 1 Protokoll (zum Zeitpunkt der Recherche bzw. des Screenings für die NVL Chronische KHK noch keine Publikation verfügbar:

Garegnani L. Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. *Cochrane Database of Systematic Reviews* 2022; 2022(5):357. [dx.doi.org/10.1002/14651858.CD014585](https://doi.org/10.1002/14651858.CD014585).

(von den n = 6 eingeschlossenen Volltexten wurden n = 3 direkt herangezogen und ein weiterer unterstützend für den Hintergrundtext; der Cochrane Review diente zum Abgleich als indirekte Evidenz für die Diskussion)

10 Recherche zu Anhang 8.1.4, 8.1.5 und 8.1.6 der 5. Auflage 2019 (S. 124ff) Z.n. elektiver PCI bei stabiler KHK: Clopidogrel oder Prasugrel oder Ticagrelor plus ASS nach elektiver PCI (Empfehlung 7-5) bzw. nach akutem Koronarsyndrom (Kapitel 7.1.4)

10.1 PICO-Frage

Fragestellung 1

- P Patient*innen mit elektiver PCI (Stentimplantation) oder nach akutem Koronarsyndrom
I Clopidogrel plus ASS
C Placebo oder OAK oder ADP-Rezeptor-Antagonist, jeweils plus ASS
O Gesamtmortalität, kardiovaskuläre Mortalität, Myokardinfarkt, unerwünschte Wirkungen

Studientyp: systematische Reviews, Metaanalysen

Sprache: englisch, deutsch

Fragestellung 2 und 3

- P Patienten nach elektiver Stentimplantation oder nach akutem Koronarsyndrom
I Ticagrelor plus ASS oder Prasugrel plus ASS
C Clopidogrel plus ASS
O Gesamtmortalität, kardiovaskuläre Mortalität, Myokardinfarkt, unerwünschte Wirkungen

Studientyp: RCT, systematische Reviews, Metaanalysen

Sprache: englisch, deutsch

10.2 Recherchestrategien

Strukturierte Suche nach aggregierter Evidenz (21.07.2017 – 10.05.2023)

Hinweis: bis November 2017 keine Treffer für SR Clopidogrel + ASS; bis Juli 2017 n = 2 Treffer SR (n = 1 IQWiG Bericht sowie n = 1 NICE Evidenzbericht, beide nach akutem Koronarsyndrom)

Systematische Suche nach aggregierter Evidenz und RCT (21.07.2017 – heute), ggf. ergänzende Suche nach Langzeitbetrachtungen ab Juli 2017, insbesondere zu unerwünschten Wirkungen, s. u.

Hinweis: bis Juli 2017 n = 10 Treffer RCT (Ticagrelor plus ASS nach akutem Koronarsyndrom) + n = 6 Treffer RCT: n = 3 Treffer RCT (Prasugrel plus ASS nach elektiver PCI) und n = 3 Treffer RCT (Prasugrel plus ASS nach akutem Koronarsyndrom)

bis Mai 2023 n = 1 Treffer (IQWiG Rapid Report, Clopidogrel, Prasugrel, Ticagrelor bei akutem Koronarsyndrom)

Systematische Suche nach aggregierter Evidenz und RCT (21.07.2017 – heute) s. u.

10.2.1 Strukturierte Suche (21. Juli 2017 – 10.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|--------------------------------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 07.2017 – 10.05.2023 |
| Suchbegriff: Clopidogrel, Prasugrel, Ticagrelor | |
| Treffer | 4 bzw. 3 bzw. 5 |

| Nr. | Suchfrage |
|-------------------------|-----------|
| Eingeschlossene Treffer | 1 |

A21-41 Clopidogrel, Prasugrel und Ticagrelor zur Prävention atherothrombotischer Ereignisse bei akutem Koronarsyndrom (22.02.2023) – Rapid Report, https://www.iqwig.de/download/a21-41_clopidogrel-prasugrel-und-ticagrelor-beim-akuten-koronarsyndrom_rapid-report_v1-0.pdf

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | Clopidogrel, Prasugrel, Ticagrelor |
| Suchzeitraum | from July 2017 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE advice |
| Treffer | 0 |
| Eingeschlossene Treffer | 0 |
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab July 2017 bis 10.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|----------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

10.2.2 Medline via Pubmed (www.pubmed.gov) (12. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #27 | Search: (#21 AND #24) NOT (#25 OR #26) | 748 |
| #26 | Search: (#21 AND #23) NOT #25 | 808 |
| #25 | Search: #21 AND #22 | 322 |
| #24 | Search: cohort studies[mesh:noexp] OR longitudinal studies[mesh:noexp] OR follow-up studies[mesh:noexp] OR prospective studies[mesh:noexp] OR retrospective studies[mesh:noexp] OR cohort[TIAB] OR longitudinal[TIAB] OR prospective[TIAB] OR retrospective[TIAB] | 3,332,239 |
| #23 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,550,402 |
| #22 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] | 663,420 |

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| | OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta] OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | |
| #21 | Search: #18 AND #19 Filters: from 2017/7/21 – 3000/12/12 | 3,231 |
| #20 | Search: #18 AND #19 | 10,522 |
| #19 | Search: Clopidogrel*[tw] OR Prasugrel*[tw] OR Ticagrelor*[tw] | 18,641 |
| #18 | Search: #11 OR #17 | 461,529 |
| #17 | Search: #12 OR #13 OR #14 OR #15 OR #16 | 187,691 |
| #16 | Search: "Percutaneous Coronary Intervention"[Mesh] | 64,853 |
| #15 | Search: bare-metal stent*[tiab] OR bare metal stent*[tiab] OR BMS[tiab] | 11,095 |
| #14 | Search: drug-eluting stent*[tiab] OR drug eluting stent*[tiab] OR drug-coated stent*[tiab] OR drug coated stent*[tiab] OR DES[tiab] | 39,495 |
| #13 | Search: PCI[tiab] | 34,230 |
| #12 | Search: (percutaneous[tiab] OR coronary[tiab]) AND (intervention*[tiab] OR revascularization*[tiab]) | 119,174 |
| #11 | Search: #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 | 347,769 |
| #10 | Search: "Coronary Thrombosis"[Mesh] | 8,349 |
| #9 | Search: "Coronary Occlusion"[Mesh] | 4,360 |
| #8 | Search: acute[tiab] AND coronary[tiab] AND syndrome*[tiab] | 44,349 |
| #7 | Search: coronary[tiab] AND thrombosis*[tiab] | 18,318 |
| #6 | Search: "Myocardial Infarction"[Mesh] | 193,633 |
| #5 | Search: "Angina, Unstable"[Mesh] | 11,324 |
| #4 | Search: "Acute Coronary Syndrome"[Mesh] | 20,086 |
| #3 | Search: coronary[tiab] AND occlusion*[tiab] | 28,768 |
| #2 | Search: myocardial infarct*[tiab] OR heart attack*[tiab] OR post-myocardial[tiab] | 233,813 |
| #1 | Search: unstable[tiab] AND angina[tiab] | 14,779 |

Hinweis: stufenweises Vorgehen: nach Einschluss der SR, ggf. zeitliche Begrenzung der RCT

10.2.3 Datenbanken der Cochrane Library (12. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|----------------------------------------------------------------------------------------------------------|-------------|
| #21 | (#18 and #19) NOT (conference proceeding):pt in Trials; Year first published: from 2017 | 1419 |
| #20 | #18 and #19 in Cochrane Reviews, Cochrane Protocols; Publication date: from 2017/07/21 | 5 |
| #19 | (Clopidogrel or Prasugrel or Ticagrelor):ti,ab,kw | 7289 |
| #18 | #11 or #17 | 70743 |
| #17 | #12 or #13 or #14 or #15 or #16 | 43658 |
| #16 | MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees | 8417 |
| #15 | (bare-metal stent* or bare metal stent* or BMS):ti,ab,kw | 4241 |
| #14 | (drug-eluting stent* or drug eluting stent* or drug-coated stent* or drug coated stent* or DES):ti,ab,kw | 8234 |
| #13 | (PCI):ti,ab,kw | 10148 |
| #12 | ((percutaneous or coronary) and (intervention* or revascularization*)):ti,ab,kw | 33817 |
| #11 | #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 | 47208 |
| #10 | MeSH descriptor: [Coronary Thrombosis] explode all trees | 565 |
| #9 | MeSH descriptor: [Coronary Occlusion] explode all trees | 510 |
| #8 | (acute coronary syndrome*):ti,ab,kw | 8865 |
| #7 | (coronary thrombosis*):ti,ab,kw | 5062 |
| #6 | MeSH descriptor: [Myocardial Infarction] explode all trees | 13934 |
| #5 | MeSH descriptor: [Angina, Unstable] explode all trees | 1335 |
| #4 | MeSH descriptor: [Acute Coronary Syndrome] explode all trees | 3286 |
| #3 | (coronary occlusion*):ti,ab,kw | 3166 |
| #2 | (myocardial infarct* OR heart attack* OR post-myocardial):ti,ab,kw | 38730 |
| #1 | (unstable angina):ti,ab,kw | 4742 |

10.2.4 Epistemonikos (www.epistemonikos.org) (12. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | (advanced_title_en:((((percutaneous OR coronary) AND (intervention* OR revascularization*) OR PCI OR (drug-eluting stent* OR drug eluting stent* OR drug-coated stent* OR drug coated stent* OR DES) OR (bare-metal stent* OR bare metal stent* OR BMS) OR (acute AND coronary AND syndrome*) OR (coronary AND (thrombosis* OR occlusion*))) OR (unstable AND angina)) AND (Clopidogrel OR Prasugrel OR Ticagrelor)))) OR advanced_abstract_en:((((percutaneous OR coronary) AND (intervention* OR revascularization*) OR PCI OR (drug-eluting stent* OR drug eluting stent* OR drug-coated stent* OR drug coated stent* OR DES) OR (bare-metal stent* OR bare metal stent* OR BMS) OR (acute AND coronary AND syndrome*) OR (coronary AND (thrombosis* OR occlusion*))) OR (unstable AND angina)) AND (Clopidogrel OR Prasugrel OR Ticagrelor)))) [Filters: classification=systematic-review, protocol=no, min_year=2017, max_year=2023] | 248 |

10.2.5 Übersicht der eingeschlossenen Treffer

| | strukturiert | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|--------------|-------------|-------------|---------------|-------------|
| Aggregierte Evidenz | | 322 | 5 | 248 | 566 |
| RCTs | | 808 | 1419 | | 2214 |
| Langzeitstudien | | 748 | | | 732 |
| GESAMT | | 1878 | 1424 | 248 | 3550 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:

A1 (Dubletten): 996

A2 (nicht englisch/deutsch): 30

A3 (Conference Abstracts): 2


Eingeschlossene Treffer insgesamt nach Ausschlüssen: 2522 + n = 1 SR aus der strukturierten Recherche

Stufenweises Vorgehen

n = 369 Studienregistereinträge ausgeschlossen; n = 2154

- SR n = 360; RCT = 163; Langzeitbetrachtungen n = 731
- **e: SR: n = 360; RCT n = 332 (ab 2021, eingeschränktes Screening); Langzeitbetrachtungen n = 52 (in 2023, eingeschränktes Screening) → n = 744**

10.3 Flowchart



TiAb: SR n = 17*, RCT n = 15, Langzeitbetrachtungen n = 2

****Hinweis:** unter Ei (n = 86) zurückgestellt wurden SR, die interessant für die Wirksamkeit und Sicherheit im Vergleich der Wirkstoffe untereinander wären, allerdings auf Grund der Vielzahl der SR, NMA sowie Subgruppenanalysen (Mehrfachpublikation einzelner Studien) hier nicht betrachtet wurden; Auswahl s. Zusammenfassung

*aus der Recherche ergaben sich aktuelle systematische Übersichtsarbeiten zur Fragestellung, weshalb das RCT Screening eingeschränkt wurde auf den Zeitraum ab 2021; ergänzend wurden Langzeitbetrachtungen aus 2023 berücksichtigt

SR z. B.

Gelbenegger G. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A meta-analysis. *Vascul Pharmacol* 2021; 138:106858. <https://www.ncbi.nlm.nih.gov/pubmed/33753284>.

11 Recherche zu Anhang 8.1.7 der 5. Auflage 2019 (S. 124ff) Z.n. elektiver PCI bei stabiler KHK: Elektive PCI und Indikation zur OAK (Empfehlung 7-6 und Empfehlung 7-7)

11.1 PICO-Frage

- P** Patient*innen mit stabiler KHK, Z.n. elektiver PCI und Indikation zur OAK
I Duale Therapie (OAK plus ein Thrombozytenaggregationshemmer)
C Triple Therapie (OAK plus zwei Thrombozytenaggregationshemmer)
O Gesamtmortalität, kardiovaskuläre Mortalität, Myokardinfarkt, unerwünschte Wirkungen (v.a. Blutungen)

Studientyp: RCT, Metaanalysen, systematische Reviews

Sprache: englisch, deutsch

11.2 Recherchestrategien

Strukturierte Suche nach aggregierter Evidenz (03.05.2018 – 10.05.2023)

Hinweis: bis Mai 2018 n = 1 Treffer nach SR (Auf die Extraktion und Bewertung der älteren Reviews wurde aus Gründen der Redundanz verzichtet.)

Systematische Suche nach aggregierter Evidenz und RCT (11.01.2018 – heute)

Hinweis: bis Januar 2023 n = 3 Treffer

11.2.1 Strukturierte Suche (Mai 2018 – 10.05.2023)

IQWiG (www.iqwig.de)

| Nr. | Suchfrage |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Filter | Projekte, Abschlussberichte, Dossierbewertungen, Rapid Reports |
| Suchzeitraum | 05.2018 – 10.05.2023 |
| Suchbegriff: Antikoagulantien, Antikoagulanzen, Antikoagulation, Acetylsalicylsäure, Thrombozytenaggregation | |
| Treffer | 4 |
| Eingeschlossene Treffer | 0 |

NICE (www.nice.org.uk/guidance)

| Nr. | Suchfrage |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suchbegriffe | dual therapy, triple therapy, anticoagulants, Apixaban, Dabigatran, Edoxaban, Rivaroxaban, acetylsalicylic acid |
| Suchzeitraum | from May 2018 |
| 1. Filter | guidance (clinical guidelines, diagnostic guidance, NICE guidelines, Public health guidelines, Technology appraisal guidance, interventional procedure guidance, medical technology guidance, safe staffing guideline, social care guideline) published |
| Treffer | 7 |
| Eingeschlossene Treffer | 1 |
| 2. Filter | NICE advice |
| Treffer | 1 |
| Eingeschlossene Treffer | 0 |

| Nr. | Suchfrage |
|-----------|-----------------------|
| 2. Filter | NICE quality standard |
| Treffer | 0 |

Eingeschlossen:

- NICE-ER: Single Technology Appraisal Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [ID1397] Committee Papers. 17. Oktober 2019 <https://www.nice.org.uk/guidance/ta607/evidence/committee-papers-pdf-6955673437>

Interessante Zusatzinformation (nicht eingeschlossen):

- NICE Advice: DOAC Dipstick for detecting direct oral anticoagulants <https://www.nice.org.uk/advice/mib248>
- NICE Guidance: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban. 12. Mai 2021 <https://www.nice.org.uk/guidance/ta697>

Datenbanken der AHRQ (www.ahrq.gov/research/findings/evidence-based-reports/search.html)

| Kategorien | Suchbegriffe/ Filter (Zeitraum ab Mai 2018 bis 10.05.2023) | Treffer | Eingeschlossene Treffer |
|-------------------------------------------|---------------------------------------------------------------|---------|-------------------------|
| Full research report | Sichtung der Ergebnisliste ohne Eingabe von Suchbegriffen | 0 | 0 |
| Technology Assessment Program (completed) | | 0 | 0 |

11.2.2 Medline via Pubmed (www.pubmed.gov) (10. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| #24 | Search: (#20 AND #22) NOT #23 | 104 |
| #23 | Search: #20 AND #21 | 78 |
| #22 | Search: randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR "clinical trials as topic" [MeSH Terms:noexp] OR randomly [tiab] OR trial [ti] | 1,547,553 |
| #21 | Search: (systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta-analy*[ti] OR integrative review [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] OR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep [ta] OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation study[pt] OR validation study[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw] OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] | 660,920 |

| Nr. | Suchfrage | Anzahl |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| | OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]) | |
| #20 | Search: #6 AND #12 AND #17 AND #18 Filters: from 2018/1/11 - 3000/12/12 | 451 |
| #19 | Search: #6 AND #12 AND #17 AND #18 | 837 |
| #18 | Search: Triple therapy[tiab] OR triple-therapy[tiab] OR double therapy[tiab] OR double-therapy[tiab] OR double antiplatelet therapy[tiab] OR dual therapy[tiab] OR dual-therapy[tiab] OR dual antiplatelet therapy[tiab] | 15,189 |
| #17 | Search: #13 OR #14 OR #15 OR #16 | 167,583 |
| #16 | Search: "Anticoagulants"[Mesh] | 96,269 |
| #15 | Search: Phenprocoumon[tiab] OR Warfarin[tiab] OR Dabigatran[tiab] OR Rivaroxaban[tiab] OR Apixaban[tiab] OR Edoxaban[tiab] | 36,717 |
| #14 | Search: vitamin K antagonist*[tiab] OR non-vitamin K antagonist*[tiab] OR NOAC*[tiab] OR VKA[tiab] | 10,015 |
| #13 | Search: anticoagulant*[tiab] OR anticoagulation[tiab] | 114,959 |
| #12 | Search: #7 OR #8 OR #9 OR #10 OR #11 | 209,879 |
| #11 | Search: antiplatelet*[tiab] | 39,073 |
| #10 | Search: anti-thrombotic*[tiab] | 24,099 |
| #9 | Search: clopidogrel[tiab] OR ticagrelor[tiab] OR prasugrel[tiab] | 16,543 |
| #8 | Search: aspirin*[tiab] | 56,456 |
| #7 | Search: "Platelet Aggregation Inhibitors" [Pharmacological Action] | 154,241 |
| #6 | Search: #1 OR #2 OR #3 OR #4 OR #5 | 187,309 |
| #5 | Search: "Percutaneous Coronary Intervention"[Mesh] | 64,774 |
| #4 | Search: bare-metal stent*[tiab] OR bare metal stent*[tiab] OR BMS[tiab] | 11,073 |
| #3 | Search: drug-eluting stent*[tiab] OR drug eluting stent*[tiab] OR drug-coated stent*[tiab] OR drug coated stent*[tiab] OR DES[tiab] | 39,409 |
| #2 | Search: PCI[tiab] | 34,141 |
| #1 | Search: (percutaneous[tiab] OR coronary[tiab]) AND (intervention*[tiab] OR revascularization*[tiab]) | 118,905 |

11.2.3 Datenbanken der Cochrane Library (10. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| #20 | #6 and #12 and #17 and #18 in Trials; Year first published: from 2018 | 160 |
| #19 | #6 and #12 and #17 and #18 in Cochrane Reviews, Cochrane Protocols | 0 |
| #18 | (Triple therapy or triple-therapy or double therapy or double-therapy or double antiplatelet therapy or dual therapy or dual-therapy or dual antiplatelet therapy):ti,ab,kw | 223529 |
| #17 | #13 or #14 or #15 or #16 | 20338 |
| #16 | MeSH descriptor: [Anticoagulants] explode all trees | 6152 |
| #15 | (Phenprocoumon or Warfarin or Dabigatran or Rivaroxaban or Apixaban or Edoxaban):ti,ab,kw | 8350 |
| #14 | (vitamin K antagonist* or non-vitamin K antagonist* or NOAC* or VKA*):ti,ab,kw | 1652 |

| Nr. | Suchfrage | Anzahl |
|-----|----------------------------------------------------------------------------------------------------------|--------|
| #13 | (anticoagulant* or anticoagulation):ti,ab,kw | 16440 |
| #12 | #7 or #8 or #9 or #10 or #11 | 25623 |
| #11 | (antiplatelet*):ti,ab,kw | 7811 |
| #10 | (antithrombotic*):ti,ab,kw | 3187 |
| #9 | (clopidogrel or ticagrelor or prasugrel):ti,ab,kw | 7289 |
| #8 | (aspirin*):ti,ab,kw | 15840 |
| #7 | MeSH descriptor: [Platelet Aggregation Inhibitors] explode all trees | 5106 |
| #6 | #1 or #2 or #3 or #4 or #5 | 43658 |
| #5 | MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees | 8417 |
| #4 | (bare-metal stent* or bare metal stent* or BMS):ti,ab,kw | 4241 |
| #3 | (drug-eluting stent* or drug eluting stent* or drug-coated stent* or drug coated stent* or DES):ti,ab,kw | 8234 |
| #2 | (PCI):ti,ab,kw | 10148 |
| #1 | ((percutaneous or coronary) and (intervention* or revascularization*)):ti,ab,kw | 33817 |

11.2.4 Epistemonikos (www.epistemonikos.org) (10. Juli 2023)

| Nr. | Suchfrage | Anzahl |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| #1 | (title:(title:(percutaneous OR coronar) OR abstract:(percutaneous OR coronar))) OR abstract:(title:(percutaneous OR coronar) OR abstract:(percutaneous OR coronar))) AND (title:(intervention* OR revascularization*) OR PCI OR (drug-eluting stent* OR drug eluting stent* OR drug-coated stent* OR drug coated stent* OR DES OR bare-metal stent* OR bare metal stent* OR BMS)) OR abstract:(intervention* OR revascularization*) OR PCI OR (drug-eluting stent* OR drug eluting stent* OR drug-coated stent* OR drug coated stent* OR DES OR bare-metal stent* OR bare metal stent* OR BMS)) AND (title:(aspirin* OR clopidogrel OR ticagrelor OR prasugrel OR antithrombotic* OR antiplatelet* OR anticoagulant* OR vitamin K antagonist* OR non-vitamin K antagonist* OR NOAC* OR VKA* OR Phenprocoumon OR Warfarin OR Dabigatran OR Rivaroxaban OR Apixaban OR Edoxaban) OR abstract:(aspirin* OR clopidogrel OR ticagrelor OR prasugrel OR antithrombotic* OR antiplatelet* OR anticoagulant* OR vitamin K antagonist* OR non-vitamin K antagonist* OR NOAC* OR VKA* OR Phenprocoumon OR Warfarin OR Dabigatran OR Rivaroxaban OR Apixaban OR Edoxaban)) AND (title:(Triple therapy OR triple-therapy OR double therapy OR double-therapy OR double antiplatelet therapy OR dual therapy OR dual-therapy OR dual antiplatelet therapy) OR abstract:(Triple therapy OR triple-therapy OR double therapy OR double-therapy OR double antiplatelet therapy OR dual therapy OR dual-therapy OR dual antiplatelet therapy)) Publication type: Systematic review Publication year: 2018-2023 | 15 |

11.2.5 Übersicht der eingeschlossenen Treffer

| | strukturiert | Medline | Cochrane | Epistemonikos | Summe |
|---------------------|--------------|---------|----------|---------------|------------|
| Aggregierte Evidenz | | 78 | 0 | 15 | 93 |
| RCTs | | 104 | 160 | | 264 |
| GESAMT | | | | | 357 |

Anzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:


A1 (Dubletten): 58

A2 (nicht englisch/deutsch): 5

A3 (Conference Abstracts):

Eingeschlossene Treffer insgesamt nach Ausschlüssen: 294

11.3 Flowchart



TiAb: n = 14 SR*, n = 19 RCT + n = 2 Sonstige (gesamt n = 35)

**Hinweis: unter Ei (n = 49) zurückgestellt wurden SR und RCT, die interessant für die Wirksamkeit und Sicherheit wären, insbesondere zu AF, allerdings auf Grund der Vielzahl der SR, NMA sowie Subgruppenanalysen (Mehrfachpublikation einzelner Studien) hier nicht betrachtet wurden; Auswahl s. Zusammenfassung

*u. a. n = 1 für die Frage Dauer Triple aus 2019

E7-7 Shah R. Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: A meta-analysis of randomized clinical trials. Coron Artery Dis 2019; 30(2):116–23. <https://www.ncbi.nlm.nih.gov/pubmed/30589646>.

n = 2 für die Frage Dauer Dual aus 2023

E7-5 Costa F. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials. Eur Heart J 2023; 44(11):954–68. <https://www.ncbi.nlm.nih.gov/pubmed/36477292>.

E7-6 Montalto C. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2023; 9(3):220–30. <https://www.ncbi.nlm.nih.gov/pubmed/36427063>.

12 Evidenztabellen

12.1 Kapitel Epidemiologie

Porst et al. 2022 Krankheitslast in Deutschland


| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Porst M, Lippe Ev, Leddin J, et al. The Burden of Disease in Germany at the National and Regional Level-Results in Terms of Disability-Adjusted Life Years (DALY) from the BURDEN 2020 Study. Dtsch Arztebl Int 2022; 119(46):785-792. DOI: 10.3238/arztebl.m2022.0314. http://www.ncbi.nlm.nih.gov/pubmed/36350160. [1]</p> | <p>Objective Das Projekt BURDEN 2020 zielte darauf ab, auf Grundlage nationaler Daten eine eigenständige Krankheitslaststudie für Deutschland mit kleinräumigen Schätzungen als Pilotprojekt durchzuführen.</p> <p>Methods</p> <ul style="list-style-type: none"> - Public Health Surveillance - Bewertung der Krankheitslast der Bevölkerung - Global-Burden-of-Disease(GBD)-Studie - Datenquellen: v. a. Todesursachenstatistik, Befragungsdaten und Krankenkassenroutinedaten (alters-, geschlechts- und zumeist morbiditätsadjustiert) - DALY (Summe aus „durch Sterblichkeit verlorene Lebensjahre“ („years of life lost due to death“ [YLL]) und „mit gesundheitlichen Einschränkungen oder in Krankheit verbrachte Lebensjahre“ („years lived with disability“ [YLD]) | <p>für Deutschland (2017) gesamt</p> <ul style="list-style-type: none"> - 12,1 Millionen DALY (UI 11,9; 13,1) <ul style="list-style-type: none"> o Frauen 6,0 Millionen DALY (UI 5,9; 6,8) o Männer 6,1 Millionen DALY (UI 6,0; 6,6) - 14 584 DALY je 100 000 Einwohner (EW) <ul style="list-style-type: none"> o Frauen 14 303 DALY je 100 000 EW o Männer 14 872 DALY je 100 000 EW <p>KHK (koronare Herzkrankheit) trug am meisten zur Krankheitslast bei</p> <ul style="list-style-type: none"> - 2 321 DALY je 100 000 EW <ul style="list-style-type: none"> o Frauen 1 690 DALY je 100 000 EW o Männer 2 969 DALY je 100 000 EW - zu den Anteilen (YLD, YLL) vgl. Grafik 2 der Publikation (bei der KHK v. a. beeinflusst durch Todesfälle (YLL)): - Anteil der YLD (Morbidität) an der Krankheitslast <ul style="list-style-type: none"> o gesamt ~ 10 % o Frauen ~ 13 % o Männer ~ 7 % - Anteil der YLL (Mortalität) an der Krankheitslast <ul style="list-style-type: none"> o gesamt ~ 90 % o Frauen ~ 87 % o Männer ~ 93 % - mit dem Alter stieg die Krankheitslast für einen Teil der Erkrankungen, einschließlich der kardiovaskulären Erkrankungen - KHK – DALY je 100 000 EW im Altersverlauf <ul style="list-style-type: none"> o 25-29 Jahre: 43 o 30-34 Jahre: 92 | <p>n. a.</p> <p>Limitationen</p> <ul style="list-style-type: none"> - Auswahl an Erkrankungen im Pilotprojekt - Vielzahl an Datengrundlagen (diese sollten eine hohe Validität und räumliche Auflösung aufweisen) – hier sind spezifische Limitationen zu beachten - Ausgleichsmechanismen: z. B. morbiditätsadjustiertes Hochrechnungsverfahren sowie Plausibilitätsprüfungen - eingeschränkte Altersgruppen, da Prävalenzschätzungen für Kinder und Jugendliche nicht möglich waren | <p>Ergebnisse deuten auf alters- und geschlechtsspezifische Präventions- sowie kleinräumige Versorgungsbedarfe hin</p> <p>die Publikation enthält Grafiken z. B. zur räumlichen Verteilung der Krankheitslast in Deutschland (gesamt und krankheitsspezifisch) – Grafik 3 S. 790</p> <p>Ergebnisse des Projektes BURDEN 2020 gehen in ein Gesundheitssystem ein (www.daly.rki.de)</p> <p>die auf Krankenkassenroutinedaten basierenden epidemiologischen Kennzahlen, wie zum Beispiel Prävalenzen, nach Alter, Geschlecht und Region entstam-</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - YLL Abstand zwischen Todesalter und fernerer Lebenserwartung - YLD Jahre, die mit gesundheitlichen Einschränkungen verbracht werden <p>Outcome</p> <ul style="list-style-type: none"> - DALY „disability-adjusted life years“ (DALY) (Summe der Krankheitslast aus Mortalität („years of life lost due to death“ [YLL]) und Morbidität („years lived with disability“ [YLD]) (95%-Unsicherheitsintervalle [UI]) absolute Werte sowie rohe und altersstandardisierte Raten je 100 000 Einwohner (EW) im Jahr 2017 berichtet (europäische Standardbevölkerung 2013 | <ul style="list-style-type: none"> o 35-39 Jahre: 224 o 40-44 Jahre: 485 o 45-49 Jahre: 854 o 50-54 Jahre: 1 350 o 55-59 Jahre: 2 138 o 60-64 Jahre: 3 092 o 65-69 Jahre: 4 215 o 70-74 Jahre: 5 406 o 75-79 Jahre: 7 367 o 80-84 Jahre: 11 162 o 85-89 Jahre: 16 308 o 90-94 Jahre: 21 215 o 95+ Jahre: 24 962 <ul style="list-style-type: none"> - teilweise zeigte die Krankheitslast unterschiedliche regionale Verteilungen (96 Raumordnungsregionen (kurz ROR)); vgl. Grafik 3 der Publikation <ul style="list-style-type: none"> o für Deutschland gesamt (altersstandardisiert je 100 000 EW) <ul style="list-style-type: none"> ▪ Regionen Emscher-Lippe (Nordrhein-Westfalen) und Bremerhafen mit der höchsten Krankheitslast im Bereich von 10 492 bis 11 460 DALY je 100 000 EW ▪ Auch Sachsen-Anhalt und Teile von Thüringen und Mecklenburg-Vorpommern sowie das Saarland befinden sich in diesem Klassifikationsbereich o KHK (altersstandardisiert je 100 000 EW) <ul style="list-style-type: none"> ▪ im Osten Deutschlands höhere Krankheitslast ▪ z. B. Sachsen-Anhalt im Bereich von 2 601 bis 2 977 DALY pro 100 000 EW (altersstandardisiert) | | <p>men dem Wissenschaftlichen Instituts der AOK (WIdO) (www.krankheitslage-deutschland.de)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> z. B. Mecklenburg Vorpommern im Bereich von 2 308 bis 2 601 DALY je 100 000 EW (altersstandardisiert) | | |

Robert Koch-Institut 2022 Ergebnisdatensatz BURDEN 2020

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| <p>Robert Koch-Institut (2022): Ergebnisdatensatz BURDEN 2020 – Krankheitslast in Deutschland und seinen Regionen, Berlin:Zenodo. DOI: 10.5281/zenodo.7323766 www.daly.rki.de/map [z. g. 29.09.2023] [2]</p> | <p>s. o. Porst et al. 2022 Krankheitslast in Deutschland</p> | <p>Krankheitslast KHK Regionaler Vergleich; [z. g. 29.09.2023] (Länder, DALY (je 100 000 EW), Level 3, Alle Geschlechter, Altersstandardisiert, gesamt, Koronare Herzkrankheit)</p> <ul style="list-style-type: none"> - Baden-Württemberg 1 788 - Bayern 1 956 - Berlin 1 934 - Brandenburg 2 448 - Bremen 2 291 - Hamburg 1 704 - Hessen 2 001 - Mecklenburg-Vorpommern 2 509 - Niedersachsen 2 123 - Nordrhein-Westfalen 1 947 - Rheinland-Pfalz 2 164 - Saarland 2 410 - Sachsen 2 319 - Sachsen-Anhalt 2 900 - Schleswig-Holstein 2 136 - Thüringen 2 501 | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p style="text-align: center;">DALY – Karte</p>  <p>Robert Koch-Institut (2022): Ergebnisdatensatz BURDEN 2020 – Krankheitslast in Deutschland und seinen Regionen, Berlin:Zenodo. DOI: 10.5281/zenodo.7323766 https://www.daly.rki.de/map [z. g. 29.09.2023]</p> | | |

Robert Koch-Institut 2021 Ergebnisse GEDA 2019/2020-EHIS

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| Robert Koch-Institut (RKI). Gesundheitliche Lage der erwachsenen Bevölkerung in Deutschland – Ergebnisse der Studie GEDA 2019/2020-EHIS. J Health Monit 2021; 6(3). [3] | <p>Ziel</p> <ul style="list-style-type: none"> - Darstellung der gesundheitlichen Lage in Deutschland - Ableitung der Public-health Relevanz sowie des Einflusses auf den Versorgungsbedarf <p>Methodik</p> <ul style="list-style-type: none"> - bundesweite Befragungsstudie Gesundheit in Deutschland (GEDA 2019/2020-EHIS) - April 2019 und September 2020 - ausgewählte Indikatoren - Erwachsene Bevölkerung ab 18 Jahre (n = 22 708) - ab dem mittleren Erwachsenenalter (ab 45 Jahre) schrittweiser Prävalenzanstieg chronischer Erkrankungen <p>Ereignisse (u.a.)</p> <ul style="list-style-type: none"> - Betehen einer KHK (d. h. eines Herzinfarktes, chronischer Beschwerden infolge eines Herzinfarktes, einer koronaren Herzerkrankung oder einer Angina pectoris) | <p>Kardiometabolische Erkrankungen</p> <ul style="list-style-type: none"> - Bestehen einer KHK: 5,8% (95% KI 5,4; 6,3%) in den letzten 12 Monaten <ul style="list-style-type: none"> o Frauen 5,1% (95% KI 4,5; 5,7) o Männer 6,6% (95% KI 5,9; 7,4) - Frauen - Altersgruppe (in % (95% KI)) <ul style="list-style-type: none"> o 18 – 29 Jahre 0,8 (0,5 – 1,4) o 30 – 44 Jahre - o 45 – 64 Jahre 3,6 (2,7 – 4,6) o 65 – 79 Jahre 9,2 (7,8 – 10,9) o ≥ 80 Jahre 18,9 (15,3 – 23,1) - Bildungsstatus (in % (95% KI)) <ul style="list-style-type: none"> o Untere Bildungsgruppe 9,8 (7,7 – 12,4) o Mittlere Bildungsgruppe 4,3 (3,7 – 5,0) o Obere Bildungsgruppe 2,3 (1,9 – 2,8) - Männer - Altersgruppe (in % (95% KI)) <ul style="list-style-type: none"> o 18 – 29 Jahre 0,4 (0,2 – 0,8) o 30 – 44 Jahre - o 45 – 64 Jahre 6,4 (5,2 – 7,7) o 65 – 79 Jahre 16,5 (14,2 – 19,1) o ≥ 80 Jahre 21,9 (17,7 – 26,8) - Bildungsstatus (in % (95% KI)) <ul style="list-style-type: none"> o Untere Bildungsgruppe 6,5 (4,3 – 9,6) o Mittlere Bildungsgruppe 7,1 (6,1 – 8,2) o Obere Bildungsgruppe 5,8 (5,2 – 6,5) | n. a. | |

RKI Gesundheit in Deutschland 2015 (Todesursachenstatistik)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Robert Koch-Institut, editor. Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. Berlin: RKI; 2015. www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtld/gesundheit_in_deutschland_2015.pdf</p> <p>[4]</p> | <p>Ziel Bericht soll die evidenzbasierte Entscheidungen für mehr Gesundheit in Deutschland unterstützen</p> <p>Hintergrund elf Kapitel, die einen Überblick über den Stand und die Entwicklung der Gesundheit der Menschen in Deutschland im Jahr 2015 geben</p> <p>breite Datenbasis zum Erkrankungsspektrum, der Verteilung von Risikofaktoren, die Inanspruchnahme von Prävention und Gesundheitsversorgung größter Einfluss durch die demografischen Veränderungen sozialen Lage Qualitätssicherung der Kapitel (u. a. durch die Kommission »Gesundheitsberichterstattung und Gesundheitsmonitoring« (GBEMON))</p> <p>Quellen/Datengrundlage aus u. a. regelmäßigen großen bevölkerungsbezogene Gesundheits-erhebungen werden bevölkerungsrepräsentative Querschnittsanalysen zu einem breiten Themenspektrum ermöglicht; darüber hinaus Trendauswertungen und längsschnittliche Analysen KiGGS (»Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland«, Basiserhebung und Welle 1),</p> | <p>2.1.3 Todesursachenstatistik (S. 24ff) Altersstruktur der Verstorbenen und Todesursachen (nach ICD-10) in 2013</p> <p>84,4% der Gestorbenen ≥ 65 Jahre alt 64,9% der gestorbenen Frauen und 39,9% der gestorbenen Männer waren ≥ 85 Jahre alt 0,3% der Verstorbenen waren jünger als 1 Jahr (n = 982 Mädchen, n = 1.268 Jungen) Frauen vs. Männer: häufiger an Herz-Kreislauf-Erkrankungen (43,3 % bzw. 35,7 %), seltener an bösartigen Neubildungen (25,8 % bzw. 29,1 %) sowie an Verletzungen oder Vergiftungen (3,0 % bzw. 4,8 %) bei Krankheiten von Atmungs- oder Verdauungssystem ist die Differenz gering Veränderung im Stellenwert verschiedener Todesursachen im gesamten Sterbegeschehen (altersstandardisierte Sterberaten), Referenzpopulation = Bevölkerung der Bundesrepublik Deutschland im Jahr 1987 zwischen 1993 und 2013 hat sich die altersstandardisierte Sterberate für Herz- und Kreislauf-Erkrankungen (ICD-10: I00 – I99) nahezu halbiert bei Frauen von 561 auf 298 und bei Männern von 456 auf 228 je 100.000 Einwohner es sank der Anteil der Herz- und Kreislauf-Erkrankungen an den Todesursachen von 53,4 % auf 43,3 % bei Frauen und von 44,2 % auf 35,7 % bei Männern steigende Sterberaten gab es bei einigen selteneren Todesursachen wie Psychischen Störungen und Verhaltensstörungen (ICD-10: F00 – F99), bedingt v.a. durch die häufigere Angabe von Demenz als Todesursache, Infektiösen und parasitären Krankheiten (ICD-10: A00 – B99) sowie Krankheiten des Urogenitalsystems (ICD-10: N00 – N99) (< 28 Verstorbene je 100.000 Einwohner)</p> | <p>n. a.</p> | <p>elektronische Informationssystem der GBE: www.gbe-bund.de</p> <p>dritter bundesweiter Gesundheitsbericht für Deutschland (Vorversionen aus 1998 und 2006); der Bericht aus 2015 wurde nicht mehr aktualisiert</p> <p>in der Online-Version gibt es Verknüpfungen zu den jeweils aktuellen Daten des Statistischen Bundesamtes und anderer Datenhalter (Deep Links); Feedback zum Bericht kann gegeben werden unter: gbe@rki.de</p> <p>gesundheitliche Entwicklung über 20 Jahre sowie Weiterentwicklung in der Gesundheitsberichterstattung abgebildet (lernfähiger Entwicklungsprozess; flexibel und offen für Veränderungen)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>DEGS1 («Studie zur Gesundheit Erwachsener in Deutschland») und GEDA («Gesundheit in Deutschland aktuell» 2009, 2010, 2012), auch europaweit durchgeführte European Health Interview Survey integriert (GEDA 2014/2015-EHIS)</p> <p>weitere Gesundheitssurveys und epidemiologische Studien, Daten von Krankheitsregistern (zum Beispiel Krebs-, Herzinfarkt und Schlaganfallregister), Routinedaten der Sozialversicherungsträger (etwa der gesetzlichen Krankenkassen und der Deutschen Rentenversicherung Bund), amtliche Statistiken (wie die Todesursachenstatistik oder die Krankenhausdiagnosestatistik) und sozialwissenschaftliche Erhebungen (darunter das Sozio-oekonomische Panel)</p> <p>auch das vom Statistischen Bundesamt koordinierte elektronische Informationssystem der GBE (www.gbe-bund.de) gehört zur GBE; für bestimmte Fragestellungen hat das Statistische Bundesamt Sonderauswertungen erstellt</p> <p><i>Hinweis:</i> in der amtliche Bevölkerungsstatistik (z. B. Erkrankungs- oder Sterberaten) gab es einen Wechsel in der Datengrundlage: Ab 2011 erfolgt die Bevölkerungsfortschreibung auf Basis von aktuellen</p> | <p>39,7% der Sterbefälle Krankheiten des Kreislaufsystems (ICD-10: I00-I99) 25,0% Krebserkrankungen (ICD-10: C00-C97) 7,3 % Krankheiten des Atmungssystems (ICD-10: J00 – J99) 4,5 % Krankheiten des Verdauungssystems (ICD-10: K00 – K93) 3,8% Verletzungen und Vergiftungen (ICD-10: S00 – T98) übrigen 19,7 % andere Krankheiten</p> <p>10 häufigste Diagnosen unter den Todesursachen (2013, nach Statistisches Bundesamt (2014) Todesursachenstatistik ab 1998. Sterbefälle, Sterbeziffern (je 100.000 Einwohner, altersstandardisiert) www.gbe-bund.de (Stand: 15.04.2015))</p> <p>Frauen, Anteil in % Ischämische Herzkrankheiten (I20-I25) 13,3% Zerebrovaskuläre Krankheiten (I60-I69) 7,6% Herzinsuffizienz (I50) 6,5% Alzheimer-Krankheit und andere Demenz (F01, F03, G30) 5,2% Hypertensive Herzkrankheit / Herz- und Nierenkrankheit (I11, I13) 4,6% Brustkrebs (C50) 3,8% Lungenkrebs (C33-C34) 3,3% Chronische Krankheiten der unteren Atemwege (J40-J47) 3,2% Diabetes mellitus (E10-E14) 3,0% Darmkrebs (C18-C21) 2,6% Summe 53%</p> <p>Männer Ischämischen Herzkrankheiten (I20-I25) 15,6% Lungenkrebs (C33-C34) 6,9% Zerebrovaskuläre Krankheiten (I60-I69) 5,4% Chronische Krankheiten der unteren Atemwege (J40-J47) 4,2% Herzinsuffizienz (I50) 3,7% Darmkrebs (C18-C21) 3,2% Prostatakrebs (C61) 3,1% Unfälle (V01-X59) 2,6%</p> | | <p>im Gesundheitsbericht aus 2015 ist die soziale Differenzierung sowohl auf individueller als auch auf regionaler Ebene ein durchgehender Aspekt, die Unterscheidung zwischen alten und neuen Ländern kommt kaum noch vor</p> <p>es erfolgt ein Hinweis darauf, dass die Zuwanderung zukünftig Einfluss auf die Altersstrukturen haben kann (Zuwanderung von Menschen unter 40 Jahren und Kindern)</p> <p>neben dem Anstieg der Lebenserwartung in den vergangenen 20 Jahren auch ein allgemeiner Rückgang der todesursachenspezifischen Sterberaten vieler bedeutender Krankheiten</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Zensusdaten, deshalb ist die Vergleichbarkeit zu den Vorjahren eingeschränkt</p> <p>Definition (wichtige Indikatoren): Prävalenz: Krankheitsverbreitung, Anteil der Personen in einer Bevölkerung, die beispielsweise an einem Stichtag (Punktprävalenz), innerhalb eines Jahres (12-Monats-Prävalenz) oder im Verlauf ihres bisherigen Lebens (Lebenszeitprävalenz) unter einer bestimmten Krankheit leiden</p> <p>Inzidenz: Häufigkeit von Neuerkrankungen in einem bestimmten Zeitraum (z. B. ein Jahr), Anzahl der Neuerkrankungen oder als Anzahl der Neuerkrankungen pro 100.000 Personen (Neuerkrankungsrate)</p> <p>Mortalität: Sterblichkeit in einem bestimmten Zeitraum (z. B. ein Jahr), Anzahl der Sterbefälle oder als Anzahl der Sterbefälle pro 100.000 Personen (Sterberate) (Gesamtsterblichkeit oder krankheitsbezogen; meist altersstandardisiert)</p> <p>Altersstandardisierte Raten: Altersstandardisierung wird verwendet, um Erkrankungs- und Sterbehäufigkeiten von Bevölkerungsgruppen mit unterschiedlicher</p> | <p>Alzheimer-Krankheit und andere Demenz (F01, F03, G30) 2,5% Diabetes mellitus (E10-E14) 2,4% Summe 49,6%</p> <p>Einflussfaktoren (vorzeitige Sterblichkeit) Bezug auf Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) für die Jahre 1990 und 2010: Ernährung, Übergewicht, Bluthochdruck Rauchen</p> <p>2.3 Herz-Kreislauf-Erkrankungen (ICD-10: I00-I99) (S. 38ff) die häufigste Todesursache bei Frauen und Männern in Deutschland höchsten Kosten: 2008 wurden 14,5 % der direkten Krankheitskosten (rund 37 Milliarden Euro) verursacht durch Herz-Kreislauf-Erkrankungen größte Rolle spielen dabei die koronare Herzkrankheit (KHK) und der Schlaganfall insgesamt stetiger Rückgang der Sterberaten für Herz-Kreislauf-Erkrankungen (Fortschritt in Prävention und Therapie) als Risikofaktoren für Herz-Kreislauf-Erkrankungen angegeben: Rauchen, Adipositas, Bewegungsarmut, Fettstoffwechselstörungen, Bluthochdruck und Diabetes</p> <p>Prävalenz (GEDA, 2009-2010): KORONARE HERZKRANKHEIT (ICD-10: I20 – I25) UND AKUTER HERZINFARKT (ICD-10: I21 – I22) Durchblutungsstörung am Herzen oder ein Herzinfarkt (durch Arzt diagnostiziert) bei 6,6 % der Frauen und 9,6 % der Männer</p> | | |


| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Altersstruktur zu vergleichen; auch bei Zeitvergleichen</p> <p>(auf eine Standardbevölkerung mit einer festgelegten Altersverteilung übertragen; hier überwiegend die sogenannte »alte Europastandardbevölkerung«, so lässt sich bspw. die Entwicklung von Erkrankungen und Todesursachen im Zeitverlauf beurteilen, ohne dass demografische Veränderungen wie ein zunehmender Anteil älterer Menschen das Geschehen überlagern)</p> <p>Sterblichkeit Sterblichkeitsverhältnisse werden in Sterbetafeln abgebildet; basieren auf dem nach Alter und Geschlecht differenzierten Verhältnis zwischen den registrierten Sterbefällen und dem Bevölkerungsstand (ermittelt durch das Statistische Bundesamt auf Basis von Volkszählungen)</p> <p>Todesursachen Todesursachenstatistik gibt Aufschluss über die wichtigsten Todesursachen und ihre zeitliche Entwicklung; Daten stammen aus der Auswertung der ärztlichen Todesbescheinigungen; auf Basis der Bestattungsgesetze der Länder für alle Verstorbenen sowie für Totgeborene ab einem Geburtsgewicht von 500 g ausgestellt</p> | <p>Ende 2010 2.481.000 Frauen und 3.349.000 Männer an einer koronaren Herzkrankheit erkrankt</p> <p>Sterblichkeit koronare Herzkrankheit (KHK) bei Frauen und Männern die häufigste Todesursache in 2013 starben in Deutschland laut amtlicher Todesursachenstatistik insgesamt 61.633 Frauen und 67.175 Männer an einer KHK entspricht 13,3 % aller Todesfälle bei Frauen und 15,6 % aller Todesfälle bei Männern davon verstarben 23.916 Frauen und 30.622 Männer (5,2 % bzw. 7,1 % aller Todesfälle) an einem Herzinfarkt im Zeitraum von 1998 bis 2013 zeigt sich ein kontinuierlicher Rückgang der altersstandardisierten Sterberaten aufgrund einer KHK – wie auch in anderen hochentwickelten Ländern Westeuropas, in Australien und in den USA in Deutschland sank die Sterberate durch KHK insgesamt zwischen 1998 und 2013 bei Frauen von 102,5 auf 51,4 und bei Männern von 197,2 auf 105,0 je 100.000 Einwohner (Sterberaten standardisiert auf die alte Europastandardbevölkerung) regionale Unterschiede</p> <p>begründend für die geringere Sterblichkeit angegeben werden u. a.</p> <p>“kombinierte Effekte von verändertem Gesundheitsverhalten und zunehmend leitliniengerechter Behandlung”</p> <p>Veränderungen in der Therapie: “Langzeitbehandlung von Personen mit kardiovaskulären Risikofaktoren oder bereits bestehenden arteriosklerotischen Gefäßerkrankungen wird zunehmend an das individuelle Risiko für das Auftreten eines Herzinfarktes oder Schlaganfalls angepasst” “In der Akutbehandlung von Herzinfarkt und Schlaganfall werden invasive und medikamentöse Maßnahmen zur Wiederherstellung der Durchblutung des Herzens beziehungsweise des Gehirns mit messbaren Erfolgen eingesetzt.”</p> | | |


| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | “Eine zeitgemäße Akutversorgung geschieht heute in spezialisierten Einheiten” <i>Hinweis:</i> zitiert werden hier v. a. die Leitlinien der ESC | | |

Wissenschaftlichen Instituts der AOK (WIdO). Krankheitslage-Deutschland.de

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Wissenschaftlichen Instituts der AOK (WIdO). Krankheitslage-Deutschland.de www.krankheitslage-deutschland.de [z. g. 29.09.2023] [5] (Überblicksartikel: Breitzkreuz et al. Krankheitslastbestimmung mit Prävalenzen und Schweregraden auf Routinedatenbasis. GGW 2021. Jg. 21, Heft 1 (Januar), 24–34 | Objective Transparenz zur gesundheitlichen Beeinträchtigung bei ausgewählten Krankheiten unter allen Einwohnern in den Regionen Deutschlands <ul style="list-style-type: none"> - Ermittlung der gesundheitlichen Beeinträchtigung der Bevölkerung im Rahmen einer Krankheitslastberechnung Methods <ul style="list-style-type: none"> - Wissenschaftliche Institut der AOK (WIdO) - Robert Koch-Institut - Umweltbundesamt - Forschungsprojekt BURDEN 2020 - „Global Burden of Disease“ (GBD)-Studie - Todesursachenstatistik, Befragungsdaten, Umweltdaten, Routinedaten - etabliertes methodisches Instrumentarium aus drei Säulen: <ul style="list-style-type: none"> o Abrechnungsdaten der > 27 Millionen AOK-Versicherten o Prävalenzkonzepts, das die | 1-Jahresprävalenz (Berichtsjahr 2017) Anzahl bundesweit (Deutschland): 4,91 Mio aus 82,7 Mio Menschen absolut (5,94%) <ul style="list-style-type: none"> - Baden-Württemberg (BW) 528 Tsd. (Prävalenz 4,80%) - Bayern (BY) 661 Tsd. (Prävalenz 5,10%) - Berlin (BE) 183 Tsd. (Prävalenz 5,09%) - Brandenburg (BR) 200 Tsd. (Prävalenz 7,98%) - Bremen (HB) 35,3 Tsd. (Prävalenz 5,19%) - Hamburg (HH) 83,4 Tsd. (4,58%) - Hessen (HE) 330 Tsd. (5,30%) - Mecklenburg-Vorpommern (MV) 126 Tsd. (Prävalenz 7,81%) - Niedersachsen (NI) 454 Tsd. (Prävalenz 5,71%) - Nordrhein-Westfalen (NW) 1,11 Mio (Prävalenz 6,22%) - Rheinland-Pfalz (RP) 246 Tsd. (Prävalenz 6,05%) - Saarland (SL) 71,8 Tsd. (Prävalenz 7,21%) - Sachsen (SN) 204 Tsd. (Prävalenz 7,45%) - Sachsen-Anhalt (ST) 226 Tsd. (Prävalenz 10,2%) - Schleswig-Holstein (SH) 166 Tsd. (Prävalenz 5,75%) - Thüringen (TH) 183 Tsd. (Prävalenz 8,47%) Anzahl bundesweit (Deutschland) Frauen 2,10 Mio aus 41,9 Mio gesamt (5,01%) Männer 2,81 Mio aus 40,8 Mio gesamt (6,90%) nach Alter <ul style="list-style-type: none"> - 20-44 Jahre 70,5 Tsd. (Prävalenz 0,281%) <ul style="list-style-type: none"> o Frauen 25,8 Tsd. (Prävalenz 0,21%) o Männer 44,7 Tsd. (Prävalenz 0,35%) | n. a. | Methodendokument online verfügbar: https://krankheitslage-deutschland.de/dokumente/Methodendokumentation.pdf |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Herausforderung beim Umgang mit einer dynamischen, offenen Kohorte berücksichtigt</p> <ul style="list-style-type: none"> alters-, geschlechts- und morbiditätsadjustierendes Hochrechnungsverfahren, das Aussagen über alle Einwohner in den Regionen Deutschlands erlaubt <p>Berichtsjahr 2017</p> <p>Schweregrade bzw. Folgezustände sind als BURDEN 2020-spezifische Schweregrade im Sinne der Krankheitslastberechnung und nicht als klinische Schweregrade da einige BURDEN-Schweregrad-Zustände selten vorliegen, wird ausschließlich eine bundesweite Hochrechnung nach Alter und Geschlecht – ohne Anwendung des morbiditätsadjustierenden Verfahrens und ohne regionale Differenzierung - umgesetzt</p> <p>Outcomes</p> | <ul style="list-style-type: none"> 45-59 Jahre 608 Tsd. (Prävalenz 3,13%) <ul style="list-style-type: none"> Frauen 185 Tsd. (Prävalenz 1,92%) Männer 422 Tsd. (Prävalenz 4,33%) 60-69 Jahre 993 Tsd. (Prävalenz 9,96%) <ul style="list-style-type: none"> Frauen 343 Tsd. (Prävalenz 6,67%) Männer 649 Tsd. (Prävalenz 13,5%) 70-74 Jahre 625 Tsd. (Prävalenz 17,2%) <ul style="list-style-type: none"> Frauen 238 Tsd. (Prävalenz 12,3%) Männer 387 Tsd. (22,8%) 75-79 Jahre 994 Tsd. (Prävalenz 23,2%) <ul style="list-style-type: none"> Frauen 423 Tsd. (Prävalenz 17,7%) Männer 571 Tsd. (Prävalenz 30,0%) 80-84 Jahre 849 Tsd. (Prävalenz 30,4%) <ul style="list-style-type: none"> Frauen 415 Tsd. (Prävalenz 25,2%) Männer 433 Tsd. (Prävalenz 37,9%) 85+ Jahre 773 Tsd. (Prävalenz 35,2%) <ul style="list-style-type: none"> Frauen 467 Tsd. (Prävalenz 30,1%) Männer 306 Tsd. (Prävalenz 43,2%) | | |




| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|----------|----------|-------|-----|-----|------|-------|------|------|------|-------|------|------|------|-------|------|------|------|-------|------|------|------|-------|------|------|------|-----|------|------|------|--|--|
| | <ul style="list-style-type: none"> - Berechnung der Krankheitsprävalenzen zur Bestimmung der Krankheitslage in Deutschland | <p>▼ Anzahl nach Alter und Geschlecht</p>  <table border="1"> <caption>Estimated data from the bar chart 'Anzahl nach Alter und Geschlecht'</caption> <thead> <tr> <th>Alter</th> <th>♂ (Tsd.)</th> <th>♀ (Tsd.)</th> <th>Σ (Tsd.)</th> </tr> </thead> <tbody> <tr> <td>20-44</td> <td>~50</td> <td>~50</td> <td>~100</td> </tr> <tr> <td>45-59</td> <td>~150</td> <td>~250</td> <td>~400</td> </tr> <tr> <td>60-69</td> <td>~300</td> <td>~350</td> <td>~650</td> </tr> <tr> <td>70-74</td> <td>~250</td> <td>~350</td> <td>~600</td> </tr> <tr> <td>75-79</td> <td>~400</td> <td>~500</td> <td>~900</td> </tr> <tr> <td>80-84</td> <td>~350</td> <td>~450</td> <td>~800</td> </tr> <tr> <td>85+</td> <td>~250</td> <td>~450</td> <td>~700</td> </tr> </tbody> </table> | Alter | ♂ (Tsd.) | ♀ (Tsd.) | Σ (Tsd.) | 20-44 | ~50 | ~50 | ~100 | 45-59 | ~150 | ~250 | ~400 | 60-69 | ~300 | ~350 | ~650 | 70-74 | ~250 | ~350 | ~600 | 75-79 | ~400 | ~500 | ~900 | 80-84 | ~350 | ~450 | ~800 | 85+ | ~250 | ~450 | ~700 | | |
| Alter | ♂ (Tsd.) | ♀ (Tsd.) | Σ (Tsd.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20-44 | ~50 | ~50 | ~100 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 45-59 | ~150 | ~250 | ~400 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 60-69 | ~300 | ~350 | ~650 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 70-74 | ~250 | ~350 | ~600 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 75-79 | ~400 | ~500 | ~900 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 80-84 | ~350 | ~450 | ~800 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 85+ | ~250 | ~450 | ~700 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Kardiovaskuläre Erkrankungen Koronare Herzkrankheit 1-Jahresprävalenz</p> <p>Prävalenz in %</p> <ul style="list-style-type: none"> 10,20 7,98 7,21 5,75 5,19 4,58 | | |

Zentralinstitut für die kassenärztliche Versorgung (Zi) – Versorgungsatlas – Dashboard – Koronare Herzkrankheit (2021)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland (Zi). Versorgungsatlas – Dashboard häufige chronische Krankheiten www.versorgungsatlas.de/dashboard/#/evaluation/1005 [z. g. 29.09.2023] [6]</p> | <p>Hintergrundinformation: www.versorgungsatlas.de/fileadmin/pdf/Dashboard/Versorgungsatlas-Dashboard_ID-1005_KHK1.pdf</p> <p>Quelle</p> <ul style="list-style-type: none"> - Dashboard - basierend auf bundesweiten pseudonymisierten, krankenkassenübergreifenden vertragsärztlichen Abrechnungsdaten gemäß § 295 SGB V - 2015-2021 - Grundlage ärztlicher Diagnosecode (ICD-10-GM) - Prävalente Fälle (mind. 2 Quartale im Beobachtungsjahr mit Zusatzkennzeichen („gesichert“): <ul style="list-style-type: none"> o für KHK: I20. , I21. , I22. , I23. , I24. , I25 - rohe und alters- bzw. geschlechtsstandardisiert | <p>Berichtszeitraum 2021 4 321,618 absolut standardisierte Diagnoseprävalenz (Koronare Herzkrankheit) 5,72 %</p> <ul style="list-style-type: none"> - Frauen: 3,87 % - Männer: 8,20 % - Verhältnis Männer : Frauen (2021): 1,52 - Veränderung seit 2021: -105 316 (-2,4 %) | <p>n. a.</p> | <p>weitere Details s. a. Holstiege J, Akmatov MK, Steffen A, Bätzing J. Die ischämische Herzerkrankung in der vertragsärztlichen Versorgung – Zeitliche Trends und regionale Variationen. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi). Versorgungsatlas Bericht Nr. 20/04. Berlin 2020. URL: https://doi.org/10.20364/VA.20.04</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Diagnoseprävalenz (%) pro KV-Bereich, Kassenärztliche Vereinigung (2021)</p> <p>Roh Standardisiert</p>  <p>Diagnoseprävalenz nach Alters- und Geschlechtsgruppen (2021)</p> <ul style="list-style-type: none"> - 0-14 Jahre <ul style="list-style-type: none"> o Frauen 0,00% o Männer 0,00% | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - 15-19 Jahr <ul style="list-style-type: none"> o Frauen 0,01% o Männer 0,01% - 20-29 Jahre <ul style="list-style-type: none"> o Frauen 0,03% o Männer 0,04% - 30-39 Jahre <ul style="list-style-type: none"> o Frauen 0,11% o Männer 0,22% - 40-49 Jahre <ul style="list-style-type: none"> o Frauen 0,52% o Männer 1,45% - 50-59 Jahre <ul style="list-style-type: none"> o Frauen 1,97% o Männer 6,01% - 60-69 Jahre <ul style="list-style-type: none"> o Frauen 5,73% o Männer 15,05% - 70-79 Jahre <ul style="list-style-type: none"> o Frauen 12,74% o Männer 26,60% - 80-89 Jahre <ul style="list-style-type: none"> o Frauen 21,93% o Männer 37,70% - ≥90 Jahre <ul style="list-style-type: none"> o Frauen 27,62% o Männer 42,77% <p>Diagnoseprävalenz nach KV-Bereich (2021)</p> <p>Baden-Württemberg 4,86%</p> <p>Hamburg 5,20%</p> <p>Bayern 5,21%</p> <p>Bremen 5,25%</p> <p>Hessen 5,46%</p> <p>Niedersachsen 5,47%</p> <p>Westfalen-Lippe 5,70%</p> <p>Sachsen 5,71%</p> <p>Berlin 5,79%</p> <p>Rheinland-Pfalz 5,84%</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | Schleswig-Holstein 5,86% Nordrhein 6,18% Brandenburg 6,54% Mecklenburg-Vorpommern 6,67% Thüringen 6,68% Saarland 6,69% Sachsen-Anhalt 8,00% | | |

12.2 Kapitel Diagnostik

Risikoeinschätzung

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| 33523 | Evidenzbericht 2023 zur: S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung, in Überarbeitung, geplante Fertigstellung: 30.09.2023: https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung [7,8] | 2023 | Fragestellung unterschiedliche Fragestellungen aktualisiert bzw. untersucht, von besonderer Relevanz K1: Welche diagnostische Aussagekraft haben klinische Vorhersageregeln (gegebenenfalls einzelne Symptome, Zeichen und Risikofaktoren) hinsichtlich der Diagnose einer Koronaren Herzkrankheit (KHK) bei Patienten mit Brustschmerz in der Primärversorgung? Studientyp Leitlinie bzw. Evidenzberichte zur Leitlinie, in der Aktualisierung, Update der Evidenz u. a. zum Marburger Herz-Score (Evidenzberichte vgl. Anhang zur LL bzw. zum LL-Report) systematische Recherche in Medline, Embase März 2008 bzw. Juni 2009 sowie Literaturlistensuche; Update nach | Fragestellung K1: ursprüngliche Recherche bereits veröffentlicht (n = 4 Arbeiten eingeschlossen für den hausärztlichen Versorgungsbereich) n = 3 SR neu berücksichtigt - identifizierten klinische Vorhersageregeln <ul style="list-style-type: none"> - INTERCHEST Rule, - Sox Rule; - Gencer Rule, - Marburg Heart Score, - aus den letzten drei war die diagnostische Aussagekraft für die hausärztliche Versorgungsebene evaluiert worden, n = 3 SR (vgl. a. S. 42ff) aus diesen SR gingen n = 6 Primärstudien hervor; ergänzend ermittelt wurde eine weitere Publikation (gesamt: n = | AMSTAR 2 moderate y-py-y-y-n-py-y-y-n-y-y-y (basierend u. a. auf der Vorversion, vorbehaltlich der Veröffentlichung) | E | basierend auf einem Evidenzbericht der S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung, in Überarbeitung, geplante Fertigstellung: 30.09.2023: https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung insbesondere für für die NVL Empfehlungen 4-2 und 4-3 der Version 6.0 der NVL Chronische KHK relevante Evidenzaktualisierung; (vgl. Fragestellung K1 im Evidenzbericht zudem Ergebnisse zur Fragestellung im Kapitel 4.2.1 (Seite 41ff)); es ergeben sich keine inhaltlichen |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| | | | <p>SR und Primärstudien (01.10.2008 - 01.10.2021)</p> <p>Qualitätsbewertung Graduierung mittels SIGN-Schema (modifizierte Version); Bewertung der internen und externen Validität (Verzerrungsrisiko und Übertragbarkeit); QUADAS 2 für diagnostische Studien, AMSTAR für systematische Übersichtsarbeiten</p> <p>Ein- und Ausschlusskriterien Für die erste Version der Leitlinie Studien eingeschlossen, die - die diagnostische Aussagekraft von klinischen Vorhersageregeln bzw. von einzelnen Zeichen und Symptomen - bei Patient*innen mit Brustschmerz - für die Diagnose einer KHK bzw. eines ACS - in verschiedenen Versorgungsebenen untersucht hatten</p> <p>Für das Update der Recherche wurden Studien eingeschlossen, die - die diagnostische Aussagekraft von klinischen Vorhersageregeln (Zeichen, Symptome, keine Laborbefunde) bzw. von einzelnen Zeichen und Symptomen - bei Patient*innen mit Brustschmerz - für die Diagnose einer KHK bzw. eines ACS untersuchten.</p> <p>In Suche 1 (Aggregierte Evidenz)</p> <p>zusätzlich (gezielte Suche): - Studientyp: Meta-Analyse/ systematisches Review</p> | <p>7), Tabelle 15, erster Teil im Bericht (S. 60ff)</p> <p><i>Hinweis:</i> eine der neu eingeschlossenen SR (Quelle 25 Harskamp et al BMJ open 2019) berichtete den aktuellsten Suchzeitraum, die breiteste Suche sowie Angaben zur diagnostischen Güte der Vorhersageregeln); Bewertung gute Übertragbarkeit; SIGN 2++</p> <p>Ergebnisse: Marburg Heart Score, n = 1 SR (Quelle 25) sensitivity (86%–91%) specificity (61%–81%) positive predictive value (PPV) (23%–35%) negative predictive value (NPV) (97%–98%) AUC 0.90 (95% CI 0.87–0.93), n = 1 Studie (n = 672 Patient*innen) sowie AUC 0.84 (95% CI = 0.80 - 0.88), n = 1 weitere Studie (n = 844 Patient*innen) zur Validierung), deutscher Versorgungskontext</p> <p>- der Marburger Herz-Score n = 2 externe Validierungsstudien guter methodischer Qualität</p> <p>- Marburg Heart Score more sensitive in detecting coronary disease than the clinical judgement of the general practitioner; n = 1 SR</p> <p>- recommended for rule out of CAD in low-risk general practice populations with intermittent-type chest pain (level of evidence of 2 ; definitions of the</p> | | | Änderungen/Einflüsse auf die Empfehlungen; allerdings sollte die Evidenz im Hintergrundtext aktualisiert werden |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | <p>- Versorgungsebene: keine Einschränkung</p> <p>In Suche 2 (Primärstudien)</p> <p>zusätzlich (gezielte Suche):</p> <ul style="list-style-type: none"> - Studientyp: diagnostische Primärstudie - Setting: hausärztliche Versorgungsebene - Studie berichtet die unabhängige Aussagekraft einzelner Zeichen und Symptome (d.h. nach multivariater Adjustierung) <p>Outcome diagnostische Aussagekraft Sensitivität/Spezifität, PPV, NPV</p> | <p>Mount Sinai Evidence-Based Medicine Working group)</p> <p>diagnostic performance of Gencer rule PPV : 20%–34%, NPV : 95%–99%) and INTERCHEST PPV: 35%–43%, NPV : 96%–98% appear comparable, but requires further validation</p> <ul style="list-style-type: none"> - ergänzend werden Hinweise berichtet, die den Einsatz des MHS mit einer besseren klinischen Einschätzung der Hausärzt*innen in Verbindung bringen (zusätzlich als klinische Hinweise angegeben: Transparenz, leichte Anwendbarkeit, Augenscheinvalidität) - Mehrheit der Patient*innen mit stabiler KHK, daher Aussagekraft für ACS eingeschränkt (n = 1 SR berichtet, dass: In general practice, there is currently no clinical decision aid that can safely rule out ACS): - Grijseels rule <ul style="list-style-type: none"> - sensitivity : 91%, - specificity : 37%, - PPV : 57%, - NPV : 82%) Bruins Slot <ul style="list-style-type: none"> - sensitivity : 97%, - specificity : 10%, - PPV : 23%, - NPV : 92%) (Quelle 25 aus 2019) | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | | <p>- eine ergänzende Primärstudie aus 2020 liefert hier weitere Daten (auch zum MHS) zu MACE (major adverse cardiac events), welche die Aussage bestätigt, allerdings den INTERCHEST score als am besten diskriminierend beschreibt (mit guter Sensitivität und Spezifität); im Vergleich zur ärztlichen Einschätzung ohne Score-Unterstützung gibt es vergleichbare Werte für die Sensitivität, Spezifität und einen Hinweis auf eine bessere Vorhersage bei Anwendung des Cut-off von 2 Punkten in Bezug auf MACE, ACS (vgl. S. 69)</p> <p>zudem interessant: Wie häufig ist das Symptom „Brustschmerz“ Beratungsanlass in der allgemeinärztlichen Praxis? - Häufigkeit des Symptoms „Thoraxschmerz“ im allgemeinmedizinischen, primärärztlichen Setting: 0,68 – 3,0% (6–11) (Häufigkeit der Patientenkontakte mit Thoraxschmerz bezogen auf Patientenkontakte gesamt) bzw. 15,5 - 67,4 Patient*innen mit Thoraxschmerz/ 1000 Patient*innen und Jahr (7, 12–14) - Heterogenität beschrieben (Grund: u. a. Unterschiede in den Gesundheitssystemen sowie untersuchten Zeiträumen) - in Studien mit guter methodischer Qualität/ Übertragbarkeit: Häufigkeit des Beratungsanlasses 1-3% (2++), n = 3 Arbeiten</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | | <p>Welche Erkrankungen sind in welcher Häufigkeit Ursache für das Symptom „Brustschmerz“ in der allgemeinärztlichen Praxis?</p> <p>- systematische Literaturübersicht mit geringem Verzerrungspotential: für die KHK (chronische KHK und ACS) eine Häufigkeit von 9,7-14,8%</p> <p>- häufigste Ursache mit 24,5-49,8 %: Brustwandsyndrom (BWS) (2++), n = 1 Arbeit</p> <p>Tabelle 6: Ursachen des Brustschmerzes aus ausgewählten Studien. (SIGN 2++) vgl. S. 23 Evidenzbericht Ursache des Brustschmerzes Prozent, Häufigkeit</p> <p>Chronische KHK 8-11% 75/672 (15) 135/1212 (9) 71/868 (22)</p> <p>Akutes Koronarsyndrom 2-4% 10/672 (15) 44/1212 (9) 21/868 (22)</p> <p>Brustwandsyndrom 43-47% 287/672 (15) 565/1212 (9)</p> <p>Psychogene Ursachen 10-12% 77/672 (15) 115/1212 (9)</p> <p>Erkrankungen der Atemwege 10-12% 69/672 (15)</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| | | | | 146/1212 (9) Ösophageale Ursachen 4-7% 48/672 (15) 42/1212 (9) Hypertensive Krise 1-4% 5/672 (15) 48/1212 (9) Arrhythmien 1-2% 10/672 (15) 10/1212 * Lungenembolie < 0,5% 2/672 (15) 1/1212 * Aortenstenose < 0,5% 1/672 (15) Myo-/Perikarditis < 0,5% 3/1212 * Kardiomyopathie < 0,5% 4/672 (15) Aortendissektion 0/672 (15) < 0,1% 0/1212 * < 0,1% * Nicht publizierte Daten der Studie von Bösner et al. 2009 (9) | | | |
| 33573 | Harskamp RE, Laeven SC, Himmelreich JC, Lucassen WAM, van Weert HCPM. Chest pain in general practice: a systematic review of prediction rules. BMJ Open 2019; 9(2):e027081. doi: 10.1136/bmjopen- | 2019 | Fragestellung aim to identify and assess the performance of existing clinical decision aids/rules for stable angina and/or acute coronary syndrome in patients with chest pain that are applicable and | n = 8 studies included which evaluated n = 5 different clinical decision rules (CDR) for rule out CAD: - Gencer rule - the Marburg Heart Score - INTERCHEST | AMSTAR 2 low y-py-n-y-y-n-y-y-n-y-y-y keine Metaanalyse eine kritische Domäne wurde nicht erfüllt (keine Angabe | E | Literaturlistensuche basierend auf einem Evidenzbericht der S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| | 2018-027081. https://pub-med.ncbi.nlm.nih.gov/30819715/ [9] | | have been validated in low-resource general practice or equivalent settings Studientyp systematic review (following the PRISMA-Guidelines); PubMed, Embase, CINAHL and Google Scholar (up to 17 October 2018) Ein- und Ausschlusskriterien - original studies in adults (≥18 years of age) - enrolment in primary care setting - patients with chest pain - suspected coronary artery disease, acute coronary syndrome - in general practice, primary care practice - language of publication: English, Dutch or German - studies with a retrospective study design were excluded - in-hospital, emergency department (ED) and/or preselected outpatient populations were not eligible Qualitätsbewertung QUADAS-2 tool (online supplement) assessed whether a clinical decision rule (CDR) was ready for application in clinical practice (level of evidence for each rule using the definitions of the Mount Sinai Evidence-Based Medicine Working group) Intervention prediction rule, decision model or decision aid (may include items from history taking, physical examination, laboratory | for rule out ACS - Grijseels rule - Bruins Slot rule overall quality of the studies was moderate (QUADAS 2) - n = 6 studies with high risk of bias in reference standard (assessor not blinded to the index test results) - CDRs have been developed based on readily available clinical information - Marburg Heart Score was most extensively tested with good overall discrimination - (C-statistic of 0.84–0.90) - sensitivity of 86%–89%, - specificity of 64%–81%, - PPV of 23%–40% - NPV of 97%–98% - diagnostic properties illustrating its consistent diagnostic performance in terms of sensitivity and specificity - sensitivity (+8.0%) and specificity (+5.8%) were higher as unaided clinical judgement - the level of evidence is 2 for the Marburg Heart Score, which implicates that this rule can be used in a general practice setting of low-risk patients with intermittent chest pain with confidence in its accuracy - INTERCHEST rule has a number of quality concerns (not validated) - C-statistic of 0.84, - sensitivity 82%–88%, - specificity 74%–82%, | einer Liste der ausgeschlossenen Studien mit dem Ausschlussgrund) | | primärärztliche Versorgung, in Überarbeitung, geplante Fertigstellung: 30.09.2023: https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung authors noted that during office hours, 1.5% of all consultations and 4% of all new episodes are related to chest pain additionally, highest frequency of chest pain consultations is in the age category 45 to 64 years, with notable differences between men and women in its presentation |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| | | | and electrocardiographic data) Referenz clinical outcomes that we used as reference diagnosis were (1) any form of coronary artery disease (CAD) or coronary heart disease; or (2) a more restricted form including unstable angina or myocardial infarction (referred to as acute coronary syndrome) in patients with acute chest pain Outcome diagnostic test characteristics of included rules, including: sensitivity, specificity, negative and positive prediction values | - PPV of 35%–43% - NPV of 96%–98% - Gencer rule has limited evidence (validated only in one study, lower specificity (42%-71) - C-statistic: 0.75–0.95, - sensitivity 87%–98%, - specificity 42%–71% | | | |
| 33571 | Juarez-Orozco et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Heart J Cardiovasc Imaging. 2019 Nov 1;20(11):1198-1207. doi: 10.1093/ehjci/jez054. https://pubmed.ncbi.nlm.nih.gov/30982851/ | 2019 | Fragestellung to provide a pooled estimation of contemporary PTPs of significant CAD across traditionally considered clinical patient categories, and to re-evaluate the utility of application of exercise ECG, ICA, CCTA, PET, stress CMR, and SPECT according to such contemporary PTPs, while exploring novel progressive ruling-out thresholds Studientyp Übersichtsarbeit (since last operational estimations by Genders et al. was performed), search and cross-referencing, other sources (search string is available within an online-supplement) Ein- und Ausschlusskriterien (i) demonstrated consistency of methods for identification of significant CAD and | n = 3 trials - Foldyna et al. – PROMISE - Reeh et al. - Cheng et al. - CONFIRM)* n = 15 815 patients (mean age 59 ± 11 years) - significant CAD as any luminal narrowing of >50% - overall prevalence of significant CAD in the pooled population ranged from 1 to 52% (mean of 14.9%) - corresponds to about a 66% decrease in average from the values defined by Genders et al. 2011 used in the 2013 ESC guidelines across all patient categories. updated pooled PTPs of obstructive CAD across the clinical patient categories: Table 2 Pre-test probabilities of obstructive CAD in symptomatic patients | n. a. | E | Literaturlistensuche (basierend auf der ESC 2019); European Heart Journal (2020) 41, 407/477 https://pubmed.ncbi.nlm.nih.gov/31504439/ 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2020) 41, 407/477) s. a. Figure 2 Utility of non-invasive techniques for detection of significant CAD (ICA, FFR)* * Updated diagnostic technique selection tool for all patient categories based |
| | [10] | | | | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------------------|-------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------|--------------|-----------------|--------------|-------|-------|-------|-------|-------|-------|---------|--------|-------|--------|-------|---------|--------|--------|--------|-------|---------|---------|--------|---------|-----|---------|---------|---------|---------|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | <p>(ii) stratified their PTP estimates according to sex, age, and type of chest pain as established in current guidelines.</p> <p>Intervention exercise ECG, ICA, CCTA, PET, stress CMR, and SPECT</p> <p>Kontrolle i. e. ICA and fractional flow reserve (FFR)</p> <p>Outcomes continuous baseline variables from the included reports CAD prevalence data</p> | <p>according to age, gender, and the nature of symptoms (pooled analysis of n = 3 studies) (Men / Women)</p> <table border="1"> <thead> <tr> <th>Age (years)</th> <th>Typical (%)</th> <th>Atypical (%)</th> <th>Non-anginal (%)</th> <th>Dyspnoea (%)</th> </tr> </thead> <tbody> <tr> <td>30-39</td> <td>3 / 5</td> <td>4 / 3</td> <td>1 / 1</td> <td>0 / 3</td> </tr> <tr> <td>40-49</td> <td>22 / 10</td> <td>10 / 6</td> <td>3 / 2</td> <td>12 / 3</td> </tr> <tr> <td>50-59</td> <td>32 / 13</td> <td>17 / 6</td> <td>11 / 3</td> <td>20 / 9</td> </tr> <tr> <td>60-69</td> <td>44 / 16</td> <td>26 / 11</td> <td>22 / 6</td> <td>27 / 14</td> </tr> <tr> <td>70+</td> <td>52 / 27</td> <td>34 / 19</td> <td>24 / 10</td> <td>32 / 12</td> </tr> </tbody> </table> <p>In addition to the classic Diamond and Forrester classes, patients with dyspnoea only or dyspnoea as primary symptom are included. The dark green shaded regions denote the groups in which non-invasive testing is most beneficial (pre-test probability >15%). The light green shaded regions denote the groups with pre-test probability of CAD between 5 and 15% in which the testing for diagnosis may be considered based on clinical judgement.</p> <p>pooled estimate CAD cases (n) 2350 CAD prevalence (%) 14.9 men (n (%)) 7573 (48) women (n (%)) 8222 (52) BMI (kg/m² (SD)) 28.2 (5.5) arterial hypertension (n (%)) 8691 (55) diabetes mellitus (n (%)) 2485 (16) dyslipidaemia (n (%)) 9432 (60) smokers (n (%)) 5494 (35)</p> <p>- groups of participant subjects: atypical angina (59%)</p> | Age (years) | Typical (%) | Atypical (%) | Non-anginal (%) | Dyspnoea (%) | 30-39 | 3 / 5 | 4 / 3 | 1 / 1 | 0 / 3 | 40-49 | 22 / 10 | 10 / 6 | 3 / 2 | 12 / 3 | 50-59 | 32 / 13 | 17 / 6 | 11 / 3 | 20 / 9 | 60-69 | 44 / 16 | 26 / 11 | 22 / 6 | 27 / 14 | 70+ | 52 / 27 | 34 / 19 | 24 / 10 | 32 / 12 | | | <p>on sex, age, and type of chest pain, considering both ICA (upper panel) and FFR (lower panel) as the reference standard. The colour gradients inform the confidence with which a negative result can rule-out disease (i.e. by driving the post-test probability below 15, 10, or 5). CAD is directly rule-out with a PTP < .5. a</p> <p>The categories corresponding to dyspnoea as the predominant or only symptom; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; FFR, fractional flow reserve; ICA, invasive coronary angiography; PET, positron emission tomography; SPECT, single photon emission computed tomography. Adapted from Knuuti et al.</p> |
| Age (years) | Typical (%) | Atypical (%) | Non-anginal (%) | Dyspnoea (%) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 30-39 | 3 / 5 | 4 / 3 | 1 / 1 | 0 / 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 40-49 | 22 / 10 | 10 / 6 | 3 / 2 | 12 / 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 50-59 | 32 / 13 | 17 / 6 | 11 / 3 | 20 / 9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 60-69 | 44 / 16 | 26 / 11 | 22 / 6 | 27 / 14 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 70+ | 52 / 27 | 34 / 19 | 24 / 10 | 32 / 12 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | | <p>non-anginal pain (25%) typical angina (16%)</p> <p>- overall prevalence of significant CAD: 1 to 52% (mean of 14.9%) (pooled population), which corresponds to about a 66% decrease in average from the values defined by Genders et al. 2011 used in the 2013 ESC guidelines across all patient categories (former average PTP = 44.5%)</p> <p>- patients with significant CAD: atypical angina (58%) typical angina (29%) non-anginal pain (14%)</p> <p>- patients with significant CAD were older and more often male</p> <p>- PTP ranges in which it is possible to rule-out the disease by driving the post-test probability below the following thresholds of post-test probability: <15, <10, and <5%</p> <p>- The ruling-out capabilities of the included techniques were remarkable in ruling-out CAD across all clinical patient categories with a post-test probability of at least <15%</p> <p>- ICA demonstrated the most restricted profile for ruling-out FFR-significant CAD, particularly, in clinical groups that convey the highest PTP estimates (males with typical anginal above 50 years old)</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risikoeinschätzung | | | | | | | |
| | | | | - a clear nonlinear function linking the PTP with the rate of false positive and negative findings at each extreme of PTP | | | |
| [11] | Haase et al. Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data. BMJ. 2019 Jun 12;365:11945. doi: 10.1136/bmj.11945. https://pubmed.ncbi.nlm.nih.gov/31189617/ | 2019 | <p>Fragestellung to determine whether coronary computed tomography angiography (CTA) should be performed in patients with any clinical probability of coronary artery disease (CAD), and whether the diagnostic performance differs between subgroups of patients</p> <p>Studientyp Prospectively designed meta-analysis of individual patient data from prospective diagnostic accuracy studies</p> <p>Medline, Embase, and Web of Science for published studies; unpublished studies via contact with investigators (COME-CCT), protocol, registered at PROSPERO</p> <p>Schuetz GM, Schlattmann P, Achenbach S, et al. Individual patient data meta-analysis for the clinical assessment of coronary computed tomography angiography: protocol of the Collaborative Meta-Analysis of Cardiac CT (CoMe-CCT). Syst Rev 2013;2:13. doi:10.1186/2046-4053-2-13</p> <p>Qualitätsbewertung Risk of Bias Tool, QUADAS-2 tool</p> <p>Ein- und Ausschlusskriterien</p> <ul style="list-style-type: none"> - prospective diagnostic accuracy studies - compared coronary CTA with coronary angiography | <p>Individual patient data from 5 332 patients (n = 65 prospective diagnostic accuracy studies)</p> <p>n = 63 published and two unpublished</p> <p>risk of bias was low for all items in most studies, and applicability concerns were not present in any of the included studies assessed by the QUADAS-2 tool</p> <p>patient baseline characteristics vgl. Tabelle 1</p> <p>pretest probability range of 7-67%, treat threshold of more than 50% and the no-treat threshold of less than 15%</p> <p>post-test probability were obtained using CTA</p> <p>a pretest probability of 7% (95%CI):</p> <ul style="list-style-type: none"> - PPV of CTA 50.9% (43.3% to 57.7%) - NPV of CTA 97.8% (96.4% to 98.7%) <p>pretest probability of 67%:</p> <ul style="list-style-type: none"> - PPV 82.7% (78.3% to 86.2%) - NPV 85.0% (80.2% to 88.9%) <p>overall (CTA):</p> <ul style="list-style-type: none"> - sensitivity 95.2% (92.6% to 96.9%) - specificity 79.2% (74.9% to 82.9%) | <p>AMSTAR-2 low</p> <p>Y-Y-N-Y-Y-N-Y-Y-Y-Y-Y-Y-Y</p> <p>eine kritische Domäne wurde nicht erfüllt (keine Angabe einer Liste der ausgeschlossenen Studien mit dem Ausschlussgrund)</p> | Ei | Literaturlistensuche (geeignete Prätestwahrscheinlichkeitsspanne für die CT-Koronarangiographie, welche der Publikation der DISCHARGE Group (supplement zu NEJM 2022) zugrunde liegt (CCTA vs. ICA; eine Publikation die unter den n = 4 Publikationen eingeschlossen wurde) |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | <ul style="list-style-type: none"> - using at least a 50% diameter reduction as a cutoff value for obstructive CAD - patients needed to have a clinical indication for coronary angiography due to suspected CAD - both tests had to be performed in all patients <p>angina pectoris was classified as typical angina, atypical angina, non-anginal chest pain, or other chest discomfort according to Diamond and Forrester</p> <p>Intervention coronary CTA</p> <p>Kontrolle coronary angiography (ICA)</p> <p>Outcome primary:</p> <ul style="list-style-type: none"> - positive predictive value (PPV) - negative predictive value (NPV) <p>of CTA as a function of clinical pretest probability of obstructive CAD, analysed by a generalised linear mixed model</p> <p>secondary:</p> <ul style="list-style-type: none"> - sensitivity and specificity <p>no-treat/treat threshold model was used (based on obtained post-test probabilities of less than 15% in case of negative CTA and above 50% in case of positive CTA. Sex, angina pectoris</p> | <p>CTA using more than 64 detector rows vs. CTA using up to 64 rows</p> <ul style="list-style-type: none"> - empirical sensitivity (93.4% vs. 86.5%, P=0.002) - specificity (84.4% vs. 72.6%, P<0.001). - AUC for CTA was 0.897 (0.889 to 0.906) <ul style="list-style-type: none"> - diagnostic performance of CTA slightly lower in women than in men (AUC 0.874 (0.858 to 0.890) vs. 0.907 (0.897 to 0.916), P<0.001) - diagnostic performance of CTA was slightly lower in patients older than 75 (0.864 (0.834 to 0.894), P=0.018 v all other age groups) - patients older than 75: <ul style="list-style-type: none"> o sensitivity 93.2% (88.6% to 96.0%) o specificity 73.6% (65.7% to 80.2%) - diagnostic performance was not significantly influenced by angina pectoris type (typical angina 0.895 (0.873 to 0.917), atypical angina 0.898 (0.884 to 0.913), non-anginal chest pain 0.884 (0.870 to 0.899), other chest discomfort 0.915 (0.897 to 0.934)) | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|---------------------------|----------|------|-------------------------------------------------------------|------------|----------------------|-----|-----------|
| Risikoeinschätzung | | | | | | | |
| | | | type, age, and number of computed tomography detector rows) | | | | |

CT-Koronarangiografie

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| 33569 33640 | [D22-01] Computertomographie-Koronarangiographie zur Diagnosestellung bei Patientinnen und Patienten mit Verdacht auf eine chronische koronare Herzkrankheit, Letzte Aktualisierung 17.02.2023. [D22-01] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Computertomografie-Koronarangiografie mit oder ohne funktionelle Beurteilung zur Diagnose einer chronischen koronaren Herzkrankheit. Abschlussbericht. Projekt: D22-01. Version 1.1. 2023 (IQWiG-Berichte; 1570) [cited: 2023-07-03]. https://www.iqwig.de/projekte/d22-01.html , Stand 20.06.2023. [12,13] | 2023 | Fragestellung Fragestellung 1: Nutzenbewertung von diagnostischen Strategien mit Anwendung einer kontrastverstärkten Computertomografie-Koronarangiografie (CCTA) vs. diagnostische Strategien der gleichen Zielsetzung ohne Anwendung einer CCTA Studientyp systematische Übersichtsarbeit zu SR aus RCT sowie RCT (Medline, HTA Database, NICE, AHRQ, Vorarbeiten des IQWiG sowie Embase, Cochrane, Studienregister, Herstelleranfragen, Referenzlisten), letzte Suche Frage 1 20.09.2022 Ein- und Ausschlusskriterien P: Patient*innen mit Verdacht auf eine chronische koronare Herzkrankheit, bei denen nach Durchführung der Basisdiagnostik die Indikation zur weiterführenden nicht invasiven Diagnostik besteht Randomisierte kontrollierte Studien (RCT), Systematische Übersichtsarbeiten zur Identifizierung von Primärstudien | Fragestellung 1 gesamt: n = 1 systematische Übersichtsarbeit, n = 15 RCT kontrastverstärkten Computertomografie-Koronarangiografie (CCTA) vs. funktionelle Verfahren (fV): n = 11 Studien (CAPP [10], CARE-CCTA [11], CATCH [12], CT-STAT [13], Goldstein 2007 [14], IAEA-SPECT/CTA [15], Min 2012 [16], Nabi 2016 [17], PERFECT [18], PROMISE [19] und SCOT-HEART [20]) kontrastverstärkten Computertomografie-Koronarangiografie (CCTA) vs. invasiver Koronarangiografie (ICA): n = 4 Studien (CAD-MAN [21], CONSERVE [22], DISCHARGE [23] und Reis 2022 [24]) n = 3 geplante sowie n = 3 laufende Studien u. a. aus Registern sowie n = 3 Studien mit unklarem Status Charakteristika der Studien vgl. S. 8-12 im Bericht sowie S. 81-103 im Bericht | <i>AMSTAR 2: high</i> <i>y-y-y-y-y-n-y-y-py-y-y-y-y-y-y</i> <i>Hinweis zu den RCT:</i> CCTA vs. fV niedriges Verzerrungspotential endpunktübergreifend für n = 4 Studien hohes Verzerrungspotential endpunktübergreifend für n = 7 Studien (u. a. unklare Erzeugung der Randomisierungsfrequenz) --> für diese 7 Studien keine weitergehende endpunktspezifische Bewertung CCTA vs. direkte ICA niedriges Verzerrungspotential endpunktübergreifend für n = 3 Studien hohes Verzerrungspotential endpunktübergreifend für n = 1 Studie (unklare Verdeckung der Gruppenzuteilung) | E | Sachverständige haben wissenschaftliche Forschungsaufträge für das Institut bearbeitet; Vorbericht ist eine vorläufige Nutzenbewertung es wird angeführt, dass bei Ausschluss eines ACS und anderer Ursachen bei pektangioser Beschwerden, mittels Elektrokardiogramm (EKG) und Laborbestimmung plus Anamnese und körperlicher Untersuchung, je nach Vor-testwahrscheinlichkeit, unterschiedliche bildgebende nicht invasive und invasive Verfahren zur Verfügung stehen, um eine stabile stenosierende KHK als wahrscheinlichste Verdachtsdiagnose zu bestätigen (vgl. NVL Chronische KHK Version 6.0) starke Negativempfehlung |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | <p>Qualitätsbewertung qualitative Ergebnissicherheit wurde endpunktübergreifend und endpunktspezifisch des Verzerrungspotenzials bewertet; Metaanalysen und Sensitivitätsanalysen wurden durchgeführt sowie Effektmodifikatoren untersucht; endpunktübergreifende Bewertung des Nutzens und Schadens</p> <p>Intervention diagnostische Strategien mit Anwendung einer CCTA</p> <p>Kontrolle diagnostische Strategien der gleichen Zielsetzung ohne Anwendung einer CCTA</p> <p>Endpunkte Mortalität Morbidität gesundheitsbezogene Lebensqualität Nebenwirkungen</p> <p>(zur Morbidität berichtet (mit unterschiedlicher Verteilung zwischen den Studien) u. a. Myokardinfarkt, Schlaganfall, instabile Angina pectoris, Angina pectoris, unnötige invasive Diagnostik)</p> | <p>3 Auswertungszeiträume definiert - bis 30 Tage nach Untersuchung = periprozedural - 6-24 Monate = mittelfristig - 2-5 Jahre = langfristig</p> <p>Ergebnisse Fragestellung 1 CCTA vs. funktionelle Verfahren</p> <p>Gesamt mortalität niedriges Verzerrungspotential n = 4 Studien hohes Verzerrungspotential n = 6 Studien</p> <p>periprozedural – mittelfristig OR 0,77 (95 % KI 0,40; 1,50), (hohe Ergebnissicherheit), n = 4 Studien (CATCH, IAEA-SPECT/CTA, PROMISE und SCOT-HEART) gesamt -</p> <p>langfristig OR 0,99 (95 % KI 0,77; 1,28), n = 2 Studien (SCOT-HEART und PROMISE) gesamt (n / N) 117 / 7 069 vs. 118 / 7 080</p> <p>kardiovaskuläre Mortalität niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 5 Studien</p> | <p>Lebensqualität verwertbare Angaben zur Lebensqualität allgemein wurden für die CCTA vs. fV ausschließlich aus n = 2 Studien berichtet (CATCH; SCOT-HEART); für die CCTA vs. ICA zu n = 1 Studie (DISCHARGE); für die krankheitsbezogene Lebensqualität konnte nur ein Teil der vorliegenden Daten verwendet werden (aus n = 1 Studie (SCOT-HEART) zu CCTA vs. fV und n = 0 zu CCTA vs. ICA)</p> | | <p>gegen die ICA bei niedriger und mittlerer Vortestwahrscheinlichkeit, aber Zunahme an ICAs in Deutschland (im Jahr 2019 ca. 510 000 ICAs; dabei lag bei etwa 30 % der Indikationen, die zu einer ICA geführt haben, kein pathologischer Befund vor [NVL, IQTIG]; möglicher Grund: CCTA zählt – im Gegensatz zur ICA (mit und ohne Messung der fraktionellen Flussreserve) – nicht zum Leistungsumfang der GKV)</p> <p>Abschlussbericht im Vergleich zum Vorbericht</p> <p>Neben redaktionellen Änderungen ergaben sich folgende Spezifizierungen oder Änderungen im Abschlussbericht:</p> <ul style="list-style-type: none"> Studie PROTECT (im Vorbericht als Studie mit unklarem Status) wurde aufgrund neuer Daten (Publikation) abgeschlossen Studie TARGET (im Vorbericht als Studie mit unklarem Status) wurde berücksichtigt |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | periprozedural – mittelfristig OR 0,53 (0,17; 1,66), (hohe Ergebnissicherheit); n = 2 Studien (CATCH, SCOT-HEART) gesamt – langfristig - Myokardinfarkt niedriges Verzerrungspotential n = 3 Studien hohes Verzerrungspotential n = 6 Studien periprozedural – mittelfristig gesamt - CATCH OR 0,29 (95 % KI 0,06; 1,39), (hohe Ergebnissicherheit), (n / N) 2 / 285 vs. 7 / 291 PROMISE OR 0,67 (95 % KI 0,37; 1,21), (hohe Ergebnissicherheit), (n / N) 18 / 4996 vs. 27 / 5007 SCOT-Heart OR 0,62 (95 % KI 0,37; 1,07), (hohe Ergebnissicherheit), (n / N) 22 / 2073 vs. 35 / 2073 (qualitative Bewertung, da die beiden gewählten statistischen Verfahren (random effect modell nach Knapp und Hartung + Sensitivitätsanalyse nach | | | <ul style="list-style-type: none"> und ergänzend dargestellt (Publikation) Begriff für das Krankheitsbild der nicht obstruktiven KHK wurde in Kapitel 1 ergänzt in Kapitel 1 wurde klarer dargestellt, dass bei dem CCS (in Abgrenzung zum ACS) die Ischämie nur unter Belastung auftritt Charakterisierung der Intervention im CCTA-Arm der Studie DISCHARGE wurde im Bericht im Abschnitt 4.2.1 und in Tabelle 18 angepasst für die ergänzend dargestellte Studie PRECISE wurde ein Manuskript eingereicht, aus welchem zusätzliche Daten zur Verfügung standen (Folge: Überarbeitung der Verzerrungspotenzialbewertung und Berücksichtigung von 2 weiteren Endpunkten (kardiovaskuläre Mortalität, instabile Angina Pectoris) Daten zum Endpunkt krankheitsspezifische Lebensqualität, gemessen anhand des Gesamtscore des SAQ-7 aus der Studie |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>DerSimonian) nicht statistisch signifikant waren (vgl. Bericht S. 23); zudem wurde eine ergänzende Auswertung aller Studien mit hoher und mäßiger Ergebnissicherheit durchgeführt: OR = 0,61 (95 % KI 0,41; 0,89), (hohe und mäßige Ergebnissicherheit), n = 8 Studien (CAPP, CARE-CCTA, CATCH, CT-STAT, Goldstein 2007, PERFECT, PROMISE, SCOT-HEART) sowie ein 95 % Prädiktionsintervall (0,41; 0,89) angegeben (neueres Verfahren zur Abschätzung der Sicherheit des Effektschätzers)</p> <p>langfristig OR 0,65 (95 % KI 0,48; 0,87), (hohe Ergebnissicherheit), n = 2 Studien (PROMISE, SCOT-HEART) gesamt (n / N) 74 / 7069 vs. 113 / 7080</p> <p>Schlaganfall niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 1 Studie</p> <p>periprozedural -</p> <p>mittelfristig OR 0,71 (0,23; 2,25), (hohe Ergebnissicherheit), n = 1 Studie (SCOT-HEART) (n / N) 5 / 2 073 vs. 7 / 2 073</p> <p>langfristig -</p> <p>instabile Angina pectoris</p> | | | <p>FORECAST wurden ergänzt</p> <ul style="list-style-type: none"> in Kapitel 5 wurde ein Abschnitt zum Wert der Diagnose einer nicht obstruktiven KHK eingefügt Nutzenaussage zu Fragestellung 2 wurde geändert, siehe Abschnitt 4.4 im Vorbericht war im Ergebnisabschnitt 4.3.4.8 dargestellt, dass die Ergebnisse der Studie PRECISE nur ergänzend berichtet werden; jetzt im vorangehenden Abschnitt 4.3.1 zu den Studiencharakteristika dieses Vorgehen begründet und in allen Tabellen, die Daten zur Studie PRECISE enthalten, jeweils anhand einer Fußnote auf die rein ergänzende Darstellung der Studie verwiesen bei der nur ergänzend berichteten Studie PRECISE wurde (wie bei der Studie TARGET) auf die Darstellung der Bewertung des Verzerrungspotenzials und der Ergebnisse zu End- |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 5 Studien periprozedural - mittelfristig OR 1,34 (0,88; 2,04), (hohe Ergebnis-sicherheit), n = 2 Studien (CATCH, PROMISE) gesamt - langfristig - Angina pectoris niedriges Verzerrungspotential n = 1 Studie hohes Verzerrungspotential n = 1 Studie periprozedural - mittelfristig - Einzelstudien gesamt - CAPP OR 0,20 (0,08; 0,50), n = 1 Studie (n / N) 6 / 243 vs. 27 / 245 SCOT-HEART OR 1,11 (0,79; 1,54), n = 1 Studie (n / N) 76 / 2 073 vs. 69 / 2 073 langfristig - Gesundheitszustand (EQ-5D VAS) niedriges Verzerrungspotential – | | | punkten in den Abschnitten 4.3.3 und 4.3.4 verzichtet (Daten in den Abschnitten A3.3.1.2 und A3.3.2.) Abschlussbericht Version 1.1 im Vergleich zum Abschlussbericht Version 1.0 <ul style="list-style-type: none"> Abschnitt A1.2 ein fehlerhafter Verweis nun auf Kapitel 5 korrigiert und an gleicher Stelle eine formale Anpassung durch Ergänzung eines Aufzählungspunkts vorgenommen Abschnitt A1.2 wurde ein Aufzählungspunkt zur nun deutlicher gekennzeichneten ergänzenden Darstellung der Studie PRECISE hinzugefügt |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | hohes Verzerrungspotential n = 2 periprozedural – mittelfristig Mittelwertdifferenz (MWD) -0,70 (95 % KI -1,50; 0,10), n = 2 Studien (CARE- CCTA, PROMISE) MW (SD) Studienbeginn vs. Stu- dienende CCTA 65,0 (14,5) vs. 69,0 (13,8) ge- genüber SPECT 65,1 (12,4) vs. 69,7 (11,9) (n) 441 vs. 424 CCTA 72,0 (19,5) vs. 74,7 (20,3) ge- genüber fV 72,4 (19,8) vs. 74,9 (21,2) (n) 2679 vs. 2525 langfristig - unnötige invasive Diagnostik niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 2 Stu- dien OR 0,77 (95 % KI 0,64; 0,94), (hohe Ergebnissicherheit), n = 2 Studien (CATCH, PROMISE) gesamt – (n / N) 14 / 285 vs. 23 / 291, n = 1 Stu- die (n / N) 170 / 4996 vs. 213 / 5007, n = 1 Studie | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>gesundheitsbezogene Lebensqualität niedriges Verzerrungspotential – hohes Verzerrungspotential n = 2</p> <p>periprozedural -</p> <p>mittelfristig SF-12 oder SF-36 körperlicher Summenscore MWD -0,07 (95 % KI -0,13; 0,00), n = 2 Studien (CATCH, SCOT-HEART) MW (SD) Studienbeginn vs. Studienende CCTA 44,2 (0,2) vs. 45,0 (0,3) gegenüber fV 44,0 (0,2) vs. 46,0 (0,3) (n) 1777 vs. 1705 SF-12 oder SF-36 psychischer Summenscore MWD -0,05 (95 % KI -0,12; 0,02), n = 2 Studien (CATCH, SCOT-HEART) MW (SD) Studienbeginn vs. Studienende CCTA 46,1 (0,3) vs. 47,8 (0,3) gegenüber fV 46,7 (0,3) vs. 48,6 (0,3) (n) 1777 vs. 1705</p> <p>langfristig -</p> <p>unerwünschte Ereignisse niedriges Verzerrungsrisiko n = 2 hohes Verzerrungsrisiko n = 2 es lagen kaum verwertbare Daten vor</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>periprozedural (bis 30 Tage nach Untersuchung) in beiden Gruppen nach Untersuchung keine Komplikationen, n = 1 Studien n = 3 Patient*innen mit schweren Blutungen vs. n = 3 Patient*innen mit schweren Blutungen sowie n = 9 SUE (u.a. ventrikuläre Tachykardien), n = 1 Studie</p> <p>mittelfristig (6-24 Monate) in beiden Gruppen nach Untersuchung keine Komplikationen, n = 2 Studien keine SUE, n = 1 Studie</p> <p>langfristig -</p> <p>CCTA vs. direkte ICA</p> <p>Gesamtmortalität niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 2 Studien</p> <p>periprozedural –</p> <p>mittelfristig Peto-OR 1,79 (95 % KI 0,19; 17,27); n = 1 Studie (CONVERSE) gesamt (n / N) 2 / 784 vs. 1 / 719</p> <p>langfristig -</p> <p>kardiovaskuläre Mortalität niedriges Verzerrungspotential n = 2 Studien</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>hohes Verzerrungspotential n = 1 Studie</p> <p>periprozedural –</p> <p>mittelfristig -</p> <p>langfristig OR 0,47 (0,19; 1,12), n = 2 Studien (CAD-MAN, DISCHARGE) gesamt (n / N) 7 / 1 975 vs. 15 / 1 915</p> <p>Myokardinfarkt niedriges Verzerrungspotential n = 2 Studien hohes Verzerrungspotential n = 2 Studien</p> <p>periprocedural OR 0,41 (0,14; 1,25), n = 2 Studien (CAD-MAN, DISCHARGE) gesamt (n / N) 4 / 1 975 vs. 10 / 1 915</p> <p>mittelfristig OR 0,66 (0,13; 3,38), n = 2 Studien (CONDERVE, Reis 2022) gesamt (n / N) 2 / 893 vs. 3 / 824</p> <p>langfristig OR 1,16 (0,64; 2,09), n = 2 Studien (CAD-MAN, DISCHARGE) gesamt (n / N) 24 / 1 975 vs. 20 / 1 915</p> <p>Schlaganfall niedriges Verzerrungspotential n = 2 Studien</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>hohes Verzerrungspotential n = 2 Studien</p> <p>periprozedural -</p> <p>mittelfristig OR 0,65 (95 % KI 0,13; 3,32), n = 2 Studien (CONSERVE, Reis 2022) gesamt (n / N) 2 / 899 vs. 3 / 824</p> <p>langfristig OR 0,47 (95 % KI 0,22; 0,99), n = 2 Studien (CAD-MAN, DISCHARGE) gesamt (n / N) 10 / 1975 vs. 21 / 1915</p> <p>instabile Angina pectoris niedriges Verzerrungspotential n = 1 Studie hohes Verzerrungspotential n = 2 Studien</p> <p>periprozedural -</p> <p>mittelfristig OR 1,13 (0,47; 2,74), n = 2 Studien (CONSERVE, Reis 2022) gesamt (n / N) 11 / 893 vs. 9 / 824</p> <p>langfristig -</p> <p>Angina pectoris niedriges Verzerrungspotential - hohes Verzerrungspotential n = 2 Studien</p> <p>periprozedural -</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>mittelfristig OR 1,21 (0,98; 1,50), n = 2 Studien gesamt (n / N) 210 / 1 893 vs. 171 / 1 829</p> <p>langfristig -</p> <p>Gesundheitszustand (EQ-5D VAS) niedriges Verzerrungspotential – hohes verzerrungspotential n = 1</p> <p>periprozedural –</p> <p>mittelfristig MWD -0,20 (95 % KI -1,25; 0,87), n = 1 Studie (DISCHARGE) MW (SD) Studienbeginn vs. Studienende CCTA 67,8 (17,4) vs. 70,4 (18,6) gegenüber ICA 66,5 (17,5) vs. 69,9 (18,1) (n) 1592 vs. 1521</p> <p>langfristig MWD 0,31 (95 % KI -0,76; 1,38), n = 1 Studie (DISCHARGE) MW (SD) Studienbeginn vs. Studienende CCTA 67,8 (17,4) vs. 71,8 (16,4) gegenüber ICA 66,5 (17,5) vs. 71,1 (16,7) (n) 1395 vs. 1313</p> <p>unnötige invasive Diagnostik niedriges Verzerrungspotential n = 2 Studien</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | hohes Verzerrungspotential n = 2 Studien CAD-MAN OR 0,01 (0,00; 0,02), (hohe Ergebnis-sicherheit) (n / N) 6 / 167 vs. 137 / 162 DISCHARGE OR 0,03 (0,02; 0,03), (hohe Ergebnis-sicherheit) (n / N) 111 / 1808 vs. 1260 / 1753 gesundheitsbezogene Lebensquali-tät niedriges Verzerrungspotential – hohes Verzerrungspotential n = 1 periprozedural – mittelfristig SF-12 körperlicher Summenscore MWD 0,12 (95 % KI -0,37; 0,61) MW (SD) Studienbeginn vs. Stu-dienende CCTA 44,1 (9,1) vs. 46,7 (8,9) gegen-über ICA 43,4 (9,3) vs. 46,1 (9,1) (n) 1551 vs. 1489 langfristig SF-12 körperlicher Summenscore MWD 0,26 (95 % KI -0,27; 0,78) MW (SD) Studienbeginn vs. Stu-dienende CCTA 44,1 (9,1) vs. 48,4 (8,7) gegen-über | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | ICA 43,4 (9,3) vs. 47,8 (8,7) (n) 1392 vs. 1310 unerwünschte Ereignisse niedriges Verzerrungsrisiko n = 2 hohes Verzerrungsrisiko n = 1 periprozedural (bis 30 Tage nach Untersuchung) in beiden Behandlungsgruppen keine SUE, n = 1 Studie n = 6 Patient*innen mit SUE vs. n = 22 SUE (u. a. Arrhythmie, Herzstillstand, kardiale Tamponade) OR 0,26 (95 % KI 0,11; 0,64), n = 1 Studie mittelfristig (6-24 Monate) keine SUE vs. n = 2 Patient*innen mit schweren Blutungen, n = 1 Studie | | | |
| 33569 | [D22-01] Computertomographie-Koronarangiografie zur Diagnosestellung bei Patientinnen und Patienten mit Verdacht auf eine chronische koronare Herzkrankheit, Letzte Aktualisierung 17.02.2023. [12] | 2023 | Fragestellung 2: Nutzenbewertung von diagnostischen Strategien mit Anwendung einer kontrastverstärkten Computertomografie-Koronarangiografie (CCTA) mit der Option einer anschließenden CT-basierten funktionellen Beurteilung vs. diagnostische Strategien der gleichen Zielsetzung ohne die Option einer CT-basierten funktionellen Beurteilung (ilm Falle eines mindestens vergleichbaren Nutzens der CCTA gemäß Fragestellung 1 können die diagnostischen Vergleichsstrategien zudem die CCTA beinhalten) Einschlusskriterien s. Fragestellung 1 | Fragestellung 2 n = 0 systematische Übersichtsarbeiten, n = 5 RCT CCTA mit Option einer CT-basierten funktionellen Beurteilung vs. Strategien ohne Option einer CT-basierten funktionellen Beurteilung: n = 4 Studien (mit 2 verschiedenen Verfahren zur funktionellen Beurteilung als Ergänzung zur CCTA: - Computertomografie(CT)-basierte Messung der fraktionellen Flussreserve (FFR), kurz (CT-FFR) (FORECAST, PRECISE, TARGET), wobei PRECISE und TARGET nicht | Verzerrungspotential endpunktübergreifend für die CATCH-2 Studie und FORCAST als niedrig eingestuft, für die Studie Yu 2020 als hoch (adäquate Erzeugung der Randomisierungsfrequenz sowie verdeckte Gruppeneinteilung mit unklar klassifiziert) daher für Yu 2020 für alle Endpunkte hohes Verzerrungspotential für die beiden anderen Studien alle Endpunkte mit niedrigem Verzerrungspotential | | Abschlussbericht im Vergleich zum Vorbericht Neben redaktionellen Änderungen ergaben sich folgende Spezifizierungen oder Änderungen im Abschlussbericht: ▪ Studie PROTECCT (im Vorbericht als Studie mit unklarem Status) wurde aufgrund neuer Daten (Publikation) abgeschlossen |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>ausreichend den Einschlusskriterien entsprachen – Ausschluss aus der Bewertung, ergänzend descriptiv dargestellt</p> <p>- CT-basierte Messung der myokardialen Perfusion (CTP) (CATCH-2, Yu 2020)</p> <p>beide Verfahren sind technisch nicht vergleichbar, daher sind zusammenfassende Metaanalysen nicht sinnvoll</p> <p>n = 2 laufende Studien sowie n = 1 Studien mit unklarem Status</p> <p>Ergebnisse nach Auswertungszeitpunkten</p> <ul style="list-style-type: none"> - von bis zu 30 Tagen nach der Untersuchung dem periprozeduralen Auswertungszeitraum, - von 6 bis 24 Monaten dem mittelfristigen Auswertungszeitraum und - von 2 bis 5 Jahren dem langfristigen Auswertungszeitraum zugeordnet <p>es lagen nur Daten zum mittelfristigen Zeitpunkt vor</p> <p>Fragestellung 2 Gesamtmortalität CATCH-2, 18 Monate</p> <ul style="list-style-type: none"> - n = 3/300 (1,0%) vs. n = 3/300 (1,0%) | <p>bewertet, Ausnahme die Lebensqualität (SAQ-7 (aus FORECAST): hohes Verzerrungspotential durch fehlende Verblindung und subjektive Erhebung</p> | | <ul style="list-style-type: none"> Studie TARGET (im Vorbericht als Studie mit unklarem Status) wurde berücksichtigt und ergänzend dargestellt (Publikation) Begriff für das Krankheitsbild der nicht obstruktiven KHK wurde in Kapitel 1 ergänzt in Kapitel 1 wurde klarer dargestellt, dass bei dem CCS (in Abgrenzung zum ACS) die Ischämie nur unter Belastung auftritt Charakterisierung der Intervention im CCTA-Arm der Studie DISCHARGE wurde im Bericht im Abschnitt 4.2.1 und in Tabelle 18 angepasst für die ergänzend dargestellte Studie PRECISE wurde ein Manuskript eingereicht, aus welchem zusätzliche Daten zur Verfügung standen (Folge: Überarbeitung der Verzerrungspotenzialbewertung und Berücksichtigung von 2 weiteren Endpunkten (kardiovaskuläre Mortalität, instabile Angina Pectoris) Daten zum Endpunkt krankheitsspezifische |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <ul style="list-style-type: none"> - Peto-OR 1,00 [0,20; 4,99], p >0,999, hohe Ergebnisqualität <p>FORECAST, 9 Monate</p> <ul style="list-style-type: none"> - n = 2/699 (0,3%) vs. n = 0/700 (0%) - OR 5,02 [0,24; 104,78], p = 0,171, hohe Ergebnisqualität <p>PRECISE, 11,8 Monate</p> <ul style="list-style-type: none"> - n = 5/1057 (0,5%) vs. n = 7/1046 (0,7%) - HR 0,74 [0,24; 2,35], p = k. A. <p>Yu 2020, 12 Monate</p> <ul style="list-style-type: none"> - n = 0/120 (0%) vs. n = 0/120 (0%), mäßige Ergebnisqualität - k. A. <p>kardiovaskuläre Mortalität</p> <p>CATCH-2, 18 Monate</p> <ul style="list-style-type: none"> - n = 0 / 300 vs. 0 / 300, hohe Ergebnissicherheit - k. A. <p>PRECISE, 11,8 Monate</p> <ul style="list-style-type: none"> - n = 1/1057 (0,1%) vs. n = 2/1046 (0,2%) - k. A. <p>TARGET, 12,2 Monate</p> <ul style="list-style-type: none"> - n = 2/587 (0,3%) vs. n = 1/589 (0,2%) - OR 0,96 (0,20; 18,85), p = 0,60 <p>Yu 2020</p> <ul style="list-style-type: none"> - n = 0 / 120 (0%) vs. n = 0 / 120 (0%), mäßige qualitative Ergebnissicherheit - k. A. | | | <p>Lebensqualität, gemessen anhand des Gesamtscore des SAQ-7 aus der Studie FORECAST wurden ergänzt</p> <ul style="list-style-type: none"> ▪ in Kapitel 5 wurde ein Abschnitt zum Wert der Diagnose einer nicht obstruktiven KHK eingefügt ▪ Nutzensaussage zu Fragestellung 2 wurde geändert, siehe Abschnitt 4.4 ▪ im Vorbericht war im Ergebnisabschnitt 4.3.4.8 dargestellt, dass die Ergebnisse der Studie PRECISE nur ergänzend berichtet werden; jetzt im vorangehenden Abschnitt 4.3.1 zu den Studiencharakteristika dieses Vorgehen begründet und in allen Tabellen, die Daten zur Studie PRECISE enthalten, jeweils anhand einer Fußnote auf die rein ergänzende Darstellung der Studie verwiesen ▪ bei der nur ergänzend berichteten Studie PRECISE wurde (wie bei der Studie TARGET) auf die Darstellung der Bewertung |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>MACE PRECISE, 11,8 Monate</p> <ul style="list-style-type: none"> - n = 18/1057 (1,7%) vs. n = 12/1046 (1,1%) - HR 1,57 (0,76; 3,27), p = k.A. <p>Herzinfarkt CATCH-2, 18 Monate</p> <ul style="list-style-type: none"> - n = 1/300 (0,3%) vs. 2/300 (0,7%) - Peto-OR 0,51 (0,05; 4,94), p = 0,683, hohe Ergebnissicherheit <p>FORECAST, 9 Monate</p> <ul style="list-style-type: none"> - n = 9/699 (1,3%) vs. 3/700 (0,4%) - OR 3,03 (0,82; 11,24), p = 0,084, hohe Ergebnissicherheit <p>PRECISE, 11,8 Monate</p> <ul style="list-style-type: none"> - n = 13/1057 (1,2%) vs. 5/1046 (0,5%) - HR 2,67 (0,94; 7,52), p = k.A. <p>TARGET, 12,2 Monate</p> <ul style="list-style-type: none"> - n = 7/587 (1,2%) vs. n = 9/589 (1,5%) - OR 0,78 (0,29; 2,10), p = 0,683 <p>Yu 2020, 12 Monate</p> <ul style="list-style-type: none"> - n = 0/120 (0%) vs. 0/120 (0%) | | | <p>des Verzerrungspotenzials und der Ergebnisse zu Endpunkten in den Abschnitten 4.3.3 und 4.3.4 verzichtet (Daten in den Abschnitten A3.3.1.2 und A3.3.2.)</p> <p>Abschlussbericht Version 1.1 im Vergleich zum Abschlussbericht Version 1.0</p> <ul style="list-style-type: none"> ▪ Abschnitt A1.2 ein fehlerhafter Verweis nun auf Kapitel 5 korrigiert und an gleicher Stelle eine formale Anpassung durch Ergänzung eines Aufzählungspunkts vorgenommen <p>Abschnitt A1.2 wurde ein Aufzählungspunkt zur nun deutlicher gekennzeichneten ergänzenden Darstellung der Studie PRECISE hinzugefügt</p> |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <ul style="list-style-type: none"> - k. A., mäßige Ergebnissicherheit <p>Schlaganfall FORCAST, 9 Monate</p> <ul style="list-style-type: none"> - n = 0/699 (0%) vs. 1/700 (0,1%) - OR 0,33 (0,01; 8,20), p = 0,530 <p>instabile Angina pectoris CATCH-2, 18 Monate</p> <ul style="list-style-type: none"> - n = 1/300 (0,3%) vs. n = 1/300 (0,3%) - Peto-OR 1,00 (0,06; 16,02), p > 0,999 <p>PRECISE, 11,8 Monate</p> <ul style="list-style-type: none"> - n = 9/1057 (0,9%) vs. n = 5/1046 (0,5%) - k. A. <p>TARGET, 12,2 Monate</p> <ul style="list-style-type: none"> - n = 39/587 (6,6%) vs. n = 44/589 (7,5%) - OR 0,88 (0,56; 1,38), p = 0,683 <p>Angina Pectoris CATCH-2, 18 Monate</p> <ul style="list-style-type: none"> - n = 18/300 (6,0%) vs. n = 24/300 (8,0%) - OR 0,73 (0,39; 1,38), p = 0,530 <p>Vermeidung unnötiger invasiver Diagnostik CATCH-2</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|---------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <ul style="list-style-type: none"> - n = 15/300 (4,3%) vs. n = 35/300 (11,7%) - OR 0,34 (0,18; 0,66), p > 0,001, hohe Ergebnissicherheit <p>FORCAST</p> <ul style="list-style-type: none"> - n = 30/699 (4,3%) vs. n = 62/700 (8,9%) - OR 0,46 (95 % KI 0,29; 0,72), p < 0,001, hohe Ergebnissicherheit <p>PRECISE</p> <ul style="list-style-type: none"> - n = 27/1057 (2,6%) vs. n = 107/1046 (10,2%) - HR 0,18 (95 % KI 0,12; 0,30), p < 0,001 <p>TARGET</p> <ul style="list-style-type: none"> - n = 88/608 (14,5%) vs. n = 184/608 (30,3%) - OR 0,39 (95 % KI 0,29; 0,52), p < 0,001 <p>krankheitsspezifische Lebensqualität, FORECAST (SAQ-7), 9 Monate</p> <ul style="list-style-type: none"> - MWD: -1,9; 95 %-KI: [-4,93; 1,13]; p = 0,22, mäßige Ergebnissicherheit <p>TARGET (SAQ-7), 12,2 Monate</p> <ul style="list-style-type: none"> - MWD: -0,8 (-1,99; 0,39), p = 0,15 <p>unerwünschten Ereignisse es lagen keine Daten vor</p> | | | |
| 33570 | [GA20-01] CT- oder MRT-Diagnostik bei Verdacht auf chronische koronare Herzkrankheit: eine Evidenzkartierung, Letzte Aktualisierung 30.06.2020. | 2020 | Fragestellung Kartierung der Evidenz zu nicht invasiven diagnostischen Verfahren mittels computertomografischer Koronarangiografie und Magnetresonanztomografie | n = 24 systematische Übersichtsarbeiten (SR) relevant, n = 9 SR eingeschlossen (n = 4 zur RCT und n = 5 zur diagnostischen | n.a. | E | Dieser Bericht wurde ohne die Beteiligung externer Sachverständiger erstellt. Für die eingeschlossenen |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| [14] | <p>www.iqwig.de/download/ga20-01_herz-ct-oder-mrt-bei-verdacht-auf-khk_arbeitspapier_v1-0.pdf</p> | | <p>Studientyp Systematische Übersichtsarbeit auf Basis randomisierter kontrollierter Studien Basis von Studien zur diagnostischen Güte (MEDLINE, NICE, AHRQ, ab 2015)</p> <p>Ein- und Ausschlusskriterien P: Personen mit Verdacht auf chronische koronare Herzkrankheit</p> <p>*selektierten Populationen mit Vorerkrankungen wie Mitralklappeninsuffizienz, Diabetes oder einer Nierenerkrankung wurden nicht eingeschlossen, ebenso Personen, die bereits eine perkutane Koronarintervention in Form eines Stents erhielten, eine Bypassoperation erhielten oder infolge einer Restenose erneut behandelt werden</p> <p>Intervention computertomografischer Koronarangiografie (CTA) und Magnetresonanztomografie (Stress-MRT) (*Mehrschicht-Spiral-CT, Stress-Perfusions-MRT und Dobutamin-Stress-MRT)</p> <p>Kontrolle invasive Koronarangiografie (ICA) ggf. mit Messung der fraktionellen Flussreserve (FFR) sowie zu den nicht invasiven Verfahren (Myokard-Perfusions-Single-Photonen-Emissions-Computer-Tomografie, Stress-Echokardiografie,</p> | <p>Güte) sowie n = 3 Leitlinien zu Teststrategien zur Diagnose einer chronischen KHK</p> <p>Charakteristika der eingeschlossenen Arbeiten s. Tabelle 4 (RCT), S.14 sowie Tabelle 11 ab S. 23 (diagnostische Güte) im Bericht; SR zu RCT schlossen 3-6 Primärstudien ein, SR zur diagnostischen Güte 10-65 (CTA) sowie 4-67 (Stress-MRT)</p> <p>PROMISE mit n = 10 003 und SCOT-HEART mit n = 4146 waren die beiden größten Studien aus den n = 4 SR zu RCT zur CTA</p> <p>Ergebnisse: CTA-basiert vs. ICA Gesamtmortalität kein Effekt Myokardinfarkt: , n = 3 SR Notwendigkeit einer nachgeschalteten ICA, n = 1 SR</p> <p>MRT-basiert Gesamtmortalität - unzureichende Datenlage Myokardinfarkt - unzureichende Datenlage Notwendigkeit einer nachgeschalteten ICA, n = 1 SR</p> | | | <p>systematischen Übersichten und Leitlinien wurde keine detaillierte Prüfung in Form einer Bewertung ihrer Qualität vorgenommen. Für RCT sollte die Randomisierungsfrequenz sowie Gruppenteilung geprüft werden. Grund: Evidenzkartierung war das Ziel</p> <p>Zum Nutzen und Schaden nicht invasiver CTA- und Stress-MRT-Diagnostik bei Personen mit Verdacht auf KHK liegt aussagekräftige Evidenz vor (RCT/SR). Daher wäre eine Nutzenbewertung eines der beiden oder beider Verfahren sinnvoll möglich.</p> <p>Die 3 ausgewählten evidenzbasierten Leitlinien empfehlen übereinstimmend nicht invasive Verfahren als 1. Test zur Diagnose einer KHK. (vgl. S. 33ff)</p> <p>Tabelle 6 beschreibt, dass der Einsatz der CTA im Vergleich zur ICA zu einer statistisch signifikant geringeren Häufigkeit von Myokardinfarkten führte; dennoch wird aus den Arbeiten berichtet, dass trotz</p> |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|----------------------------------------------|-------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | Belastungs-Elektrokardiogramm und computertomografische Messung der fraktionellen Flussreserve) oder invasiven Koronarangiografie ggf. mit Messung der fraktionellen Flussreserve oder mit der klinischen Nachbeobachtung als Referenztest Outcome Gesamtmortalität (S. 17 bzw. S. 20) Myokardinfarkt (S. 18 bzw. S. 21) Notwendigkeit einer nachgeschalteten ICA (S. 19 bzw. S. 21) ergänzend diagnostische Güte: Sensitivität und Spezifität | | | | bereits erfolgter CTA teilweise eine ICA im Anschluss (mit unterschiedlicher Häufigkeit) notwendig ist (mit Hinweis auf die Bildqualität) - Abhängigkeit von der Strategie zur Diagnose und damit dem Versorgungskontext; es wird von 490 000 isolierten ICA in Deutschland im Jahr 2018 berichtet Hintergrund: Morphologische Verfahren dienen dem direkten Nachweis von Stenosen, wohingegen die funktionellen Verfahren die Folgen von Stenosen für die Durchblutung des Herzmuskelgewebes nachweisen. Weitere nicht invasive Verfahren in der Versorgung sind neben der Stress-Perfusions-MRT und der Dobutamin-Stress-MRT die 3 ebenfalls funktionellen Verfahren Myokard-Perfusions-Single-Photonen-Emissions-Computer-Tomografie (SPECT), Stress-Echokardiografie und Belastungs-Elektrokardiogramm (EKG) |
| ergänzende/weiterführende Information | | | | | | | |
| 33518 | Rolf, A. et al. Positionspapier Erbringung kardialer CT-Leistungen Kardiologie 2023 · 17:81–94. | 2023 | Hintergrund Nationale Herz-Kreislauf-Strategie in Deutschland | es werden u. a. die Indikation sowie Mindestanforderungen an die Befunde | n. a. | Ei | Auto*innen schlussfolgern, dass ein kooperatives He- |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| [15] | <p>https://doi.org/10.1007/s12181-023-00599-z, https://leitlinien.dgk.org/2023/positionspapier-qualitaetskriterien-fuer-die-erbringung-kardialer-ct-leistungen/</p> | | <p>kardiale Computertomografie ein bildgebendes Verfahren mit definierter Indikation für die Diagnostik und Therapievorbereitung</p> <p>Ziel des Positionspapies der DGK Indikationen und Qualitätskriterien für die Durchführung, Befundung und Interpretation der kardialen CT aus Sicht der kardiologischen Fachgesellschaft (Leitfaden Heart-Team-Modell)</p> <p>Intervention CT-Koronarangiografie - Untersuchungsablauf (stabile Herzfrequenz <60/min ist anzustreben, um die Wahrscheinlichkeit von Artefakten zu minimieren und die Anwendung von Verfahren zur Reduktion der Strahlenexposition zu erlauben, ohne die Bildqualität negativ zu beeinflussen)</p> <p>Alle der folgenden Kriterien müssen gewährleistet sein – Vor Untersuchungsbeginn Beurteilung von Herzrhythmus und -frequenz anhand zumindest 1-Kanal EKG in tiefer Inspiration – Medikamentöse Senkung der Herzfrequenz bei Ruhfrequenz >65/min durch die Gabe von Betablockern oral (genügend zeitlicher Vorlauf: zumindest 45 min vor der Untersuchung) oder Ivabradin (Vorlauf zumindest 24 h vor der Untersuchung) und zusätzlich ggf. β-Blockern i.v. (Metoprolol bis 40mg)</p> | <p>derung beschrieben sowie Anforderungen an die Untersuchung sowie klinischen Angaben und die technischen Qualitätskriterien sowie Logistische und organisatorische Qualitätskriterien; ergänzt um Kriterien zur Qualitätskontrolle</p> <p>- es wird angegeben, dass etwa 200 Kardiologen aktuell die Qualifikation im Level II und III für die kardiale CT besitzen (s. u.) sowie rund 350 für Level II und III für die kardiale MRT - ergänzt um die Angabe von 294 Radiologen mit analogem Level Q2 sowie 195 mit analogem Level Q3 der radiologischen Zertifizierungsprogramme (allerdings sind CT und MRT hier kombiniert angegeben für eine Qualifikation) - geforderte Mindestanforderung: Qualifikation auf Level II bzw. Q2</p> <p>gemeinsame Kompetenzen (für jeden Schritt von Indikation bis Therapieempfehlung): diagnostischer Pfad mit Selektion des angemessenen Verfahrens (patientenindividuelle Beschwerden und Risikoprofil zu berücksichtigen) sowie lokale Verfügbarkeit und Expertise</p> <p>nur die Patient*innen sollen Zugang zur Methode bekommen, die a) davon wirklich profitieren, b) bei denen eine Leitlinienindikation vorliegt, und c) sichergestellt ist, dass der Befund zu</p> | | | <p>art-Team-Modell mit gemeinsamer Erbringung der Leistung durch Radiologen und Kardiologen ist am besten geeignet erscheint, die Qualitätsziele zu erreichen und eine nicht evidenzbasierte, Zusatzleistungen provozierende und damit das Gesundheitssystem zusätzlich signifikant belastende Leistungsausweitung zu vermeiden.</p> <p>es wird auf eine sich stetig weiterentwickelnde Evidenzlage hingewiesen</p> <p>Abb 1 auf S. 90 zeigt die Pfade und Qualitätskriterien des kooperativen Modells für die CCTA (ambulant und stationär) im Überblick</p> <p>ältere Versionen: Update 2020: Giannitsis, E., Post, F., Haerer, W. et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung für „Chest Pain Units“. Kardiologie (2020). https://doi.org/10.1007/s12181-020-00417-w https://leitlinien.dgk.org/2020/kriterien-der-deutschen-gesellschaft-fuer-kardiologie-</p> |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | |
| | | | <p>– Gabe von Nitraten zur Koronardilatation, abgesehen von Patientinnen/Patienten mit Kontraindikationen</p> <p>– Kontrastmittelflussrate $\geq 5 \text{ ml/s}$</p> <p>Nachsorge: Bei der CCTA-Überwachung für zumindest 30 min nach Gabe blutdruck- und herzfrequenzwirksamer Medikamente</p> <p>Während der Prämedikation ist auf eine ausreichende Überwachung der Patientinnen/Patienten zu achten. In Notfallmedizin geschultes ärztliches und Assistenzpersonal muss unmittelbar verfügbar sein, um auf Bradykardie oder Hypotonie reagieren zu können.</p> | <p>einer unmittelbaren klinischen Konsequenz führt, ohne eine Kette weiterer (für die Patient*innen belastende und das Gesundheitssystem kostenintensive) Folgeuntersuchungen mit nichtinvasiver Diagnostik und nachfolgend eventuell dann doch invasiver Diagnostik zur Absicherung nach sich zu ziehen</p> <p>geforderte Angaben zur Untersuchung sind:</p> <ol style="list-style-type: none"> 1. Symptomatik des Patienten, 2. kardiovaskulären Risikofaktoren, 3. Vortestwahrscheinlichkeit für eine KHK und 4. relevanten Vorerkrankungen (insbesondere Vorbefunde aus der Echokardiographie oder anderen bildgebenden Verfahren sind zu dokumentieren) <p>Für die CCTA sind Kontraindikationen zur medikamentösen Senkung der Herzfrequenz (z.B. AV-Block, Vormedikation mit Kalziumantagonisten vom Nicht-Dihydropyridin-Typ) und zur Gabe von Nitraten (z. B. hypertroph-obstruktive Kardiomyopathie, Aortenklappenstenose, PDE-5-Hemmer-Einnahme) bezüglich der Indikationsstellung zu beachten und in der Anforderung zu dokumentieren.</p> <p>technischen Parameter des eingesetz-</p> | | | <p>herz-und-kreislaufforschung-fuer-chest-pain-units-2/</p> <p>Perings, S., Smetak, N., Kelm, M. et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. für „Brustschmerz-Ambulanzen“. <i>Kardiologe</i> (2016) 10: 301. doi:10.1007/s12181-016-0074-4 https://leitlinien.dgk.org/2016/kriterien-der-deutschen-gesellschaft-fuer-kardiologie-herz-und-kreislaufforschung-e-v-fuer-brustschmerz-ambulanzen-update-2016/</p> <p>H. Reinecke, M. Braun, L. Frankenstein et al. (2015) Kriterien für die Notwendigkeit und Dauer von Krankenhausbehandlungen bei Koronarangiografien und –Interventionen <i>Kardiologe</i> 2015 · 9:295–302 https://leitlinien.dgk.org/2015/kriterien-fuer-die-notwendigkeit-und-dauer-von-krankenhausbehandlungen-bei-koronarangiografien-und-interventionen/</p> |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | <p>ten CT-Gerätes und das Untersuchungsprotokoll beeinflussen Bildqualität und Strahlenexposition bei CT-Untersuchungen des Herzens in maßgeblicher Weise</p> <ul style="list-style-type: none"> - empfohlen werden hier CT-Systeme, die sowohl über die Möglichkeit zur Spiral/Helikalk-Akquisition mit retrospektiv EKG-synchronisierter Bildrekonstruktion als auch zur axialen Akquisition mit prospektiver EKG-Triggerung verfügen - Für CT-Untersuchungen des Herzens außerhalb der Koronararterien mit geringerer Ortsauflösung sind ggf. geringere Anforderungen ausreichend - die DGK hat zudem 3 Kompetenzebenen definiert, die es dem Programmkandidaten ermöglichen, diese Qualifikation in konsekutiven Schritten zu erwerben und die Weiterbildung zum Kardiologen um spezielle Inhalte zu erweitern, Level 1 zur Stellung der richtigen Indikation, Level II zur selbständigen Planung, Durchführung und Befundung (beinhaltet Praxisanwendungen), Level III (über 12-Monate Praxiseinsatz mit mind. 300 Befundungen + vertiefende Ausbildung im Katheterlabor) <p>(u. a. mindestens 3-jährige Grundausbildung in allgemeiner Kardiologie sowie Erfahrungen in der Echokardiographie und im Katheterlabor)</p> | | | |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CT-Coronarangiografie | | | | | | | | |
| 33519 | <p>Sieren et al. Current Status of Cardiovascular Imaging in Germany: Structured Data from the National Certification Program, ESCR Registry, and Survey among Radiologists. <i>Rofo</i>. 2022 Feb;194(2):181-191. doi: 10.1055/a-1554-9236. Epub 2021 Aug 12.</p> <p>https://pubmed.ncbi.nlm.nih.gov/34384112/</p> <p>[16]</p> | 2022 | <p>Fragestellung Überblick über die in radiologischen Einrichtungen in Deutschland angebotenen kardiovaskulären Bildgebungen (KVB)</p> <p>Studientyp Registerstudie, - Datenbank des nationalen Zertifizierungsprogramms der Deutschen Röntgengesellschaft (DRG) von 2015-2021 - bundesweite online-Umfrage aus 2019 (ambulant und stationär) aus n = 18 Fragen - Daten aus dem Register der European Society of Cardiovascular Radiology (ESCR)</p> <p>Endpunkte Anzahl der für die KVB zertifizierten Zentren und Personen Anzahl durchgeführter kardialer CT- und MRT-Untersuchungen Befundgewohnheiten Teilnahme am ESCR-Register</p> <p>*certification levels: Q1 (basic knowledge) to Q3 (comprehensive knowledge, instructor)</p> | <p>n = 71 Zentren und n = 1278 Personen waren für KVB zertifiziert - Q1 n = 902 (71 %), Q2 n = 227 (18 %), Q3 n = 149 (12 %) - Cardiovascular Imaging Working Group (WG CVI) mit n = 1612 registrierten Mitgliedern in 2021 - deutlicher Anstieg seit 2015 - Teilnahmequote am ESCR-Register: bei 48 %</p> <p>Umfrage: n = 184 Teilnehmende bzw. Rückmeldungen (n = 30 aus Universitätskliniken, n = 76 aus Kliniken, n = 78 aus privaten Praxen) (Umfrageteilnehmende: n = 262 (38 %) aus Universitätskliniken, n = 289 (42 %) aus Kliniken und n = 144 (21%) aus privaten Praxen)</p> <p>- n = 69 286 CT-Untersuchungen / Jahr --- n = 30 682 (44 %) in Universitätskliniken --- n = 27 521 (40 %) in Kliniken --- n = 11 083 (16 %) in privaten Praxen</p> <p>- n = 64 281 MRT-Untersuchungen / Jahr --- n = 22 630 (33 %) in Universitätskliniken --- n = 28 151 (40 %) in Kliniken --- n = 13 500 (20 %) in privaten Praxen</p> <p>- von den 99 PLZ-Regionen in Deutschland haben n = 56 (57 %) einen direkten Zugang zu zertifizierten Zentren</p> | n. a. | | Ei | <p>Autor*innen leiten flächendeckende Verfügbarkeit der KVB durch Radiologen ab; regionale Cluster werden beschrieben</p> <p>sowohl ambulant als auch stationär hochqualifizierte Expertise</p> <p>Versorgungssicherstellung und wirtschaftliche Nachhaltigkeit werden als Herausforderungen beschrieben</p> <p>es wird ergänzend das Zertifizierungsprogramm der DRG beschrieben, das u. a. ein Online-Angebot zur Weiterqualifizierung enthält (CONRAD)</p> |

| Nr. | Referenz | Jahr | Charakteristika | Ergebnisse | Methodische Qualität | A/E | Kommentar |
|------------------------------|----------|------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-----|-----------|
| CT-Coronarangiografie | | | | | | | |
| | | | | Umfrage und ESCR-Register: - Befunde zumeist durch Radiologen, in geringem Maße in gemeinsamen Konsensus-Meetings mit nichtradiologischen Fachdisziplinen durchgeführt - n = 88 (48 %) der Institutionen dokumentieren ihre Ergebnisse in ESCR Registern --- n = 181 deutsche Präsenzen berichten kardiale MR und n = 160 kardiale CT Fälle im Register | | | |

12.3 Kapitel Therapieplanung und gemeinsame Entscheidungsfindung

IQWiG ThemenCheck Medizin – Behandlungsgespräche (gemeinsame Entscheidungsfindung)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Behandlungsgespräche: Führt eine gemeinsame Entscheidungsfindung von Arzt und Patient bei der Therapiewahl zu besseren Ergebnissen? HT22-01. www.iqwig.de/sich-einbringen/themencheck-medicin/berichte/ht22-01.html Stand: 04.09.2023 (vorläufiger Bericht) [17] | Fragestellungen Ziele sind <ul style="list-style-type: none"> - die Nutzenbewertung verschiedener Interventionen (oder Kombination) zur Unterstützung der gemeinsamen Entscheidungsfindung von Ärzt*innen/Leistungserbringer*innen und Betroffenen (Shared Decision Making) - im Vergleich oder zum Standardvorgehen ohne Shared Decision Making | n = 9 SR bewertet (AMSTAR-II), n = 2 mit niedrig bis kritisch eingestuft, daher aus der Nutzenbewertung ausgeschlossen n = 7 SR mit hoher bis moderater AMSTAR-II-Bewertung (n = 252 RCT) [4,8,9,13,25-27] (Seite 34) <ul style="list-style-type: none"> - n = 3 fokussierten auf „Entscheidungshilfen für Patientinnen und Patienten“ (Scalia 2019 [28], Stacey 2017 [13], Yen 2021 [27]) - n = 4 fokussierten auf Interventionen bei Betroffenen, Leistungserbringer*innen oder beiden im Vergleich zum Standard (Jull 2021 [25], Legaré 2018 [4], NICE A 2021 [8] und NICE B 2021 [9]) | n.a. Evidenzqualität für die berichteten statistisch signifikanten Ergebnisse aus Meta-Analysen wurde durch die Autor*innen mit niedrig bis hoch bewertet (Herabstufung teils wegen schwerer Design-Mängel, Verzerrungsrisiko, Heterogenität, indirekter Evidenz, unzureichender Präzision); tlw. geprüft durch Sensitivitätsanalysen insbesondere bei der SDM-Intervention „Entscheidungshilfen“ war die | Hinweis: Dieser Bericht wurde durch externe Sachverständige erstellt. Der vorläufige HTA-Bericht wird zur Anhörung gestellt. die Autor*innen schlussfolgern, dass für die patientenrelevanten Endpunkte Mortalität, Morbidität und Lebensqualität |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - Bestimmung der Kosten (Interventionskosten) - Bewertung der Kosteneffektivität verschiedener Interventionen - die Aufarbeitung ethischer, sozialer, rechtlicher und organisatorischer Aspekte <p>Die Themenvorschlagende interessiert sich für die Frage, ob Maßnahmen wie die gemeinsame bzw. partizipative Entscheidungsfindung von Ärztin und Arzt und Patientin und Patient Einfluss auf das Behandlungsergebnis und die Patientenzufriedenheit haben können.</p> <p>Methodik HTA-Bericht; u. a. systematische Übersichtsarbeit zu SR (fokussierte Informationsbeschaffung ab 2010) in MEDLINE, HTA Database, Referenzlisten SR, zudem bei NICE, Agency of Healthcare Research and Quality (AHRQ)</p> <ul style="list-style-type: none"> - letzte Suche am 07.11.2022 (Suchzeitraum ab 2017) <p>zur gesundheitsökonomischen Bewertung sowie ethischen, sozialen und rechtlichen Betrachtung vgl. Bericht ab S. 31; zudem wurden Interviews mit Betroffenen durchgeführt</p> <p>Ein- und Ausschlusskriterien</p> | <p>Fokus:</p> <ul style="list-style-type: none"> o (a) zur Vorbereitung auf ein Gespräch, o (b) zur Verbesserung der Gesundheitskompetenz der Betroffenen, o (c) zur Präferenzerhebung, o (d) zur Patienten-Aktivierung, o (e) zur Unterstützung der Betroffenen durch Dritte, o (f) zur Dokumentation der Versorgung, o (g) Kombinationen der genannten Interventionen <ul style="list-style-type: none"> - Studien wurden in sehr unterschiedlichen Indikationen, Ländern und Settings (ambulant und/oder stationär) durchgeführt - meisten RCT aus den USA oder Europa - häufig im Bereich des Screenings oder der Behandlung von onkologischen, Herz-Kreislauf- und psychischen Erkrankungen <p>n = 5 Evidenzberichte des NICE zum Nutzen und Schaden von SDM-Interventionen (seit 2015), in 2021 veröffentlichte Leitlinie des NICE zum Thema (Quelle s. u.) werden eingangs im Bericht beschrieben</p> <p>Ergebnisse Übersicht: Tabelle 1 (PROMs), Tabelle 2 (SDM-bezogene) und Tabelle 3 (weitere Endpunkte) des Berichts</p> <p>für die folgenden Vergleiche wurden Endpunkte berichtet:</p> <ol style="list-style-type: none"> 1) Entscheidungshilfen vs. Standardversorgung 2) SDM-Interventionen bei Betroffenen vs. Standardversorgung bzw. andere SDM-Interventionen bei Betroffenen 3) SDM-Interventionen bei Leistungser*innen vs. Standardversorgung bzw. andere SDM-Interventionen bei Leistungserbringer*innen 4) SDM-Interventionen bei beiden vs. Standardversorgung bzw. andere SDM-Interventionen bei beiden | <p>Interpretation der Ergebnisse erschwert durch eine fehlende Einordnung der Effektgröße bzw. Relevanz (eingeschränktes Vertrauen in die Ergebnisse), eine Bewertung und Diskussion der Ergebnisse wird gewünscht</p> <p>für andere SDM-Interventionen wurden die Evidenzqualität als zu niedrig bzw. die Aussagesicherheit als unzureichend bewertet (u. a. schwache Effektschätzer)</p> <p>hohe klinische und inhaltliche Heterogenität wird berichtet (Indikation, Population, Intervention, Vergleiche, Endpunkte (Operationalisierung)), zeigt sich auch in einer statistischen Heterogenität (nur wenige Studien konnten zusammengefasst werden)</p> <p>eigene, zusätzliche MA wurden daher nicht durchgeführt</p> <p>eine grobe Kosten(Aufwands-)schätzung war möglich, für die Regelversorgung konnten aber keine verbindlichen Angaben gegeben werden</p> <ul style="list-style-type: none"> - die gesundheitsökonomische Auswertung wird durch die Autor*innen mit einer Vermutung gegeben, dass für bestimmte Indikationen und Populationen im Vergleich zum Standard kosteneffektiv | <p>kein Nutzen oder Schaden von SDM-Interventionen im Vergleich zur Standardversorgung ohne SDM bzw. Im Vergleich zu anderen SDM-Interventionen abgeleitet werden kann</p> <p>für die Intervention "Entscheidungshilfen" wurden 6 von 17 untersuchte SDM-bezogene Endpunkte mit einem Vorteil im Vergleich zur Standardversorgung ohne SDM bewertet:</p> <ul style="list-style-type: none"> ▪ „Umsetzung von SDM/ Einbindung des Patienten“, ▪ „Arzt-Patient-Kommunikation“, ▪ „Wissen“, ▪ „richtige Einschätzung von Risiken“, ▪ „Übereinstimmung zwischen informierter Präferenz und Entscheidung“ ▪ „Entscheidungskonflikt“ <p>Nachteile wurden für keine der SDM-Interventionen und Vergleiche gefunden</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - erwachsene (> 18 Jahre) und einwilligungsfähige Betroffene - keine Beschränkung auf bestimmtes Krankheitsbild - Leistungserbringer*innen - SR, RCT (Ergebnisse aus nicht-RCT wurden nicht berücksichtigt) - SR vor 2010 wurden nicht herangezogen (da erst ab da eine systematische Aufbereitung in Studien erfolgte, dort wurden verbindliche Standards definiert) <p>Qualitätsbewertung AMSTAR-II, keine eigene Bewertung der in SR eingeschlossenen RCT, Qualitätsbewertung der SR wurde übernommen (Evidenzqualität, hoch, moderat, niedrig und sehr niedrig; abweichend von den Bezeichnungen des IQWiG („Ergebnissicherheit“) und des Cochrane Netzwerks („Aussagesicherheit“))</p> <p>Intervention Zur Unterstützung einer gemeinsamen Entscheidungsfindung (SDM-Interventionen):</p> <ul style="list-style-type: none"> - SDM-Schulung von Ärzt*innen oder anderen an der Behandlung beteiligten Personen (z. B. anhand von Fallbeispielen) - Decision Coaching von Betroffenen durch bspw. | <p>Ergebnisse zu den patientenrelevanten Endpunkten in Tabelle 8, Tabelle 9, Tabelle 10 und Tabelle 11 (Matrix Tabelle 1, S. 37) zeigen die Landkarte der Beleglage für die jeweiligen SDM-Interventionen und Vergleiche (Matrix s. a. Tabelle 2 und 3, S. 38):</p> <p>z. B. kein Anhaltspunkt, Hinweis oder Beleg für einen Nutzen/Schaden für die Endpunkte:</p> <ul style="list-style-type: none"> • HRQoL für 1), 2), 3) und 4) • Angst, Depression, andere psychische Belastung für 1) und 2) <p>keinen der patientenrelevanten Endpunkte (Mortalität, Morbidität und gesundheitsbezogene Lebensqualität) erbrachten Nutznachweise (es fehlte hochwertige Evidenz zu diesen Endpunkten, in den RCT entweder gar nicht oder als sekundäre Endpunkte erhoben), Fokus überwiegend auf SDM-bezogenen Endpunkten:</p> <p>Matrix der ermittelten Daten in Tabelle 1, S. 37 (keine berichteten Daten zur Gesamtmortalität, in n = 4 SR Angaben zur Mortalität (Gesundheitszustand/Symptome aus Einzelstudien), in n = 7 SR Angaben zu Nebenwirkungen (u. a. Angst/Depression) – darunter in n = 4 aus Metaanalysen, in n = 5 SR Angaben zur Lebensqualität – darunter in n = 1 SR aus Metaanalysen)</p> <p>Endpunkt Nutzen-Aussage (aus Perspektive der SDM-Intervention, im Vergleich zur Standardversorgung oder vergleichbarer Intervention)</p> <p>Entscheidungshilfen</p> <ul style="list-style-type: none"> - Gesamtmortalität keine Daten berichtet - Morbidität (Gesundheitszustand/ Symptome aus Einzelstudien) <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede - HRQoL | <p>oder gar kosteneinsparend sein könnten</p> | <p>es wird als plausible eingeschätzt, dass ein Mehr an Wissen, Umsetzung der SDM, Einbindung der Betroffenen, bessere Kommunikation und eine Verringerung von Entscheidungskonflikten die gemeinsame Entscheidungsfindung im Versorgungsalltag fördern können</p> <p>SDM-Interventionen seien geeignet, die Autonomie der Betroffenen zu stützen (Recht auf Selbstbestimmung) und zudem die Erfüllung der Anforderungen aus dem Patientenrechtegesetz zu unterstützen</p> <p>soziale Sicht: für die Implementierung von SDM-Interventionen ist es wichtig, dass sie auf die Bedarfe aller sozialen Gruppen angepasst und gut zugänglich gemacht werden</p> <p>als hindernde Faktoren beschrieben werden u. a. Zeitmangel</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>qualifizierte Pflegefachpersonen (Entscheidungsbegleitung)</p> <ul style="list-style-type: none"> - evidenzbasierte Entscheidungshilfen oder Patientinformationen - Maßnahmen zur Aktivierung bzw. Motivation von Betroffenen (bspw. zur Kommunikation oder aktiven Beteiligung am Entscheidungsprozess) – Leitfaden 3 Fragen (Welche Möglichkeiten?, Vor-/Nachteile?, Wahrscheinlichkeit, dass Vor-/Nachteile eintreten?) <p>Allein oder in Kombination</p> <p>Vergleich Standard ohne SDM-Intervention oder andere SDM-Intervention</p> <p>Endpunkte patientenrelevante Endpunkte</p> <ul style="list-style-type: none"> - Mortalität, - Morbidität, - Nebenwirkungen wie Angst, Depression, - Unerwünschte Ereignisse, - gesundheitsbezogene Lebensqualität <p>Aussage zur Beleglage des (höheren) Nutzens und (höheren) Schadens in 4 Abstufungen:</p> <ul style="list-style-type: none"> - ein Beleg (höchste Aus-sagesicherheit), | <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede <p>Betroffene</p> <ul style="list-style-type: none"> - Gesamt mortalität keine Daten berichtet - Morbidität (Gesundheitszustand/ Symptome aus Einzelstudien) <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 3 SR): keine Gruppenunterschiede - HRQoL <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 4 SR): keine Gruppenunterschiede <p>Leistungserbringer*in</p> <ul style="list-style-type: none"> - Gesamt mortalität keine Daten berichtet - Morbidität (Gesundheitszustand/ Symptome aus Einzelstudien) / - HRQoL <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede o Meta-Analyse (n = 1 SR) vs. Standard: SMD: 0 (-0,06; 0,06), p = 0,94 (2 Studien) <p>Betroffene und Leistungserbringer*in</p> <ul style="list-style-type: none"> - Gesamt mortalität keine Daten berichtet - Morbidität (Gesundheitszustand/ Symptome aus Einzelstudien) / - HRQoL <ul style="list-style-type: none"> o Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede o Meta-Analyse (n = 1 SR) vs. Standard: SMD 0,20 (-0,03; 0,43), p = 0,09 (3 Studien) (physisch) o Meta-Analyse (n = 1 SR) vs. Standard: SMD 0,21 (-0,01; 0,44), p = 0,07 (3 Studien) (psychisch) <p>Nebenwirkungen (u. a. Angst, Depression)</p> <p>Entscheidungshilfen</p> <ul style="list-style-type: none"> - Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede | | <p>(z. B. im Krankenhaus) oder wirtschaftliche Fehlanreize</p> <p>die Autor*innen bewerten die gemeinsame Entscheidungsfindung aus ethischer und rechtlicher Sicht als geboten, sozial erwünscht und organisatorisch umsetzbar</p> <p>RCT werden gefordert, die die Heterogenität der Endpunkte und deren Operationalisierung reduzieren und auf validierten und konsentierten Erhebungs-Methoden und Instrumenten basieren</p> <p>neben den patientenrelevanten Endpunkten erfolgt ein Hinweis auf versorgerrelevante Endpunkte (z. B. die Berufszufriedenheit oder die Zufriedenheit mit der Kommunikation und der Behandlung) (hier nicht gemessen bzw. berichtet)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - ein Hinweis (mittlere Aussagesicherheit), - ein Anhaltspunkt (schwächste Aussagesicherheit) - keine dieser 3 Situationen (z. B. keine Daten) <p>SDM-bezogene Endpunkte (patienten- oder beobachter- bzw. versorgerberichtet, PROMs/OBOMs/CROMs), u. a.:</p> <ul style="list-style-type: none"> - Vorbereitung auf die Entscheidung von Betroffenen - Bedauern der Entscheidung (decision regret) von Betroffenen - Umsetzung von SDM / Einbindung von Betroffenen (patienten- und beobachterberichtet) - Wissen / richtige Einschätzung von Risiken durch Betroffene - Entscheidungskonflikt (decisional conflict) von Betroffenen - Selbstwirksamkeit (self-efficacy) in der Behandlungsentscheidung von Betroffenen - Arzt-Patient-Beziehung und -Kommunikation - Zufriedenheit von Betroffenen - Empowerment von Betroffenen - Übereinstimmung zwischen gewünschter und | <ul style="list-style-type: none"> - Angst (n = 2 SR): <ul style="list-style-type: none"> o SMD -0,03 (-0,27; 0,22), p = 0,83 (4 Studien), n = 1 SR o SMD 0,02 (-0,22; 0,26], p-Wert nicht berichtet (4 Studien), n = 1 SR <p>Betroffene</p> <ul style="list-style-type: none"> - Einzelstudienauswertung (n = 1 SR): keine Gruppenunterschiede - Meta-Analysen (n = 2 SR) vs. Standard: <ul style="list-style-type: none"> o SMD: 0,02 (-0,33; 0,37), p = 0,91 (2 Studien), n = 1 SR o SMD: 0,02 (-0,33; 0,37), p = 0,91 (2 Studien), n = 1 SR vs. andere Intervention: <ul style="list-style-type: none"> o SMD: -0,11 (-0,27; 0,05), p = 0,17 (2 Studien), n = 1 SR o SMD: -0,11 (-0,27; 0,05), p = 0,17 (2 Studien), n = 1 SR - Einzelstudienauswertung (n = 1 SR): Depression scheint häufiger bei niedriger Evidenzqualität <p>Leistungserbringer*innen: / Betroffene und Leistungserbringer*innen: /</p> <p>(weitere) unerwünschte Wirkungen Entscheidungshilfen: / Betroffene: / Leistungserbringer*innen: / Betroffene und Leistungserbringer*innen: /</p> <p>SDM-bezogene Endpunkte finden sich in Tabelle 12, Tabelle 13, Tabelle 14 und Tabelle 15 des Berichts (S. 56-68), Matrix der berichteten Endpunkte vgl. auch Tabelle 2/3 (insgesamt n = 17 betrachtete SDM-bezogene Endpunkte)</p> <p>z. B. richtige Einschätzung von Risiken:</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>tatsächlicher Einbindung in die Entscheidung</p> <ul style="list-style-type: none"> - Übereinstimmung zwischen gewünschter Option und getroffener Entscheidung <p><i>Hinweis:</i> Gemeinsame Entscheidungsfindung (shared decision making, SDM) ist Prozess zwischen Betroffenen und Angehörigen der Gesundheitsberufe, im Gespräch treten die Beteiligten miteinander in eine Beziehung, wobei beide eine aktive Rolle haben; es werden für die Krankheit sowie Behandlung relevante Aspekte besprochen und Informationen ausgetauscht, Zusammenhänge sowie Behandlungsmöglichkeiten werden mit Vor- und Nachteilen vorgestellt und auf das Verständnis der Inhalte überprüft; es ist Raum für Fragen und ggf. Betrachtung der und Bezug zu Lebensumstände(n), Präferenzen und Werten der Betroffenen, eine gemeinsame Zieldefinition (fundamental, funktional und symptom-spezifisch) wird angestrebt sowie eine gemeinsame Entscheidungsfindung zur Behandlung oder auch gegen eine Behandlung</p> <p>Prozess der gemeinsamen Entscheidungsfindung wird als komplex und auf verschiedenen Ebenen von Bedeutung beschrieben: auf der Mikro-, Meso- und Makroebene</p> | <ul style="list-style-type: none"> - RR 2,10 (95% KI 1,66; 2,66), p < 0,001, n = 1 SR (Entscheidungshilfen für Betroffene), n = 17 Studien, moderate Evidenzqualität <p>Zudem sind von S. 69-71 Übersichten zu den Vor/Nachteilen SDM-bezogene Endpunkte dargestellt (Tabelle 16-19)</p> <p>z. B. Entscheidungshilfen (Tabelle 12, S. 56ff, Matrix Tabelle 16, S. 69): Vorteile für</p> <ul style="list-style-type: none"> - die Umsetzung von SDM/Einbindung der Betroffenen: <ul style="list-style-type: none"> o SDM patientenberichtet (n = 1 SR): <ul style="list-style-type: none"> ▪ patientengesteuert RR: 1,28 [1,05; 1,55], p = 0,01 (15 Studien, Evidenzqualität moderat) ▪ arztgesteuert RR: 0,68 [0,55; 0,83], p = 0 (16 Studien, Evidenzqualität moderat) ▪ durch beide gesteuert RR: 0,95 [0,83; 1,10]; p=0,52 o SDM beobachterberichtet (n = 1 SR): <ul style="list-style-type: none"> ▪ SMD: 0,94 [0,40; 1,48], p = 0,0007 (9 Studien), großer Effekt o Einzelstudienauswertung (n = 1 SR): <ul style="list-style-type: none"> ▪ keine Gruppenunterschiede ▪ Bei Auswertung zusammen mit anderen SDM-Interventionen: SMD: 0,23 [0,05; 0,42], p-Wert nicht berichtet - das Wissen: <ul style="list-style-type: none"> o MD: 13,27 [11,32; 15,23], p = 0,0001 (Effekt unabhängig vom Zeitpunkt der Intervention: im/vor Gespräch) (52 Studien, Evidenzqualität hoch), n = 1 SR | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | (Mikroebene steht im Bericht zur Nutzenbewertung im Fokus; Gesundheitsökonomie, Ethik, Recht und sozialer Einfluss v. a. für die Meso- und Makroebene) | <ul style="list-style-type: none"> ○ SMD: 0,50 [0,33; 0,67] p < 0,00001 (18 Studien), mittlerer Effekt (n = 1 SR) ○ MD: 13,91 [9,01; 18,82], p-Wert nicht berichtet (11 Studien), n = 1 SR - die richtige Einschätzung von Risiken: <ul style="list-style-type: none"> ○ RR: 2,10 [1,66; 2,66], p < 0,0001 (Effekt unabhängig vom Zeitpunkt ○ der Intervention: im/vor Gespräch) (17 Studien, Evidenzqualität moderat), n = 1 SR - Vermeidung von Entscheidungskonflikten: <ul style="list-style-type: none"> ○ MD: -7,22 [-9,12; -5,31], p = 0,0001 (38 Studien, Evidenzqualität hoch), n = 1 SR ○ SMD: -0,33 [-0,56; -0,09], p = 0,007 (15 Studien), mittlerer Effekt (n = 1 SR) ○ SMD: -0,41 [-0,83; 0,02], p-Wert nicht berichtet (7 Studien), n = 1 SR ○ Bei Auswertung zusammen mit anderen ○ SDM-Interventionene: Low Literacy Scale: MD: -9,59 [-18,94; -0,24] (5 Studien), n = 1 SR - die Arzt-Patient-Kommunikation: <ul style="list-style-type: none"> ○ Einzelstudienauswertung: Arzt-Patient Kommunikation scheint besser bei unklarer Evidenzqualität (n = 1 SR) ○ RR: 1,62 [1,42; 1,84], p-Wert nicht berichtet (3 Studien), n = 1 SR - die informierte Übereinstimmung der Präferenz/Entscheidung: <ul style="list-style-type: none"> ○ RR: 2,06 [1,46; 2,91], p < 0,0001 (10 Studien, Evidenzqualität niedrig) <p>Für (fast) alle anderen Parameter und Interventionen sind in der Übersicht keine Vor- oder Nachteile festgestellt worden.</p> <p>u. a. gesundheitsökonomische Betrachtungen ab S. 73</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Quellen:</p> <p>4. Legare F, Adekpedjou R, Stacey D et al. Interventions for increasing the use of shared decision making by healthcare professionals. <i>Cochrane Database Syst Rev</i> 2018; 7: CD006732. https://dx.doi.org/10.1002/14651858.CD006732.pub4.</p> <p>7. NICE. National Institute for Health and Care Excellence: Clinical Guidelines. In: Shared decision making. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2021.; 2021.</p> <p>8. NICE. NICE Evidence Reviews Collection. Evidence review for effectiveness of approaches and activities to increase engagement in shared decision making and the barriers and facilitators to engagement: Shared decision making: Evidence review A. . In: Shared decision making. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2021.; 2021.</p> <p>9. NICE. NICE Evidence Reviews Collection. Evidence review for interventions to support effective shared decision making: Shared decision making: Evidence review B. In: Shared Decision Making. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2021.; 2021.</p> <p>10. NICE. NICE Evidence Reviews Collection. Evidence review for decision aids for people facing health treatment or screening decisions: Shared decision making: Evidence review C. In: Shared Decision Making. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2021.; 2021.</p> <p>11. NICE. NICE Evidence Reviews Collection. Evidence review for risk communication: Shared decision making: Evidence review D. . In: Shared decision making. London: National Institute for Health and Care Excellence Copyright © NICE 2021.; 2021.</p> <p>12. NICE. NICE Evidence Reviews Collection. Evidence review for effective approaches and activities to normalise shared decision making in the healthcare system: Shared decision making: Evidence review E. . In: Shared decision making. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2021.; 2021</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>13. Stacey D, Legare F, Lewis K et al. Decision aids for people facing health treatment or screening decisions. <i>Cochrane Database Syst Rev</i> 2017; 4: CD001431. https://dx.doi.org/10.1002/14651858.CD001431.pub5.</p> <p>- Aktualisierung des Cochrane-Reviews von Stacey 2017, auf Anfrage der Autorengruppe des HTA-Berichts wurde mitgeteilt, dass die Aktualisierung des Cochrane-Reviews die Ergebnisse des Reviews aus 2017 bestätigt. Die Aktualisierung wird voraussichtlich Mitte/Ende des Jahres 2023 veröffentlicht. Sie schließt 104 zusätzliche Primärstudien ein.</p> <p>25. Jull J, Kopke S, Smith M et al. Decision coaching for people making healthcare decisions. <i>Cochrane Database Syst Rev</i> 2021; 11: CD013385. https://dx.doi.org/10.1002/14651858.CD013385.pub2.</p> <p>26. Scalia P, Durand MA, Berkowitz JL et al. The impact and utility of encounter patient decision aids: Systematic review, meta-analysis and narrative synthesis. <i>Patient Educ Couns</i> 2019; 102(5): 817-841. https://dx.doi.org/10.1016/j.pec.2018.12.020.</p> <p>27. Yen RW, Smith J, Engel J et al. A Systematic Review and Meta-Analysis of Patient Decision Aids for Socially Disadvantaged Populations: Update from the International Patient Decision Aid Standards (IDPAS). <i>Med Decis Making</i> 2021; 41(7): 870-896. https://dx.doi.org/10.1177/0272989x211020317.</p> | | |

12.4 Kapitel medikamentöse Therapie - Lipidsenker

12.4.1 Statine mittlere vs. hohe Dosis (Empfehlung 7-13)

NICE (Evidence Review, statins, 2023)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Cardiovascular disease: risk assessment and reduction, including lipid modification [C] Evidence review for statins: efficacy and adverse effects</p> <p>NICE guideline CG181 Evidence review underpinning recommendations 1.4.11 to 1.4.43 and research recommendations in the NICE guideline</p> <p>May 2023</p> <p>https://www.nice.org.uk/guidance/cg181/evidence/c-risk-assessment-and-reduction-including-lipid-modification-pdf-13065827440 [18]</p> | <p>Objective aim of this review is to update the evidence on the clinical and cost effectiveness and safety of different statin intensities in people with and without established cardiovascular disease (CVD)</p> <p>Search the following databases (from November 2013) will be searched:</p> <ul style="list-style-type: none"> - Cochrane Central Register of Controlled Trials (CENTRAL) - Cochrane Database of Systematic Reviews (CDSR) - Embase - MEDLINE - Epistemonikos <p>lists of systematic reviews²</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - SR of RCT, RCT, NMA, IPD - primary and secondary prevention of CVD - adults | <p>updated Version of 2014; changes:</p> <ul style="list-style-type: none"> - outcome of non-fatal stroke was changed to non-fatal ischaemic stroke - composite outcome of combined major adverse cardiovascular events was added - no stratification by populations was planned; pre-specified subgroup analyses were performed if heterogeneity was observed <p>background information statin intensity classification based on the percentage reduction in low-density lipoprotein (LDL) cholesterol they can produce</p> <p>Intensity / LDL-cholesterol reduction (%) / Statin and dose</p> <p>Low intensity / (20% to 30%)</p> <ul style="list-style-type: none"> - Fluvastatin 20 or 40 mg - Pravastatin 5, 10, 20 or 40 mg - Simvastatin 10 mg <p>Medium intensity / (31% to 40%)</p> <ul style="list-style-type: none"> - Atorvastatin 10 mg - Fluvastatin 80 mg - Rosuvastatin 5 mg - Simvastatin 20 or 40 mg <p>High intensity / (Greater than 40%)</p> <ul style="list-style-type: none"> - Atorvastatin 20, 40 or 80 mg - Rosuvastatin 10, 20 or 40 mg | <p>AMSTAR-II high</p> <p>authors noted that for the head-to-head comparisons (studies comparing statins of different intensities or comparing different high intensity statin regimens), the majority of the efficacy evidence was of low or very low quality, with the most common reason for downgrading being imprecision (smaller number of trials and smaller pooled sample size)</p> | <p>authors noted that statins are recognised as the first-choice lipid modification therapy to reduce CVD events and were first appraised by NICE in 2006</p> <p>authorse noted that in 2014, the guideline recommended that when prescribing a statin, a statin of high intensity should be used</p> <p>(recently, clinical and epidemiological evidence on the benefits of lipid lowering has increased)</p> <p>authors noted that n = 6 relevant Cochrane reviews were identified but could not be included; because they</p> |

² Key papers: Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. (2016) Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine 374(21):2021–31 (#95); Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure 17(4):434–41 (#87)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - studies with follow-up < 1 year were excluded - cross-over RCT, non-randomized trials, conference abstracts were excluded - trials of statins with aims other than CVD prevention or lipid lowering were also excluded <p>Intervention statins (assume class effect)</p> <p>Comperator placebo, usual care, no treatment</p> <ul style="list-style-type: none"> - different intensities - high intensity vs. other high intensity drug/dose <p>Quality assessment Risk of bias (ROBIS, RoB 2.0) GRADEpro (quality of evidence)</p> <p>Outcome primary (critical)</p> <ul style="list-style-type: none"> - all-cause mortality (time-to-event) | <p>Note: Simvastatin 80 mg is no longer used because of risk of myopathy and muscle symptoms and so will not be included in the update. Any existing data on this drug dose will be removed from the analyses.</p> <p>n = 7 trials were added, n = 43 previously included studies were also retained in the analysis</p> <ul style="list-style-type: none"> - placebo controlled <ul style="list-style-type: none"> o n = 38 trials <ul style="list-style-type: none"> ▪ n = 16 primary prevention ▪ n = 20 secondary prevention³ ▪ ect. o n = 20 trials reported final LDL-cholesterol value for both arms - head-to-head statin comparisons <ul style="list-style-type: none"> o n = 14 trials <ul style="list-style-type: none"> ▪ n = 2 primary prevention ▪ n = 12 secondary prevention⁴ ▪ ect. o n = 10 trials reported final LDL-cholesterol values for both arms - adverse effect evidence (additional research question): n = 7 new RCT (n = 10 publications) and n = 24 previously included studies; n = 2 SR <ul style="list-style-type: none"> o placebo-controlled studies o (n = 16 for primary prevention, n = 12 for secondary prevention; etc.) | | <p>did not include any outcomes relevant to the protocol and 1 because all relevant studies were already included in the 2014 update of this guideline (all studies included in the reviews were cross-checked for inclusion in this review)</p> <p>authors presented that effect estimate for most comparisons and outcomes did not change sufficiently to change the conclusions from those outlined in the previous update</p> <p>(authors summary placebo-control: all outcomes showed a direction of effect favouring the use of statins to reduce the risk of fatal and non-</p> |

³ Quellen Sekundärprävention (placebo-controlled)

9, 24, 33, 75, 94, 101, 112, 137, 139, 143, 144, 151, 154, 164, 167, 170, 176, 189-191

Amarengo 2006⁹(SPARCL), Athyros 2002²⁴(GREACE), Byington 1995³³(PLAC II), Hosomi 2015⁷⁵(J-STARS), Koren 2004⁹⁴(ALLIANCE), Lemos 2003¹⁰¹(LIPS), Meade 1999¹¹²(HPS), Pitt 1995¹³⁷(PLAC I), Anon 1998¹³⁹(LIPID), Anon 1994¹⁴³(4S), Anon 2000¹⁴⁴(GISSI), Riegger 1999¹⁵¹, Sacks 1996¹⁵⁴(CARE), Shepherd 2002¹⁶⁴(PROSPER), Shukla 2005¹⁶⁷, Sola 2006¹⁷⁰, Teo 2000¹⁷⁶(SCAT), Yakusevich 2012¹⁸⁹, Yamada 2007¹⁹⁰, Yokoi 2005¹⁹¹

⁴ Quellen Sekundärprävention (head-to-head)

34, 52, 54, 78, 99, 105, 127, 129, 134, 159, 195, 196

Cannon 2004³⁴(PROVE IT TIMI 22), Deedwania 2007⁵², Egede 2013⁵⁴(VIRHISTAMI), Im 2018⁷⁸, Larosa 2005⁹⁹(TNT), Liu 2016¹⁰⁵, Nicholls 2011¹²⁷(SATURN), Nissen 2005^{128,129}(REVERSAL), Pedersen 2005¹³⁴(IDEAL), Schermund et al. 2006¹⁵⁹, Zhao 2014¹⁹⁵(CHILLAS), Zou 2003¹⁹⁶

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - cardiovascular mortality (time-to-event) - non-fatal myocardial infarction (time-to-event) - non-fatal ischaemic stroke (time-to-event) - combined major adverse cardiovascular events (CVD death, nonfatal MI, nonfatal ischaemic stroke) - quality of life, any validated measure (continuous) - time points - the minimum follow-up is 1 year - the longest available follow-up will be used for each trial, and all these timepoints will be pooled <p>(Cholesterol levels will not be included as a surrogate outcome for CVD risk because it is whether or</p> | <ul style="list-style-type: none"> ○ see also Appendix C, Appendix D, forest plots Appendix E and GRADE tables Appendix F ○ active-control studies: were not included in the review because no harm was found in terms of clinically important differences based on the absolute risk difference in the primary analysis of any statin versus placebo (s. b.) ○ note: studies with simvastatin 80 mg were excluded from analyses (different from the previous review of 2014) <p>The comparisons available were as follows:</p> <ul style="list-style-type: none"> • High versus low intensity (3 studies)^{34, 52, 78} • High versus medium intensity (4 studies)^{99, 134, 159, 195} • High versus high intensity (2 studies)^{105, 127} • Medium versus low intensity (1 study)¹⁹⁶ <p>note: combined outcome of major adverse cardiovascular events is defined differently across the literature⁵</p> <p>Results</p> <ul style="list-style-type: none"> - Table 7: Clinical evidence summary: statins vs. placebo stratified by statin intensity (page 19 ff) | | <p>fatal cardiovascular (CV) events with benefit greatest for non-fatal MI for both relative and absolute risk estimates;</p> <p>an increasing benefit in terms of the relative risk of events with increasing statin intensity was noted for the outcomes of CV mortality and non-fatal MI, which supports the recommendation of high intensity statins as the most effective option; this effect was supported by the newly added composite outcome of MACE, with limited confidence in this evidence (inconsistency of definition))</p> |

⁵ Definitions that incorporate any of the following events were excluded from the analysis for being too indirect:

- all-cause mortality
- transient ischaemic attack
- peripheral vascular disorder
- peripheral artery bypass graft
- amputation because of atherosclerotic disease
- Definitions that omit fatal or non-fatal stroke were excluded from the analysis for being too indirect.
- Definitions that included the following terms, which fall within the cardiovascular death component, were not excluded nor downgraded for indirectness:
 - Resuscitation after cardiac arrest
 - Sudden cardiac death
- Definitions that included the following terms, which fall within the cardiovascular death component, were not excluded nor downgraded for indirectness:
 - Coronary intervention procedure
 - Recanalisation

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>not a CVD event occurs that is important to patients and data on this will be available)</p> | <ul style="list-style-type: none"> ○ all-cause mortality <ul style="list-style-type: none"> ▪ low intensity vs placebo, RR 0.89 (0.84 to 0.94), (n = 13 RCT (n = 50,425 participants, high certainty of evidence) ▪ medium intensity vs placebo, RR 0.85 (0.80 to 0.90), (n = 9 RCT (n = 43,021 participants, high certainty of evidence) ▪ high intensity vs placebo, RR 0.91 (0.83 to 0.99), (n = 8 RCT (n = 43,371 participants, high certainty of evidence) ▪ etc. - Table 8: Time-to-event results for statins versus placebo (stratified by statin intensity) (page 21f) <ul style="list-style-type: none"> ○ All-cause mortality <ul style="list-style-type: none"> ▪ Low dose vs. placebo, HR 0.85 (0.78,0.92), n = 5 trials ▪ Medium dose vs. placebo, HR 0.77 (0.68, 0.87), n = 3 trials ▪ High dose vs. placebo, HR 0.89 (0.79, 1.00), n = 3 trials ▪ etc. <p>forest plots for placebo comparisons see also Appendix E page 377-385</p> <p>forest plots for high vs. low intensity statin comparisons see Appendix E page 386-387</p> <p>forest plot for high vs. high intensity statin comparisons see Appendix E page 390-391</p> <p>forest plots for medium vs. low intensity statin comparisons see Appendix E page 391</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>High versus medium intensity (forest plots for high vs. medium intensity statin comparisons see also page 388-390) Table 11: Clinical evidence summary: High versus medium intensity statin (page 23f)</p> <p>all-cause mortality</p> <ul style="list-style-type: none"> - RR 0.99 (0.89 to 1.10), (n = 2 RCT (n = 18,889 participants, low certainty of evidence) <p>cardiovascular mortality</p> <ul style="list-style-type: none"> - RR 0.92 (0.72 to 1.17), (n = 2 RCT (n = 18,889 participants, very low certainty of evidence) <p>non-fatal myocardial infarction</p> <ul style="list-style-type: none"> - RR 0.81 (0.72 to 0.91), (n = 3 RCT (n = 19,356 participants, low certainty of evidence) <p>stroke</p> <ul style="list-style-type: none"> - RR 0.87 (0.70 to 1.08), (n = 2 RCT (n = 9355 participants, low certainty of evidence) <p>major adverse cardiovascular events (MACE)</p> <ul style="list-style-type: none"> - RR 0.86 (0.75 to 1.00), (n = 3 RCT (n = 20,244 participants, very low certainty of evidence) <p>Table 12: Time-to-event results for medium versus high intensity statin (note opposite direction of effect due to comparison reported in studies) (page 24)</p> <ul style="list-style-type: none"> - all-cause mortality, HR 0.94 (0.75, 1.19), n = 3 trials - CV mortality, HR 1.09 (0.94, 1.28), n = 2 trials - Non-fatal MI, HR 1.24 (1.11, 1.40), n = 2 trials - Non-fatal stroke - - MACE, HR 1.17 (1.01, 1.36), n = 3 trials <p>adverse events</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Table 18: Clinical evidence summary: statins versus placebo (page 34 f)</p> <ul style="list-style-type: none"> - rhabdomyolysis ('myopathy' from IPD analysis), OR 2.12 (1.20 to 3.73), (n = 13 RCT (n = 103,020 participants, moderate certainty of evidence) - myalgia ('Any muscle pain' from IPD analysis), RR 1.02 (1.01 to 1.04), (n = 13 RCT (n = 103,020 participants, high certainty of evidence) <p>comparator planned (review protocol): primary analysis:</p> <ul style="list-style-type: none"> - All statins versus placebo/usual care/no treatment - If harm is found for all statins compared with control, then analyse by - Intensity categories (as defined above) - Individual agents within each intensity class <p>committee discussion: "As for the efficacy review, the committee agreed that the updated evidence review for adverse effects was largely supportive of the recommendations from the previous iteration of the guideline." (page 52)</p> <p>"Since no clinically important harms were observed when comparing all statin intensities with placebo, as stated in the review protocol, no analysis was performed to assess specific statin intensity subgroups for the adverse event outcomes." (page 54)</p> <p>note: studies with simvastatin 80 mg were excluded from analyses (different from the previous review of 2014)</p> <p>Table 32 Clinical evidence profile: statins vs. placebo (page 405ff)</p> <p>Rhabdomyolysis (myopathy from IPD analysis)</p> <ul style="list-style-type: none"> - 33/51554 (0.1%) vs. 15/51466 (0.0%) - OR 2.12 (1.20; 3.73), n = 13 studies - moderate certainty of evidence | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Rhabdomyolysis from studies not in IPD analysis</p> <ul style="list-style-type: none"> - 4/5133 (0.1%) vs. 5/4715 (0.1%) - not estimable, n = 9 studies - low certainty of evidence <p>Myalgia (Any muscle pain from IPD analysis)</p> <ul style="list-style-type: none"> - 13928/51554 (27.0%) vs. 13595/51466 (26.4%) - RR 1.02 (1.01; 1.04), n = 13 studies - high certainty of evidence <p>Myalgia from studies not in IPD analysis</p> <ul style="list-style-type: none"> - 113/1239 (9.1%) vs. 62/613 (10.1%) - RR 0.95 (0.70; 1.28), n = 3 studies - very low certainty of evidence <p>Liver adverse events</p> <ul style="list-style-type: none"> - 406/51761 (0.8%) vs. 235/51101 (0.5%) - OR 1.70 (1.46; 1.99), n = 20 studies - moderate certainty of evidence <p>New onset diabetes</p> <ul style="list-style-type: none"> - 2244/47637 (4.7%) vs. 2030/47680 (4.3%) - RR 1.11 (1.04; 1.17), n = 14 studies - high certainty of evidence <p>Worsening of diabetes</p> <ul style="list-style-type: none"> - 1/414 (0.2%) vs. 0/207 (0.0%) - OR 4.48 (0.07; 286.49), n = 1 study - Very low certainty of evidence <p>Haemorrhagic stroke</p> <ul style="list-style-type: none"> - 139/33983 (0.4%) vs. 119/34067 (0.3%) - RR 1.17 (0.92; 1.49), n = 6 studies - Moderate certainty of evidence <p>Dementia</p> <ul style="list-style-type: none"> - 43/11076 (0.4%) vs. 39/11086 (0.4%) - RR 1.11 (0.72; 1.70), n = 2 studies - Very low certainty of evidence <p>Cognitive decline or dementia (high intensity vs. placebo), decrease of at least 5 points on DSST, 2 points on mMoCA and 10% on TMT-B</p> <ul style="list-style-type: none"> - 597/807 (74.0%) vs. 599/819 (73.1%) - RR 1.01 (0.95; 1.07) - Low certainty of evidence | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | Cognitive decline or dementia (high intensity vs. placebo), based on changes in MMS or DSE score <ul style="list-style-type: none"> - 39/366 (10.7%) vs. 68/366 (18.6%) - RR 0.57 (0.40; 0.83), n = 1 study - moderate certainty of evidence Cognitive decline or dementia (medium intensity vs. placebo), cognitive impairment <ul style="list-style-type: none"> - 35/5101 (0.6%) vs. 32/5079 (0.6%) - RR 0.96 (0.59; 1.58) - very low certainty of evidence Cognitive decline (change from baseline) – Low intensity vs. placebo: Mini mental state examination (scale 0-30 – higher is better) <ul style="list-style-type: none"> - 2891 vs. 2913 - - - MD 0.06 points higher (0.04 lower to 0.16 higher) - low certainty of evidence | | |

Chehrevar et al. (RCT, high or moderate intensity Rosuvastatin, 2022)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Chehrevar M. Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention. Interv Cardiol 2022; 17:e20. https://www.ncbi.nlm.nih.gov/pub-med/36890806 [19] | Aim to determine the effective dose of statin to prevent major adverse cardiovascular events (MACEs), such as acute coronary syndrome, stroke, myocardial infarction, revascularisation and cardiac death, after PCI in patients with chronic coronary syndrome | n = 582 eligible patients <ul style="list-style-type: none"> - group 1: 5 mg rosuvastatin (n=295) - mean age 63.09 ± 10.08 years - group 2: 40 mg rosuvastatin (n=287) - mean age and 62.19 ± 10.15 years Results MACE <ul style="list-style-type: none"> - n = 24 patients in the 5 mg rosuvastatin group - n = 17 patients in the 40 mg rosuvastatin group - difference during the 1-year follow-up (p=0.66) separately (see also supplement Table 4) 5 mg vs. 40 mg <ul style="list-style-type: none"> - non-fatal MI n = 4 vs. n = 3 (p=0.64) - revascularisation n = 3 vs. n = 2 (p=0.641) | Selection bias randomization: low concealment and unpredictability: high Performance bias blinding of participants and staff: unclear Detection bias blinding of evaluation: unclear Attrition bias lost to follow-up: low ITT-analysis: | authors investigated recommendations for pre- and post-PCI statin doses |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | <ul style="list-style-type: none"> - exclusion criteria: patients with ACS, primary LDL >190 mg/dl, patients who developed statin-induced myopathy or rhabdomyolysis, persistent increase in hepatic enzyme levels or hepatic failure, pregnancy and breastfeeding, statin hypersensitivity, a history of multiple atherosclerotic events, and a history of receiving highintensity statins before the study enrolment <p>Intervention high-dose rosuvastatin (40 mg daily) (high intensity)</p> <p>Control after 1 month* high dose rosuvastatin over the next year rosuvastatin 5 mg daily (moderate intensity)</p> <p>Outcomes</p> <ul style="list-style-type: none"> - high-sensitivity C-reactive protein - MACE (defined as any hospitalisation due to acute coronary syndrome (ACS), stroke, MI, unplanned revascularisation or cardiac death) <p>*median of 28 days (range 24–37 days)</p> | <ul style="list-style-type: none"> - coronary artery bypass grafting n = 1 vs. n = 1 (p=0.87) - cerebrovascular accident n = 3 vs. n = 1 (p=0.59) - ACS n = 8 vs. n = 6 (p=0.62) - cardiac death n = 5 vs. n = 4 (p=0.63) <p>mean values of high-sensitivity C-reactive protein, LDL, HDL, Cholesterol, Triglyceride in the first hospitalisation and after 1 year see Table 2 within the publication</p> <p>safety</p> <p>40 mg rosuvastatin group</p> <ul style="list-style-type: none"> - n = 8 patients (2.78%): a rise in fasting blood sugar (at the level of impaired fasting glucose corrected by lifestyle modifications) - n = 9 patients (3.13%): an increase in alanine transaminase (ALT) - n = 15 patients (5.22%): with myalgia and myopathy - those with rising ALT levels or significant myopathy were shifted to 5 mg rosuvastatin (analyses ITT) <p>5 mg rosuvastatin group</p> <ul style="list-style-type: none"> - n = 5 patients (1.69%): a rises in fasting blood sugar (at the level of impaired fasting glucose, corrected by lifestyle modifications) - n = 5 patients (1.69%): an increase in ALT - n = 7 patients (2.37%): with myalgia and myopathy - rosuvastatin was discontinued in those with significant ALT elevation or myopathy (analyses ITT) | <p>low</p> <p>Reporting bias selective result presentation: unclear</p> <p>Other bias methods were described rarely within the publication</p> <p>sample size calculation not described</p> <p>paired t-test was used</p> | |

12.4.2 Statine Zielwert vs. feste Dosis (Empfehlung 7-14)

Hong et al. 2023 (RCT, non-inferiority design, South Korea)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <p>Hong S-J, Lee Y-J, Lee S-J, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA 2023; 329(13):1078–87. DOI: 10.1001/jama.2023.2487. http://www.ncbi.nlm.nih.gov/pub-med/36877807. [20]</p> | <p>Objective to assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease (LODESTAR Trial)</p> <p>Methods</p> <ul style="list-style-type: none"> - randomized, multicenter, noninferiority trial - open-label - patients with a coronary disease diagnosis (including stable ischemic heart disease or acute coronary syndrome (unstable angina, acute myocardial infarction)) - treated at 12 centers in South Korea - enrollment: September 9, 2016, through November 27, 2019; final follow-up: October 26, 2022 <p>Intervention LDL-C target strategy, with an LDL-C level between 50 and 70mg/dL as the target⁶</p> | <p>n = 4400 patients (n = 2200 in both groups) n = 4341 patients (98.7%) completed the trial n = 2200 vs. n = 2200 (as-randomized, ITT) n = 2108 vs. n = 2106 (per-protocol, PP)</p> <ul style="list-style-type: none"> - n = 16 vs. n = 14 withdrew consent - n = 14 vs. n = 11 lost to follow up - n = 92 vs. n = 94 did not meet protocol - mean [SD] age, 65.1 [9.9] years - n = 1228 females [27.9%] - mean weight 67 kg (SD 11) - mean high 164 bzw. 165 cm (SD 8) - hypertension 67 % (n = 1473 bzw. 1464) - previous PCI 55-57 % (n = 1243 bzw. 1214) - > 1y after unstable angina or revascularization: 40-41 % (n = 919 bzw. 874) - Lipid-lowering therapy before randomization: <ul style="list-style-type: none"> o moderate intensity: 56-58 % (n = 1284 bzw. n = 1240) o high and low intensity see Table 1 o none: 16 % (n = 334) o ezetimibe: 10-12 % (n = 253 bzw. 226) - treat-to-target group (n = 2200), 6449 person-years of follow-up (moderate-intensity and high-intensity dosing were used in 43% and 54%) - high-intensity statin therapy group (n = 2200), 6461 person-years - ezetimibe was used more in the treat-to-target group than in the high-intensity statin therapy group - mean (SD) LDL-C level for 3 years: <ul style="list-style-type: none"> o treat-to-target: 69.1 (17.8)mg/dL | <p>Selection bias randomization: low concealment and unpredictability: low</p> <p>Performance bias blinding of participants and staff: high (open-label)</p> <p>Detection bias blinding of evaluation: unclear (independent committee blinded to therapy assignment adjudicated all clinical events and assessed the clinical end points)</p> <p>Attrition bias lost to follow-up: low (ITT and PP analyses were performed, missing data were censored)</p> <p>ITT-analysis: low</p> <p>Reporting bias selective result presentation: low</p> <p>Other bias lower event rates than anticipated were observed (underpowered)</p> | |

⁶ intensity of statin treatment was divided into high or moderate intensity according to the 2013 American College of Cardiology/American Heart Association guideline for the treatment of blood cholesterol. 5 Patients were treated with rosuvastatin, 10 mg, or atorvastatin, 20 mg, for the moderate-intensity statin therapy and rosuvastatin, 20 mg, or atorvastatin, 40 mg, for the high-intensity statin therapy (for statin-naïve patients, moderate-intensity statin therapy was initiated and uptitrated if necessary)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | <p>Comperator high-intensity statin treatment, which consisted of rosuvastatin, 20mg, or atorvastatin, 40mg</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - 3-year composite (MACE) of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points <p>secondary</p> <ul style="list-style-type: none"> - new-onset diabetes - hospitalization due to heart failure - deep vein thrombosis or pulmonary thromboembolism - endovascular revascularization for peripheral artery disease - aortic intervention or surgery - end-stage kidney disease - discontinuation of study drugs due to intolerance - cataract operation - composite of laboratory abnormalities <p>nonstatin add-on therapy was not recommended strongly to avoid confounding</p> | <ul style="list-style-type: none"> o high-intensity statin group : 68.4 (20.1)mg/dL o p = 0.21 <p>results primary end point (treat-to-target vs. high-intensity statin)</p> <ul style="list-style-type: none"> - n = 177 (8.1%) vs. n = 190 (8.7%) patients - absolute difference, -0.6 percentage points [upper boundary of the 1-sided 97.5%CI, 1.1 percentage points]; P < .001 for noninferiority) <p>all-cause death</p> <ul style="list-style-type: none"> - n = 54 (2.5%) vs. n = 54 (2.5%) - absolute difference, <0.1% (95%CI, -0.9%; 0.9%); p = 0.99) <p>myocardial infarction</p> <ul style="list-style-type: none"> - n = 34 (1.6%) vs. n = 26 (1.2%) - absolute difference, 0.4% (95%CI, -0.3%; 1.1%); p = 0.23). <p>stroke</p> <ul style="list-style-type: none"> - n = 17 (0.8%) vs. n = 27 (1.3%) - absolute difference, -0.5% (95%CI, -1.1%; 0.1%); p = 0.13) <p>coronary revascularization</p> <ul style="list-style-type: none"> - n = 112 (5.2%) vs. n = 150 (7.0%) - absolute difference, -0.1 (95 % CI -1.4; 1.2), p = 0.89 <p>authors noted that no prespecified secondary end points differed statistically between the groups (Table 2) “[...] authors noted that no prespecified secondary end points differed statistically between the groups (Table 2)”</p> <p>Ergänzung:</p> <p>secondary end points (treat-to-target (n = 2200) vs. high-intensity (n = 2200), absolute difference (%), 95% CI), p-value new-onset diabetes</p> | <p>(authors note: latest guideline at the time of trial design and several randomized trials demonstrating the superiority of fixed-dose high-intensity statin therapy to fixed-dose moderate-intensity statin therapy in patients with CAD - standard;</p> <p>treat-to-target strategy had not been evaluated in RCT for this population – experimental; noninferiority was investigated, sample size calculation based on other studies)</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - n = 121 (5.6%) vs. n = 150 (7.0%) - absolute difference -1.3 (-2.8; 0.1), p = 0.07 <p>(initiation of antidiabetic drug: n = 73 vs. n = 105)</p> <p>hospitalization due to heart failure</p> <ul style="list-style-type: none"> - n = 13 (0.6%) vs. n = 7 (0.3%) - absolute difference 0.3 (-0.1; 0.7), p = 0.17 <p>deep vein thrombosis or pulmonary thromboembolism</p> <ul style="list-style-type: none"> - n = 4 (0.2%) vs. n = 5 (0.2%) - absolute difference <0.1 (-0.3; 0.2), p = 0.74 <p>(deep vein thrombosis n = 2 vs. n = 5 Pulmonary embolism n = 3 vs. n = 0)</p> <p>endovascular revascularization for peripheral artery disease</p> <ul style="list-style-type: none"> - n = 12 (0.6%) vs. n = 17 (0.8%) - absolute difference -0.2 (-0.8; 0.3), p = 0.35 <p>aortic intervention or surgery</p> <ul style="list-style-type: none"> - n = 2 (0.1%) vs. n = 3 (0.1%) - absolute difference not reported <p>(endovascular therapy n = 1 vs. n = 2 surgical therapy n = 1 vs. n = 1)</p> <p>end-stage kidney disease</p> <ul style="list-style-type: none"> - n = 3 (0.1%) vs. n = 10 (0.5%) - absolute difference -0.3 (-0.7; 0.0), p = 0.05 <p>discontinuation of statin therapy</p> <ul style="list-style-type: none"> - n = 31 (1.5%) vs. n = 46 (2.2%) - absolute difference -0.7 (-1.5; 0.1), p = 0.09 <p>cataract operation</p> <ul style="list-style-type: none"> - n = 43 (2.0%) vs. n = 42 (1.9%) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - absolute difference 0.1 (-0.8; 0.9), p = 0.90 composited of laboratory abnormalities <ul style="list-style-type: none"> - n = 18 (0.8%) vs. n = 30 (1.3%) - absolute difference - 0.5 (-1.1; 0.1), p = 0.11 (aminotransferase elevation n = 8 vs. n = 12 creatinine kinase elevation n = 3 vs. n = 8 creatinine elevation n = 7 vs. n = 11) (composite of new-onset diabetes, aminotransferase or creatine kinase elevation, or end-stage kidney disease (post hoc) <ul style="list-style-type: none"> - n = 132 (6.1%) vs. n = 177 (8.2%) - absolute difference -2.1 (-3.6; -0.5), p = 0.009 | | |

Kaldal et al. 2021 (RCT, komplexe Intervention (“hospital-based vs. primary care”), Norway)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kaldal A, Tonstad S, Jortveit J. Long-term hospital-based secondary prevention of coronary artery disease: A randomized controlled trial. BMC Cardiovasc Disord 2021; 21(1):600. DOI: 10.1186/s12872-021-02426-3. http://www.ncbi.nlm.nih.gov/pub-med/34915839 . [21] | Objective to compare long-term hospital-based treatment with follow-up at primary health care regarding new cardiovascular events and achievement of treatment targets (“secondary prevention”) Methods <ul style="list-style-type: none"> - randomized controlled trial (open) - at Sørlandet Hospital, Norway 2007–2021 - patients hospitalized due to myocardial infarction (MI) (n = 760) or after scheduled percutaneous coronary intervention (PCI) | n = 1613 participants randomized <ul style="list-style-type: none"> - hospital-based follow-up 1 year n = 788 - no hospital-based follow-up 1 year n = 752 - 2 years n = 745 vs. n = 703 - 5 years n = 582 vs. n = 537 - 10 years n = 211 vs. n = 151 <ul style="list-style-type: none"> - mean age: 62 years (SD 10) vs. 64 years (SD 9) - women: n = 178 (23%) vs. 159 (21%) - high education: n = 205 (28%) vs. n = 201 (29%) - history of prior MI: n = 205 (13%) - prior PCI: n = 209 (14%) - prior CABG: n = 91 (6%) - experienced a stroke: n = 73 (5%) Results primary mean follow-up 5.9 (SD 2.8) years vs. 5.3 (SD 2.8) years | Selection bias randomization: low concealment and unpredictability: unclear Performance bias blinding of participants and staff: high (open; hospital-based follow-up vs. primary health care) Detection bias blinding of evaluation: unclear Attrition bias lost to follow-up: unclear ITT-analysis: | secondary preventive treatment targets <ul style="list-style-type: none"> • No smoking • Blood pressure < 140/90 mmHg • LDL-cholesterol < 1.8 mmol/l (< 2.5 mmol/l until 2017, < 1.4 mmol/l from 2020) • HbA1c < 53 mmol/mol (7%) • BMI < 25 kg/m2 • Daily use of statins • Daily use of acetylsalicylic acid • Physical activity of moderate intensity ≥ 150 min weekly or of |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| | <p>(n = 677) or coronary artery bypass grafting (CABG) (n = 103)</p> <ul style="list-style-type: none"> - aged 18-80 years - exclusion criteria were lack of ability to cooperate, known alcohol drug-abuse, use of narcotics, pregnancy or breastfeeding, serious comorbidity with a life expectancy less than 2 years, or participation in other secondary prevention studies <p>Intervention</p> <ul style="list-style-type: none"> - hospital-based secondary preventive care with consultations 2 weeks, 3 months, 6 months and 1 year after the index event and annually for up to 5 years (specially trained nurses, supervised by cardiologists) <p>Comperator</p> <ul style="list-style-type: none"> - follow-up at primary health care (patients not randomized to the intervention arm were, after 1 year, formally asked to participate as controls) <p>final data collected after 10 years</p> <p>Outcomes</p> <p>primary</p> <ul style="list-style-type: none"> - all-cause mortality | <p>all-cause mortality</p> <ul style="list-style-type: none"> - n = 33 (4%) vs. n = 32 (4%), p = 0.86 - ageadjusted HR 0.96, 95% CI 0.59–1.56 <p>new PCI</p> <ul style="list-style-type: none"> - n = 144 (18%) vs. n = 179 (24%), p = 0.002 - aHR 0.71, 95% CI 0.57–0.88 <p>MI</p> <ul style="list-style-type: none"> - n = 38 (5%) vs. n = 39 (5%), p = 0,56 - aHR 0.87, 95% CI 0.56–1.37 <p>CABG</p> <ul style="list-style-type: none"> - n = 11 (1%) vs. n = 12 (2%), p = 0.71 - aHR 0.85, 95% CI 0.38–1.95 <p>stroke</p> <ul style="list-style-type: none"> - n = 33 (4%) vs. n = 30 (4%), p = 0,95 - aHR 0.98, 95% CI 0.60–1.62 <p>composite endpoint-free survival</p> <ul style="list-style-type: none"> - n = 214 (27%) vs. n = 235 (31%), p = 0.02 - age-adjusted HR 0.80, 95% CI 0.66–0.96 - due to a lower rate of PCI <p>secondary outcomes:</p> <ul style="list-style-type: none"> - supplemental material - mean blood pressure levels were significantly lower in the intervention group compared to the control group in the first 5 years of follow-up; no significant differences after 10 years (data not shown) - abstract: at 1 year, <ul style="list-style-type: none"> o systolic blood pressure 132 [SD 16] versus 142 [SD 20] mm/Hg; p < 0.001 o the differences remained significant during the first 5 years - LDL-cholesterol levels were significantly lower in the hospital-based follow-up group until annual consultations ceased (data not shown) - abstract: at 1 year, | <p>low</p> <p>Reporting bias</p> <p>selective result presentation: low</p> <p>work was supported by National Association for Public Health and Sørlandet Hospital HF, Arendal, Norway (funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript)</p> | <p>vigorous intensity ≥ 75 min weekly</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - a composite of all-cause mortality, PCI, CABG, non-fatal stroke or non-fatal MI (first event) secondary <ul style="list-style-type: none"> - proportion of participants who attained the secondary preventive treatment targets | <ul style="list-style-type: none"> o LDL-cholesterol 2.1 [SD 0.7] vs. 2.3 [SD 0.8] mmol/l; $p < 0.001$ o the differences remained significant during the first 5 years - significantly higher proportion of patients in the hospital-based follow-up group received statins during the first 2 years, as well as ezetimibe (20% vs. 7 %) (data not shown) - other secondary preventive measures (smoking cessation, physical activity, body weight, glucose control, drug adherence) did not differ (data not shown) | | |

Ersboll et al. 2023 (Register, Dänemark)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ersbøll AK, Kristensen MS, Nybo M, et al. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study. PLoS one 2023; 18(5):e0286376. DOI: 10.1371/journal.pone.0286376. http://www.ncbi.nlm.nih.gov/pubmed/37256879 . [22] | Objective to investigate trends in low-density lipoprotein cholesterol (LDL-C) goal achievement (LDL-C < 1.8 mmol/L, equivalent to 70 mg/dL), initiation of lipid-lowering therapy (LLT) and changes in LLT intensity in individuals with atherosclerotic cardiovascular disease (ASCVD) at very high risk of recurrent cardiovascular disease Source <ul style="list-style-type: none"> - residents of Funen Island, Denmark - national, population-based registers (patient, prescription, income, laboratory) - individual-level linkage of data (unique personal identification number) | n = 11,997 individuals included (discharged alive and with an LDL-C ≥ 1.8 mmol/L (70 mg/dL) before or during ASCVD hospitalization) <ul style="list-style-type: none"> - mean age 68.2 years - 59.7% males - 56.0% cohabitants - 94.5% ethnic Danes - 79.6% of ASCVD events (acute myocardial infarction, ischemic stroke and stable angina pectoris) - 14.8% with a history of diabetes - 3.7% with a history of chronic kidney disease - 62.8% (n=7533) no treatment (lipid-modifying, LLT) - 34.3% (n=4114) moderate LLT, 2.9% (n=350) intensive LLT <ul style="list-style-type: none"> o 36% (n=4313) with statins o 0.6% (n=74) with Ezitimibe o 0.4% (n=49) with other non-statins o 0.2% (n=28) with combination therapy at inclusion: <ul style="list-style-type: none"> - 37.2% LLT (initiation of lipid-lowering therapy) - 7.8% (n=350) had an intensive LLT | n. a. | epidemiological data high risk population (for cardiovascular events) – high precision for this population authors noted that data are reliable and validated (completeness) complete follow-up (individual-level up to two years) limitations: data not documented (e.g. reasons for a suboptimal LLT), health behaviour (i. e. diet, physical activity), adherence |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>study was approved by the Danish Data Protection Agency and the Danish Health and Medicines Authority</p> <p>Methods</p> <ul style="list-style-type: none"> - cohort study - individuals with incident ASCVD⁷ - index date was defined as date of hospitalization with a qualifying ASCVD diagnosis - LDL-C \geq 1.8 mmol/L - 2010-2015 - follow-up 2 years <p>Outcomes</p> <p>primary</p> <ul style="list-style-type: none"> - lipid measurements included LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol and triglycerides - lipid-lowering therapy (LLT) - statins, ezetimibe, other non-statins, and combination therapies <p>secondary</p> <ul style="list-style-type: none"> - sociodemographic and clinical characteristics were examined as associations <p>intensive LLT:</p> | <ul style="list-style-type: none"> - mean LDL-C: 3.1 mmol/L (120 mg/dL), before or during ASCVD hospitalization - mean HDL-C 1.4 mmol/L - total cholesterol 5.2 mmol/L - triglycerides 1.8 mmol/L <p>Results:</p> <p>primary</p> <ul style="list-style-type: none"> - LDL-C goal achievement in the first two years <ul style="list-style-type: none"> o from 40.5% (in 2010) to 50.6% (in 2015), (p<0.001) - LLT initiation within the first 90 days <ul style="list-style-type: none"> o from 48.6% (in 2010) to 56.0% (in 2015), (p<0.001) - initiation of intensive LLT <ul style="list-style-type: none"> o from 9.6% (in 2010) to 32.8% (in 2015) - proportion of individuals in intensive LLT before index date <ul style="list-style-type: none"> o from 2.4% (in 2010) to 3.6% (in 2015), (p<0.001) - proportion of individuals in LLT (i.e., at least one LLT prescription redemption) before index date did not change during the study period (19.2–22.3% in LLT, p = 0.36) - 33.3% to 39.4% did not initiate LLT within 365 days after index date <p>secondary</p> <p>sociodemographic and clinical characteristics associations</p> <ul style="list-style-type: none"> - initiation of LLT therapy (moderate or intensive) <ul style="list-style-type: none"> o individuals with AMI or IS at index date AMI: OR = 10.84 (95% CI: 9.41; 12.48) IS: OR = 8.77 (95% CI: 7.65; 10.05)) o younger age (<40 years): OR = 3.95 (95% CI: 2.48; 6.28); 40–49 years: OR | | <p>authors noted, that a much larger proportion of individuals with UA, SA, PAD, or coronary revascularization (e.g., PCI and CABG) should initiate LLT</p> <p>authors noted that a focus on individuals at older age and individuals with comorbidities (CKD, DM) is needed</p> |

⁷ ASCVD included acute myocardial infarction (AMI), ischemic stroke (IS), unstable angina pectoris (UA) together with a procedure of coronary angiography (CAG), stable angina pectoris (SA) together with a procedure of CAG or computerized tomography coronary angiography (CT-CAG), and peripheral artery disease (PAD) (included diagnoses (ICD 8/10 and procedure codes) see S1 Table in S1 File – supplement)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - a minimum of two prescription redemptions of one combinational drug - minimum of two prescription redemptions of statins (80 mg Simvastatin, 40–80 mg Atorvastatin or 20–40 mg Rosuvastatin) - a minimum of two prescription redemptions of statins (all doses and types) and one ezetimibe prescription redemption or - a minimum of two prescription redemptions of statins (all doses and types) and one other non-statin prescription redemption (i.e. not ezetimibe) <p>a logistic regression model was used for LDL-C goal achievement and initiating LLT therapy</p> | <p>= 2.85 (95% CI: 2.38; 3.41); 50–59 years: OR = 1.51 (95% CI: 1.34; 1.71))</p> <ul style="list-style-type: none"> o without comorbidity (not diabetes: OR = 3.12 (95% CI: 2.75; 3.53); not CKD: OR = 2.29 (95% CI: 1.78; 2.94)) o no LDL-C measurements before admission (OR = 13.17 (95% CI: 11.18; 15.51)) <ul style="list-style-type: none"> - Odds for initiation of LLT was high for individuals with a moderate to high LDL-C measurement (LDL-C at 2.4–3.8: OR = 6.99 (95% CI: 6.13; 7.96) and LDL-C>3.8: OR = 18.38 (95% CI: 15.73; 21.46)), and with a moderate to high total cholesterol, TC (TC at 4.4–5.9: OR = 4.14 (95% CI: 3.69; 4.65) and TC>5.9: OR = 9.75 (95% CI: 8.50; 11.18)) <p>trends in initiation of LLT therapy stratified by type of ASCVD (AMI and IS vs. remaining diagnoses and/or procedures)</p> <ul style="list-style-type: none"> - a higher proportion of individuals with AMI or IS initiated LLT therapy between admission and 90 days after discharge (data not shown) - among individuals with AMI or IS, the proportion initiating LLT between admission and 90 days after discharge increased during the study period from 67.4% to 74.6% - among individuals with other ASCVD diagnoses or procedures (SA, UA, PAD, CABG, PCI), the proportion initiating LLT between admission and 90 days after discharge increased during the study period from 23.1% to 25.0% | | |

Homeniuk et al. 2023 (Register, Irland)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Homeniuk R, Stanley F, Gallagher J, et al. Heartwatch: An Irish cardiovascular secondary prevention programme in primary care, a secondary analysis of patient outcomes. <i>BMJ open</i> 2023; 13(1):e063811. DOI: 10.1136/bmjopen-2022-063811. http://www.ncbi.nlm.nih.gov/pub-med/36599635. [23]</p> | <p>Objective to investigate patient follow-up data from Heartwatch: Ireland's secondary prevention programme for cardiovascular disease delivered in general practice</p> <p>Source</p> <ul style="list-style-type: none"> - based on secondary analysis of routinely collected data from Heartwatch - a national structured programme led by Irish GPs - standard protocol for the continuing care - each area employed a regional GP coordinator and nurse facilitator to assist with the deployment of Heartwatch care protocol - Heartwatch targeted 20% of general practices in Ireland and recruited 475 general practitioners across 325 practices - over 16 000 patients entered the programme - programme was designed using WHO and European Society of Cardiology guidelines on secondary prevention <p>there is a data management committee (aggregated, anonymous version of the collected data)</p> <p>Methods</p> | <p>Heartwatch overview: 2003–2020 Jan 2003-March 2020</p> <ul style="list-style-type: none"> - 300 practices - 16,000 patients - 350 000 visits - mean follow-up 7 years - > 7 000 (45%) patients have been in the programme for 8 years or more - mean 3 visits per year - male (76%) participants - median age 67 (range: 63–67) - female group were typically older, with a median age of 70 compared with 65 for males - sign up in the program with <ul style="list-style-type: none"> o 27% aged <60 years old o 33% of all participants aged between 60 and 69 years - AMI (40%) - PTCAs (35%) - CABGs (25%) - enrollment <ul style="list-style-type: none"> o 18% of patients within 1 year of the qualifying event (QE) o 32% of patients between 1 and 2 years after QE o 25% between 3 and 6 years o 26% more than 6 years after their QE <p>the 8-year cohort (2003 to 2023) n = 5 700 patients</p> <ul style="list-style-type: none"> - a minimum of one visit per year for 8 years - 38% PTCA as QE - 26% CABG as QE - 34% with a median QE-interval of 2 years - 77% male - median age at signup 65 years <p>Results</p> | <p>n. a.</p> | <p>epidemiological data</p> <p>the Strengthening the Reporting of Observational studies in Epidemiology cohort reporting guidelines were used</p> <p>Heartwatch was developed in collaboration with the Irish Heart Foundation Irish a national heart and stroke charity which supports and advocates for people who have been affected by heart and stroke</p> <p>authors noted that data come from an active clinical programme and there is no comparative or control group</p> <p>LDLc (Low-density Lipoprotein cholesterol) guideline targets changed during the programme; they noted that they have underestimated the number achieving the desired active target prior to 2016</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - retrospective descriptive study - 2003-2020 (extracted in Dec 2021) - patient population included people with a history of acute myocardial infarction (AMI), percutaneous transluminal coronary angioplasty (PTCA) or a coronary artery bypass graft (CABG) - cohort of 5700 patients with at least 8 years in the programme <p>Interventions</p> <ul style="list-style-type: none"> - standard protocol for continuing care of patients for the secondary prevention of cardiovascular disease administered by general practices <p>Outcome primary</p> <ul style="list-style-type: none"> - Continuing Care (CCare) score out of eight (calculated based on programme targets for well-known cardiovascular risk factors: exercise, systolic blood pressure, LDL cholesterol, optimally controlled glucose, smoking status, and pharmacological treatment) (based on EUROASPIRE studies) | <p>CCare score after 1 year:</p> <ul style="list-style-type: none"> - median score 5 - 5 (33% of patients) - <5 (30% of patients) - > 5 (37% of patients) <p>CCare score after 4 years:</p> <ul style="list-style-type: none"> - median score 5 - 37% of patients had individual-level improvements in their score - 36% of scores had not changed - 27% of scores decreased - >5 (44% of patients) <p>CCare score after 8 years:</p> <ul style="list-style-type: none"> - median score 5 - 36% with higher scores - 32% with same scores - 32% with lower scores - ≥6 (40% of patients) <p>within the target for SBP</p> <ul style="list-style-type: none"> - at the start of the first year: 64% of patient - after 4 years: 70% of patients - after 8 years: 67% of patients <p>LDL cholesterol < 1.8 mmol/L</p> <ul style="list-style-type: none"> - at year 1: 21% of patients - after 4 years: 26% of patients - after 8 years: 30% of patients <p>moderate exercise >210 min/min</p> <ul style="list-style-type: none"> - at year 1: 37% of patients - after 4 years: 41% of patients - after 8 years: 35% of patients <p>non-smoking</p> <ul style="list-style-type: none"> - at year 1: 88% of patients | | <p>(2016, the target level for lipoprotein cholesterol (LDLc) for very high-risk patients was changed to 1.8 mmol/L (from 3.0 mmol/L))</p> <p>authors documented a survivor bias on the available long-term information, as those with worse scores may have exited the programme earlier than 8 years</p> <p>Heartwatch does not collect outcome information such as mortality or further cardiac events, nor does it collect patient-reported outcomes</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - after 4 years: 90% of patients - after 8 years: 92% of patients <p>the rate of waist circumference within target did not change much through follow-up (waist circumference of <80cm (female) and <94cm (male)): ~ 27 % of participants</p> <p>prescribed anticoagulant/antiplatelet and lipid lowering agents</p> <ul style="list-style-type: none"> - at year 1 88% of patients - after 4 years: 94% of patients - after 8 years: 92% of patients <p>associations with the CCare score</p> <ul style="list-style-type: none"> - patient sex was predictive of better scores <ul style="list-style-type: none"> o male patients had almost a half-point advantage on females (0.432, 99% CI: 0.335 to 0.509) o female patients had lower CCare scores across all 8 years of follow-up, 26% had scores >5 in year 1, which rose to a maximum of 33% in year 4 and fell again to 28% in year 8, which was 15% points lower than the equivalent in male patients (41%, 47%–44%, respectively) - patient's age at signup does not appear to predict CCare scores - more younger patients had a CCare score >5 at signup (<60: 42%) compared with older patients (60–69: 38%, 70+: 34%) - patients who had a CABG as a QE <ul style="list-style-type: none"> o were predicted to have better scores than patients qualifying from an AMI (0.106, CI: 0.028 to 0.183, p<0.0001) - patients qualifying from a PTCA events <ul style="list-style-type: none"> o do not differ much from AMI (0.038, CI: -0.045 to 0.121, p=0.234) - number of Heartwatch visits per year | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> was predictive of higher CCare scores (0.109, CI: 0.051 to 0.168, p<0.0001) | | |

Kerneis et al. 2022 (Register, ESC-EORP-CICD-LT)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Kerneis M, Cosentino F, Ferrari R, et al. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: The ESC-EORP CICD-LT registry. Eur J Prev Cardiol 2022; 29(15):1945–54. DOI: 10.1093/eurjpc/zwac089. http://www.ncbi.nlm.nih.gov/pubmed/35653582. [24]</p> | <p>Objective to investigate clinical events at one-year follow-up from the ESC EORP CICD-LT Registry</p> <p>Source European Society of Cardiology (ESC) EORP CICD-LT registry (a prospective European registry, designed to describe the profile, management and outcomes of patients with CCS across the ESC countries)</p> <p>independent Executive Committee; Steering Committee; National coordinators; approvals of national or regional ethics committees or Institutional Review Boards; Data Management teams</p> <p>Methods</p> <ul style="list-style-type: none"> observational, longitudinal study patients with chronic coronary syndrome (CCS⁸, identified by means of a routine ambulatory visit or | <p>overall: n = 9 174 patients enrolled (across 154 centers from 20 countries) – May 2015 – July 2018) n = 6 655 participants with one-year follow-up (72.5%)</p> <ul style="list-style-type: none"> median age 67 years 73 % men 23.9% hypertension 40.4% hypercholesterolemia 30.2% diabetes mellitus 19.6% previous non-urgent coronary revascularization 36.5% previous ST-segment elevation myocardial infarction (STEMI) <p>Results at 1 year all-cause mortality n = 168 (2.5 %) all-cause rehospitalization n = 1 606 (27.1%) CV mortality n = 97 (1.5%) CV rehospitalization n = 1 220 (20.6%)</p> <ul style="list-style-type: none"> CAD related hospitalization n=661 (11.2%) heart failure n=276 (4.7%) vascular causes n=117 (2.0%) <p>Cox model identified 7 variables independently associated with an increased risk of cardiovascular events:</p> | n. a. | <p>epidemiological data</p> <p>authors noted: that selection of centers was made on a voluntary basis (center bias cannot be excluded)</p> <p>outcomes were not adjudicated; ICD codes were not used (variation of definition cannot be excluded)</p> <p>important number of missing data (one in three patients (2519, 27.4%) having an 'unknown status' (including loss of follow-up))</p> <p>pharmaceutical companies have supported the programme</p> <p>authors 'One-sentence Summary': Patients</p> |

⁸ defined as previous myocardial infarction, previous coronary revascularization or other CCS (effort-induced angina or rest angina with documented myocardial ischaemia detected by exercise or any stress imaging test or documented >50% stenosis in at least one major coronary artery on coronary angiography or asymptomatic ischaemia with a documented >50% stenosis in at least one major coronary artery on coronary angiography; Patients were excluded if they had experienced an acute coronary syndrome (ACS) in the previous 30 days)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>an elective coronary revascularization procedure)</p> <ul style="list-style-type: none"> - aged ≥ 18 years - one year follow-up - 20 countries <p>Outcomes at one year</p> <p>primary</p> <ul style="list-style-type: none"> - composite endpoint of cardiovascular death or cardiovascular rehospitalization <p>secondary</p> <ul style="list-style-type: none"> - all-cause death - cardiovascular and non-cardiac death - all cause of rehospitalization - cardiovascular, coronary artery disease (CAD) related, heart failure related, vascular related, non-cardiovascular rehospitalization | <ul style="list-style-type: none"> - age (by 10 years, HR=1.08, confidence interval (CI) [1.02-1.16]) - atrial fibrillation (HR=1.23, CI [1.05-1.44]) - stroke/TIA (HR=1.60, CI[1.32-1.95]) - severe liver disease (HR=1.70, CI[1.12-2.58]) - COPD/asthma (HR=1.33, CI[1.08-1.64]) - elevated serum creatinine (per ten mmol/l, HR=1.02, CI[1.01-1.04]) - impaired left ventricular function (left ventricular ejection fraction [LVEF] <40%), HR=1.85, CI[1.58-2.16]) <p>authors noted:</p> <ul style="list-style-type: none"> - northern Europe had the lowest cardiovascular mortality rate, southern Europe the highest (0.5% vs 2.0%, p value = 0.04) - women had a significantly higher rate of cardiovascular mortality compared to men (2.0% vs 1.3%, p value 0.02) - recommended treatment, including the number of lipid lowering agents (n = 6045 (95.4%) vs. n = 5816 (91.8%), p<0.001), decreased between baseline and one year - among the population with measured LDL-cholesterol level at one-year, 1434 patients (66.5%) were above the recommended target - 83.3% (n=2226) of the follow-up population with complete information on cardiovascular risk factors had at least one modifiable risk factor not at target according to current guidelines, including glycemia > 7mmol/l or low-density lipoprotein-cholesterol (LDL-C) 4 > 1.81 mM/l or blood pressure above 140/90 mmHg | | <p>with CCS enrolled in the CICC registry were at high risk of rehospitalization for CV causes, suggesting that the early identification of comorbidities associated with this risk (impaired left ventricular function, atrial fibrillation, previous stroke, liver, kidney and pulmonary diseases) may represent an opportunity for enhanced care and better outcomes.</p> |

12.4.3 Bempedoinsäure (neu 2023)

PICO Frage 25 der AkdÄ (Bempedoinsäure), Recherche bis Dez 2021

Zur Therapie mit Bempedoinsäure (bei maximal verträglicher Statintherapie) in der Sekundärprävention ermittelte ein Evidenzbericht der AkdÄ fünf Studien (Bempedoinsäure in Kombination mit Statinen und oder Ezetimib bzw. mit der Angabe eines Placebos ohne lipidenkende Begleittherapie gegenüber der (Therapie)-strategie ohne Bempedoinsäure) [25]. Die Studienaufbereitung wurde an anderer Stelle dokumentiert (Goldberg 2019 [26] (CLEAR Wisdom), Ray 2019 [27] (CLEAR Harmony), Ballantyne 2018 [28] (CLEAR Tranquility), Laufs 2019 [29] (CLEAR Serenity), Ballantyne 2020 [30]. Die zweite Version des Berichts ergänzt klinische Überlegungen zur Statinintoleranz (Primärprävention) [31,32].

Sayed et al. 2023 (SR, n =11 Studien, Primär- und Sekundärprävention)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Sayed A. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardio-vasc Drugs Ther 2023. https://www.ncbi.nlm.nih.gov/pub-med/37261676. [33]</p> | <p>Objective to summarize the latest evidence for the clinical efficacy and safety of bempedoic acid (BA)</p> <p>Methods</p> <ul style="list-style-type: none"> - prospectively registered on PROSPERO (CRD: 42023404231) - searching Pubmed, the Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov (March 2023) - randomized clinical trials (RCTs) of bempedoic acid (BA) - patients at an elevated risk for atherosclerotic cardiovascular disease (ASCVD) - history of one or more risk factors for ASCVD (primary prevention) - or had a pre-existing history of ASCVD (secondary prevention) | <p>n = 11 RCT [7–17 see below] (18,496 patients)</p> <ul style="list-style-type: none"> - n = 9,959 bempedoic acid - n = 8,537 control - weighted median follow-up of 40.6 months (Nissen et al. 2023); follow up varied by 2 to 12 months for the other RCT - average age 65.3 years (BA: 65.2; control: 65.4) - 45.6% were females - prevalence of diabetes 42.5% - prevalence of hypertension 78.4% <p>overall risk of bias was low 7 of 11 trials, with 4 trials being assessed as having a moderate risk of bias</p> <p>Results efficacy bempedoic acid vs. control (placebo) all-cause mortality</p> <ul style="list-style-type: none"> - RR: 1.05; 95% CI: 0.92 to 1.19 - ARD: 0.24 (95% CI -0.39; 0.96) <p>MACE</p> <ul style="list-style-type: none"> - RR: 0.87; 95% CI: 0.80 to 0.95 - ARD: -1.63% (95% CI -2.51; -0.68); NNT: 62 (95% CI 40; 147) <p>cardiovascular mortality</p> <ul style="list-style-type: none"> - RR: 1.05; 95% CI 0.89 to 1.24 - ARD: 0.16 (95% CI -0.33; 0.75) | <p>AMSTAR-II low</p> <p>authors noted: overall risk of bias was low 7 of 11 trials, with 4 trials being assessed as having a moderate risk of bias</p> <p>possibility of subgroup analysis was limited by the lack of access to patient-level data</p> <p>follow-up duration was generally less than what might be seen in clinical practice, where use of lipid-lowering treatments can span decades</p> <p>safety outcome myalgia was reported by all studies (no evidence of publication bias, funnel plot)</p> | <p>authors noted that results contrast with those of the most recent metaanalysis assessing clinical outcomes (differences are likely attributable to a lack of statistical power and imprecise estimates as the largest outcomesbased trial, CLEAR Outcomes, had not yet been published at the time of the previous meta-analyses but is included in our meta-analysis)</p> <p>authors noted that ezetimibe is the oldest drug (compared to evolocumab etc.) and is available in generic form; the high cost of evolocumab and bempedoic acid are significant barriers to</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>Quality assessment Risk of Bias 2 (RoBII) tool</p> <p>Outcome</p> <ul style="list-style-type: none"> - all-cause mortality and major adverse cardiovascular events (MACE) - MACE consisted of cardiovascular mortality, myocardial infarction, stroke, unstable angina hospitalization, and revascularization, which were analysed both separately and as a 5-component composite endpoint - safety endpoints included gout, myalgia, renal impairment, cholelithiasis, and new-onset or worsening of diabetes mellitus (DM) <p>Mantel-Haenszel method to pool estimates; relative risks (RR), absolute risk differences (ARD), and number needed to treat/harm (NNTB/H)</p> | <p>myocardial infarction</p> <ul style="list-style-type: none"> - RR: 0.76; 95% CI: 0.66 to 0.89 - ARD: -1.03% (95% CI -1.50; -0.49); NNT: 98 (95% CI 67; 207) <p>stroke</p> <ul style="list-style-type: none"> - RR: 0.87; 95% CI 0.69 to 1.08 - ARD: -0.27 (95% CI -0.61; 0.17) <p>unstable angina hospitalization</p> <ul style="list-style-type: none"> - RR: 0.70; 95% CI: 0.55 to 0.89 - ARD: -0.57% (95% CI -0.85; -0.21); NNT: 177 (95% CI 119; 484) <p>revascularization</p> <ul style="list-style-type: none"> - RR: 0.81; 95% CI: 0.72 to 0.91 - ARD: -1.31% (95% CI -1.94; -0.60); NNT: 77 (95% CI 52; 167) <p>safety</p> <p>risk of gout</p> <ul style="list-style-type: none"> - RR: 1.56; 95% CI: 1.27 to 1.91 - ARD: 0.99%; NNH: 101 <p>myalgia</p> <ul style="list-style-type: none"> - RR: 0.85; 95% CI: 0.75 to 0.95 - ARD: -0.99%; NNT: 102 <p>renal impairment</p> <ul style="list-style-type: none"> - RR: 1.35; 95% CI: 1.22 to 1.49 - ARD: 2.54%; NNH: 40 <p>cholelithiasis</p> <ul style="list-style-type: none"> - RR: 1.87; 95% CI: 1.43 to 2.44 - ARD: 1.01%; NNH: 100 <p>new/worsening DM</p> <ul style="list-style-type: none"> - RR: 0.91; 95% CI 0.83 to 1.00 - ARD: -1.24 (95% CI -2.42; 0.06) <p>(forest plots for all outcomes presented within a supplement)</p> <p>Included studies</p> <p>7. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in statin-</p> | | <p>widespread adoption in these settings</p> <p>authors additionally noted one trial in the context of statin-associated myalgias, (SAMSON trial), which showed that most statin-associated myalgias are due to the placebo effect (statins have by far the greatest body of evidence on clinical safety and efficacy)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>intolerant patients. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2215024. [32] (CLEAR Outcomes; primary and secondary prevention)</p> <p>8. Bays HE, Baum SJ, Brinton EA, et al. Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. Am J Prev Cardiol. 2021;8:100278. https://doi.org/10.1016/j.ajpc.2021.100278. (Typ 2 Diabetes mellitus; Subgruppenanalyse, primary prevention)</p> <p>9. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at High Risk for Cardiovascular Disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585. [26] (CLEAR WISDOM; primary and secondary prevention)</p> <p>10. Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC- 1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13(4):568–79. https://doi.org/10.1016/j.jacl.2019.05.003. (Charakterisierung Bempedoinsäure und Studienvorbereitung; primary prevention)</p> <p>11. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of Bempedoic Acid in patients with hypercholesterolemia and statin intolerance. J Am Heart</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Assoc. 2019;8(7):e011662. https://doi.org/10.1161/JAHA.118.011662. [29] (CLEAR SERENITY; primary and secondary prevention)</p> <p>12. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917. [27] (CLEAR HARMONY; primary and secondary prevention)</p> <p>13. Rubino J, MacDougall DE, Sterling LR, et al. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/ kexin type 9 inhibitor therapy: a randomized, controlled trial. J Clin Lipidol. 2021;15(4):593–601. https://doi.org/10.1016/j.jacl.2021.05.002. (Bempedoinsäure + proprotein convertase subtilisin/ kexin type 9 inhibitor therapy; primary prevention)</p> <p>14. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154–62. https://doi.org/10.1016/j.jacc.2013.05.050. (primary prevention; Ballantyne 2018 (CLEAR Tranquility) sowie 2020 vorhanden)</p> <p>15. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002. [28]</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>(CLEAR Tranquility; primary prevention)</p> <p>16. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593–603. https://doi.org/10.1177/2047487319864671. [30]</p> <p>(primary and secondary prevention)</p> <p>17. Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556–67. https://doi.org/10.1016/j.jacl.2015.12.025.</p> <p>(Studiencharakterisierung; primary and/or secondary prevention (?))</p> | | |

Krishna Mohan et al. 2023 (SR, n = 3 Studien, Primärprävention, Statinintoleranz bzw. max. tolerierte Statintherapie)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <p>Krishna Mohan GV. Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials. Cureus 2023; 15(5):e38662. https://www.ncbi.nlm.nih.gov/pub-med/37288183. [34]</p> | <p>Objective to evaluate the effectiveness and safety of bempedoic acid in preventing cardiovascular events among high-risk patients of cardiovascular diseases</p> <p>Methods</p> <ul style="list-style-type: none"> - meta-analysis of RCT following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines | <p>n = 3 Studien (n = 16 978 patients)</p> <ul style="list-style-type: none"> - n = 9 001 bempedoic acid - n = 7 977 placebo - sample size range 779 to 13 970 - follow-up range 12 to 60 months - Goldberg et al 2019 (max. tolerated statins: bempedoic acid vs. placebo) - Ray et al. 2019 (max. tolerated statins: bempedoic acid vs. placebo) - Nissen et al. 2023 (statin intolerant patients: bempedoic acid vs. placebo) <p>Results (n = 3 studies, bempedoic acid vs. placebo)</p> | <p>AMSTAR-II low</p> <p>risk of bias was rated as low for most domains (selective reporting was noted)</p> <p>heterogeneity in study co-mediations, such as no statin versus maximally tolerated statin and additional ezetimibe was reported as limitation</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - database Medline, the Cochrane Library of Clinical Trials, and EMBASE until April 15, 2023 - cardiovascular outcomes between patients receiving bempedoic acid (alone or in combination with other drugs or interventions) and those receiving a placebo - RCT - follow-up at least 12 months - studies that did not report the primary outcome (MACE) were excluded <p>Quality assessment Cochrane risk of bias tool (7 domains)</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization <p>secondary</p> <ul style="list-style-type: none"> - LDL-C - Safety (adverse events and serious adverse events) | <p>primary</p> <p>MACE</p> <ul style="list-style-type: none"> - incidence 11,5% - RR 0.86 (95% CI: 0.80-0.94) <p>cardiovascular death</p> <ul style="list-style-type: none"> - RR 1.05 (95% CI 0.89-1.24) <p>myocardial infarction</p> <ul style="list-style-type: none"> - RR 0.76 (95% CI 0.65-0.89) <p>stroke</p> <ul style="list-style-type: none"> - RR 0.98 (95% CI 0.78-1.24) <p>coronary revascularization</p> <ul style="list-style-type: none"> - RR 0.81 (95% CI 0.72-0.91) <p>hospitalization due to instable angina</p> <ul style="list-style-type: none"> - RR 0.69 (95% CI 0.54-0.88) <p>secondary</p> <p>LDL-C (heterogeneity reported)</p> <ul style="list-style-type: none"> - MD -17.47 (95% CI: -21.13, -13.81) <p>adverse events</p> <ul style="list-style-type: none"> - RR 1.01 (95% CI: 1.00-1.03) <p>risk of SAE</p> <ul style="list-style-type: none"> - RR: 1.02 (95% CI: 0.96-1.08) <p>Included studies Goldberg 2019 [26] (CLEAR Wisdom) Ray 2019 [27] (CLEAR Harmony) Nissen 2013 [32] (CLEAR Outcome)</p> | | |

Lin et al. 2022 (SR, n = 6 Studien, Primär- und Sekundärprävention)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <p>Lin Y. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: A systematic review and meta-analysis. <i>BMJ Open</i> 2022; 12(2):e048893. https://www.ncbi.nlm.nih.gov/pubmed/35210334. [35]</p> | <p>Objectives to assess efficacy and safety of bempedoic acid (BA) for clinical outcomes in high cardiovascular (CV) risk patients</p> <p>Methods</p> <ul style="list-style-type: none"> - sources: MEDLINE, Cochrane Central Register of Controlled Trials, Google Scholar, Embase, ClinicalTrials.gov, Clinical Trial Results and the American College of Cardiology web site - randomised controlled trials (RCT) of BA vs placebo in high CV risk patients reporting clinical outcomes were included <p>Quality assessment Risk of Bias; GRADE</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - major adverse cardiovascular events (MACE), - all-cause mortality, - CV mortality and - non-fatal myocardial infarction (MI) <p>safety</p> <ul style="list-style-type: none"> - new onset or worsening of diabetes mellitus (DM), - muscular disorders, | <p>n = 6 studies (n = 3,956 patients), n = 5 phase 3 and n = 1 phase 2 studies</p> <ul style="list-style-type: none"> - n = 3 studies with patients treated with max. tolerated statin therapy - n = 3 studies with statin intolerance or after discontinuation of lipid-lowering therapy - patients between 55 and 67 years old - suffered from a considerable CV risk profile (high rates of ASCVD, DM, HeFH or chronic kidney disease (CKD)) - and insufficient control of serum lipid levels - follow-up: ranged from 4 to 52 weeks <p>Results MACE</p> <ul style="list-style-type: none"> - 4,7% (BA) vs. 5,5% (placebo) - OR 0.84, 95% CI 0.61 to 1.15; p=0.27, n = 4 studies (n = 3413 patients) <p>all-cause mortality</p> <ul style="list-style-type: none"> - 0.7% (BA) vs. 0.3% (placebo) - OR 2.37; 95% CI 0.80 to 6.99; p=0.12, n = 5 studies (n = 3895 patients) <p>CV mortality</p> <ul style="list-style-type: none"> - 0.4% (BA) vs. 0.3% (placebo) - OR 1.66; CI 0.45 to 6.04; p=0.44, n = 3 studies (n = 3353 patients) <p>non-fatal MI</p> <ul style="list-style-type: none"> - 1.1% (BA) vs. 2.0% (placebo) - OR 0.57; 95% CI 0.32 to 0.99; p = 0.05 (borderline-significant trend), n = 4 studies (n = 3413 patients) <p>coronary revascularisation</p> <ul style="list-style-type: none"> - OR 0.82; 95% CI 0.55 to 1.22; p=0.32 (supplement) <p>non-fatal stroke</p> | <p>AMSTAR-II low</p> <p>(eine kritische Domäne konnte nicht erfüllt werden: Darlegung der ausgeschlossenen Volltexte mit Ausschlussgrund)</p> <p>authors noted: low event rates within limited follow-ups may cause imprecise effect estimates</p> <p>heterogeneity in length of follow-up and background lipid-lowering therapy</p> <p>prespecified sensitivity analyses did not change the overall effect</p> <p>GRADE: low certainty of evidence for MACE and all-cause mortality moderate certainty of evidence for CV mortality and non-fatal MI</p> | <p>patients with high cardiovascular risk and in those with established atherosclerotic cardiovascular disease</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - gout and - worsening of renal function | <ul style="list-style-type: none"> - OR 1.26, 95% CI 0.42 to 3.76; p=0.68 (supplement) <p>hospitalisation for heart failure</p> <ul style="list-style-type: none"> - OR 2.33; 95% CI 0.67 to 8.11; p=0.19 (supplement) <p>hospitalisation for unstable angina</p> <ul style="list-style-type: none"> - OR 0.94; 95% CI 0.51 to 1.74; p=0.84 (supplement) <p>safety</p> <p>risk of new-onset or worsening of DM</p> <ul style="list-style-type: none"> - 3.8% (BA) vs. 5.5% (placebo) - OR 0.68; 95% CI 0.49 to 0.94; p = 0.02, n = 3 studies (n = 3622 patients) <p>risk of gout</p> <ul style="list-style-type: none"> - 1.5% (BA) vs. 0.5% (placebo) - OR 3.29; 95% CI 1.28 to 8.46; p=0.01 <p>serum uric acid</p> <ul style="list-style-type: none"> - 5.1% (BA) vs. 2.0% (placebo) - OR 2.60; 95% CI 1.15 to 5.91; p=0.02 (supplement) <p>risk of muscular disorders</p> <ul style="list-style-type: none"> - 10.9% (BA) vs. 9.1% (placebo) - OR 2.60; 95% CI 1.15 to 5.91; p=0.06 <p>worsening of renal function</p> <ul style="list-style-type: none"> - 0.7% (BA) vs. 0.1% (placebo) - OR 4.24; 95% CI 0.98 to 18.39; p =0.05 <p>serum creatinine levels</p> <ul style="list-style-type: none"> - 0.8% (BA) vs 0.4% (placebo) - OR 2.01; 95% CI 0.67 to 6.02; p=0.21 (supplement) <p>upper respiratory tract infection</p> <ul style="list-style-type: none"> - OR 0.82; 95% CI 0.63 to 1.06; p=0.13 (supplement) <p>urinary tract infection</p> <ul style="list-style-type: none"> - OR 0.84, 95% CI 0.62 to 1.14; p=0.25 (supplement) <p>neurocognitive disorders</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - OR 1.00, 95% CI 0.58 to 1.74; p=0.99 (supplement) <p>nasopharyngitis</p> <ul style="list-style-type: none"> - OR 0.88; 95% CI 0.68 to 1.14; p=0.33 (supplement) <p>LDL-C level</p> <ul style="list-style-type: none"> - MD in LDL-C levels from baseline: <ul style="list-style-type: none"> o -19.93% (95% CI -21.55 to -18.31); p<0.01 (BA vs. placebo) <p>total cholesterol</p> <ul style="list-style-type: none"> - MD -12.43%; 95% CI -13.42 to -11.43, p<0.01 <p>non-high density lipoprotein cholesterol (non-HDL-C)</p> <ul style="list-style-type: none"> - MD -15.27%; 95% CI -16.59 to -13.95, p<0.01 <p>apolipoprotein B (apoB)</p> <ul style="list-style-type: none"> - MD -13.20%; 95% CI -14.47 to -11.93, p<0.01 <p>high-density lipoprotein cholesterol levels</p> <ul style="list-style-type: none"> - MD -7.5%, 95% CI -8.30 to -6.61, p<0.01 <p>triglyceride levels</p> <ul style="list-style-type: none"> - MD 3.35%, 95% CI -1.78 to 8.49, p=0.20 <p>Included studies</p> <p>6 Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. <i>Atherosclerosis</i> 2018;277:195–203. [28]</p> <p>7 Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>Eur J Prev Cardiol</i> 2020;27:2047487319864671. [30]</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>8 Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial. JAMA 2019;322:1780–8. [26]</p> <p>9 Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019;8:e011662. [29]</p> <p>10 Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of Bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:1022–32. [27]</p> <p>11 Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014;34:676–83.</p> | | |

Dai et al. 2021 (SR, n = 10 Studien, Primär- und Sekundärprävention)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <p>Dai L. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2021; 28(8):825–33. https://www.ncbi.nlm.nih.gov/pub-med/34298558. [36]</p> | <p>Objective to conduct a meta-analysis to quantitatively appraise the efficacy and safety of bempedoic acid</p> <p>Methods</p> <ul style="list-style-type: none"> - preferred reporting items for systematic review and meta analyses guidelines were used | <p>n = 10 studies (n = 4 142 patients)</p> <ul style="list-style-type: none"> - n = 2 736 BA - n = 1 368 placebo - duration of intervention: 4 – 52 weeks - range of participants: 56 to 2 230 - n = 3 studies patients with hypercholesterolemia and statin-intolerance - n = 1 study patients with hypercholesterolemia and typ 2 diabetes mellitus <p>Results</p> | <p>AMSTAR-II low</p> <p>(eine kritische Domaine konnte nicht erfüllt werden: Darlegung der ausgeschlossenen Volltexte mit Ausschlussgrund)</p> <p>authors noted that all included studies were associated with low risk of performance bias, detection bias and reporting bias</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | <ul style="list-style-type: none"> - PubMed, Embase, Web of Science and Scopus; reference lists from inception to 30 January 2020 - randomized controlled trials - compared the efficacy and safety of bempedoic acid (ETC-1002) with placebo - patients with hypercholesterolemia <p>Quality assessment</p> <ul style="list-style-type: none"> - risk of bias (Cochrane Collaborations tool) and heterogeneity were assessed <p>Outcomes efficacy and safety parameters related to the treatment</p> | <p>data from week 12 or less</p> <p>BA vs. placebo, n = 10 studies</p> <p>LDL-C levels MD -23.16%, 95% CI -26.92% to -19.04%; p < 0.00001</p> <p>non-HDL-C level MD -18.30%, 95% CI -21.65% to -14.95%; p < 0.00001</p> <p>total cholesterol level MD -14.62%, 95% CI -17.08% to -12.16%; p < 0.00001</p> <p>apoB level MD -14.77%, 95% CI -16.85% to -12.70%; p < 0.00001</p> <p>HDL-C level MD -3.80%, 95% CI -5.54% to -2.06%; p < 0.00001</p> <p>triglycerides MD 1.09%, 95% CI -4.94% to 7.12%; p = 0.72</p> <p>safety</p> <p>risk of overall adverse events OR 1.02, 95% CI 0.88; 1.18; p = 0.82</p> <p>serious adverse events OR 1.07, 95% CI 0.87 to 1.30; p = 0.54</p> <p>muscle-related adverse events OR 1.21, 95% CI 0.97 to 1.51; p = 0.09</p> <p>study drug-related adverse events OR 1.36, 95% CI 1.05 to 1.76; p = 0.05</p> <p>adverse events leading to discontinuation OR 1.44, 95% CI 1.14 to 1.82; p = 0.002</p> <p>pain in extremity OR 1.68, 95% CI 1.06 to 2.65; p = 0.03</p> | <p>risk of bias in allocation concealment was generally unclear apart from two studies</p> <p>one study was rated as high risk of bias because there were some differences in baseline characteristics among the treatment groups</p> <p>considerable heterogeneity was reported for LDL-C</p> <p>authors noted possible publication bias; probably, some outcomes are vulnerable for incompleteness or different definition/measurement (e. g. laboratory data) as well as affected by duration and study situation (e. g. adverse events)</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>gout OR 2.70, 95% CI 1.08 to 6.75; p = 0.03</p> <p>uric acid levels more than placebo MD 0.74mg/dl, 95% CI 0.50 to 0.99; p < 0.00001</p> <p>creatinine levels MD 0.04 mg/dl, 95% CI 0.03 to 0.05; p < 0.00001</p> <p>subgroups</p> <p>(1) (n=6) patients with hypercholesterolemia LDL-C level -18.31% 95% CI -19.85% to -16.76%; p< 0.00001 (n = 5 studies: enrolled patients at high risk for CVD receiving maximally tolerated statins or high-dose statins, who were randomized to treatment with bempedoic acid (180mg) or placebo)</p> <p>(2) (n=3) patients with hypercholesterolemia and statin-intolerance LDL-C level -24.87% 95% CI -27.66% to -22.08%; p < 0.00001</p> <p>(3) (n=1) patients with hypercholesterolemia and type 2 diabetes mellitus (T2DM) LDL-C level -38.09% 95% CI -45.97% to -31.83%; p < 0.00001</p> <p>data from week 24 BA vs. placebo, n = 3 studies LDL-C level MD -16.42%, 95% CI -18.16% to -14.69%; p < 0.00001</p> <p>non-HDL-C MD -14.97%, 95% CI -19.38% to -10.57%; p < 0.00001</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | TC MD -12.69%, 95% CI -16.31% to -9.06%; p < 0.00001 apoB MD -14.70%, 95% CI -17.42% to -11.98%; p < 0.00001 HDL-C MD -5.18%, 95% CI -6.19% to -4.16%; p < 0.00001 triglycerides MD 0.96%, 95% CI -4.08% to 6.01%; p < 0.00001 | | |

IQWiG Bericht 2021 (Bempedoinsäure, Primär- und Sekundärprävention)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| A20 -92: Version 1.0 28.01.2021. IQWiG-Berichte – Nr. 1033. Bempedoinsäure (primäre Hypercholesterinämie und gemischte Dyslipidämie) – Nutzenbewertung gemäß § 35a SGB V [37] | <p>Fragestellung Ziel des Berichts ist die Bewertung des Zusatznutzens von Bempedoinsäure zusätzlich zu diätetischer Therapie und ggf. anderen lipidsenkenden Medikamenten im Vergleich zur zweckmäßigen Vergleichstherapie bei erwachsenen Patientinnen und Patienten mit primärer Hypercholesterinämie (heterozygot familiär und nicht familiär) oder gemischter Dyslipidämie</p> <p>Methodik Die Bewertung erfolgte auf Basis eines Dossiers des pharmazeutischen Unternehmers (pU). Das Dossier wurde dem IQWiG am 30.10.2020 übermittelt.</p> <p>NCT02666664, NCT02988115, NCT02991118</p> | <p>Ergebnisse Fragestellung 1: Patient*innen, bei denen medikamentöse und diätetische Optionen zur Lipidsenkung nicht ausgeschöpft worden sind</p> <ul style="list-style-type: none"> - Informationsbeschaffung des pU: RCT CLEAR HARMONY [27] (im Folgenden als Studie HARMONY benannt), CLEAR WISDOM [26] (im Folgenden als Studie WISDOM benannt) und CLEAR SERENITY [29] (im Folgenden als Studie SERENITY benannt) - zur Ableitung des Zusatznutzens (durch pU): HARMONY und WISDOM - Studie SERENITY wird ergänzend dargestellt (u. a. Studiendauer von 24 Wochen) - Vorgehen wird als sachgerecht bewertet - Das IQWiG bewertet die vom pU eingeschlossenen Studien HARMONY und WISDOM für die Bewertung des Zusatznutzens von Bempedoinsäure als nicht geeignet | <p>AMSTAR-II critically low (Hinweis: die vorgelegten Studien entstammen dem Dossier des pharmazeutischen Unternehmers und wurden durch dessen Informationsbeschaffung dokumentiert; eine genaue Angabe der Methodik/Recherche erfolgte nicht, ausschließlich eine Zusammenfassung)</p> <p>eine formale Risk-of-Bias Bewertung ist nicht ersichtlich, allerdings eine Darstellung der Limitationen der Studien; eine Liste ausgeschlossener Volltexte ist nicht verfügbar</p> | <p>die Bewertung wurde unter Einbindung externer Sachverständiger</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Indikation</p> <ol style="list-style-type: none"> 1) Erwachsene mit primärer Hypercholesterinämie (heterozygot familiär und nicht familiär) oder gemischter Dyslipidämie, bei denen medikamentöse und diätetische Optionen zur Lipidsenkung nicht ausgeschöpft worden sind 2) Erwachsene mit primärer Hypercholesterinämie (heterozygot familiär und nicht familiär) oder gemischter Dyslipidämie, bei denen medikamentöse (außer Evolocumab) und diätetische Optionen zur Lipidsenkung ausgeschöpft worden sind <p>Zweckmäßige Vergleichstherapie</p> <ol style="list-style-type: none"> 1) maximal tolerierte medikamentöse Therapie nach Maßgabe des Arztes unter Berücksichtigung von Statinen, Cholesterinresorptionshemmern und Anionenaustauschern 2) Evolocumab oder LDL-Apherese (als „ultima ratio“ bei therapierefraktären Verläufen)d ggf. mit begleitender medikamentöser lipidsenkender Therapie | <ul style="list-style-type: none"> - Begründung: HARMONY und WISDOM sind randomisierte, doppelblinde, multizentrische Studien zum Vergleich von Bempedoinsäure mit Placebo, jeweils in Kombination mit einer lipidsenkenden Hintergrundtherapie; eingeschlossen wurden erwachsene Patient*innen mit hohem kardiovaskulärem Risiko (definiert als atherosklerotische kardiovaskuläre Erkrankung [ASCVD] oder heterozygoter familiärer Hypercholesterinämie [HeFH]), deren Low-Density-Lipoprotein-Cholesterin(LDL-C)-Wert unter bestehender lipidsenkender Therapie nicht ausreichend kontrolliert war - HARMONY und WISDOM sind nicht geeignet, um Aussagen zum Zusatznutzen von Bempedoinsäure abzuleiten, da die zweckmäßige Vergleichstherapie gemäß Festlegung des G-BA nicht umgesetzt ist (während bei den Patient*innen im Interventionsarm in beiden Studien eine Therapieeskalation durch die Verabreichung von Bempedoinsäure erfolgte, führten die Patient*innen im Vergleichsarm ihre unzureichende lipidsenkende Hintergrundtherapie fort. Erst ab Woche 24 war unter der Voraussetzung, dass definierte LDL-C-Schwellenwerte (> 170 mg/dl und ≥ 25 % erhöht gegenüber Studienbeginn) überschritten wurden, eine Anpassung der Hintergrundtherapie möglich) - nach Randomisierung wurde im Vergleichsarm bei lediglich 9 % (Studie WISDOM) bzw. 10 % (Studie HARMONY) der Patient*innen eine Anpassung der lipidsenkenden Therapie vorgenommen <p>Fragestellung 2: Patient*innen, bei denen medikamentöse (außer Evolocumab) und diätetische Optionen zur Lipidsenkung ausgeschöpft worden sind</p> <ul style="list-style-type: none"> - Informationsbeschaffung des pU: für erwachsene Patient*innen mit primärer Hypercholesterinämie | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>(heterozygot familiär und nicht familiär) oder gemischter Dyslipidämie, bei denen medikamentöse (außer Evolocumab) und diätetische Optionen zur Lipidsenkung ausgeschöpft worden sind</p> <ul style="list-style-type: none"> ○ keine Daten zur Bewertung des Zusatznutzens von Bempedoinsäure gegenüber der zweckmäßigen Vergleichstherapie <p>vom pU wird die Anzahl der GKV-Patient*innen in der Zielpopulation mit insgesamt 262 154 für die Fragestellung 1 sowie eine Spanne von 15 145 bis 16 971 Patient*innen der GKV-Zielpopulation angegeben (Einflussfaktoren könnten hier die Anpassung der Prävalenz sowie geändertes Verhalten in Bezug auf den Lebensstil sein)</p> <p>geschätzte Jahrestherapiekosten (GKV):</p> <ul style="list-style-type: none"> - Bempedoinsäure allein oder in Kombination mit lipidsenkenden Therapien: 1 659,71 – 4 253,55 € - maximal tolerierte medikamentöse Therapie nach Maßgabe des Arztes unter Berücksichtigung von Statinen, Cholesterinresorptionshemmern und Anionenaustauschern: 26,37 – 2 593,84 € - Evolocumabe oder LDL-Apherese (als „ultima ratio bei therapierefraktären Verläufen) ggf. mit begleitender medikamentöser lipidsenkender Therapie: 5 857,36 – 69 913,04 € <p>Eingeschlossene Studien Goldberg 2019 [26] (CLEAR Wisdom) Ray 2019 [27] (CLEAR Harmony) Laufs 2019 [29] (CLEAR Serenity) Charakteristika der eingeschlossenen Studien vgl. Anhang A ab S. 38 im Bericht</p> | | |

NICE Single Technology Appraisal 2020 (Bempedoinsäure, Primär- und Sekundärprävention)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Single Technology Appraisal Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515] Committee Papers. [38]</p> | <p>Objective to identify efficacy and safety studies of bempedoic acid and its comparator treatments for patients with primary hypercholesterolaemia or mixed dyslipidaemia when optimised lipid-lowering therapy including statins does not appropriately control LDL-C or when statins are contraindicated or not tolerated</p> <p>Methods</p> <ul style="list-style-type: none"> - systematic literature review (May 2019, a pre-specified protocol) - databases (MEDLINE, MEDLINE In-Process, Embase, BIOSIS and The Cochrane Library) - addition of bibliographies of systematic reviews and key articles - methodologies were critically appraised according to NICE requirements - patients with primary hypercholesterolaemia or mixed dyslipidaemia when optimised lipid-lowering therapy including statins does not appropriately control LDL-C or when statins are contraindicated or not tolerated <p>Intervention</p> | <p>clinical development programme for bempedoic acid evaluated the efficacy of bempedoic acid in reducing LDL-C as an add-on therapy to other lipid-modifying therapies (LMTs), including maximally tolerated statins (which may mean no or low statin dose) or ezetimibe or PCSK9 inhibitors, for the treatment of patients whose LDL-C levels are not currently controlled with current standard of care for dyslipidemia</p> <p>n = 15 studies (phase 1), n = 10 studies (phase 2), n = 5 RCT (phase 3): (CLEAR Harmony, Wisdom, Serenity, Tranquility, and Study 1002FDC-053)</p> <ul style="list-style-type: none"> - bempedoic acid 180 mg either as monotherapy or in combination with stable background LMT (lipid-modifying therapy) for 12 to 52 weeks - efficacy evaluated in n = 16 trials (phase 2 and 3) - pooled meta-analysis (n = 4 studies, n = 3,623 patients, phase 3 studies) - phase 3 bempedoic acid programme evaluated >3,600 unique patients including >3,000 high-risk patients with LDL-C \geq 70 mg/dL (1.8 mmol/L) who had ASCVD and/or heterozygous familial hypercholesterolemia (HeFH), or presence of other CVD risk factors, and were receiving maximally tolerated statin therapy - additionally n = 614 patients were included with hypercholesterolaemia who had a history of statin intolerance with a broader range of risk factors for CV events - ongoing open label extension (OLE) study (1002-050) for safety, enrolled patients who received bempedoic acid 180 mg QD for 78 weeks after completion of the 52-week CLEAR-HARMONY study (the parent 1002-040 study) - further phase 3 global, CV outcomes trial is ongoing (CLEAR CVOT, 1002-043), primary outcome MACE (composite endpoint of CV death, non-fatal | <p>AMSTAR-II high</p> | <p>(der gesamte Bericht umfasst etwa 900 Seiten)</p> <p>Table 3 page 20 major atherosclerotic cardiovascular disease risk factors</p> <p>Table 4 page 22 cardiovascular risk categories (ESC)</p> <p>Table 6 page 33 High-risk and very high-risk patients included in 2019 ESC/EAS dyslipidaemia guidelines</p> <p>epidemiology in UK: ~15% in adult UK population affected by hypercholesterolaemia; often associated with comorbidities such as diabetes or CV disease</p> <p>study of 200 cohorts and more than 2 million participants demonstrated that there is a dose-dependent log-linear association between LDL-C burden and risk of ASCV (Ference et al. (2017), page 21 (fig 1)</p> <p>dyslipidaemia characterised by elevated</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> ▪ Bempedoic acid, alone or with a statin, with or without other lipid-lowering therapy Bempedoic acid in an FDC with ezetimibe, alone or with a statin <p>Comperator When statins are contraindicated or not tolerated:</p> <ul style="list-style-type: none"> ▪ Ezetimibe ▪ Evolocumab (with or without another lipidlowering therapy) ▪ Alirocumab (with or without another lipidlowering therapy) <p>When statins are contraindicated or not tolerated, and ezetimibe does not appropriately control LDL-C:</p> <ul style="list-style-type: none"> ▪ Ezetimibe (when evolocumab and alirocumab are not appropriate) ▪ Evolocumab (with or without another lipidlowering therapy) ▪ Alirocumab (with or without another lipidlowering therapy) <p>When maximally tolerated statin dose does not appropriately control LDL-C:</p> <ul style="list-style-type: none"> ▪ Ezetimibe with a statin ▪ Evolocumab with a statin (with or without another lipid-lowering therapy) ▪ Alirocumab with a statin (with or without another lipid-lowering therapy) | <p>myocardial infarction (MI), non-fatal stroke, and coronary revascularisation) – CLEAR Outcomes study</p> <ul style="list-style-type: none"> - phase 2 studies (1002-008 and 1002-009) investigated LDL-C level - characteristics of included studies presendend from page 40 to 44, page 48 to 54, page 57 to 61, page 72ff - for baseline characteristics see page 62 to 70 and 75ff <p>Results</p> <ul style="list-style-type: none"> - LS mean difference from placebo in percentage change from baseline to week 12 in LDL-C <ul style="list-style-type: none"> o ranged from -15.7% to -38.0% (P < 0.001) (Ballantyne et al., 2019a; Esperion Therapeutics data on file, 2019c; Laufs et al., 2019; Ray et al., 2019b) - patients receiving maximally tolerated statin, LS mean reduction from baseline in LDL-C for bempedoic acid compared with placebo <ul style="list-style-type: none"> o -15.1% vs 2.4% (in CLEAR Wisdom) o -16.5% vs -1.6% (in CLEAR Harmony) o -17.2% vs +1.8% (in 1002FDC-053 (Ballantyne et al., 2019a; Esperion Therapeutics data on file, 2019c; Laufs et al., 2019; Ray et al., 2019b) o -23.6% vs -1.3% (in CLEAR Serenity) o -23.5% vs +5% (Ballantyne et al., 2018) o mean change in LDL-C of -28.5% (CLEAR Tranquility) <p>summary clinical effectiveness (NICE), see also Table 27, page 100f and Table 28, page 108 bempedoic acid trials</p> <ul style="list-style-type: none"> - n = 4 completed phase 3 trials (n = 3,623 patients) (CLEAR Harmony, CLEAR Wisdom, CLEAR Serenity, CLEAR Tranquility) n = 2 phase 2 RCT | | <p>LDL-C and triglycerides (< 1.7 mmol/L) and/or reduced or elevated high-density lipoprotein cholesterol (HDL-C) (Carroll et al., 2017), page 19</p> <p>consistent evidence from multiple types of clinical and genetic studies that clearly establish that LDL-C is a causal factor of atherosclerotic cardiovascular disease (ASCVD) and that cumulative LDL burden is a determinant for initiation and progression of ASCVD (Agabiti Rosei and Salvetti, 2016; Ciccarelli et al., 2018; Ference et al., 2017; Graham et al., 2012; Herrington et al., 2016)</p> <p>authors noted, that lowering of LDL-C is associated with a reduction in the incidence of major coronary events, ischaemic strokes, and revascularisations (citation Baigent et al., 2011)</p> <p>therapy generally maintained for life with LDL targets of < 135 mg/dL</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>When maximally tolerated statin dose with ezetimibe does not appropriately control LDL-C:</p> <ul style="list-style-type: none"> Ezetimibe with a statin (when evolocumab and alirocumab are not appropriate) Evolocumab with a statin (with or without another lipid-lowering therapy) Alirocumab with a statin (with or without another lipid-lowering therapy) <p>Quality assessment Tables Quality assessment of phase 2 study 1002-008 and -009, page 90 to 92 (checklist) Tables Quality assessment of phase 3 studies, page 93 to 99 (checklist)</p> <p>(goal of the clinical development programme for bempedoic acid was to evaluate the efficacy of bempedoic acid in reducing LDL-C as an add-on therapy to other LMTs, including maximally tolerated statins (which may also mean no statin at all) or ezetimibe, for the treatment of adults with primary hyperlipidaemia who require additional lowering of LDL-C)</p> <p>Outcomes</p> <ul style="list-style-type: none"> Plasma lipid and lipoprotein levels, including LDL-C, non-HDL-C, apolipoprotein B and lipoprotein a Requirement of procedures including LDL apheresis and revascularisation | <p>(bempedoic acid 180 mg at 12 weeks (Study 1002-008 and Study 1002-009):</p> <ul style="list-style-type: none"> treatment with bempedoic acid resulted in significant LDL-C reductions at 12 weeks vs. placebo in patients with hypercholesterolaemia on maximally tolerated statin dose or with statin intolerance reductions were observed at the first post-baseline study visit (week 4) and were maintained throughout the duration of the studies LS mean percentage change in LDL-C from baseline to week 12, n = 2 studies (CLEAR Harmony, CLEAR Wisdom): <ul style="list-style-type: none"> -16.0 for bempedoic acid 1.8 for placebo between-group difference [95% CI], -17.8 [-19.5, -16.0]; P < 0.001) absolute mean reduction from baseline to week 12 in LDL-C (greater in patients treated with bempedoic acid vs placebo) <ul style="list-style-type: none"> bempedoic acid, -19.8 mg/dL; placebo, 0.3 mg/dL significantly greater percentage of patients in the bempedoic acid group achieved LDL-C < 70 mg/dL at week 12 compared with placebo (28.9% vs 8.0%; P < 0.001) LS mean percentage change in LDL-C from baseline to week 12, n = 2 studies (CLEAR Serenity and CLEAR Tranquility): <ul style="list-style-type: none"> -23.0 for bempedoic acid 1.5 for placebo | | <p>in children and < 55-70 mg/dL in adults depending on CV risk level (55 mg/dL is the target for very high-risk patients) (Mach et al., 2019; Volpe et al., 2017).</p> <p>in UK, statins and ezetimibe are currently the most common pharmacological treatments for lowering LDL-C levels</p> <p>Bempedoic acid (BA) Bempedoic acid fixed-dose combination with ezetimibe (180mg/10mg) (BA = adenosine triphosphate (ATP) citrate lyase (ACL) inhibitor) (Ezetimibe = NPC1L1 (sterol transporter) inhibitor)</p> <p>BA and statins both inhibit cholesterol synthesis in the liver; BA is inactive in skeletal muscle Ezetimibe inhibits gastrointestinal cholesterol absorption and upregulates LDL receptors</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> ▪ Fatal and non-fatal cardiovascular events ▪ Mortality ▪ Adverse effects of treatment ▪ Health-related quality of life | <ul style="list-style-type: none"> ▪ between-group difference [95% CI], -24.5 [-27.8, -21.1]; P < 0.001) <ul style="list-style-type: none"> ○ absolute mean reduction from baseline to week 12 in LDL-C (greater in patients treated with bempedoic acid vs placebo) <ul style="list-style-type: none"> ▪ bempedoic acid, -36.5 mg/dL ▪ placebo, 0.6 mg/dL - bempedoic acid lowered LDL-C levels similarly across subgroups in the phase 3 trials (patients treated with maximally tolerated statins received additional LDL-C reductions with the addition of bempedoic acid, while larger reductions in LDL-C were observed in patients not taking statins); in post-hoc subgroup analyses by ezetimibe use at baseline, the treatment effect of bempedoic acid was similar in patients with and without ezetimibe) - compared with placebo, treatment with bempedoic acid added to background lipid-lowering therapy significantly reduced levels of apolipoprotein (apo B), non-HDL-C, and total cholesterol (TC) <p>fixed dose combination (FDC) (NICE), see also Table 29, page 111</p> <ul style="list-style-type: none"> - FDC of bempedoic acid and ezetimibe has been studied in one, double-blind phase3 study (1002FDC-053) with adult patients at high risk of CVD due to ASCVD, HeFH, or multiple CVD risk factors receiving maximally tolerated statin therapy; treatment with FDC resulted in significant reductions in LDL-C at week 12 from baseline compared with placebo - FDC lowered LDL-C levels similarly across subgroups - supporting evidence for FDC in statin-intolerant patients is available from the CLEAR Tranquility study which investigated bempedoic acid and | | <p>To note, two technologies are covered: bempedoic acid and bempedoic acid fixed-dose combination with ezetimibe.</p> <p>EMA (centralized procedure) marketing authorisation in March and April 2020)</p> <p>The proposed positions in the treatment pathway are as follows:</p> <ul style="list-style-type: none"> - when statins are contraindicated or not tolerated, and ezetimibe does not appropriately control low-density lipoprotein cholesterol (LDL-C) - when maximally tolerated statin dose with ezetimibe does not appropriately control LDL-C |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>ezetimibe given as separate tablets; pharmacokinetic studies have shown the two presentations to be equivalent (Esperion Therapeutics data on file, 2019e; Esperion Therapeutics data on file, 2019f)</p> <ul style="list-style-type: none"> - LS mean reduction from baseline in LDL-C: <ul style="list-style-type: none"> o -36.2% for FDC vs o (increase of) 1.8% for placebo o difference vs placebo for LS means was -38% (Ballantyne et al., 2019a; Ballantyne et al., 2019b) <p>adverse reactions</p> <p>overview analysis of safety (phase 3 and phase 2)</p> <ul style="list-style-type: none"> - frequent adverse events slightly higher rates with bempedoic acid than with placebo - small changes in laboratory parameters (creatinine increases, uric acid increases, haemoglobin decreases, and liver function test elevations), some occurred more frequently with bempedoic acid - increased creatinine, hepatic enzyme elevations, decreased haemoglobin, and anaemia are considered to represent adverse reactions - uric acid increased was an adverse reaction (incidence of gout) - discontinuation of therapy was reported (e. g. for musculoskeletal disorders) - (data not show, blackened) <p>pathways</p> <p>Figure 2 Current NICE pathway and recommendations for LDL-C lowering (page 28)</p> <ul style="list-style-type: none"> - entry: persons at high risk of cardiovascular disease - pathway: a) before offering treatment (information and advice), b) treatments not to use, c) lifestyle changes | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - pathway a) primary prevention (statin, ezetimibe if statin is contraindicated), secondary prevention (statin, ezetimibe if statin is contraindicated) <ul style="list-style-type: none"> o statin intolerance (follow-up and monitoring) o intolerance (1) or insufficient response to lipid-lowering therapy (2) o for (1) ezetimibe (first), PCSK9 (second, if appropriate, as dual-combination) o for (2) ezetimibe + statin (first), PCSK9 (second, if appropriate, as triple-combination) <p>Figure 3 Current NICE pathway and recommendations and proposed placement of bempedoic acid and fixed dose combination FDC (page 36f)</p> <ul style="list-style-type: none"> - same as figure 2, except special recommendations were given within an added table for different situations <p>Indication for bempedoic acid (EMA): Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> ▪ in combination with a statin or a statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, ▪ alone or in combination with other lipid-lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated. <p>Indication for bempedoic acid and ezetimibe FDC (EMA): Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:</p> <ul style="list-style-type: none"> ▪ in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ▪ alone in patients who are either statin intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, ▪ in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin <p>recommendations (NICE) patients at risk of CVD and with FH (familial hypercholesterolaemia) be treated with statins of high intensity and low cost (NICE, 2016a; NICE, 2016b; NICE, 2016c; NICE, 2017)</p> <ul style="list-style-type: none"> - for primary prevention: atorvastatin 20 mg - for secondary prevention: atorvastatin 80 mg - intolerant to high-intensity statins: treatment with the maximum tolerated dose <p>patients who do not reach therapeutic targets on statin therapy after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy, combination therapy with ezetimibe is recommended (Menzin et al., 2017; Volpe et al., 2017)</p> <p>proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (subcutaneous injection and indicated for patients with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet)</p> <ul style="list-style-type: none"> - PCSK9 inhibitors alirocumab and evolocumab (NICE, 2017; Volpe et al., 2017): <ul style="list-style-type: none"> ▪ Patients with primary heterozygous-familial hypercholesterolaemia and LDL-C persistently above 5.0 mmol/L, or 3.5 mmol/L if patients have a high or very high risk of CVD ▪ Patients with primary non-familial hypercholesterolaemia and LDL-C persistently above 4.0 mmol/L if patients have a high risk for CVD, or 3.5 mmol/L if patients have a very high risk of CVD | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>although a range of effective therapies are available, there are certain patient groups with high unmet need, particularly the following:</p> <ul style="list-style-type: none"> ▪ statin therapy is contraindicated or not tolerated and ezetimibe does not adequately control LDL-C, particularly where alirocumab and evolocumab are not appropriate ▪ maximally tolerated statin dose with ezetimibe does not adequately control LDL-C, particularly where alirocumab and evolocumab are not appropriate <p>for previous recommendations see also page 33f</p> <p>Included studies Goldberg 2019 [26] (CLEAR Wisdom) Ray 2019 [27] (CLEAR Harmony) Ballantyne 2018 [28] (CLEAR Tranquility) Laufs 2019 [29] (CLEAR Serenity) Ballantyne 2020 [30].</p> <p>other studies n = 10 Phase 2 n = 15 Phase 1</p> <p>Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) also available [39]</p> | | |

Nissen et al. 2023 (RCT, Primär- und Sekundärprävention; 50% KHK, 23% Statintherapie)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Nissen SE. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388(15):1353–64. | Objective to determine the effects of bempedoic acid on adverse cardiovascular events in a mixed population of | n = 13 970 patients (randomized between Dec 2016 and Aug 2019) - n = 6 992 bempedoic acid - n = 6 978 placebo - mean age 65.5 ± (SD 9.0) | Selection bias randomization: low concealment and unpredictability: | authors noted at 6 months after randomization, the central laboratory began to |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>https://www.ncbi.nlm.nih.gov/pub-med/36876740. [32]</p> <p>Nicholls S. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021; 235:104–12. https://www.ncbi.nlm.nih.gov/pub-med/33470195. [40]</p> | <p>patients for whom primary or secondary prevention is clinically indicated but who were unable or unwilling to take guideline-recommended doses of statins</p> <p>Methods CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen) Outcomes trial</p> <ul style="list-style-type: none"> - double-blind, randomized, placebo-controlled trial - patients at 1250 sites in 32 countries - 18 to 85 years of age - patients met either of two criteria for increased cardiovascular risk: <ul style="list-style-type: none"> o a previous cardiovascular event (secondary-prevention patients) o or clinical features that placed them at high risk for a cardiovascular event (primary-prevention patients) - patients report being unable or unwilling to receive statins owing to an adverse effect that had started or increased during statin therapy and resolved or improved after statin therapy was discontinued ("statin-intolerant" patients) - other lipid-lowering therapies were permitted, such | <ul style="list-style-type: none"> - female 48.2% (n = 6 740) - diabetes n = 6 373 (45.6%) - previous cardiovascular event n = 9764 (69.9%) - primary prevention n = 2 100 (30.0%) vs. 2 106 (30.2%) - secondary prevention n = 4892 (70.0%) vs. n = 4872 (69.8%) <ul style="list-style-type: none"> o coronary artery disease: n = 3 574 (51,1%) vs. n = 3536 (50.7%) o other: peripheral arterial disease, cerebrovascular atherosclerotic disease - statin n = 3174 (22.7%) - ezetimibe n = 1612 (11.5%) - mean LDL-cholesterol: 139.0 mg per deciliter (3.59 mmol per liter) - mean high-density lipoprotein cholesterol: 49.5 mg per deciliter (1.28 mmol per liter) - median triglyceride: 159.0 mg per deciliter (1.80 mmol per liter) - median high-sensitivity C-reactive protein (CRP): 2.3 mg per liter - median follow-up 40.6 months - premature discontinuation of the trial occurred in 2035 patients (29.1%) BA and in 2212 patients (31.7%) in the placebo group - complete assessment of the primary end point was available for 13,313 patients (95.3%), and vital status was available for 13,886 (99.4%) - data on the key efficacy end points at the trial sites in Ukraine were censored after the start of the conflict on February 24, 2022 <p>Results</p> <p>primary four-component MACE</p> <ul style="list-style-type: none"> - n = 819 (11.7%) vs. n = 927 (13.3%) - HR 0.87 (95% CI 0.79; 0.96), p = 0.004 <p>secondary</p> | <p>low</p> <p>Performance bias blinding of participants and staff: low</p> <p>Detection bias blinding of evaluation: low (independent committee blinded to therapy assignment adjudicated all clinical events and assessed the clinical end points)</p> <p>Attrition bias lost to follow-up: unclear (ITT, missing data (trial sites in Ukraine on Feb 2022) were censored), authors noted that data are reported without imputation unless otherwise noted ITT-analysis: low</p> <p>Reporting bias selective result presentation: low (only patients who had reported that they were unable or unwilling to take statins, a factor that resulted in a high mean LDL cholesterol level at baseline)</p> | <p>notify the investigator, who remained unaware of the trial-group assignments and laboratory values, if the LDL cholesterol level in a patient was 25% or higher than the baseline level; patients were counseled on healthy dietary guidelines and reminded to take all lipid-regulating medications; if repeat testing confirmed that the LDL cholesterol level exceeded the threshold, the investigator could adjust the lipid-lowering regimen according to the standard of care and local guidelines</p> <p>authors noted that trial enrolled a mixture of patients for whom primary or secondary prevention of cardiovascular disease is clinically indicated</p> <p>although the incidence of a primary end-point event was higher among the patients with pre-existing cardiovascular disease, the</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| | <p>as ezetimibe, niacin, bile acid resins, fibrates, or proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors, administered as monotherapy or in combinations</p> <ul style="list-style-type: none"> - 4-week run-in period during which they received single-blind placebo <p>Intervention bempedoic acid at a daily oral dose of 180 mg</p> <p>Controll matching placebo</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization <p>secondary</p> <ul style="list-style-type: none"> - hierarchical order, included a three-component composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction; fatal or nonfatal myocardial infarction; coronary revascularization; fatal or nonfatal stroke; death from cardiovascular | <p>three-component MACE</p> <ul style="list-style-type: none"> - n = 575 (8.2%) vs. n = 663 (9.5%) - HR 0.85 (95 % CI 0.76 to 0.96), p = 0.006 <p>fatal or nonfatal myocardial infarction</p> <ul style="list-style-type: none"> - n = 261 (3.7%) vs. n = 334 (4.8%) - HR 0.77 (95% CI 0.66 to 0.91), p = 0.002 <p>coronary revascularization</p> <ul style="list-style-type: none"> - n = 435 (6.2%) vs. n = 529 (7.6%) - HR 0.81 (95% CI 0.72 to 0.92), p = 0.001 <p>fatal or nonfatal stroke</p> <ul style="list-style-type: none"> - n = 135 (1.9%) vs. n = 158 (2.3%) - HR 0.85 (95% CI 0.67 to 1.07), p = 0.16 <p>death from cardiovascular causes</p> <ul style="list-style-type: none"> - n = 269 (3.8%) vs. n = 257 (3.7%) - HR 1.04 (95% CI 0.88 to 1.24) <p>death from any cause</p> <ul style="list-style-type: none"> - n = 434 (6.2%) vs. n = 420 (6.0%) - HR 1.03 (95% CI 0.90 to 1.18) <p>hospitalisation for unstable angina</p> <ul style="list-style-type: none"> - n = 91 (1.3%) vs. n = 137 (2.0%) - HR 0.66 (95% CI 0.50 to 0.86) <p>new-onset type 2 diabetes mellitus</p> <ul style="list-style-type: none"> - n/N = 429/3848 (11.1%) vs. n/N = 433/3749 (11.5%) - HR 0.95 (95% CI 0.83 to 1.09) <p>change from baseline in secondary lipid and biomarker mean percent change in mean LDL cholesterol level at 6 mo (95% CI)</p> <p>-21.1 (-21.6 to -20.5) vs. -0.8 (-1.4 to -0.2)</p> | | <p>hazard ratio in the primary-prevention subgroup was lower than that in the secondary prevention population</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | causes; and death from any cause | <p>difference -20.3 (95% CI -21.1 to -19.5)</p> <p>median percent change in high-sensitivity CRP level at 6 mo (95% CI) -22.2 (-23.5 to -20.8) vs. 2.4 (0.0 to 4.2) difference -21.6 (95% CI -23.7 to -19.6)</p> <p>mean percentage-point change in glycated hemoglobin level at 12 mo in patients with inadequately controlled type 2 diabetes mellitus (95% CI) -0.04 (-0.12 to 0.03) vs. -0.01 (-0.09 to 0.06) difference -0.03 (95% CI -0.14 to 0.08)</p> <p>adverse events any adverse event that started or worsened after the first dose of a trial agent — no. (%) - 6040 (86.3) vs. 5919 (85.0) serious adverse event that started or worsened after the first dose of a trial agent — no. (%) - 1767 (25.2) vs. 1733 (24.9) adverse event leading to discontinuation of the trial regimen — no. (%) - 759 (10.8) vs. 722 (10.4) prespecified adverse events of special interest Myalgia — no. (%) - 393 (5.6) vs. 471 (6.8) Discontinuation of the trial regimen because of myalgia — no. (%) - 124 (1.8) vs. 129 (1.9) New-onset diabetes in patients without diabetes at baseline — no./total no. (%) - 621/3856 (16.1) vs. 640/3740 (17.1) New-onset diabetes in patients with prediabetes at baseline — no./total no. (%) - 569/2918 (19.5) vs. 586/2877 (20.4)</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>New-onset diabetes in patients with normoglycemia at baseline — no./total no. (%)</p> <ul style="list-style-type: none"> - 52/938 (5.5) vs. 54/863 (6.3) <p>Worsening hyperglycemia — no./total no. (%)</p> <ul style="list-style-type: none"> - 713/3145 (22.7) vs. 746/3224 (23.1) <p>Hypoglycemia — no. (%)</p> <ul style="list-style-type: none"> - 304 (4.3) vs. 267 (3.8) <p>Metabolic acidosis — no. (%)</p> <ul style="list-style-type: none"> - 13 (0.2) vs. 11 (0.2) <p>Elevated hepatic-enzyme level — no. (%)</p> <ul style="list-style-type: none"> - 317 (4.5) vs. 209 (3.0) <p>Renal impairment — no. (%)</p> <ul style="list-style-type: none"> - 802 (11.5) vs. 599 (8.6) <p>Neurocognitive disorders — no. (%)</p> <ul style="list-style-type: none"> - 58 (0.8) vs. 69 (1.0) <p>Atrial fibrillation — no. (%)</p> <ul style="list-style-type: none"> - 229 (3.3) vs. 246 (3.5) <p>Adjudicated tendon rupture — no. (%)</p> <ul style="list-style-type: none"> - 86 (1.2) vs. 66 (0.9) <p>Tendinopathies — no. (%)</p> <ul style="list-style-type: none"> - 118 (1.7) vs. 128 (1.8) <p>Malignant conditions — no. (%)</p> <ul style="list-style-type: none"> - 321 (4.6) vs. 341 (4.9) <p>Other adverse events — no. (%)</p> <p>Hyperuricemia 763 (10.9) vs. 393 (5.6)</p> <p>Gout 215 (3.1) vs. 143 (2.1)</p> <p>Cholelithiasis 152 (2.2) vs. 81 (1.2)</p> <p>Laboratory results after 6 mo — mg/dl</p> <p>Change from baseline in uric acid level</p> <p>0.76±1.2 vs. -0.03±1.0</p> <p>Change from baseline in creatinine level</p> <p>0.05±0.2 vs. 0.01±0.2</p> <p>Laboratory results after 12 mo</p> <p>Change from baseline in glycated hemoglobin level — %</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------|----------------------------------|-----------|
| | | 0.04±0.74 vs. 0.06±0.70 | | |

Laufs et al. 2022 (RCT-Subgruppenanalyse, Bempedoinsäure ohne Statintherapie, Patient*innencharakteristika)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| <p>Laufs U. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol 2022; 16(3):286–97. https://www.ncbi.nlm.nih.gov/pub-med/35346603. [41]</p> | <p>Objective to assess the LDL-C lowering effect of bempedoic acid in patients not taking statins (who were previously unable to tolerate any statin dose) as well as evaluating a phase 3 study investigating bempedoic acid plus ezetimibe FDC</p> <p>Methods</p> <ul style="list-style-type: none"> - post hoc analysis - pooled analysis of data - patients enrolled in four phase 3 bempedoic acid studies (12 to 52 weeks in duration) - patients not taking concomitant statins (Phase 3 No Statin Cohort) - patients could still be receiving other stable lipid-lowering therapy, such as ezetimibe - patients in bempedoic acid plus ezetimibe FDC study who were not receiving statins were also assessed as the (BA + EZE FDC No Statin Cohort) <p>Outcome</p> | <p>1) Phase 3 No Statin Cohort (n = 586 patients) BA (n = 394) vs. Placebo (n = 192)</p> <ul style="list-style-type: none"> - mean age 64.9 (9.9) years - 12.8% with a history of ASCD - 24.1% with diabetes mellitus - 67,1% with hypertension <p>mean (SD) baseline LDL-C: 148.7 (40.6) mg/dL median (Q1, Q3) baseline hsCRP: 2.4 (1.1, 4.5) mg/L 58.0% of patients received nonstatin background lipid-lowering therapy, primarily ezetimibe muscle symptoms were the reason for stopping prior statin therapy for 514 (87.7%) patients</p> <p>2) BA+EZE FDC (n = 106 patients) FDC (n = 33), BA (n = 27), Ezetimibe (n = 32), Placebo (n = 14)</p> <p>mean baseline LDL-C: 168.6 mg/dL</p> <p>Results at week 12 Phase 3 No Statin Cohort LDL-C levels: -26.6% vs -0.1%; P < 0.001 placebo-corrected least squares mean difference -26.5% (95% CI, -29.7% to -23.2%); P < 0.001 absolute mean (SD) reduction in LDL-C level 41.0 (32.6) mg/dL vs. 1.2 (24.7) mg/dL</p> <p>fixed-dose combination of bempedoic acid with ezetimibe LDL-C levels: -38.8% vs 0.4%</p> | n. a. | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - percent change from baseline to week 12 in LDL-C levels - safety and tolerability were assessed by laboratory values and adverse events | <p>mean difference -39.2% (95% CI, -51.7% to -26.7%); P < 0.001 absolute mean (SD) reduction in LDL-C level 8.3 (44.1) mg/dL vs. 0.0 (25.6) mg/dL</p> <p>safety Phase 3 No Statin Cohort adverse events</p> <ul style="list-style-type: none"> - incidence rate 137.0 vs. 117.0 per 100 person years <p>serious adverse events</p> <ul style="list-style-type: none"> - incidence rate 14.8 vs. 13.8 per 100 person years <p>treatment- emergent AEs leading to discontinuation</p> <ul style="list-style-type: none"> - incidence rate 32.8 vs. 24.3 per 100 person years - most common reason: myalgia (5.8 vs. 10.6 per 100 person years) <p>adverse events of special interest</p> <p>muscle-related disorders</p> <ul style="list-style-type: none"> - incidence rate 26.4 vs. 28.6 per 100 person-years <p>myalgia</p> <ul style="list-style-type: none"> - incidence rate 9.5 vs. 14.8 per 100 person years <p>pain in the extremity</p> <ul style="list-style-type: none"> - incidence rate 6.9 vs. 4.2 per 100 person years <p>gout</p> <ul style="list-style-type: none"> - incidence rate 3.2 vs. 1.1 per 100 person years <p>blood uric acid increased</p> <ul style="list-style-type: none"> - incidence rate 11.1 vs. 3.2 per 100 person years <p>hepatic enzyme elevation</p> <ul style="list-style-type: none"> - incidence rate 8.5 vs. 2.1 per 100 person years <p>new-onset diabetes/hyperglycemia</p> <ul style="list-style-type: none"> - incidence rate 4.8 vs. 5.3 per 100 person years <p>renal disorders</p> <ul style="list-style-type: none"> - incidence rate 4.2 vs. 3.2 per 100 person years <p>Bempedoic Acid Plus Ezetimibe FDC No Statin Cohort (BA+ezetimibe, BA, Ezetimib vs. placebo)</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | adverse events <ul style="list-style-type: none"> - incidence rate 75.8, 77.8, 68.8 vs. 42.9 per 100 person years serious adverse events <ul style="list-style-type: none"> - incidence rate 3.0, 11.1, 9.4 vs. 7.1 per 100 person years reatment- emergent AEs leading to discontinuation <ul style="list-style-type: none"> - incidence rate 9.1, 11.1, 12.5 vs. 0 per 100 person years adverse events of special interest muscle-related disorders <ul style="list-style-type: none"> - incidence rate 6.1, 11.1, 12.5 vs. 7.1 per 100 person years Included studies CLEAR Harmony (NCT02666664) CLEAR Wisdom (NCT02991118) CLEAR Serenity (NCT02988115) CLEAR Tranquility (NCT03001076) BA plus ezetimibe FDC study (NCT03337308), Ballantyne 2020 | | |

Ballantyne et al. 2022 (RCT-open-label extension, CLEAR-Harmony, Patient*innencharakteristika)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ballantyne CM. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). The American journal of cardiology 2022; 174:1–11. | Objective CLEAR Harmony open-label extension (OLE) study was conducted to build on findings from the CLEAR Harmony parent study and evaluate the long-term safety and efficacy of bempedoic acid for up to 130 weeks Methods | n = 1 462 patients (BA) open-label extension (OLE) <ul style="list-style-type: none"> - n = 970 (66%) from patients from BA (CLEAR Harmony) - n = 492 (34%) from placebo (CLEAR Harmony) - mean age 66.9 ± 8.7 years - male 73.9% (n = 1 081) - white (race) 96.5% (n = 1 411) - ASCV 96.3% (n = 1 408) - history of diabetes n = 409 (28.0%) | n. a. single-arm design study focused on patients with established ASCVD and/or HeFH, most received BA in combination with moderate or high intensity statin therapy | authors noted that data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedures |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| https://www.ncbi.nlm.nih.gov/pub-med/35483979 [42] | <ul style="list-style-type: none"> - phase 3, multicenter, OLE study (NCT03067441) - all protocols were approved by institutional review board - between Feb 2017 and Nov 2019 - open-label for 78 weeks - 4-week follow-up - patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) - completed the CLEAR Harmony parent study - tolerated the study drug (bempedoic acid or placebo) - patients who had received placebo and switched to bempedoic acid treatment in the OLE study received up to 78 weeks of bempedoic acid treatment - patients were ineligible if <ul style="list-style-type: none"> o had a medical condition that could affect study assessments or required adjustments to background lipid-modifying therapies during the first 12 weeks | <ul style="list-style-type: none"> - history of hypertension n = 1161 (79.4%) - baseline LDL-C (mg/dL) 101.6 ± 28.2 - baseline statin only n = 1215 (83.1%) - baseline statin intensity <ul style="list-style-type: none"> o low n = 88 (6.0%) o moderate n = 562 (38.4%) o high n = 812 (55.5%) - baseline ezetimibe n 132 (9.0%) - all enrolled patients received at least 1 dose of the study drug during the OLE - most patients completed 78 weeks of OLE (86%-87%) - mean exposure (BA) 1.4 (±0.3) years <p>Results</p> <p>primary</p> <p>treatment-emergent adverse events (TEAEs)</p> <ul style="list-style-type: none"> - overall incidence (regardless of causality) <ul style="list-style-type: none"> o overall OLE 78.2% (n = 1 143) o up to 130 weeks 78.1% (n = 758) o up to 78 weeks 78.3% (n = 492) <p>serious TEAEs</p> <ul style="list-style-type: none"> - overall incidence (regardless of causality) <ul style="list-style-type: none"> o overall OLE 20.5% (n = 299) o up to 130 weeks 20.8% (n = 202) o up to 78 weeks 19.7% (n = 97) <p>TEAEs leading to discontinuation</p> <ul style="list-style-type: none"> - overall incidence (regardless of causality) <ul style="list-style-type: none"> o overall OLE 7.8% (n = 114) o up to 130 weeks 7.1% (n = 69) o up to 78 weeks 9.1% (n = 45) - most common: <ul style="list-style-type: none"> o myalgia n = 9 (0.6%) o muscle spasms n = 8 (0.5%) - incidence did not increase with a longer duration <p>fatal outcomes</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> ○ had a known sensitivity to bempedoic acid ○ were receiving other investigational drugs during the parent study ○ were female, of child-bearing age, and pregnant, lactating, or unwilling to use an accepted method of birth control during the study <p>Outcomes</p> <p>primary</p> <ul style="list-style-type: none"> - long-term safety <ul style="list-style-type: none"> ○ treatment-emergent adverse events (TEAEs), serious TEAEs, and ○ adverse events of special interest (AESIs) <p>secondary</p> <ul style="list-style-type: none"> - effectiveness <ul style="list-style-type: none"> ○ LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, triglycerides, apolipoprotein B (Apo B), | <ul style="list-style-type: none"> - overall incidence (regardless of causality) <ul style="list-style-type: none"> ○ overall OLE 0.9% (n = 13) ○ up to 130 weeks 1.0% (n = 10) ○ up to 78 weeks 0.6% (n = 3) <p>most common (>0.5%) (study drug-related):</p> <ul style="list-style-type: none"> - muscle spasms 1.7% (n = 25) - myalgia 1.4% (n = 21) - pain in extremity 0.7% (n = 10) - arthralgia 0.6% (n = 9) - dizziness 0.6% (n = 9) <p>adverse events of special interest (OLE, gesamt - n = 1462)</p> <ul style="list-style-type: none"> - muscular disorders n = 124 (8.5%) <ul style="list-style-type: none"> ○ muscle spasms n = 48 (3.3%) ○ myalgia pain in extremity n = 41 (2.8%) ○ muscular weakness n = 41 (2.8%) - creatinine kinase elevation n = 27 (1.8%) - new-onset or worsening diabetes mellitus n = 81 (5.5%) - renal disorders n = 41 (2.8%) - gout n = 38 (2.6%) - hypoglycaemia n = 18 (1.2%) - neurodegenerative disorders n = 13 (0.9%) <p>exposure-adjusted incidence per 100 person years (PY)</p> <ul style="list-style-type: none"> - 3.9 for new-onset or worsening diabetes mellitus - 6.1 for muscular disorders - 1.9 for renal disorders - 1.8 for gout - 1.3 for creatine kinase elevations - 1.4 for hepatic enzyme elevations - 0.9 for hypoglycaemia - 0.6 for neurocognitive disorders <p>authors noted that</p> <ul style="list-style-type: none"> - prespecified AESIs were reported during the OLE study at a similar rate as that reported in the parent study (e. g. incidence of gout was 2.6%, and | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>and high-sensitivity C-reactive protein (hsCRP)</p> | <p>the incidence of new-onset or worsening of diabetes was 5.5%)</p> <ul style="list-style-type: none"> - laboratory abnormalities observed during the OLE study also followed similar patterns as those observed in the parent study and did not worsen with a longer duration of bempedoic acid exposure - no new safety signals were identified - patients with a history of diabetes were more likely to have fasting glucose levels ≥ 126 mg/dl and haemoglobin A1c levels $\geq 6.5\%$ after 78 weeks of treatment in the OLE study (48.7% and 58.9%) than patients without a history of diabetes (4.6% and 5.3%) <p>secondary LDL-C from parent study baseline to week 78 of the OLE study</p> <ul style="list-style-type: none"> - mean change <ul style="list-style-type: none"> o -14.2 % ($\pm 0.9\%$) o -16.0 mg/dl (± 1.0 mg/dl) <p>adjudicated cardiovascular events n = 108 (7.4%)</p> <p>MACE</p> <ul style="list-style-type: none"> - CV death n = 6 (0.4%) - Nonfatal myocardial infarction n = 23 (1.6%) - Nonfatal stroke n = 14 /1.0%) - Coronary revascularization n = 53 (3.6%) - Hospitalization for UA n = 20 (1.4%) <p>Non-MACE</p> <ul style="list-style-type: none"> - Non-CV death n = 3 (0.2%) - Non coronary revascularization n = 24 (1.6%) - Hospitalization for heart failure n = 9 (0.6%) <p>authors documented also laboratory abnormalities (see Table 4)</p> | | |

12.4.4 Zusatzinformation Ezetimib (Empfehlung 7-15)

Zhan et al. Ezetimib (SR, 2018)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Zhan et al. 2018. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events (Review). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012502.pub2/epdf/full [43]</p> | <p>Objectives to assess the efficacy and safety of ezetimibe for the prevention of cardiovascular disease (CVD) and all-cause mortality</p> <p>Search methods searched CENTRAL, MEDLINE, Embase and Web of Science on 27 June 2018, and two clinical trial registry platforms on 11 July 2018; checked reference lists</p> <p>Selection criteria</p> <ul style="list-style-type: none"> - randomised controlled trials (RCTs) that compared ezetimibe versus placebo or ezetimibe plus other lipid-modifying drugs versus other lipid-modifying drugs alone - follow-up at least 12 months - adults with or without CVD - cluster RCT, cross-over trials and non-randomized trials were excluded <p>Quality assessment Cochrane risk of bias tool (Higgins 2011); GRADE (quality of evidence)</p> <p>Intervention ezetimibe or ezetimibe + other lipid-modifying drug(s)</p> | <p>n = 26 RCT (108 records) (n = 23,499 participants)</p> <ul style="list-style-type: none"> - n = 26 trials for ezetimibe + other lipid-modifying drugs vs. other lipid-modifying drugs (alone or + placebo) - ezetimibe dose: 10 mg/day - lipid-modifying drug: <ul style="list-style-type: none"> o n = 25 trials statine (simvastatin, atorvastatin, rosuvastatin, pitavastatin, fluvastatin) o n = 1 trial fenofibrate - statin dose was the same initial dose in n = 18 studies (I vs. C) - statin dose was a double-dose for comparator in n = 7 studies (usual dose for I) - n = 0 trials for ezetimibe vs. placebo - number of participants randomized 18 to 18,144 - mean age 46 – 84 years - n = 10 studies with mostly male participants - analyses driven by two large studies (IMPROVE-IT 2015 and HIJ-PROPER 2017), findings were driven by the largest study (IMPROVE-IT; weights in the MA 41.5% to 98.4%) - n = 3 studies with three intervention arms - follow-up 1 – 6 years - n = 14 studies with participants with existing atherosclerotic CVD (e. g. n = 4 studies with acute coronary syndrome, n = 6 studies with coronary heart disease); other studies recruited participants with e. g. hypercholesterolaemia (at risk) - n = 21 studies included in meta-analyses - n = 3 ongoing studies and n = 4 awaiting classifications were reported | <p>AMSTAR-II high</p> <p>authors accepted conference abstracts, if primary publications were available</p> <p>funnel plot did not indicate a strong possibility of publication bias</p> <p>authors grade the quality of evidence for major adverse cardiovascular events as moderate (mainly due to potential bias) and for all-cause mortality as high</p> | <p>authors documented that the effect of ezetimibe monotherapy in preventing CVD and all-cause mortality remain uncertain (included studies presented results for ezetimibe combined with lipid-modifying drugs)</p> <p>authors noted that none of the included studies reported quality of life</p> <p>authors cited n = 5 previous published reviews</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Controll placebo or active treatment</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - major adverse cardiovascular events (MACE), defined as a composite outcome of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalisation for unstable angina, or coronary revascularisation procedures - all-cause mortality <p>secondary</p> <ul style="list-style-type: none"> - myocardial infarction (MI) (fatal and non-fatal) - ischaemic stroke (fatal and non-fatal) - cardiovascular mortality - coronary revascularisation - adverse events (AEs) including hepatopathy, myopathy, rhabdomyolysis, cancer, gallbladder-related disease and discontinuation due to AEs - lipid parameters (total cholesterol, LDL-C, HDL-C, triglycerides) - health-related quality of life (using any well-validated scale) | <p>n = 5 studies specified composite of cardiovascular events as primary outcome (HIJ-PROPER 2017; IMPROVE-IT 2015; Kouvelos 2013; Liu 2017; Wang 2016)</p> <p>n = 5 studies specified serum lipid parameters as primary outcome</p> <p>n = 10 of included studies specified MACE as an outcome (definition of MACE was not consistent)</p> <p>n = 3 studies specified all-cause mortality as an outcome (HIJ-PROPER 2017; IMPROVE-IT 2015; PRECISE-IVUS 2015)</p> <p>incomplete or unclear data were reported for n = 13 studies, other domains of the risk of bias tool were often classified as unclear</p> <p>Outcomes</p> <p>ezetimibe plus statins vs. statins alone</p> <p>primary</p> <p>major adverse cardiovascular events</p> <ul style="list-style-type: none"> - risk ratio (RR) 0.94, 95% confidence interval (CI) 0.90 to 0.98 (decrease from 284/1000 to 267/1000, 95% CI 256 to 278; 21,727 participants; 10 studies; moderate-quality evidence) <p>(secondary</p> <p>non-fatal myocardial infarction (MI)</p> <ul style="list-style-type: none"> - RR 0.88, 95% CI 0.81 to 0.95 (decrease from 105/1000 to 92/1000, 95% CI 85 to 100; 21,145 participants; 6 studies; moderate-quality evidence) <p>non-fatal stroke</p> <ul style="list-style-type: none"> - RR 0.83, 95% CI 0.71 to 0.97 (decrease 32/1000 to 27/1000, 95% CI 23 to 31; 21,205 participants; 6 studies; moderate-quality evidence) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>need for coronary revascularisation</p> <ul style="list-style-type: none"> - RR 0.94, 95% CI 0.89 to 0.99 (decrease from 196/1000 to 184/1000, 95% 175 to 194; 21,323 participants; 7 studies)) <p>safety</p> <p>risk of hepatopathy</p> <ul style="list-style-type: none"> - RR 1.14, 95% CI 0.96 to 1.35; (20,687 participants; 4 studies; low-quality evidence) <p>risk of myopathy</p> <ul style="list-style-type: none"> - RR 1.31, 95% CI 0.72 to 2.38; (20,581 participants; 3 studies; very low-quality evidence) <p>risk of rhabdomyolysis wide CIs and low event rate</p> <p>risk of cancer, gallbladder-related disease and discontinuation due to adverse events little or no differences</p> <p>ezetimibe plus statins or fenofibrate vs. statins or fenofibrate alone</p> <p>primary</p> <p>all-cause mortality</p> <ul style="list-style-type: none"> - RR 0.98, 95% CI 0.91 to 1.05; (21,222 participants; 8 studies; high-quality evidence) <p>(secondary</p> <p>cardiovascular mortality</p> <ul style="list-style-type: none"> - RR 1.00, 95% CI 0.89 to 1.12; (19457 participants; 6 studies; moderate-quality evidence) <p>serum lipids might further reduce the low-density lipoprotein cholesterol (LDL-C), total cholesterol and triglyceride levels and likely increase the high-density lipoprotein cholesterol levels (substantial heterogeneity))</p> | | |

12.4.5 Zusatzinformation PCSK9 (Empfehlung 7-16)

Schmidt et al. PCSK9 (SR, Primär- und Sekundärprävention, 2020)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Schmidt et al. 2020. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review). https://www.cochrane-library.com/cdsr/doi/10.1002/14651858.CD011748.pub3/epdf/full [44]</p> | <p>Objectives Primary to quantify the effects of PCSK9 inhibitors on CVD, all-cause mortality, myocardial infarction, and stroke, compared to placebo or active treatment(s) for primary and secondary prevention Secondary to quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of influenza, hypertension, type 2 diabetes, and cancer, compared to placebo or active treatment(s) for primary and secondary prevention</p> <p>Search methods searching CENTRAL, MEDLINE, Embase, and Web of Science in December 2019; ClinicalTrials.gov and the International Clinical Trials Registry Platform in August 2020 and screened the reference lists of included studies</p> <p>This is an update of the review first published in 2017.</p> <p>Selection criteria</p> <ul style="list-style-type: none"> - parallel-group and factorial randomised controlled trials (RCTs) - follow-up of at least 24 weeks | <p>updated Version</p> <ul style="list-style-type: none"> - bococuzumab and RG7652 were removed - n = 7 additional trials evaluating alirocumab or evolocumab were included <p>study characteristics</p> <ul style="list-style-type: none"> - n = 24 studies (n = 34 references) (data on 60,997 participants) - n = 18 trials (n = 26,583 participants) alirocumab - n = 6 trials (n = 34,435 participants) evolocumab - placebo controlled: <ul style="list-style-type: none"> o n = 12 trials (alirocumab) o n = 3 trials (evolocumab) - active treatment: <ul style="list-style-type: none"> o n = 6 trials (alirocumab) o n = 3 trials (evolocumab) - ~29% (n = 7721) female - ~ 10% (n = 4590) had no history of CVD - most of available studies preferentially enrolled people with either established CVD or at a high risk already - outpatient care settings - all participants received background lipid-lowering treatment or lifestyle counselling - follow-up 6 to 36 months (vs. placebo) - follow-up 6 to 12 months (vs. active treatment) - authors calculated two weeks' equivalence dosage - evidence in low- to medium-risk settings is minimal - n = 4 ongoing trials were identified | <p>AMSTAR-II moderate</p> <p>authors accepted conference abstracts, if primary publications were available</p> <p>asymmetry for the funnel plot was reported and explained by smaller studies</p> <p>authors noted that most trials were at low risk of bias; note: the domains blinding and incomplete outcome data were classified as high or unclear risk of bias for some studies</p> <p>analytics like multiple imputation or mixed-effects models were used</p> <p>authors classified clinical outcomes for PCSK9 inhibitors vs. placebo as high certainty of evidence and vs. active treatment as (very) low certainty of evidence</p> <p>downgrading of evidence was explained by a lack of precision and small sample size, open-label design</p> | <p>authors noted that data on quality of life were unavailable for all studies</p> <p>authors cited two previous systematic reviews and three meta-analyses (relation to other published evidence)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - adult participants with or without a history of CVD - compared PCSK9 inhibitors alirocumab or evolocumab to placebo or active treatments such as statins, ezetimibe, or a combination of these - cluster RCT, cross-over trials and non-randomized trials were excluded <p>Quality assessment Cochrane Risk of bias tool (Higgins 2011); certainty of evidence (GRADE)</p> <p>Intervention alirocumab or evolocumab</p> <p>Control placebo or active treatment (e.g. statins, ezetimibe or combinations)</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - composite of CVD, defined as urgent coronary revascularisation, unstable angina pectoris, non-fatal and fatal myocardial infarction (MI), non-fatal and fatal stroke, and CHD death - all-cause mortality - MI - stroke <p>secondary</p> <ul style="list-style-type: none"> - Adverse events, specifically: | <p>incomplete or unclear outcome data were reported for n = 11 trials; for some studies the domain blinding was rated as high risk of bias (e. g. open-label design)</p> <p>outcomes primary alirocumab vs. placebo</p> <p>risk of CVD events</p> <ul style="list-style-type: none"> - absolute risk difference (RD) -2% - odds ratio (OR) 0.87, 95% confidence interval (CI) 0.80 to 0.94; 10 studies, 23,868 participants; high-certainty evidence) <p>risk of mortality</p> <ul style="list-style-type: none"> - RD -1% - OR 0.83, 95% CI 0.72 to 0.96; 12 studies, 24,797 participants; high-certainty evidence) <p>risk of MI</p> <ul style="list-style-type: none"> - RD -2% - OR 0.86, 95% CI 0.79 to 0.94; 9 studies, 23,352 participants; high-certainty evidence) <p>risk of stroke</p> <ul style="list-style-type: none"> - RD 0% - OR 0.73, 95% CI 0.58 to 0.91; 8 studies, 22,835 participants; high-certainty evidence). <p>alirocumab vs. ezetimibe and statins</p> <p>risk of CVD</p> <ul style="list-style-type: none"> - RD 1% - OR 1.37, 95% CI 0.65 to 2.87; 3 studies, 1379 participants; low-certainty evidence) <p>risk for mortality</p> <ul style="list-style-type: none"> - RD was -1% - OR 0.51, 95% CI 0.18 to 1.40; 5 studies, 1333 participants; low-certainty evidence) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> ○ influenza ○ T2DM ○ cancer ○ hypertension | <p>risk for MI</p> <ul style="list-style-type: none"> - RD was 1% - OR 1.45, 95% CI 0.64 to 3.28; 5 studies, 1734 participants; low-certainty evidence) <p>risk for stroke</p> <ul style="list-style-type: none"> - RD less than 1% - OR 0.85, 95% CI 0.13 to 5.61; 5 studies, 1734 participants; low-certainty evidence) <p>evolocumab vs. placebo</p> <p>risk for CVD</p> <ul style="list-style-type: none"> - RD -2% - OR 0.84, 95% CI 0.78 to 0.91; 3 studies, 29,432 participants; high-certainty evidence) <p>risk for mortality</p> <ul style="list-style-type: none"> - RD less than 1% - OR 1.04, 95% CI 0.91 to 1.19; 3 studies, 29,432 participants; high-certainty evidence) <p>risk for MI</p> <ul style="list-style-type: none"> - RD -1% - OR 0.72, 95% CI 0.64 to 0.82; 3 studies, 29,432 participants; high-certainty evidence) <p>risk for stroke</p> <ul style="list-style-type: none"> - RD less than -1% - OR 0.79, 95% CI 0.65 to 0.94; 2 studies, 28,531 participants; high-certainty evidence) <p>evolocumab vs. ezetimibe and statins</p> <p>risk for CVD events</p> <ul style="list-style-type: none"> - RD less than -1% - OR 0.66, 95% CI 0.14 to 3.04; 1 study, 218 participants; very low-certainty evidence) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | risk for all-cause mortality <ul style="list-style-type: none"> - RD less than 1% - OR 0.43, 95% CI 0.14 to 1.30; 3 studies, 5223 participants; very low-certainty evidence) risk and for MI <ul style="list-style-type: none"> - RD less than 1% - OR 0.66, 95% CI 0.23 to 1.85; 3 studies, 5003 participants; very low-certainty evidence) insufficient data on any stroke forest plots for adverse events see Appendix page 64 ff (wide confidence intervals and non statistic significant results) | | |

12.4.6 Zusatzinformation Statinintoleranz

Meza-Contreras et al. 2023. Statin intolerance management (SR)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Meza-Contreras et al. Endocrine. 2023. Statin intolerance management: a systematic review. 2023 https://pub-med.ncbi.nlm.nih.gov/36459335/ [45] | Objective to characterize the range of expert recommendations about the care of patients with statin intolerance Search PubMed, EMBASE, Scopus, Cochrane, online textbooks, SR, guidelines (published in the past 5 years) (search on April, 1 2022) <ul style="list-style-type: none"> - registered in PROSPERO - protocol was modified (an explicit definition of statin intolerance was removed as inclusion criterion) | n = 26 articles <ul style="list-style-type: none"> - n = 1 was added post hoc - n = 14 (54%) with definition of statin intolerance - n = 24 (92%) suggested a sequenced approach (management of statin intolerance) with n = 12 different approaches (konsensbasiert) statin intolerance definition <ul style="list-style-type: none"> - n = 14 (54%) - most offered own definitions - simple definition (n = 3): <ul style="list-style-type: none"> o "statin therapy discontinued because of symptoms attributed to taking statins" - other definitions <ul style="list-style-type: none"> o "required intolerance to ≥ 2 different statins" (n = 7) | AMSTAR-II critically low (u. a. keine Liste der ausgeschlossenen Studien mit Ausschlussgrund verfügbar; keine Risk-of-Bias- bzw. Qualitätsbewertung der Artikel, ausschließlich Bewertung, ob systematisch gesucht wurde) Limitations mostly, narrative reviews of the last 5 years were included none of the included articles described a systematic process to identify, review and synthesize the research evidence | Selektiv ermittelter Artikel aus der AG Arbeit; zur Diskussion, da die Definition sowie die Strategien zum (zumeist schrittweisen) Umgang aus Empfehlungen aus (zumeist narrative) Übersichten innerhalb der vergangenen 5 Jahre zusammengefasst wurden, die Frage für die NVL nicht priorisiert, aber für die Diskussion als relevant eingestuft wurde |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - articles offered recommendations for the management of statin intolerance - expert narrative reviews, systematic reviews, or clinical practice guidelines published in the last 5 years - described the clinical situation as statin intolerance or as discontinuation (or threat of discontinuation) of statins due to adverse effects attributed to statins - offered a management strategy to address this problem in adults at any level of risk for ASCVD (atherosclerotic cardiovascular disease) <p>Outcome definition and described statin intolerance</p> <p>problem definitions, goals, steps, sequence, and supportive evidence of supposed strategies</p> <p>(e.g., stop statin, offer same statin, offer alternative statin, offer other lipid lowering agent, calculate ASCVD risk, engage in shared decision making, measure creatine kinase) their type (e.g., education, communication, decision making, diagnostic, intervention, referral) and sequence</p> | <ul style="list-style-type: none"> o “abnormal test results” (n = 6) o “muscle-related symptoms” (n = 3) o “a broader range of symptoms” (n = 11) <ul style="list-style-type: none"> - n = 12 (46%) used a definition that required resolution of symptoms or laboratory abnormalities after statin discontinuation (n = 11) <p>management strategies</p> <ul style="list-style-type: none"> - n = 24 (92%): stepwise approach for the management of statin intolerance with <ul style="list-style-type: none"> o n = 12 different strategies o 1st step (n = 23) <ul style="list-style-type: none"> ▪ exclusion of other causes (n = 9) ▪ recalculating CV risk (n = 7) ▪ creatinine kinase level (n = 3) ▪ rechallenge (n = 1) ▪ other (n = 3) o 2nd step (n = 22) <ul style="list-style-type: none"> ▪ exclusion of other causes (n = 7) ▪ creatinine kinase level (n = 5) ▪ rechallenge (n = 4) ▪ recalculating CV risk (n = 2) ▪ other (n = 4) o 3rd step (n = 19) <ul style="list-style-type: none"> ▪ rechallenge (n = 6) ▪ creatinine kinase level (n = 5) ▪ exclusion of other causes (n = 2) ▪ recalculating CV risk (n = 3) ▪ other (n = 3) o 4th step (n = 12) <ul style="list-style-type: none"> ▪ rechallenge (n = 9) ▪ other (n = 1) o 5th step (n = 1) <ul style="list-style-type: none"> ▪ rechallenge (n = 1) <p>other causes for muscle symptoms:</p> | <p>only one of the included articles described a process for the development and grading of their recommendations</p> | <p>(nicht empfehlungsbe-gründend)</p> <p>large variation in definition and strategies without structured processes used to develop these recommendations and evidence to support the recommended strategies</p> <p>most common early step in strategies: 39% exclusion of other causes</p> <p>next common step: recalculating CV risk and quantification of CK levels</p> <p>determinants to decide whether statin therapy</p> <ul style="list-style-type: none"> • could be continued, • changed to a lower dose or • to a different statin, or • stopped (e.g., large elevations consistent with rhabdomyolysis) <p>non considered reducing ASCVD risk</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | (e.g., before everything else, key branching step, next step) | <ul style="list-style-type: none"> experts recommended excluding vitamin D deficiency, drug-drug interactions, intense exercise, hypothyroidism, and dermato- or polymyositis and other myopathies either as a primary cause of muscle symptoms or as factors that could increase the risk of statin-associated muscle symptoms <p>rechallenging</p> <ul style="list-style-type: none"> implemented, after a washout period of 2 to 6 weeks (wash out duration was not required or not reported in 13 (50%)) using low-dose statin (25 (96%)), taking long-acting statins on alternate days (20 (77%)), switching to another statin (24 (92%)), or taking a generic statin (1 (4%)) <p>definitions and proposed strategies n (%)</p> <ul style="list-style-type: none"> Offer a definition of statin intolerance 14 (54) Offer a stepwise strategy 24 (92) <p>Strategies</p> <ul style="list-style-type: none"> Exclusion of other causes of symptoms 23 (88) Measure creatine kinase levels 16 (62) Measure alanine transaminase levels 3 (12) Supplement creatine 1 (4) Measure vitamin D levels 10 (38) Estimate symptom scores or use the SAMS-CI instrument 6 (23) Recalculate ASCVD risk 14 (54) Evaluate symptom severity 10 (38) Stop statins 25 (96) Maintain statins 7 (27) Rechallenge with statins 26 (100) Measure coronary artery calcium 1 (4) <p>Stop/maintain then:</p> <ul style="list-style-type: none"> Use a lower dose 25 (96) Administer on alternate days 20 (77) Switch to another statin 24 (92) | | <p>through nonlipid pathways</p> <p>no article reported on the safety and efficacy of their management algorithm</p> <p>58% recommended patient education</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - Use a generic statin 1 (4) - Use same statin and dose 4 (15) Switch to non-statin 15 (58) - Ezetimibe 15 (58) - Fibrates 4 (15) - PCSK-9 inhibitor 13 (50) - Bile acid sequestrant 5 (19) - Nutraceuticals 3 (12) - Bempedoic acid 2 (8) - Ion exchange resin 1 (4) Adding non-statin drug 26 (100) - Ezetimibe 25 (96) - Fibrates 2 (8) - PCSK-9 inhibitor 23 (88) - Bile acid sequestrant 8 (31) - Bempedoic acid 5 (19) - Nutraceuticals 4 (15) - Coenzyme Q10 3 (12) - Phytosterols 1 (4) - Ion exchange resin 1 (4) - Patient education 15 (58) - Shared decision making 0 (0) <p><i>ASCVD atherosclerotic cardiovascular disease, PCSK-9 proprotein convertase subtilisin/kexin type 9, SAMS-CI Statin-Associated Muscle Symptom Clinical Index</i></p> | | |

12.5 Kapitel medikamentöse Therapie – Thrombozytenaggregationshemmer

12.5.1 Zusatzinformation Protonenpumpenhemmer bei (Risiko für) gastrointestinale Blutungen

Hinweis: die Recherche wurde aus der NVL Kreuzschmerz übernommen (Suche am 01. August 2022); die TiAb-Screeningtable wurde in Bezug auf möglicherweise ergänzend relevante Evidenz überprüft und die Ergebnisse der NVL Kreuzschmerz übernommen, die Aktualität und Gültigkeit der Recherche wurde als gegeben gesehen (Stand: 14.12.2023)

12.5.1.1 PPI bei NSAR-Anwendung (tlw. indirekte Evidenz)

Rostom et al. 2021 Prevention of gastroduodenal ulcers (NSAID-induced), SR

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Rostom A. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2021; 2021(10):195. dx.doi.org/10.1002/14651858.CD002296. [46]</p> <p><i>Protokoll (noch keine Publikation vorhanden (15.12.2023)):</i> Garegnani L. Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. Cochrane Database of Systematic Reviews 2022; 2022(5):357. dx.doi.org/10.1002/14651858.CD014585. [47]</p> | <p>Objective to review the effectiveness of the prostaglandin analogue (PA) misoprostol, H2-receptor antagonists (H2RA), and proton pump inhibitors (PPI) for the prevention of NSAID induced upper GI toxicity, among patients requiring chronic NSAID use</p> <p>secondary to review effect on NSAID induced GI symptoms</p> <p>Search SR and meta-analysis</p> <p>MEDLINE from 1966 to May 2009, Current Contents for six months prior to May 2009, EMBASE to May 2009, and the Cochrane Controlled Trials Register from 1973 to May 2009; recent conference proceedings were reviewed;</p> <p>search strategy was used to supplement the Canadian NSAID consensus conference (2007-2008)</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - RCT - NSAID > 3 weeks - prophylaxis of NSAID-induced ulcer - prostaglandin analogues (PA), | <p>n = 41 RCTs</p> <p>n = 39 RCT included (n=23 misoprostol, n = 12 H2RA, n = 9 PPI)</p> <ul style="list-style-type: none"> - some studies considered more than one active intervention - seven studies were used for head to head comparisons - for PPI: six direct; five head to head - all included studies were RCT in participants with arthritis who were taking traditional NSAID in an outpatient setting <p>Results note: only results for PPI were extracted</p> <p>PPI vs. placebo (prevention of NSAID induced upper GI toxicity)</p> <ul style="list-style-type: none"> - n = 6 RCT (n = 1259 participants) - (Graham 2002; Bianchi Porro 2000; Hawkey 1998; Ekstrom 1996; Cullen 1998; Lai 2003) <p>4 to 11 week study (n = 1, Lai 2023)</p> <p>endoscopic gastric ulcer</p> <ul style="list-style-type: none"> - n = 1 study (n = 43 participants) - n = 1/22 vs. n = 7/21 - Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.02] <p>endoscopic duodenal ulcer</p> <ul style="list-style-type: none"> - n = 1 study (n = 43 participants) - n = 1/22 vs. n = 2/21 - Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.05, 4.88] <p>total endoscopic ulcers</p> <ul style="list-style-type: none"> - n = 1 (n = 43 participants) | <p>AMSTAR-II high</p> <p>majority of the studies were of reasonable quality with a Jadad score of three or greater (20 studies - Q3; ten studies - Q4; two studies Q5)</p> <p>nine studies received a Jadad Score of two or less</p> <p>publication bias was documented</p> <p>for PPI no significant differences were observed by quality</p> | <p>arthritic and inflammatory conditions were addressed</p> <p>included were participants with arthritis</p> <p>common side effects of NSAID such as nausea and dyspepsia correlate poorly with serious adverse GI event</p> <p>authors noted endoscopic ulcers in up to 40% of chronic NSAID users</p> <p>serious NSAID induced GI complications such as haemorrhage, perforation or death are much less common, occurring collectively with an incidence of about 1.5% per year</p> <p>authors concluded that PPI are effective at reducing the risk of endoscopic gastric and duodenal NSAID induced ulcers</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - H2-receptor antagonists (H2RA) or - proton pump inhibitors (PPI) - prevention of chronic NSAID induced upper GI toxicity <p>Intervention H2-antagonists, Proton pump inhibitors and misoprostol (each used for the prophylaxis of NSAID induced gastroduodenal ulcers)</p> <p>Comperator placebo or vs. another</p> <p>Quality assessment validated quality instrument (Jadad 1996)</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - endoscopic ulcers (gastric, duodenal and gastroduodenal) - clinical ulcer complications (haemorrhage, perforation, pyloric obstruction or death) <p>secondary</p> <ul style="list-style-type: none"> - symptoms - drop-outs | <ul style="list-style-type: none"> - n = 2/22 vs. n = 9/21 - Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.05, 0.87] <p>clinical ulcer (POB)</p> <ul style="list-style-type: none"> - n = 1 study (n = 43 participants) - n = 0/22 vs. n = 4/21 - Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.86] <p>clinical ulcer - PUB (POB + symptomatic ulcer)</p> <ul style="list-style-type: none"> - n = 1 study (n = 43 participants) - n = 1/22 vs. n = 9/21 - Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.56] <p>8 weeks or longer studies (n = 6)</p> <p>endoscopic gastric ulcer</p> <ul style="list-style-type: none"> - n = 6 studies (n = 1230 participants) - n = 93/744 vs. n = 131/486 - Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.31, 0.50] <p>endoscopic duodenal ulcer</p> <ul style="list-style-type: none"> - n = 5 studies (n = 883 participants) - n = 10/508 vs. n = 38/375 - RR 0.20; 95% CI 0.10 to 0.39 <p>total endoscopic ulcer</p> <ul style="list-style-type: none"> - n = 6 studies (n = 1259 participants) - n = 108/766 vs. n = 177/493 - RR 0.34; 95% CI 0.28 to 0.42 <p>12 weeks or longer studies</p> <p>endoscopic gastric ulcer</p> <ul style="list-style-type: none"> - n = 5 studies (n = 1187 participants) - n = 92/722 vs. n = 124/465 - Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.32, 0.51] <p>endoscopic duodenal ulcer</p> <ul style="list-style-type: none"> - n = 4 studies (n = 840 participants) - n = 9/486 vs. n = 36/354 - Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.09, 0.37] <p>total endoscopic ulcers</p> <ul style="list-style-type: none"> - n = 5 studies (n = 1216 participants) - n = 106/744 vs. n = 168/472 - Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.28, 0.43] | | <p>authors noted that: several factors influence the risk of NSAID related upper GI toxicity:</p> <ul style="list-style-type: none"> - increasing age (>65) - previous peptic ulcer disease - co-morbid medical illnesses - type of NSAID - use of multiple NSAID - combined use of NSAID and corticosteroids (Fries 1991; Bollini 1992; Gabriel 1991; Silverstein 1995; Hallas 1995; Hansen 1996; Laporte 1991; Rodriguez 1997; Hochain 1995) <p>younger patients without co-morbidities or previous GI NSAID complications can be</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------|
| | | <p>clinical ulcers</p> <ul style="list-style-type: none"> - small studies in high risk participants suggest that PPI can reduce the risk of clinically important ulcer complications - a small 8 week study found that PPI reduce the risk of endoscopic ulcers but there were also fewer bleeds or symptomatic ulcers in the PPI group compared to placebo (Lai 2003) <p>symptoms</p> <ul style="list-style-type: none"> - n = 4 omeprazole trials (Cullen 1998; Ekstrom 1996; Hawkey 1998; Yeomans 1998) - omeprazole significantly reduced "dyspeptic symptoms" as defined by the authors - in the combined analysis, drop-outs overall and drop-outs due to side effects were not different from placebo - results supported by a recent study by Hawkey et al that reported statistically significant improvement in dyspeptic symptoms in NSAID participants taking esomeprazole compared to placebo (Hawkey 2005) <p>toxicity</p> <p>dropouts overall</p> <ul style="list-style-type: none"> - n = 2 studies (n = 833 participants) - n = 66/544 vs. n = 39/289 - Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.62, 1.29] <p>dropouts due to side effects</p> <ul style="list-style-type: none"> - n = 4 studies (n = 1113 participants) - n = 32/699 vs. n = 15/414 - Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.66, 2.15] <p>diarrhea</p> <ul style="list-style-type: none"> - n = 2 studies (n = 832 participants) - n = 34/544 vs. n = 11/288 - Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.85, 3.22] <p>abdominal pain</p> | | <p>treated with a traditional NSAID alone (Rostom 2009; Maetzel 1998)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - n = 2 studies (n = 832 participants) - n = 14/544 vs. n = 9/288 - Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.39, 1.98] flatulence <ul style="list-style-type: none"> - n = 1 study (n = 430 participants) - n = 7/275 vs. n = 5/155 - Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.25, 2.44] dyspepsia <ul style="list-style-type: none"> - n = 2 studies (n = 345 participants) - n = 19/169 vs. n = 40/176 - Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.30, 0.82] | | |

Scally et al. 2018 Prevention and treatment of peptic ulcer disease, SR

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Scally B. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. <i>Lancet Gastroenterol Hepatol</i> 2018; 3(4):231–41. https://www.ncbi.nlm.nih.gov/pub-med/29475806. [48]</p> | <p>Objective to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data from all relevant unconfounded randomised trials of gastroprotectant drugs</p> <p>Search MEDLINE and Embase from Jan 1, 1950, to Dec 31, 2015</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - RCT - people with no ulcer at baseline - people with a non-bleeding ulcer at baseline | <p>n = 849 trials (142 485 participants)</p> <ul style="list-style-type: none"> - n = 580 prevention trials (110 626 participants), - n = 233 healing trials (24 033 participants), and - n = 36 trials for the treatment of acute upper gastrointestinal bleeding (7826 participants) <ul style="list-style-type: none"> - comparisons of one gastroprotectant drug vs. another available in 345 trials (64 905 participants) <ul style="list-style-type: none"> o n = 160 prevention trials (32 959 participants), o n = 167 healing trials (28 306 participants), and o n = 18 trials for treatment of acute upper gastrointestinal bleeding (3640 participants) <ul style="list-style-type: none"> - median number of patients in each trial <ul style="list-style-type: none"> o n = 78 (IQR 44·0–210·5) - median duration <ul style="list-style-type: none"> o 1·4 months (0·9–2·8) <p>results gastroprotectants vs. placebo</p> | <p>AMSTAR-II low</p> <p>(eine Liste der ausgeschlossenen Studien ist nicht verfügbar; allerdings eine sehr detaillierte Aufbereitung der großen Anzahl eingeschlossener Studien sowie Analysen zu publication bias)</p> <p>they did exploratory analyses according to drug dose; NSAID use at randomisation</p> <p>network meta-analysis approach was used</p> <p>small study bias was reported</p> | <p>authors noted that in the context of peptic ulcer disease, gastroprotectants—and in particular PPIs—are effective in ulcer prevention, ulcer healing, and in reducing rebleeding</p> <p>additionally, authors noted a large ongoing COMPASS trial of pantoprazole versus placebo in 17 000 patients with stable cardiovascular disease that might provide useful safety information, and could also help to determine the true size of any beneficial effects</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - people presenting with upper gastrointestinal bleeding at baseline - with or without confirmed diagnosis of peptic ulcer disease - gastroprotectant drug - studies with participants with non-peptic upper gastrointestinal bleeding (eg, from varices) were excluded <p>Intervention PPI, prostaglandin analogue, or H2RA</p> <p>Comperator placebo or vs. another</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - ulcer development, bleeding, and - mortality overall | <p>prevention trials, gastroprotectant drugs</p> <ul style="list-style-type: none"> - development of endoscopic ulcers <ul style="list-style-type: none"> o n = 152 studies o 1889/18042 (10%) vs. 3502/13255 (26%) o odds ratio [OR] 0.27, 95% CI 0.25–0.29; p<0.0001 o PPI <ul style="list-style-type: none"> ▪ OR 0.20 (0.17; 0.23) ▪ 314/6541 (5%) vs. 937/4912 (19%), n = 29 studies - symptomatic ulcers <ul style="list-style-type: none"> o n = 51 studies o 523/9857 (5%) vs. 1136/9444 (12%) o 0.25, 0.22–0.29; p<0.0001 o PPI <ul style="list-style-type: none"> ▪ OR 0.15 (0.09; 0.23) ▪ 28/2585 (1%) vs. 152/2587 (6%), n = 8 studies - mortality <ul style="list-style-type: none"> o n = 51 studies o 574/15844 (3%) vs. 496/13063 (4%) o 0.85, 0.69–1.04; p=0.11 o PPI <ul style="list-style-type: none"> ▪ OR 1.01 (0.50; 2.05) ▪ 37/7471 (>1%) vs. 31/5352 (1%), n = 18 studies - upper gastrointestinal bleeding <ul style="list-style-type: none"> o n = 49 studies o 90/14139 (1%) vs. 221/12130 (2%) o 0.40, 0.32–0.50; p<0.0001 - larger proportional reductions in upper gastrointestinal bleeding were observed for PPIs than for other gastroprotectant drugs <ul style="list-style-type: none"> o PPIs 0.21, 99% CI 0.12–0.36; o prostaglandin analogues 0.63, 0.35–1.12; o H2RAs 0.49, 0.30–0.80; phet=0.0005 | | <p>as most frequent cause of peptic ulcer disease Helicobacter pylori infection and the use of NSAID (non-steroidal anti-inflammatory drug), including ASS, were reported</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - gastroprotectant drugs were effective in preventing bleeding irrespective of the use of non-steroidal anti-inflammatory drugs (phet=0.56) - PPIs were effective in prevention of endoscopic and symptomatic ulcers irrespective of the use of NSAIDs, although for endoscopic ulcers the proportional odds reduction appeared to be greater in those not taking NSAIDs at trial entry (appendix) <p>healing trials, gastroprotectants</p> <ul style="list-style-type: none"> - endoscopic ulcer healing <ul style="list-style-type: none"> o 3.49, 95% CI 3.28–3.72; p<0.0001 - with PPIs more effective (5.22, 99% CI 4.00–6.80) than prostaglandin analogues (2.27, 1.91–2.70) and H2RAs (3.80, 3.44–4.20; phet<0.0001) - weitere Daten vgl. Publikation sowie Appendix <p>trials among patients with acute bleeding, gastroprotectants</p> <ul style="list-style-type: none"> - further bleeding <ul style="list-style-type: none"> o OR 0.68, 95% CI 0.60–0.78; p<0.0001 - blood transfusion <ul style="list-style-type: none"> o 0.75, 0.65–0.88; p=0.0003 - further endoscopic intervention <ul style="list-style-type: none"> o 0.56, 0.45–0.70; p<0.0001 - surgery <ul style="list-style-type: none"> o 0.72, 0.61–0.84; p<0.0001 - mortality <ul style="list-style-type: none"> o OR 0.90, 0.72–1.11; p=0.31 - PPIs had larger protective effects than did H2RAs for further bleeding (phet=0.0107) and blood transfusion (phet=0.0130) - Weitere Daten vgl. Publikation und Appendix <p>they found no clear evidence that any individual PPI or prostaglandin analogue was more effective for the prevention of</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | symptomatic ulcer than any other of the same class (appendix) found no evidence that individual PPIs differed in their effects on bleeding (phet=0.48; appendix) | | |

Mo et al. 2015 PPI in prevention of low-dose ASS-associated upper GI injuries, SR

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mo C. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21(17):5382–92. https://www.ncbi.nlm.nih.gov/pubmed/25954113 . [49] | <p>Objective to determine the preventive effect and safety of proton pump inhibitors (PPIs) in low-dose acetylsalicylic acid (ASS) (LDA)-associated gastrointestinal (GI) ulcers and bleeding</p> <p>Search</p> <ul style="list-style-type: none"> - systematic review and meta-analysis - Medline, Embase, Cochrane Trial register (to December 2013), conference abstracts <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - RCT - age ≥ 18 years - patients taking low-dose ASS (LDA) for at least 2 continuous weeks - regardless of the combined - medication used, medical condition, and comorbidities in the patients - non-RCT, cohort studies, case-control studies, pharmacokinetic experiments, | n = 10 trials (n = 8780 participants) <ul style="list-style-type: none"> - published in US or Japan between 2002 and 2012 - participants ranged from 62 to 1876 (intervention) vs. 61 to 1885 (control) - duration ranged from 4 to 52 weeks - used PPI: esomeprazole, pantoprazole, omeprazole, rabeprazole, lansoprazole <ul style="list-style-type: none"> o dose ranged from 10 to 40 mg/d - used control: placebo, cytoprotective agents (gefarnate 100 mg/d) and H2RA (famotidine 20-80 mg/d) - population varied (all had a high risk of gastrointestinal bleeding) <ul style="list-style-type: none"> o n = 4 RCT with patients with ulcer/erosion or with a history of peptic ulcer, o n = 3 RCT with Helicobacter pylori (H. pylori)-negative patients or patients whose infection had been eradicated, o n = 4 RCT with hierarchical analysis according to the infection status of H. pylori, o n = 4 RCT with patients with acute coronary syndrome and myocardial infarction who were treated with dual antiplatelet therapy (LDA+clopidogrel) and PPI, o n = 4 RCT performed endoscopy in the patients before and after treatment, | AMSTAR-II low (keine Liste der ausgeschlossenen Studien verfügbar) authors classified risk of bias mostly as low risk of bias, some studies showed unclear risk of bias in selection bias and/or detection bias (allocation concealment was rate das unclear risk of bias in 75% oft he studies); high risk of bias was reported for one study in the category of other bias (not excluded from meta-analysis) funnel plot indicated an asymmetric distribution that suggested the presence of publication bias authors included studies published in english language (only) | authors noted that with the use of low-dose acetylsalicylic acid for primary and secondary prevention the incidence of LDA-associated upper gastrointestinal (GI) injuries has been increased authors disussed available evidence (including evidence from cohort studies) and concluded that the research question probably could be extendet (this publication focused on preventive effect of PPI) |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>case reports were excluded</p> <ul style="list-style-type: none"> - studies with short-term or intermittent use of LDA were excluded <p>Intervention oral proton pump inhibitors (PPI)</p> <p>Comperator</p> <ul style="list-style-type: none"> - placebo, - a cytoprotective agent, - or an H2 receptor antagonist (H2RA) <p>Quality assessment Cochrane Risk of Bias Tool</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - adverse GI events (hemorrhage, ulcer, perforation, or obstruction) - incidence of LDA-related peptic ulcer and upper gastrointestinal bleeding - incidence of major adverse cardiovascular events (MACE) and diarrhea | <ul style="list-style-type: none"> o n = 4 RCT only conducted endoscopy after treatment - n = 5 compared preventive effect of PPI with placebo - n = 2 compared PPI with gefarnate - n = 3 compared PPI with famotidine <p>Results risk of LDA-associated upper GI ulcers PPI vs. control (placebo, gefarnate and H2RA)</p> <ul style="list-style-type: none"> - n = 46/4684 vs. n = 179/3781 - OR = 0.16; 95%CI: 0.12-0.23, n = 8 studies <p>PPI vs. placebo</p> <ul style="list-style-type: none"> - n = 30/4045 vs. n = 95/3248 - OR = 0.20; 95%CI: 0.13-0.30, n = 4 studies <p>LDA-associated GI bleeding PPI vs. control (placebo, gefarnate and H2RA)</p> <ul style="list-style-type: none"> - n = 19/4834 vs. n = 71/3932 - OR = 0.27; 95%CI: 0.16-0.43, n = 10 studies <p>PPI vs. placebo</p> <ul style="list-style-type: none"> - n = 11/4140 vs. 43/3334 - OR = 0.26; 95%CI: 0.14-0.49, n = 5 studies <p>patients with dual anti-platelet therapy of LDA and clopidogrel LDA-associated GI bleeding PPI vs. control (placebo, gefarnate and H2RA)</p> <ul style="list-style-type: none"> - n = 14/2190 vs. n = 41/2184 - OR = 0.36; 95%CI: 0.15-0.87, n = 4 studies <p>risk of major adverse cardiovascular events (MACE) PPI vs. control (placebo, gefarnate and H2RA)</p> <ul style="list-style-type: none"> - n = 92/2190 vs. n = 92/2184 - OR = 1.00; 95%CI: 0.76-1.31, n = 4 studies | | |

12.5.1.2 Häufigkeit von Blutungsereignissen bei geringen Dosen von ASS

García Rodríguez et al. 2016 Blutungsrisiko bei geringer Dosierung von ASS (SR, Beobachtungsstudien)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| García Rodríguez LA. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One 2016; 11(8):e0160046. https://www.ncbi.nlm.nih.gov/pub-med/27490468 . [50] | <p>Objective to determine the risks of the most clinically relevant adverse effect, GI bleeding, and the serious but rare event, ICH, in patients taking low-dose aspirin in real-world settings; the influence of risk factors was also assessed</p> <p>Search</p> <ul style="list-style-type: none"> - Medline, Embase (up to March 2015) - no published protocol <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - observational studies - epidemiology, ASS and ASS safety (long-term, low dose) - reviews, editorials, comments, clinical trials and pediatric studies were excluded - studies using only aspirin doses higher than 325 mg per day were excluded <p>Intervention low-dose aspirin (75–325 mg per day)</p> <p>Outcome primary</p> | <p>n = 39 articles</p> <ul style="list-style-type: none"> - n = 23 case-control studies (one case-crossover study) (some were nested in well-defined cohorts) - n = 16 cohort studies (one long-term, post-trial follow-up of a RCT) - n = 23 from Europe (n = 7 from Spain, n = 7 from UK), n = 9 from USA - duration of ASS use: 1 month to > 20 years - reported follow-up: 4-14 years - maximum time period between stopping ass use and the study index date ranged from 7 to 90 days <p>Results low-dose ass vs. non-use all gastrointestinal bleeding (n = 8 studies with n = 5 cohorts)</p> <ul style="list-style-type: none"> - n = 2 studies (cohorts): no increase in the risk of GI bleeding - n = 6 studies with statistically significant increased risk - RR 0.99–4.64, with most studies reporting values between 0.99 and 1.6 - pooled estimates: <ul style="list-style-type: none"> o RR 1.4 (95% CI: 1.2–1.7), overall, n = 8 studies o RR 1.7 (95% CI: 1.2–2.5) for case-control studies (n = 3) and o RR 1.3 (95% CI: 1.0–1.7) for cohort studies (n = 5) o significant heterogeneity was reported, especially for cohort studies - highest risk reported in Japanese patients (LDA for CVD for > 1 year, wide confidence intervals) - overall incidence (as cases per 1000 person-years), Fig 3 | <p>AMSTAR-II critically low</p> <p>(keine Liste der ausgeschlossenen Studien verfügbar; ein Instrument zur Bewertung des Risk-of-Bias ist nicht beschrieben, allerdings erfolgt eine Bewertung in der Diskussion, die Prüfung eines Publication Bias wird nicht angegeben)</p> <p>(Hinweis: das Instrument ist nur eingeschränkt anwendbar, da u. a. Beobachtungsstudien gesucht wurden und die Limitationen u. a. dieses Publikationstyps in der Diskussion beschrieben sind)</p> <p>Supplement online verfügbar; Download nur als Word-File etc. verfügbar</p> <p>observational studies are more prone to bias from confounding factors than RCT</p> <p>they identified between-study heterogeneity (e. g. differences in design, bleeding definition)</p> | <p>authors noted that In the secondary prevention of cardiovascular disease (CVD), the absolute benefits of aspirin far outweigh the absolute risks of major bleeding events</p> <p>bleeding risk associated with low-dose aspirin use should be identified by factors that influence the risk of bleeding with ass therapy and the magnitudes of these effects on the risk (e. g. taking concomitant medications with increased risk of GI bleeding: including anticoagulants, other antiplatelet agents, and non-steroidal anti-inflammatory drugs (NSAID))</p> <p>authors noted that the majority of studies reported increased RR of GI bleeding, which is consistent with findings from previous MA of RCT (range 1.31–1.96)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - incidences of GI bleeding and ICH (intracranial (including intracerebral) hemorrhage) and measures of their association secondary: <ul style="list-style-type: none"> - factors with potential predictive effects on the risk of bleeding, such as age, history of peptic ulcer, and H. pylori infection - effects of medications taken concomitantly with low-dose ass (including proton pump inhibitors [PPIs], clopidogrel, and non-steroidal anti-inflammatory drugs [NSAIDs]) on the risk of bleeding were also documented | <ul style="list-style-type: none"> o n = 2 cohort studies (USA), o one involved only men <ul style="list-style-type: none"> ▪ 1.39 events per 1000 person-years o the other involved only women <ul style="list-style-type: none"> ▪ 1.67 events per 1000 person-years <p>upper gastrointestinal bleeding (UGIB) (n = 24 studies, with n = 7 cohort studies)</p> <ul style="list-style-type: none"> - statistically significant increase in risk on UGIB in most studies <ul style="list-style-type: none"> o RR 2.3 (95% CI: 2.0–2.6), overall, n = 24 studies o RR range 1.4–4.0 and pooled estimate RR 2.3 (95% CI: 2.0–2.7) for case-control studies (n = 17) o RR range (1.2–4.5) and pooled estimate RR 2.0 (95% CI: 1.5–2.7) for cohort studies (n = 7 studies) o significant heterogeneity was reported o n = 1 study reported LDA in primary and secondary prevention of CVD: RR for UGIB was higher in primary prevention: <ul style="list-style-type: none"> ▪ adjusted RR [95% CI]: ▪ 1.90 [1.59–2.26] and 1.40 [1.14–1.72], respectively ▪ baseline absolute risk of ▪ UGIB was higher in the secondary than in the primary prevention cohort (patients were older and more likely to have a history of ulcers and concomitant medication use (e. g. NSAID, clopidogrel, oral anticoagulants) ▪ absolute increase in risk of UGIB was higher in secondary prevention cohort | | <p>cohort studies showed increased risk of UGIB with more frequent dosing; a possible correlation between dose and risk of bleeding did not find any consistent effects</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ○ n = 8 studies analysed effect of ass dose or dosing regimen: <ul style="list-style-type: none"> ▪ n = 2 with increase in the risk of UGIB with increasing frequency of doses ▪ n = 1 with a clear dose-dependency for UGIB ▪ n = 4 with little difference in RR for different low-dose aspirin regimens ○ n = 2 studies suggested that the duration of continuous low-dose aspirin treatment up to 10 or 20 years has little effect on the RR of UGIB, when adjusted for treatment dose ○ n = 2 studies shown that the risk of UGIB with low-dose aspirin is greatest during the first 2 months of therapy, and decreases with increasing treatment duration - overall incidence (as cases per 1000 person-years), Fig 3 <ul style="list-style-type: none"> ○ n = 4 studies (USA, UK, Danish cohort) ○ range 0.70–3.64 cases per 1000 person-years <p>lower gastrointestinal bleeding (s. within the publication page 9): overall incidence 0.48–0.74 cases per 1000 person-years (n = 3 studies), Fig 3</p> <p>risk of intracranial hemorrhage (ICH, s. within the publication page 9 ff), n = 7 studies (n = 3 cohorts, n = 3 case-control studies, n = 1 case-crossover study)</p> <ul style="list-style-type: none"> - RR 0.82–1.71 across the studies, - for most studies the 95% CI included 1.0 - pooled estimates <ul style="list-style-type: none"> ○ RR 1.4 (95% CI 1.2–1.7) overall, n = 7 studies | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ○ RR 1.0 (95% CI: 0.8–1.2) for case–control studies (n = 4) and ○ RR 1.5 (95% CI: 1.4–1.7) for cohort studies (n = 3) ○ high heterogeneity was reported for case-control studies <p>- overall incidence (n = 1 study, cohort of patients with non-valvular atrial fibrillation)</p> <ul style="list-style-type: none"> ○ 8.0 cases per 1000 person-years <p>potential predictive factors</p> <ul style="list-style-type: none"> - age (S2, S3 and S4 Fig) <ul style="list-style-type: none"> ○ n = 4 studies (with increasing age and increased incidence of major bleedings) ○ n = 8 studies (with no clear evidence that the RR of bleeding with low-dose aspirin increases with increasing age) ○ incidence generally higher in men than in women ○ increase of 3.24 cases per 1000 person-years in men aged ≥ 70 years compared with men aged 16–59 years, n = 1 study ○ increase of 2.22 cases per 1000 person-years in men aged ≥ 80 years compared with men aged 40–59 years, n = 1 study - (history of) peptic ulcer and Helicobacter pylori infection (S2 Table) <ul style="list-style-type: none"> ○ association with increased UGIB - concomitant medication (S3 Table) <ul style="list-style-type: none"> ○ association with increased UGIB ○ NSAID (high dose) ○ Clopidogrel + ASS ○ Selective serotonin reuptake inhibitors (SSRI) - effects of PPI on risk of major bleeding events (+ low-dose ASS) <ul style="list-style-type: none"> ○ available for n = 6 studies (S3 Table) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ○ major bleeding: <ul style="list-style-type: none"> ▪ PPI vs. no PPI: adjusted RR 0.84 (95% CI 0.80; 0.88), n = 1 study ○ UGIB: PPI vs. no PPI: <ul style="list-style-type: none"> ▪ OR 0.97 (0.65; 1.44), n = 1 ▪ OR 0.6 (0.5; 0.8), n = 1 ▪ OR 0.4 (0.3; 0.5), n = 1 ▪ OR 0.62 (0.35; 1.08), n = 1 ▪ OR 0.37 (0.18; 0.75), n = 1 ▪ OR 0.2 (0.1; 0.9), n = 1 <p>overall: the incidence of GI bleeding with low-dose ASS was 0.48–3.64 cases per 1000 personyears</p> <p>for upper and lower GI bleeding, the RR with low-dose ASS were 2.3 (2.0–2.6) and 1.8 (1.1–3.0), respectively</p> <p>neither ASS dose nor duration of use had consistent effects on RR for upper GI bleeding</p> <p>the estimated RR for ICH with low-dose ASS was 1.4 (1.2–1.7) overall</p> <p>ASS was associated with increased bleeding risks when combined with non-steroidal anti-inflammatory drugs, clopidogrel and selective serotonin reuptake inhibitors compared with monotherapy</p> <p>by contrast, concomitant use of proton pump inhibitors decreased upper GI bleeding risks relative to ASS monotherapy</p> | | |

12.5.1.3 Langzeittherapie mit PPI

Freedberg et al. 2017 Langzeittherapie mit PPI, Risiken und Vorteile (Übersichtsartikel)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------|
| <p>Freedberg DE. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. <i>Gastroenterology</i> 2017; 152(4):706–15. https://www.ncbi.nlm.nih.gov/pub-med/28257716. [51]</p> | <p>Objective To evaluate the risks associated with long-term use of proton pump inhibitors (PPI)</p> <p>Methods</p> <ul style="list-style-type: none"> - recommendations based on expert opinion - search in Pubmed, Embase, Cochrane library (through July 2016), clinical Trials <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - Gastroesophageal reflux disease (GERD) - Barrets esophagus (BE) - Non-steroidal anti-inflammatory drug (NSAID) bleeding prophylaxis <p>Intervention Proton pump inhibitors (PPI)</p> <p>Quality assessment GRADE</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - adverse effects | <p>Table 1.Summary of Evidence for Potential PPI-Associated Adverse Effects</p> <p>Potential adverse effect</p> <p>Types of studies</p> <p>Threats to validity</p> <p>Overall quality of evidence</p> <p>Kidney disease</p> <ul style="list-style-type: none"> - Observational only - Modest effect size - Residual confounding would bias towards harm - Absence of dose-response effect - Very low <p>Dementia</p> <ul style="list-style-type: none"> - Observational only - Modest effect size - Residual confounding would bias towards harm - Very low <p>Bone fracture</p> <ul style="list-style-type: none"> - Observational only - Inconsistent results - Modest effect size - Residual confounding would bias towards harm - Low or very low <p>Myocardial infarction</p> <ul style="list-style-type: none"> - Observational - RCT - Results differ between RCTs and observational studies - Secondary analysis of RCT data - Modest effect size - Residual confounding would bias towards harm - Very low <p>Small intestinal bacterial overgrowth</p> <ul style="list-style-type: none"> - Observational | <p>n. a.</p> <p>(Überblicksartikel; Methodik nicht bzw. unzureichend beschrieben)</p> | <p>Artikel zur Diskussion; konsensbasierte Empfehlungen</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - Crossover - Sparse data - Residual confounding would bias towards harm - Protopathic bias - Low <p>Spontaneous bacterial peritonitis</p> <ul style="list-style-type: none"> - Observational only - Modest effect size - Residual confounding would bias towards harm - Very low <p>Clostridium difficile infection</p> <ul style="list-style-type: none"> - Observational only - Modest effect size - Residual confounding would bias towards harm - Low <p>Pneumonia</p> <ul style="list-style-type: none"> - Observational - RCT - Results differ between RCTs and observational studies - Secondary analysis of RCT data - Modest effect size - Absence of dose-response effect - Residual confounding would bias towards harm - Protopathic bias - Very low <p>Micronutrient deficiencies</p> <ul style="list-style-type: none"> - Observational only - Inconsistent results - Modest effect size - Absence of dose-response effect - Residual confounding would bias towards harm - Low or very low <p>Gastrointestinal malignancies</p> <ul style="list-style-type: none"> - Observational - RCT - Results differ between RCTs and observational studies - RCTs use surrogate outcomes | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - Modest effect size - Residual confounding would bias towards harm - Confounding by indication and protopathic bias - Very low <p><i>Note:</i> Assessments regarding the quality of evidence are based on the methodology of the GRADE Working Group (see inset)</p> <p>Table 2 absolute (% per patient/year) and relative risks (% increase) for adverse events associated with long-term PPI (je n = 1 study)</p> <ul style="list-style-type: none"> - Chronic kidney disease <ul style="list-style-type: none"> o 0.1%-0.3% per patient/year o 10-20% increase - Dementia <ul style="list-style-type: none"> o 0.07%-1.5% per patient/year o 4-80% increase - Bone fracture <ul style="list-style-type: none"> o 0.1%-0.5% per patient/year o 30% to 4-fold increase - Myocardial infarction <ul style="list-style-type: none"> o – o no association in RCT - Small intestinal bacterial overgrowth <ul style="list-style-type: none"> o unable to calculate o 2-fold to 8-fold increase - Campylobacter or salmonella infection <ul style="list-style-type: none"> o 0.03%-0.2% per patient/year o 2-fold to 6-fold increase - Spontaneous bacterial peritonitis <ul style="list-style-type: none"> o 3%-16% per patient/year o 50% to 3-fold increase - Clostridium difficile infection <ul style="list-style-type: none"> o 0%-0.09% per patient/year o No risk to 3-fold increase - Pneumonia <ul style="list-style-type: none"> o – o No association in RCT - Micronutrient deficiencies | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ○ 0.3%-0.4% per patient/year ○ 60-70% increase - Gastrointestinal malignancies <ul style="list-style-type: none"> ○ – ○ No association in RCT <p>Best Practice Recommendations</p> <p>Best Practice Advice 1: Patients with GERD and acid-related complications (i.e., erosive esophagitis or peptic stricture) should take a PPI for short-term healing and for long-term symptom control. <i>Rationale:</i> PPIs are highly effective in healing esophagitis and for GERD symptom control, and this benefit is likely to outweigh PPI-related risks. There is no evidence for or against PPIs in asymptomatic patients with healed esophagitis or for PPIs beyond 12 months.</p> <p>Best Practice Advice 2: Patients with uncomplicated GERD who respond to short-term PPIs should subsequently attempt to stop or reduce them. Patients who cannot reduce PPIs should consider ambulatory esophageal pH/impedance monitoring before committing to lifelong PPIs to help distinguish GERD from a functional syndrome. The best candidates for this strategy may be patients with predominantly atypical symptoms or those who lack an obvious predisposition to GERD (eg, central obesity, large hiatal hernia). <i>Rationale:</i> Short-term PPIs are highly effective for uncomplicated GERD. Most patients with uncomplicated GERD respond to short-term PPIs and are subsequently able to reduce PPIs to less than daily dosing. Because patients who cannot reduce PPIs face lifelong therapy, we would consider testing for an acid-related disorder in this situation. However, there is no high-quality evidence on which to base this recommendation.</p> <p>Best Practice Advice 3: Patients with Barrett's esophagus and symptomatic GERD should take a long-term PPI.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p><i>Rationale:</i> PPIs have a clear symptomatic benefit and a possible benefit in slowing progression of Barrett's. There is likely to be a net benefit for long-term PPIs in these patients.</p> <p>Best Practice Advice 4: Asymptomatic patients with Barrett's esophagus should consider a long-term PPI.</p> <p><i>Rationale:</i> The evidence that PPIs slow progression of Barrett's is low in quality but the evidence of PPI adverse effects is also low in quality. Because there is no high quality evidence on either side of this question, this is a weak recommendation and this decision should be individualized with patients.</p> <p>Best Practice Advice 5: Patients at high risk for ulcer-related bleeding from NSAIDs should take a PPI if they continue to take NSAIDs.</p> <p><i>Rationale:</i> PPIs are highly effective in preventing ulcer-related bleeding in appropriately selected patients who take NSAIDs, and this benefit is likely to outweigh PPI-related risks.</p> <p>Best Practice Advice 6: The dose of long-term PPIs should be periodically reevaluated so that the lowest effective PPI dose can be prescribed to manage the condition.</p> <p><i>Rationale:</i> Long-term PPI users often receive PPIs at doses higher than necessary to manage their condition. Since PPI reduction is often successful, it is logical to periodically reevaluate PPI dosing so that the minimum necessary dose is prescribed.</p> <p>Best Practice Advice 7: Long-term PPI users should not routinely use probiotics to prevent infection.</p> <p><i>Rationale:</i> There is no evidence for or against probiotics to prevent infections in long-term users of PPIs.</p> <p>Best Practice Advice 8: Long-term PPI users should not routinely raise their intake of calcium, vitamin B12 or magnesium beyond the Recommended Dietary Allowance (RDA).</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p><i>Rationale:</i> There is no evidence for or against use of vitamins or supplements beyond the RDA in long-term users of PPIs. Many adults fall below the RDA in several vitamins or minerals and, in these adults, it is reasonable to raise intake to meet the RDA regardless of PPI use.</p> <p>Best Practice Advice 9: Long-term PPI users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vitamin B12.</p> <p><i>Rationale:</i> There is no evidence for or against dedicated testing for patients taking long-term PPIs. Such screening (eg, for iron or vitamin B12 deficiency) can be offered but is of no proven benefit.</p> <p>Best Practice Advice 10: Specific PPI formulations should not be selected based on potential risks.</p> <p><i>Rationale:</i> There is no convincing evidence to rank PPI formulations by risk.</p> | | |

12.5.2 Empfehlung 7-3 Clopidogrel vs. ASS (Stellenwert in der Monotherapie)

Tan et al. 2023 Clopidogrel oder ASS - Monotherapie (SR, nach 6-12 Monaten dualer Therapie, nach PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Tan BE-X. Clopidogrel vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. <i>Curr Probl Cardiol</i> 2023; 48(8):101174. https://www.ncbi.nlm.nih.gov/pub-med/35341798. [52]</p> | <p>Objective to assess the efficacy and safety of clopidogrel vs. ASS in post-PCI population after completing DAPT (duale antiplatelet therapy)</p> <p>Methods</p> <ul style="list-style-type: none"> - Systematic review and meta-analysis according to the PRISMA guidelines | <p>n = 5 articles (n = 13,850 patients)</p> <ul style="list-style-type: none"> - n = 5,601 (40.4%) Clopidogrel - n = 8,249 (59.6%) ASS - mean age 64.1 years - high prevalence of comorbidities (hypertension 45-83%, dyslipidemia 13-80%, diabetes 21-42%, chronic kidney disease 8-40%) - all patients with drug-eluting stent - no patient received bare-metal stent - n = 1 RCT, n = 4 observational cohort studies <ul style="list-style-type: none"> o clopidogrel vs. ASS o following completion of DAPT after PCI | <p>AMSTAR-II moderate</p> <p>Subgruppenanalysen und Sensitivitätsanalysen wurden präspezifiziert (u. a. um ein Risiko für Bias oder geringe Studienqualität zu berücksichtigen)</p> | <p>HOST EXAM 2021 enthalten in der Metaanalyse</p> <p>Autor*innen berichten, dass die Analysen durch diese Studie geleitet wurden (Einfluss auf das Ergebnis u.a. durch Studiengröße, statistische Power; in</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - Registration in PROSPERO (CRD42022301139) - PubMed (Ovid), Cochrane, CINAHL, Google Scholar (through Feb 2022) - medical librarian involved <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - trials and observational studies - adult patients (≥18 years) - patients after PCI - after completion of DAPT for a minimum of 1 month - other P2Y12 inhibitors were excluded (ticagrelor, prasugrel) <p>Quality assessment</p> <p>Cochrane Risk-of-Bias tool instrument of national institute of health (NIH) for observational studies</p> <p>Intervention</p> <p>clopidogrel monotherapy*</p> <p>Comperator</p> <p>ASS monotherapy*</p> <p>*following completion of dual therapy (DAPT)</p> <p>Outcomes</p> <ul style="list-style-type: none"> - major adverse cardiac events (MACE) - cardiac death - all-cause death - major bleeding | <ul style="list-style-type: none"> - mean follow-up 12 to 36 months <ul style="list-style-type: none"> o n = 2 studies follow-up from day of PCI o n = 3 studies follow-up from day of monotherapy o duration of DAPT before monotherapy 1-18 months <p>n = 3 studies were rated as fair quality, n = 1 observational study as poor quality, n = 1 studie as low risk of bias</p> <p>Results</p> <p>clopidogrel vs. ASS (monotherapy, after DAPT)</p> <p>MACE</p> <ul style="list-style-type: none"> - n = 205 (3.6%) vs. n = 341 (4.2%) - risk ratio (RR) 0.77 (95% confidence interval (CI) 0.65-0.91), P=0.003, n = 5 studies <p>all-cause death</p> <ul style="list-style-type: none"> - n = 97 (1.8%) vs. n = 150 (1.9%) - RR 1.06 (95% CI 0.81-1.39), P=0.66, n = 4 studies <p>cardiac death</p> <ul style="list-style-type: none"> - n = 48 (0.9%) vs. n = 61 (1.2%) - RR 0.87 (95% CI 0.53-1.41), P=0.56, n = 4 studies <p>major bleeding</p> <ul style="list-style-type: none"> - n = 47 (0.8%) vs. n = 80 (1.1%) - RR 0.74 (95% CI 0.42-1.30), P=0.29, n = 5 studies <p>MI</p> <ul style="list-style-type: none"> - n = 73 (1.3%) vs. n = 102 (1.3%) - RR 1.01 (95% CI 0.64-1.60), P=0.95, n = 5 studies <p>repeat revascularization</p> <ul style="list-style-type: none"> - n = 154 (3.3%) vs. n = 108 (3.1%) - RR 0.88 (95% CI 0.71-1.09), P=0.23, n = 3 studies <p>target vessel revascularization</p> <ul style="list-style-type: none"> - n = 42 (1.2%) vs. n = 68 (1.3%) - RR 0.76 (95% CI 0.52-1.13), P=0.18, n = 3 studies | <p>duration of DAPT following PCI varied between studies (possible heterogeneity), results of sensitivity analysis were stable for all outcomes</p> <p>HOST EXAM was rated as low risk of bias for all criteria except for performance bias due to the open-label design; observational studies as fair (3) or poor (1)</p> <p>limited external validity due to all studies comprised of the East Asian population (authors noted that clopidogrel hypo-responsiveness is known to be greater in the East Asian population than in Caucasians (CYP2C19 polymorphism) and that thrombotic events are lower in East Asian patients compared with Caucasian patients receiving clopidogrel (citation: Kang et al. Korean Circ J 2018 https://pubmed.ncbi.nlm.nih.gov/29968428/: “East Asian patients have a unique ischemic and bleeding risk profile”; “revious data suggested that East Asian patients have unique features with regard to the response to antiplatelet agents. On comparing Western and East Asian patients, it was found that East Asian patients have a lower rate of ischemic events and higher rate of bleeding events after PCI, despite a higher on-treatment platelet reactivity, which is referred to as the “East Asian paradox.”)</p> | <p>Subgruppenanalysen nicht statistisch signifikant, nach Ausschluss der Studie, Tendenz aber ähnlich)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - myocardial infarction (MI) - stroke <p>prespecified subgroup analyses were planned (e. g. related to study type)</p> | <p>stent thrombosis</p> <ul style="list-style-type: none"> - n = 18 (0.3%) vs. n = 27 (0.3%) - RR 0.96 (95% CI 0.35-2.59), P=0.93, n = 4 studies <p>any stroke</p> <ul style="list-style-type: none"> - n = 34 (0.7%) vs. n = 95 (1.5%) - RR 0.51 (95% CI 0.35-0.76), P=0.0008, n = 3 studies <p>ischemic stroke</p> <ul style="list-style-type: none"> - n = 21 (0.4%) vs. n = 37 (0.7%) - RR 0.55 (95% CI 0.32-0.94), P=0.03, n = 3 studies <p>hemorrhagic stroke</p> <ul style="list-style-type: none"> - n = 4 (0.0%) vs. n = 18 (0.4%) - RR 0.24 (95% CI 0.09-0.68), P=0.007, n = 2 studies | | |

Gragnano et al. 2023 P2Y12 Hemmer oder ASS - Monotherapie (SR, Sekundärprävention, duale Vortherapie war möglich)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <p>Gragnano F. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol 2023; 82(2):89–105. https://www.ncbi.nlm.nih.gov/pub-med/37407118. [53]</p> | <p>Objective to compare P2Y12-inhibitor monotherapy vs. ASS in patients with CAD</p> <p>Methods</p> <ul style="list-style-type: none"> - PRISMA guided - PANTHER collaborative initiative (CRD42021290774) - systematic review and patient-level meta-analysis - RCT - patients with established CAD - prevention of cardiovascular events (secondary prevention) | <p>n = 7 RCT (n = 24 325 individual patients) (ASCET, CADET, CAPRIE, DACAB, GLASSY, HOST-EXAM, TICAB)</p> <ul style="list-style-type: none"> - n = 12 178 (P2Y12) <ul style="list-style-type: none"> o n = 7 545 (62.0%) clopidogrel o 4 633 (38.0%) ticagrelor - n = 12 147 (ASS) - mean age 64.3 years - female 21.7 % - ACS ~ 60.6 % - CCS ~ 39.4 % - hypertension ~ 60 % - hypercholesterolemia ~ 60 % - previous myocardial infarction ~ 56 % - diabetes mellitus ~ 25 % - PCI ~ 54 % - CABG ~10.6 % - no revascularization ~ 30 % | <p>AMSAR-II low</p> <p>(keine Liste der ausgeschlossenen Volltexte mit Ausschlussgrund vorhanden)</p> <p>Limitations (authors note)</p> <ul style="list-style-type: none"> - open-label design (n = 4 studies) - no correction for multiple testing was performed - results not generalizable to patients with prasugrel monotherapy - duration of treatment varied (6-36 months) | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - initial DAPT phase after randomization was allowed - studies with oral anticoagulation or other antithrombotic agents were excluded <p>Intervention P2Y12-inhibitor monotherapy</p> <p>Comperator ASS monotherapy</p> <p>Quality assessment Cochrane Risk-of Bias tool</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - composite of cardiovascular death, myocardial infarction, stroke <p>secondary</p> <ul style="list-style-type: none"> - major bleeding (BARC type 3 or 5) - adverse clinical events (defined as composite of primary outcome and major bleeding) | <ul style="list-style-type: none"> - statins ~ 89 % - ASS high dose (primary study population) ~ 19 % - ASS low dose (primary study population) ~ 30 % - median treatment duration 557 days (IQR 369-734 days) <p>n = 2 trials classified as low risk of bias, n = 5 trials classified with some concerns</p> <p>Results primary at median follow up of 493 days (P2Y12-inhibitors vs. ASS)</p> <ul style="list-style-type: none"> - n = 675 (3.58%) vs. n = 765 (4.07%) - HR 0.88 (95% CI 0.79; 0.97), P=0.012, n = 24 325 patients - Number-needed to treat 121 over 2 years <p>secondary</p> <p>all-cause death</p> <ul style="list-style-type: none"> - n = 404 (2.10%) vs. n = 386 (2.00%) - HR 1.04 (95% CI 0.91; 1.20), P=0.56, n = 24 325 patients <p>cardiovascular death</p> <ul style="list-style-type: none"> - n = 280 (1.45%) vs. n = 273 (1.42%) - HR 1.02 (95% CI 0.86; 1.20), P=0.82, n = 24 325 patients <p>myocardial infarction</p> <ul style="list-style-type: none"> - n = 283 (1.49%) vs. n = 366 (1.93%) - HR 0.77 (95% CI 0.66; 0.90), P<0.001, n = 24 325 patients - NNT 136 <p>stroke</p> <ul style="list-style-type: none"> - n = 202 (1.06%) vs. n = 239 (1.25%) - HR 0.84 (95% CI 0.70; 1.02), P=0.076, n = 24 325 patients <p>stent thrombosis</p> <ul style="list-style-type: none"> - n = 8 (0.09%) vs. n = 19 (0.21%) - HR 0.42 (95% CI 0.19; 0.97), P=0.041, n = 12 503 | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | major bleeding - n = 146 (0.76%) vs. n = 167 (0.87%) - HR 0.87 (95% CI 0.70; 1.09), P=0.23, n = 24 325 patients any bleeding - n = 646 (3.54%) vs. n = 587 (3.22%) - HR 1.10 (0.98; 1.23), P=0.10, n = 24 325 patients adverse clinical events - n = 785 (4.19%) vs. n = 874 (4.68%) - HR 0.89 (95% CI 0.81; 0.98), P=0.020, n = 24 325 patients treatment effect was consistent across all prespecified subgroups associations: geographical regions (Asian may derive enhanced benefit from P2Y12 inhibitors) | | |

Chiarito et al. 2020 P2Y12 Hemmer oder ASS - Monotherapie (SR, Sekundärprävention, Langzeittherapie)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chiarito M. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis. Lancet 2020; 395(10235):1487–95. https://www.ncbi.nlm.nih.gov/pub-med/32386592 . [54] | Objective to compare monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention Methods <ul style="list-style-type: none"> - systematic review and meta-analysis - of randomised trials - study registered in PROSPERO (CRD42018115037) - PRISMA guidelines were used - monotherapy for secondary prevention | n = 9 studies (n = 42 108 patients) (TASS, CAPRIE, STAMI, AAASPS, CADET, ASCET, SOCRATES, DACAB, TICAB) <ul style="list-style-type: none"> - year of publication 1989-2019 - coronary artery disease: n = 5 studies (STAMI, CADET, ASCET, DACAB, TICAB) - cerebrovascular disease: n = 3 studies (TASS, AAASPS, SOCRATES) - n = 1 studie (cerebrovascular, coronary, and peripherer artery disease) - n = 21 043 (P2Y₁₂-inhibitors) - n = 21 065 (ASS) - n = 24 508 patients after a cerebrovascular event - n = 7956 patients after a myocardial infarction - n = 3192 patients with the presence of stable coronary artery disease | AMSTAR-II low (keine Liste der ausgeschlossenen Volltexte mit Ausschlussgrund vorhanden) n = 3 studies were rate das low risk of bias, n = 6 studies with some concerns pre-specified subgroup and sensitivity analyses were performed post-hoc estimated stratified analysis to assess the effect of the estimated risk of bias | authors first excluded the GLOBAL LEADERS trial due to the design, but noted that 1 year after randomisation the patients received ticagrelor monotherapy or aspirin monotherapy for the subsequent year, with no significant differences between the two treatment strategies |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> patients with cerebrovascular, coronary, or peripheral artery disease (established atherosclerosis) searched PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register of Controlled Trials (on Dec 18, 2019) reviewed references from identified articles; searched abstracts from 2017 to 2019 presented at relevant scientific meetings studies comparing dual vs. single antiplatelet therapy, studies assessing anti-thrombotic agents different from aspirin or P2Y12 inhibitors, and studies not reporting clinical outcomes were excluded studies with less than 1 months of active comparison were excluded <p>Intervention P2Y12 inhibitor</p> <p>Comperator aspirin</p> <p>Quality assessment Cochrane risk-of-bias tool (RoB 2)</p> <p>Outcomes co-primary endpoints</p> | <ul style="list-style-type: none"> n = 6452 patients with the presence of peripheral artery disease mean age 59.2 – 66.7 years follow-up 3 months to 3 years patients lost to follow up 0.35%-0.36% hypertension 39.2-89.9% dyslipidaemia 36.0-81.7% chronic coronary syndromes 14.0 (CAPRIE) - 100% (ASCET) prior myocardial infarction 4.1-100% PAD 4.0-38.0% diabetes 14.9-42.7% <p>results P2Y12 inhibitor vs. ASS monotherapy (only studies that reported outcomes are included)</p> <p>all cause death</p> <ul style="list-style-type: none"> 887/21 040 vs. 903/21 068 odds ratio [OR] 0.98 (95% CI 0.89; 1.08), n = 9 studies <p>vascular death</p> <ul style="list-style-type: none"> 574/20 447 vs. 595/20 476 OR 0.97 (0.86; 1.09), n = 7 studies <p>stroke</p> <ul style="list-style-type: none"> 1137/20 949 vs. 1235/20 975 OR 0.92 (0.82; 1.06), n = 8 studies <p>myocardial infarction</p> <ul style="list-style-type: none"> 357/19 514 vs. 437/19 525 OR 0.81 (0.66; 0.99), n = 8 studies number needed to treat 244 <p>any bleeding</p> <ul style="list-style-type: none"> 1293/20949 vs. 1259/20975 OR 1.08 (0.91; 1.29), n = 8 studies, p=0.37 <p>major bleeding</p> <ul style="list-style-type: none"> 213/18613 vs. 237/18657 OR 0.90 (0.74; 1.10), n = 7 studies, p=0.30 <p>fatal bleeding</p> <ul style="list-style-type: none"> 33/18019 vs. 32/18026 OR 1.05 (0.59; 1.85), n = 5 studies, p=0.85 | <p>effect modifiers ere assessed</p> <p>studies for prasugrel not reported</p> <p>authors noted limitations (e. g.):</p> <ul style="list-style-type: none"> stratified analyses might not have sufficient power to detect significant differences between groups different bleeding definitions (limited reliability) | <p>they added a extended analysis by including the outcomes of the GLOBAL LEADERS trial beyond the first year of follow-up, contributing to the post-hoc analysis with an additional 15 729 patients; results were were consistent with the primary analysis (appendix)</p> <p>authors noted that costeffectiveness should be thoroughly evaluated in different health-care systems before any changes are made in current recommendations on anti-thrombotic secondary prevention strategies (risk profiles should be recognised)</p> <p><i>pathways:</i> authors added that atherosclerosis progression and subsequent ischaemic events share the same common pathophysiological pathway in different arterial territories</p> <p>guidelines recommended long-term treatment with ASS</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - myocardial infarction and stroke (ischaemic) secondary endpoints <ul style="list-style-type: none"> - all-cause death and vascular death - safety: bleeding and major bleeding | intracranial bleeding <ul style="list-style-type: none"> - 56/18619 vs. 76/18636 - OR 0.74 (0.52; 1.04), n = 5 studies, p=0.084 gastrointestinal bleeding <ul style="list-style-type: none"> - 202/12932 vs. 288/12933 - OR 0.59 (0.39; 0.89), n = 5 studies, p=0.012 <p>additional information</p> <ul style="list-style-type: none"> - stratified analysis of ischaemic outcomes according to type of P2Y12 inhibitor used (ie, ticlopidine, clopidogrel, or ticagrelor) showed findings consistent with the primary analysis (figure 3 within the publication) - meta-regression analysis: type of P2Y12 inhibitor had no apparent effect - ischaemic outcomes stratified by type of qualifying disease were consistent with the primary analysis - meta-regression analysis did not show any significant interaction between qualifying disease and treatment effects <p>authors conclusion/discussion</p> <ul style="list-style-type: none"> - P2Y12 inhibitor monotherapy vs. ASS monotherapy: associated with comparable risks of all-cause death, vascular death, and stroke, and a marginal risk reduction for myocardial infarction in the setting of secondary prevention - high number needed to treat and the absence of any major effect on death questions the clinical relevance of the marginally lower risk of myocardial infarction observed with P2Y12 inhibitors compared with ASS | | over clopidogrel or others for secondary prevention (cardiovascular and cerebrovascular) an clopidogrel for PAD profound platelet inhibition with dual antiplatelet therapy (independent mechanisms for platelet activation) has been shown to reduce the risk of ischaemic events, but at the cost of an increase in the risk of major bleeding – ASS + P2Y12 inhibitors |

Yuan et al. 2019 Clopidogrel oder ASS - Monotherapie (SR, Sekundärprävention, stabile CAD)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Yuan J. Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. Adv Ther 2019; 36(8):2062–71. https://www.ncbi.nlm.nih.gov/pub-med/31154631. [55]</p> | <p>Objective to systematically compare ASS versus clopidogrel monotherapy for the treatment of patients with stable coronary artery disease (CAD)</p> <p>Methods</p> <ul style="list-style-type: none"> - Cochrane Central, EMBASE, MEDLINE, Google Scholar - PRISMA guideline - monotherapy - patients with CAD - patients with cardiovascular disease - patients with percutaneous coronary intervention <p>Intervention clopidogrel monotherapy</p> <p>Comperator ASS monotherapy</p> <p>Quality assessment Cochrane Collaboration for the randomized controlled trials Newcastle–Ottawa Scale (NOS) for the observational studies</p> <p>Outcomes</p> <ul style="list-style-type: none"> - composite outcomes: combination of cardiovascular death, myocardial infarction (MI), and stroke - all-cause mortality - cardiac death | <p>n = 3 studies (CAPRIE, CORONOR, Park et al. 2016)</p> <ul style="list-style-type: none"> - n = 2 observational studies - n = 1 sub-study of a RCT - n = 5 497 ASS - n = 2 544 clopidogrel - mean age 62 to 68.2 years - men 72-78% - comorbidities: hypertension (51-65%), dyslipidemia 28-41%, diabetes mellitus (20-42%), and smoking (11-30%) <p>results clopidogrel vs. ASS (follow-up 2-3 years) composite endpoint</p> <ul style="list-style-type: none"> - 65/1544 vs. 179/4497 - OR 0.99 [0.47–2.10] p=0.98, n = 2 studies <p>all-cause death</p> <ul style="list-style-type: none"> - 104/2544 vs. 226/5497 - OR 1.05 [0.82–1.33] p=0.71, n = 3 studies <p>cardiac death</p> <ul style="list-style-type: none"> - 28/1544 vs. 68/4497 - OR 0.89 [0.17–4.74] p=0.89, n = 2 studies <p>myocardial infarction</p> <ul style="list-style-type: none"> - 22/1544 vs. 74/4497 - OR 0.84 [0.52–1.36] p=0.48, n = 2 studies <p>stroke</p> <ul style="list-style-type: none"> - 22/1544 vs. 56/4497 - OR 1.26 [0.39–4.06] p=0.70, n = 2 studies <p>BARC-defined bleeding</p> <ul style="list-style-type: none"> - 22/1544 vs. 52/4497 - OR 1.28 [0.78–2.12] p=0.33, n = 2 studies | <p>AMSTAR-II moderate</p> <p>moderate risk of bias (RCT), low bias risk (observational studies)</p> <p>sensitivity analyses were carried out</p> <p>funnel plot: there was little to moderate evidence of publication bias</p> <p>limitations (authors note) total number of participants was not sufficient to reach a significant conclusion</p> <p>other bleeding outcomes and stent thrombosis were unfortunately not assessed</p> | <p>authors noted that guidelines recommend treatment with DAPT (ass + clopidogrel) following coronary angioplasty with DES</p> <p>clopidogrel is used for only 6 months to 1 year, whereas aspirin is continually used throughout</p> <p>in CAD patients with high risk of bleeding, the use of clopidogrel is a relative contraindication</p> <p>ASA is used as a single antiplatelet agent</p> <p>patients with chronic gastritis, especially nonsteroidal anti-inflammatory drug-induced gastritis, ASA is often avoided, and therefore, those patients rely only on clopidogrel as a single antiplatelet drug</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - myocardial infarction - stroke - bleeding (BARC grade 3 or above) mean follow-up period ranging from 2 to 3 years | | | |

Kang et al. 2023 ASS vs. Clopidogrel Monotherapie (RCT-Kohorte, nach 12 Monaten dualer Therapie, nach PCI, 5 Jahres-Daten)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kang J. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. Circulation 2023; 147(2):108–17. https://www.ncbi.nlm.nih.gov/pub-med/36342475 . [56] | <p>Objective</p> to perform a posttrial extended follow-up of the patients enrolled in the HOST-EXAM trial to compare the longer-term outcomes between clopidogrel and ASS monotherapy | n = 5 438 patients <ul style="list-style-type: none"> - event-free for 6 to 18 months after PCI and duale therapy between 2014 and 2018 - n = 9 patients of the total population withdrew - n = 618 used different antiplatelet regimen - n = 94 lost to follow up - PP (per protocol): <ul style="list-style-type: none"> o n = 4717 patients o n = 2431 patients (clopidogrel) o n = 2286 patients (ASS) - median follow-up: 5.8 years (interquartile range, 4.8–6.2 years) - mean age 63.3±10.7 years - 69.5-70.6% dyslipedemia - 61.4% hypertension - 33.8% diabetes mellitus - 12.4% chronic kidney disease - 71.9% ACS as clinical diagnosis at the time of PCI - discontinuation rate: <ul style="list-style-type: none"> o clopidogrel 8.0% [216 of 2648 patients] o ASS 13.5% [367 of 2710 patients]; P<0.001 <p>Results</p> primary (Clopidogrel vs. ASS) composite <ul style="list-style-type: none"> - n = 311 (12.8%) vs. n = 387 (16.9%) - hazard ratio, 0.74 (95% CI, 0.63–0.86); P<0.001 | n. a. extended follow-up of a randomized clinical trial (open-label) per protocol analysis was performed authors noted that the trial was not powered to evaluate the impact of antiplatelet therapy on mortality | authors noted that because the original HOST-EXAM trial mandated the allocated antiplatelet therapy up to 24 months after enrollment, the posttrial follow-up antiplatelet prescription was at the discretion of the treating physician hypothesis was superiority of clopidogrel as long-term maintenance monotherapy agent (no additional sample size calculation was performed after termination of the original study) analyses of the 5 year follow-up; continuing follow-up for up to 10 years |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - randomized after termination of the original study <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - patients ≥ 20 years - underwent PCI with drug-eluting stents - maintained dual antiplatelet therapy without any clinical events during 12±6 months after PCI - no restriction on the clinical diagnosis at the index PCI period, stenosis location, length, or number of lesions/vessels at the time of PCI <p>Intervention clopidogrel monotherapy* (75 mg once daily)</p> <p>Comperator ASS monotherapy* (100 mg once daily)</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - composite of all-cause death, nonfatal MI, stroke, readmission attributable to ACS, and major bleeding complications (defined as Bleeding Academic Research Consortium (BARC) type 3 or greater bleeding) <p>secondary</p> | <ul style="list-style-type: none"> - absolute risk reduction 4.1% (95% CI, 2.1%–6.2%) - number needed to treat 24 <p>secondary thrombotic composite</p> <ul style="list-style-type: none"> - n = 196 patients (8.1%) vs. n = 273 (11.9%) - HR, 0.66 [95% CI, 0.55–0.79]; P<0.001 <p>any bleeding (BARC type 2 or greater)</p> <ul style="list-style-type: none"> - n = 110 patients (4.5%) vs. n = 140 patients (6.1%) - HR, 0.74 [95% CI, 0.57–0.94]; P=0.016 <p>all-cause death</p> <ul style="list-style-type: none"> - n = 150 (6.2%) vs. n = 136 (6.0%) - HR 1.04 (95% CI, 0.82–1.31); P=0.742 <p>cardiovascular death</p> <ul style="list-style-type: none"> - n = 69 (2.8) vs. n = 71 (3.1) - HR 0.92 (0.66–1.28), P= 0.602 <p>nonfatal MI</p> <ul style="list-style-type: none"> - n = 40 (1.6) vs. n = 53 (2.3) - HR 0.71 (0.47–1.07), P= 0.102 <p>Stroke</p> <ul style="list-style-type: none"> - n = 37 (1.5) vs. n = 66 (2.9) - HR 0.53 (0.35–0.79), P= 0.002 <p>Ischemic stroke</p> <ul style="list-style-type: none"> - n = 27 (1.1) vs. n = 42 (1.8) - HR 0.61 (0.37–0.98), P=0.041 <p>Hemorrhagic stroke</p> <ul style="list-style-type: none"> - n = 10 (0.4) vs. n = 24 (1.1) - HR 0.39 (0.19–0.82), P=0.013 <p>Readmission attributable to ACS</p> <ul style="list-style-type: none"> - n = 111 (4.6) vs. n = 176 (7.7) - HR 0.59 (0.47–0.75), p <0.001 <p>Major bleeding (BARC type 3 or greater)</p> <ul style="list-style-type: none"> - n = 62 (2.6) vs. n = 90 (3.9) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - composite end points included the thrombotic composite end point (defined as cardiac death, nonfatal MI, ischemic stroke, readmission attributable to ACS, and definite or probable stent thrombosis) and any bleeding (defined as BARC type 2 or greater bleeding) <p><i>note:</i> methods described in: Lee et al; HOST-EXAM Investigators. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial. Am Heart J. 2017;185:17–25. doi: 10.1016/j.ahj.2016.12.001</p> <p>HOST-EXAM Extended study had a separate study protocol, approved by the institutional review board</p> | <ul style="list-style-type: none"> - HR 0.65 (0.47–0.90), p=0.008 <p>Any revascularization</p> <ul style="list-style-type: none"> - n = 129 (5.3) vs. n = 157 (6.9) - HR 0.77 (0.61–0.98), p = 0.030 <p>Target lesion revascularization</p> <ul style="list-style-type: none"> - n = 53 (2.2) vs. n = 68 (3.0) - HR 0.73 (0.51–1.05), p=0.089 <p>Target vessel revascularization</p> <ul style="list-style-type: none"> - n = 76 (3.1) vs. n = 98 (4.3) - HR 0.73 (0.54–0.98), p = 0.039 <p>Definite or probable stent thrombosis</p> <ul style="list-style-type: none"> - n = 12 (0.5) vs. n = 17 (0.7) - HR 0.67 (0.32–1.39), p=0.280 <p>analysis at 2 years showed consistent effects throughout the follow-up period</p> | | |

Rhee et al. 2023 ASS vs. Clopidogrel Monotherapie (RCT-Kohorte, nach 12 Monaten dualer Therapie, nach PCI, Diabetes mellitus, post-hoc Analyse, 2 Jahre)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| <p>Rhee T-M. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. JAMA Cardiol 2023; 8(6):535–44. https://www.ncbi.nlm.nih.gov/pub-med/37043192. [57]</p> | <p>Objective post hoc subgroup analysis of HOST-EXAM trial sought to investigate the association of diabetes with the risk of clinical outcomes at 24 months and compare outcomes between clopidogrel and ASS monotherapy</p> <p>Methods</p> <ul style="list-style-type: none"> - HOST-EXAM trial was an investigator-initiated, prospective, randomized controlled trial - open-label, Korea <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> - patients maintained DAPT without clinical events for 6 to 18 months after PCI (drug-eluting stents) - enrolled between March 2014 to May 2018 - presence of diabetes (treatment or diagnosis) <p>Intervention clopidogrel monotherapy for 24 months</p> <p>Comperator ASS monotherapy for 24 months</p> <p>Outcome primary</p> | <p>at 24 months follow-up n = 5438 patients</p> <ul style="list-style-type: none"> - mean age 63,5 years - n = 2661 patients (clopidogrel) vs. n = 2677 (ASS) - without diabetes: n = 1785 vs. 1793 - with diabetes: n = 1860 (34.2%) <ul style="list-style-type: none"> o n = 925 (clopidogrel) vs. n = 935 (ASS) o balanced for baseline characteristics, excepted previous stroke (numerically higher in ASS arm) o patients with comorbidities more prevalent in patients with diabetes compared with the no diabetes group o patients with diabetes had higher proportion of 3-vessel disease <p>Results</p> <p>patients with diabetes (clopidogrel vs. ASS)</p> <p>primary at 24 months (composite)</p> <ul style="list-style-type: none"> - n = 53 (6.3%) vs. n = 84 (9.2%) - HR 0.69 (95% CI 0.49; 0.96), P=0.03 - Absolute risk difference (ARD) 2.7 - Number needed to treat (NNT) 37 <p>secondary at 24 months thrombotic composite</p> <ul style="list-style-type: none"> - n = 36 (4.0%) vs. n = 53 (5.8%) - HR 0.68 (95% CI 0.45; 1.04), P=0.07 <p>any bleeding</p> <ul style="list-style-type: none"> - n = 24 (2.7%) vs. n = 37 (4.1%) - HR 0.65 (95% CI 0.39; 1.09), P=0,11 <p>major cardiovascular events</p> <ul style="list-style-type: none"> - n = 28 (3.1%) vs. n = 50 (5.4%) - HR 0.56 (95% CI 0.35; 0.89), p=0.01 <p>patients without diabetes (clopidogrel vs. ASS)</p> | <p>n. a.</p> <p>Limitations (authors note):</p> <ul style="list-style-type: none"> - open-label design - randomization was not stratified for diabetes status - lower-than-expected event rates (limited statistical power) - correction for multiple testing was not performed - population (performed solely in a Korean population) | <p>post hoc analysis of HOST-EXAM trial</p> <p>authors interpreted results as hypothesis generating at best</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>composite of all-cause death, nonfatal MI, stroke, readmission attributable to ACS, and major bleeding complications (defined as Bleeding Academic Research Consortium (BARC) type 3 or greater bleeding)</p> <p>secondary</p> <ul style="list-style-type: none"> - composite end points included the thrombotic composite end point (defined as cardiac death, nonfatal MI, ischemic stroke, readmission attributable to ACS, and definite or probable stent thrombosis) and any bleeding (defined as BARC type 2 or greater bleeding) <p>protocol was presented within the supplements; protocol of the original study was published previously</p> | <p>primary at 24 months</p> <ul style="list-style-type: none"> - n = 94 (5.3%) vs. n = 123 (7.0%) - HR 0.76 (95% CI 0.58; 1.00), P=0.046 - ARD 1.6% - NNT 63 <p>secondary at 24 months</p> <p>thrombotic composite</p> <ul style="list-style-type: none"> - n = 63 (3.6%) vs. n = 93 (5.3%) - HR 0.68 (95% CI 0.49; 0.93), P=0.02 <p>any bleeding</p> <ul style="list-style-type: none"> - n = 37 (2.1%) vs. n = 50 (2.8%) - HR 0.74 (95% CI 0.48; 1.13), P=0.17 <p>major cardiovascular events</p> <ul style="list-style-type: none"> - n = 55 (3.1%) vs. n = 53 (3.0%) - HR 1.04 (95% CI 0.72; 1.52), P=0.83 <p>predictors of the primary composite end point:</p> <ul style="list-style-type: none"> - increasing age - ASS monotherapy - in patients with diabetes also HDL cholesterol level less than 40 mg/dL - in patients without diabetes male sex <p>components of the composite see Table 2 page 540 within the publication</p> | | |

Koo et al. 2021 ASS vs. Clopidogrel Monotherapie (RCT-Kohorte, nach 12 Monaten dualer Therapie, nach PCI, 2-Jahresdaten)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Koo B-K. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021; | <p>Objective</p> <p>to compare head to head the efficacy and safety of aspirin and clopidogrel monotherapy in patients who received PCI for coronary artery disease and required chronic maintenance antiplatelet therapy</p> | <p>n = 5438 patients</p> <ul style="list-style-type: none"> - clopidogrel group (2710 [49.8%]) - aspirin group (2728 [50.2%]) - mean age 63 years - male 75 % - hypertension 61 % - dyslipidemia 69% | <p>Selection bias</p> <p>randomization: low</p> <p>concealment and unpredictability: low</p> <p>Performance bias</p> | <p>authors noted that standard therapy after PCI is dual antiplatelet therapy for 6–12 months followed by</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 397(10293):2487–96. https://www.ncbi.nlm.nih.gov/pub-med/34010616 . [58] | <p>Methods</p> <ul style="list-style-type: none"> - investigator-initiated, prospective, randomised, open-label, multicentre trial at 37 study sites in South Korea - registered with ClinicalTrials.gov, NCT02044250 - HOST-EXtended Antiplatelet Monotherapy (HOST-EXAM) trial - trial protocol was approved by the institutional review board - patients aged at least 20 years - maintained dual antiplatelet therapy without clinical events for 6–18 months after percutaneous coronary intervention with drug-eluting stents (DES) - patients with any ischaemic and major bleeding complications were excluded - patients with known hypersensitivity or contraindications for clopidogrel were excluded <p>Intervention clopidogrel 75 mg once daily (monotherapy)⁹</p> | <ul style="list-style-type: none"> - previous myocardial infarction 16% - 50% one vessel disease - 18% three vessel disease - days from PCI to randomisation 383 vs. 380 - 97% second generation DES (drug-eluting stent) - DAPT at randomization: <ul style="list-style-type: none"> o ASS + clopidogrel ~ 82% o ASS + ticagrelor ~ 10% o ASS + prasugrel ~ 8% - completed 24-months follow-up: <ul style="list-style-type: none"> o n = 2661 vs. n = 2677 o ITT and PP analyses o n = 91 (1.7%) patients lost to follow-up <p>results</p> <p>primary clopidogrel vs. ASS (completed in 5338 (98.2%) patients during 24-month composite)</p> <ul style="list-style-type: none"> - 152 (5.7%) 207 (7.7%) - HR 0.73 (0.59–0.90) p=0.003 - NNT 51 <p>thrombotic composite</p> <ul style="list-style-type: none"> - 99 (3.7%) 146 (5.5%) - HR 0.68 (0.52–0.87) p=0.003 - NNT 59 <p>any bleeding (BARC type ≥2)</p> <ul style="list-style-type: none"> - 61 (2.3%) 87 (3.3%) - HR 0.70 (0.51–0.98) p=0.036 - NNT 111 <p>all-cause death</p> <ul style="list-style-type: none"> - 51 (1.9%) 36 (1.3%) - HR 1.43 (0.93–2.19) p=0.101 <p>cardiac death</p> <ul style="list-style-type: none"> - 19 (0.7%) 14 (0.5%) | <p>blinding of participants and staff: high (open-label; participants and study investigators not masked to the assigned group)</p> <p>Detection bias blinding of evaluation: high (open-label; participants and study investigators not masked to the assigned group)</p> <p>Attrition bias lost to follow-up: low ITT-analysis: low</p> <p>Reporting bias selective result presentation: low</p> <p>open-label design (all endpoints had a standardised definition and were specifically adjudicated by an independent committee that was unaware of the treatment group)</p> <p>funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report</p> <p>observed event rate of the primary endpoint was lower than what was anticipated in the sample size calcu-</p> | <p>indefinite duration of antiplatelet monotherapy with ASS as recommendation of choice and clopidogrel as alternative in patients who do not tolerate ASS</p> <p>previous identified studies (n = 2, CAPRIE, ASCET) were neither done in a dedicated percutaneous coronary intervention population nor done in the contemporary drug-eluting stent era</p> |

⁹when patients previously using potent P2Y12 inhibitors were randomly assigned to the clopidogrel group, clopidogrel 600 mg loading was recommended for ticagrelor users, while prasugrel users switched to clopidogrel 75 mg without a loading dose

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | <p>Comperator ASS 100 mg once daily (monotherapy) for 24 months</p> <p>Outcomes superiory analyses primary - composite of all-cause death, non-fatal myocardial infarction, stroke, re-admission due to acute coronary syndrome, and Bleeding Academic Research Consortium (BARC) bleeding type 3 or greater secondary individual components of the primary endpoint, revascularisation, and minor gastrointestinal complications post-hoc secondary thrombotic composite (defined as cardiac death, non-fatal myocardial infarction, ischaemic stroke, readmission due to acute coronary syndrome, and definite or probable stent thrombosis) and any bleeding (defined as BARC type ≥ 2 bleeding)</p> | <p>- HR 1.37 (0.69–2.73) p=0.374 non-cardiac death - 32 (1.2%) 22 (0.8%) - HR 1.47 (0.85–2.52) p=0.167 non-fatal myocardial infarction - 18 (0.7%) 28 (1.0%) - HR 0.65 (0.36–1.17) p=0.150 stroke - 18 (0.7%) 43 (1.6%) - HR 0.42 (0.24–0.73) p=0.002 ischaemic stroke - 14 (0.5%) 26 (1.0%) - HR 0.54 (0.28–1.04) p=0.064 haemorrhagic stroke - 4 (0.2%) 17 (0.6%) - HR 0.24 (0.08–0.70) p=0.010 readmission due to ACS - 66 (2.5%) 109 (4.1%) - HR 0.61 (0.45–0.82) p=0.001 major bleeding (BARC type ≥ 3) - 33 (1.2%) 53 (2.0%) - HR 0.63 (0.41–0.97) p=0.035 any revascularisation - 56 (2.1%) 69 (2.6%) - HR 0.82 (0.57–1.16) p=0.261 target lesion revascularisation - 24 (0.9%) 36 (1.4%) - HR 0.67 (0.40–1.12) p=0.130 target vessel revascularisation - 37 (1.4%) 48 (1.8%) - HR 0.78 (0.50–1.19) p=0.245 definite or probable stent thrombosis - 10 (0.4%) 16 (0.6%) - HR 0.63 (0.29–1.39) p=0.251 any minor gastrointestinal complications¹⁰</p> | <p>lation, suggesting a possibility of selection bias or under-reporting of events and possible type II error (false-negative results)</p> <p>prespecified subgroup analyses</p> <p>secondary endpoints were not adjusted for multiple testing</p> <p>follow-up duration of 24 months might be too short to give a concrete conclusion, considering the fact that maintenance antiplatelet therapy is administered indefinitely (extended study up to 10 years)</p> <p>study was done in an east Asian population who are known to have lower rates of thrombotic events compared with those of White people (limit the generalisability)</p> <p>50–60% of the east Asian population carry loss-of-function mutations of the CYP2C19 gene causing an attenuated antiplatelet effect of clopidogrel</p> | |

¹⁰ such as epigastric soreness, dyspepsia, abdominal pain, nausea, vomiting, diarrhoea, constipation, melena, or haematochezia

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - 272 (10·2%) 320 (11·9%) - HR0·85 (0·72–1·00) p=0·048 <p>no statistically significant interaction for various subgroups</p> | | |

12.5.3 Empfehlung 7-5 duale Therapie nach invasiven Verfahren (zwei Thrombozytenaggregationshemmer; in Bezug auf die Therapiedauer)

Costa et al. 2023 Dauer einer dualen Therapie (SR/MA, Thrombozytenaggregation, nach PCI, hohes Blutungsrisiko)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Costa F. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials. Eur Heart J 2023; 44(11):954–68. https://www.ncbi.nlm.nih.gov/pub-med/36477292. [59]</p> | <p>Objective to estimate the impact of an abbreviated DAPT (≤3 months) compared with standard DAPT (≥6 months) after PCI in HBR patients, using the totality of available evidence from randomized clinical trials (RCTs)</p> <p>HBR = high bleeding risk</p> <p>to provide a homogenized definition for HBR patients, this was set in all studies according to a PD (PRECISE-DAPT) score ≥25, in keeping with current guideline recommendations</p> <p>Methods</p> <ul style="list-style-type: none"> - PRISMA and MOOSE guidance - registered in PROSPERO (CRD42021284004) - searched PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register | <p>n = 11 RCT (RESET, OPTIMIZE, GLOBAL LEADERS, GLASSY, REDUCE, SMART CHOICE, STOPDAPT-2, TWILIGHT, TICO, ONE-MONTH DAPT, STOPDAPT-2-ACS, MASTER-DAPT) (n = 9006 patients with high bleeding risk, undergoing PCI with coronary stenting)</p> <ul style="list-style-type: none"> - abbreviated DAPT, n = 4476 <ul style="list-style-type: none"> o ASS + clopidogrel, ticagrelor, or prasugrel (P2Y₁₂-inhibitor) followed by ASS (n = 6 studies) o ASS + clopidogrel, ticagrelor, or prasugrel (P2Y₁₂-inhibitor) followed by P2Y₁₂-inhibitor (n = 5 studies) - standard DAPT, n = 4530 - abbreviated DAPT 1-3 months - standard DAPT 6-12 months - mean age 70.7 – 80 years - women: 40% - ASC: 32 – 100 % (mean 58 %) - stable 35 – 68 % - hypertension 67 – 91.6 % - dyslipidemia 45 – 83 % - previous myocardial infarction 2.4 – 29 % - DES was used in all patients - multi vessel disease 26% - DAPT at discharge: <ul style="list-style-type: none"> o ASS 95 – 100 % | <p>AMSTAR-II low</p> <p>(keine Liste der ausgeschlossenen Volltexte mit Ausschlussgrund vorhanden), <i>Hinweis</i>: Supplement ist leider nur als Word-Dokument verfügbar (docx), daher aktuell nicht einsehbar</p> <p>ad-hoc and post-hoc subgroup analyses were performed</p> <p>sensitivity analyses were presented</p> <p>authors noted that study quality was high, with blinded adjudication of events by an independent clinical event committee assuring a low probability of performance bias</p> <p>Limitations (authors note)</p> <p>abbreviated DAPT entailed different types of single antiplatelet therapy upon DAPT withdrawal (i.e. aspirin, clopidogrel, prasugrel, or ticagrelor</p> | <p>„graphical abstract“ vorhanden</p> <p>authors noted that current guidelines recommend 3 or 6 months of DAPT in high bleeding risk patients undergoing PCI for ACS or CCS or shorter treatment, based on consensus opinion</p> <p>authors noted that patients on OAC were excluded from the analysis despite being a recognized HBR criterion; concurrent treatment with OAC is frequent, presenting in up to 10% of patients undergoing PCI, OAC per se is different from other HBR criteria</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>of Controlled Trials (articles published between 1 January 2000 and 31 October 2021), reference lists</p> <ul style="list-style-type: none"> - RCT - PCI for ACS or CCS - patients after PCI - minimum follow-up of 12 months - patients treated with oral anticoagulants (OAC) were excluded (for those that recruited patients with and without OAC, outcome data were selectively extracted) - events occurring during study phases investigating other treatment strategies than a DAPT duration comparison were censored <p>Quality assessment RoB-2 tool</p> <p>Intervention</p> <ul style="list-style-type: none"> - DAPT (dual antiplatelet therapy), abbreviated (≤ 3 months) <p>Comperator</p> <ul style="list-style-type: none"> - DAPT, standard (≥ 6 months) DAPT duration <p>Outcomes co-primary safety and efficacy endpoints</p> | <ul style="list-style-type: none"> o clopidogrel 42 – 100 % o ticagrelor 0 – 100 % o prasugrel 0 – 13 % <ul style="list-style-type: none"> - alternative definition for HBR: in n = 7/11 RCT <ul style="list-style-type: none"> o n = 6545 HBR patients <ul style="list-style-type: none"> ▪ abbreviated DAPT, n = 3212 ▪ standard DAPT, n = 3333 <p>main results abbreviated DAPT vs. standard DAPT</p> <p>major or clinically relevant non-major bleeding</p> <ul style="list-style-type: none"> - RR 0.76 (95% CI 0.61; 0.94), n = 11 studies <p>major bleeding</p> <ul style="list-style-type: none"> - RR 0.80 (95% CI 0.64; 0.99), n = 11 studies <p>major adverse cardiovascular events 1</p> <ul style="list-style-type: none"> - RR 0.97 (95% CI 0.74; 1.26), n = 11 studies <p>major adverse cardiovascular events 2</p> <ul style="list-style-type: none"> - RR 0.92 (95% CI 0.77; 1.10), n = 11 studies <p>net adverse clinical events</p> <ul style="list-style-type: none"> - RR 0.94 (95% CI 0.78; 1.14) <p>all-cause death</p> <ul style="list-style-type: none"> - RR 0.91 (95% CI 0.68; 1.23), n = 11 studies <p>cardiovascular death</p> <ul style="list-style-type: none"> - RR 0.79 (95% CI 0.65; 0.95), n = 11 studies <p>myocardial infarction</p> <ul style="list-style-type: none"> - RR 0.84 (95% CI 0.51; 1.38) <p>stroke</p> <ul style="list-style-type: none"> - RR 1.15 (95% CI 0.84; 1.60) <p>definite stent thrombosis</p> <ul style="list-style-type: none"> - RR 0.73 (95% CI 0.35; 1.50) <p>definite or probable stent thrombosis</p> <ul style="list-style-type: none"> - RR 0.84 (95% CI 0.58; 1.20) <p>fatal bleeding</p> <ul style="list-style-type: none"> - RR 0.63 (95% CI 0.24; 1.70) | <p>monotherapy), which in some instances were based on physician preference</p> <p>risk of unmeasured confounding was reported</p> <p>specific HBR features (e.g. history of prior intracranial bleeding, recent prior stroke, active bleeding, or bleeding within 1–2 months of study inclusion) were exclusion criteria in many of the included studies</p> <p>RCT tend to select a lower-risk population compared with real-world patients</p> | <p>OAC drives a higher risk for bleeding due to its biological effect on systemic coagulation, but it also affects the ischaemic risk, reducing the risk of stent-related and non-stent related ischaemic events</p> <p>(European guidelines peri-procedural treatment with DAPT followed immediately after by P2Y12 inhibitor monotherapy is recommended for OAC patients whereas such an approach has not been tested in randomized studies in patients without indication for OAC)</p> <p>(PCI patients generally are treated with single antiplatelet therapy indefinitely after stenting, lifelong antiplatelet therapy is not recommended in most OAC patients due to the HBR from this combination)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - major or clinically relevant non-major bleeding (MCRB) and - major adverse cardiovascular events (MACE) - up to 12 months after PCI <p>two different composite endpoints of MACE for all-cause death, myocardial infarction (MI) or stroke (i.e. MACE 1), and cardiovascular (CV) death, MI, or stroke (i.e. MACE 2)</p> <p>other safety endpoints of major bleeding (MB) as per the study definition as well as individual endpoints according to the Bleeding Academic Research Consortium (BARC) and thrombolysis in MI bleeding definitions</p> <p>other efficacy endpoints, including Net Adverse Clinical Events (NACE), all-cause death, CV death, MI, stroke, and stent thrombosis,</p> | <p>(results for sensitivity analyses see Supplementary material online, Figs S2 and S3: results were consistent when using the TIMI or BARC bleeding definitions)</p> <p>(funnel plots for bleeding endpoints ect. are presented in Supplementary material online, Figure S4A and B, C and D and S5)</p> <p>results of subgroup analyses</p> <p>clinical presentation at time of PCI (ACS or CCS) abbreviated DAPT vs. standard DAPT</p> <p>MCRB (p=0.62)</p> <ul style="list-style-type: none"> - ACS 0.79 (0.55; 1.13) - CCS 0.87 (0.68; 1.10) <p>MB (p= 0.17)</p> <ul style="list-style-type: none"> - ACS 0.76 (0.52; 1.10) - CCS 1.08 (0.71; 1.60) <p>MACE 1 (p=0.70)</p> <ul style="list-style-type: none"> - ACS 1.01 (0.78; 1.33) - CCS 0.94 (0.68; 1.31) <p>MACE 2 (p=0.91)</p> <ul style="list-style-type: none"> - ACS 0.93 (0.76; 1.14) - CCS 0.91 (0.66; 1.22) <p>NACE (p=0.91)</p> <ul style="list-style-type: none"> - ACS 0.97 (0.75; 1.30) - CCS 0.99 (0.70; 1.40) <p>death (p=0.76)</p> <ul style="list-style-type: none"> - ACS 0.96 (0.69; 1.40) - CCS 0.90 (0.60; 1.40) <p>CV death (p=0.97)</p> <ul style="list-style-type: none"> - ACS 0.88 (0.64; 1.20) - CCS 0.87 (0.57; 1.30) <p>(Figure 5)</p> <p>type of antiplatelet therapy continuation after short DAPT discontinuation (continued aspirin or a P2Y12 inhibitor after DAPT discontinuation) abbreviated DAPT vs. standard DAPT</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>MCRB (p=0.43) MB (p=0.83) MACE 1 (p=0.55) MACE 2 (p=0.59) other explored endpoints (see Supplementary material online, Figure S7)</p> <p><i>type of DES implanted</i> abbreviated DAPT vs. standard DAPT MCRB (p=0.06) MB (p=0.02) MACE 1 (p=0.12) all-cause mortality (pint= 0.08) MACE 2 (p=0.23) CV mortality (p=0.85) (see Supplementary material online, Figure S8)</p> <p>authors noted: main findings:</p> <ul style="list-style-type: none"> (i) abbreviated DAPT for 1 or 3 months was associated with lower MCRB, MB and CV mortality compared with standard DAPT in HBR patients treated with PCI; (ii) abbreviated DAPT was similarly effective compared with standard DAPT for the prevention of MACE, stent thrombosis, and other ischaemic events, irrespective of clinical presentation and type of antiplatelet agent administered after short DAPT discontinuation; (iii) these findings remained consistent irrespective of the HBR definition, either based on PD score or the ARC-HBR framework, as endorsed by guidelines (Structured Graphical Abstract) | | |

Gelbenegger et al. 2021 optimale Dauer und Therapie (SR/MA, Thrombozytenaggregation, nach PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Gelbenegger G. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A meta-analysis. <i>Vascul Pharmacol</i> 2021; 138:106858. https://www.ncbi.nlm.nih.gov/pub-med/33753284. [60]</p> | <p>Objective to compare very short-term (1–3 months), short-term (6 months), standard-term (12 months) and long-term (>12 months) DAPT durations for efficacy and safety</p> <p>Methods</p> <ul style="list-style-type: none"> - Systematic review, meta-analysis - PRISMA - PROSPERO registration no: CRD42020163719 - search until Dec 2019 - RCT - Comparing different DAPT durations - details available within an online appendix <p>Comparison different durations of DAPT were categorized into:</p> <ul style="list-style-type: none"> - very short-term (1-3 months) - short-term (6 months) - standard-term (12 months) - long-term (> 12 months) <p>due to the large heterogeneity of compared DAPT durations in the studies, DAPT comparisons in the overall analysis were termed “any longer-term” DAPT and “any shorter-term” DAPT</p> <p>Outcomes primary</p> | <p>n = 26 studies (n = 103.394 patients)</p> <ul style="list-style-type: none"> - all except for one study exclusively included patients who had undergone placement of a drug-eluting stent (DES) - n = 13 studies DAPT with clopidogrel - n = 10 studies DAPT with P2Y₁₂-inhibitor - n = 3 studies with ticagrelor - n = 5 studies with a concept of monotherapy with P2Y₁₂-inhibitor - details are available within an online supplement <p>results longer DAPT vs. shorter DAPT (standard DAPT vs. early drop of ASS or P2Y₁₂-I, followed by monotherapy of P2Y₁₂-I or ASS)</p> <p>MACE according to treatment regimen standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - n = 657/16088 vs. n = 616/16057 - RR 1.06 (0.95; 1.18), p = 0.26, n = 5 studies <p>any longer-term DAPT vs. early drop of P2Y₁₂ inhibitor (short-term DAPT, 6 months), followed by ASS monotherapy</p> <ul style="list-style-type: none"> - n = 1 885/39222 vs. n = 1 599/32027 - RR 0.88 (0.81; 0.96), p = 0.002, n = 21 studies <p>MACE according to P2Y12-inhibitor long-term DAPT (> 12 months, prasugrel or ticagrelor) vs. standard-term DAPT (12 months)</p> <ul style="list-style-type: none"> - RR 0.76, 95% CI, 0.63–0.93, p = 0.007, n = 3 studies - prasugrel: RRR 48% (95% CI, 0.38–0.71) - ticagrelor: RRR 16% (95% CI, 0.77–0.92) <p>long-term DAPT (> 12 months, clopidogrel) vs. standard-term DAPT (12 months)</p> | <p>AMSTAR-II critically low</p> <p>(u. a. keine Liste der ausgeschlossenen Volltexte mit Ausschlussgrund vorhanden, keine Risk-of-Bias Bewertung beschrieben und auch keine Berücksichtigung bei der Analyse und Diskussion der Ergebnisse, die Untersuchung eines Publication Bias wurde nicht beschrieben), <i>Hinweis:</i> Supplement ist leider nur als Word-Dokument verfügbar (docx), daher aktuell nicht einsehbar</p> <p>sensitivity and subgroup analyses were performed</p> <p>large sample size</p> <p>several studies did not report on outcomes of interest</p> <p>three different bleeding definitions were used in the trials</p> <p>analysis may be underpowered for individual adverse cardiovascular events, especially in subgroup analyses on specific DAPT durations, types of antiplatelet agent and clinical presentations</p> | <p>authors noted that:</p> <p>long-term DAPT with prasugrel or ticagrelor suggested for patients with high ischemic and low bleeding risk</p> <p>long-term DAPT with prasugrel or ticagrelor suggested for ACS patients with high ischemic and low bleeding risk</p> <p>very short term DAPT followed by drop of ASS or P2Y12-inhibitors suggested for patients with high bleeding and low ischemic risk</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - MACE (the composite of myocardial infarction, stroke and cardiovascular death) - Major bleeding <p>secondary</p> <ul style="list-style-type: none"> - myocardial infarction - stroke - all-cause death - cardiovascular death - stent thrombosis (definite and probable) <p>details on study outcome and definitins are available within an online appendix</p> | <ul style="list-style-type: none"> - RR 0.91, 95% CI, 0.71–1.17, p = 0.47, n = 5 studies <p>MACE according to ACS any longer-term DAPT (prasugrel, ticagrelor) vs. any shorter-term DAPT</p> <ul style="list-style-type: none"> - RR 0.84, 95% CI, 0.77–0.92, p = 0.0001, n = 3 studies - RRR 16% <p>any longer-term DAPT (clopidogrel) vs. any shorter-term DAPT</p> <ul style="list-style-type: none"> - RR 1.04, 95% CI, 0.89–1.20, p = 0.64, n = 8 studies <p>TIMI major bleeding any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - n = 433/30773 vs. n = 167/23693 - RR 1.85 (1.54; 2.22), p < 0.00001, n = 15 studies <p>BARC 3-5 major bleeding any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - n = 595/28378 vs. n = 409/28219 - RR 1.54 (1.21; 1.97), p = 0.0005, n = 13 studies <p>BARC 3-5 major bleeding according to treatment regimen drop of ass standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - n = 279/14559 vs. 217/14530 - RR 1.61 (0.96; 2.71), p = 0.07, n = 4 studies <p>drop of P2Y₁₂-I any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - n = 287/13092 vs. n = 168/12956 - RR 1.63 (1.22; 2.17), p = 0.001 n = 8 studies | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>myocardial infarction (overall) any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - RR 0.84, 95% CI, 0.73–0.95, p = 0.008 - RRR 16% - detail available within an online supplement <p>myocardial infarction according to treatment regimen drop of ASS standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - n = 384/16088 vs. n = 373/16057 - RR 1.03 (0.89; 1.18), p = 0.72, n = 5 studies <p><i>note:</i> text and forest plot differ (text: very short term vs. standard-term DAPT duration; forest plot: longer vs. shorter DAPT)</p> <p>drop of P2Y₁₂-I any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - n = 929/39222 vs. n = 864/32027 - RR 0.76 (0.66; 0.87), p = 0,0001, n = 21 studies - RRR 24% <p>stroke (overall) any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - RR 0.93, 95% CI, 0.81–1.06, p = 0.25 - detail available within an online supplement <p>stroke according to treatment regimen drop of ASS standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - RR 0.96, 95% CI, 0.61–1.51, p = 0.85 - detail available within an online supplement <p>drop of P2Y₁₂-I</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - RR 0.90, 95% CI, 0.77–1.05, p = 0.19 - detail available within an online supplement <p>all-cause mortality (overall)</p> <p>any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - RR 1.04, 95% CI, 0.97–1.13, p = 0.28 - detail available within an online supplement <p>all-cause mortality according to treatment regimen</p> <p>drop of ASS</p> <p>standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - RR 1.13, 95% CI, 0.97–1.31, p = 0.12 - detail available within an online supplement <p>drop of P2Y₁₂-I</p> <p>any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - RR 1.02, 95% CI, 0.92–1.14, p = 0.64 - detail available within an online supplement <p>cardiovascular mortality (overall)</p> <p>any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - RR 0.97, 95% CI, 0.86–1.10, p = 0.65 - detail available within an online supplement <p>cardiovascular mortality according to treatment regimen</p> <p>drop of ASS</p> <p>standard-term DAPT (12 months) vs. early drop of ASS (very short term DAPT, 1-3 months), followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - RR 1.37, 95% CI, 0.96–1.95, p = 0.08 - detail available within an online supplement <p>drop of P2Y₁₂-I</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - RR 0.93, 95% CI, 0.82–1.06, p = 0.27 - detail available within an online supplement <p>stent thrombosis (overall)</p> <p>any longer-term DAPT vs. any shorter DAPT</p> <ul style="list-style-type: none"> - RR 0.73, 95% CI, 0.57–0.94, p = 0.02 - RRR 27% - detail available within an online supplement <p>stent thrombosis according to treatment regimen</p> <p>standard-term DAPT (12 months) vs. very short term DAPT (1-3 months) with drop of ass, followed by P2Y₁₂-I monotherapy</p> <ul style="list-style-type: none"> - n = 90/16088 vs. n = 91/16057 - RR 1.00 (0.74; 1.34), p = 0.98, n = 5 studies <p>any longer-term DAPT vs. any shorter DAPT with drop of P2Y₁₂ inhibitor, followed by ASS monotherapy</p> <ul style="list-style-type: none"> - n = 142/20058 vs. n = 223/19919 - RR 0.64 (0.47; 0.88), p = 0.0006, n = 16 studies <p>authors concluded:</p> <ol style="list-style-type: none"> In trials with P2Y₁₂ inhibitor drop and continuation of aspirin monotherapy, any longer-term DAPT duration is associated with a significant reduction of MACE, MI and ST but a higher risk of major bleeding as compared with any shorter-term DAPT duration; High ischemic risk patients treated with potent P2Y₁₂ inhibitors such as prasugrel and ticagrelor showed a significantly lower risk of MACE with long-term DAPT of >18 months compared with standard-term DAPT of 12 months. Likewise, in the ACS population, the extent of reduction of ischemic events with | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | longerterm DAPT duration group was significant only in patients treated with potent P2Y12 inhibitors; iii) Very short-term DAPT (1–3 months) with either aspirin or P2Y12 inhibitor drop is associated with satisfactory efficacy and safety as compared with standard-term DAPT duration of 12 months. | | |

CADT 2019 (HTA, verlängerte duale Therapie Thrombozytenaggregationshemmer (>12 Monate); nach PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Canadian Agency for Drugs and Technologies in Health. Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Recommendations. 2019 Mar. https://pubmed.ncbi.nlm.nih.gov/31246385 [61]</p> <p>Canadian Agency for Drugs and Technologies in Health. Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Project Protocol. 2018 Feb. https://pubmed.ncbi.nlm.nih.gov/30260612 [62]</p> | <p>Research Question What are the comparative clinical efficacy and safety of a shorter duration (six months to 12 months) versus a longer duration (longer than 12 months) of DAPT following PCI with BMS or DES insertion in:</p> <ul style="list-style-type: none"> - all post-PCI patients - those with a prior MI - those presenting with ACS - those with diabetes - different age subgroups - those who smoke. <p>Compared with a shorter treatment duration (six months to 12 months), what are the comparative clinical efficacy and safety of ASA plus clopidogrel, prasugrel, or ticagrelor when used for a longer duration (longer than 12 months) of DAPT following PCI with BMS or DES insertion in:</p> <ul style="list-style-type: none"> - all post-PCI patients - those with a prior MI | <p>n = 7 RCT</p> <ul style="list-style-type: none"> - clopidogrel most common (n = 3 trials), (OPTIDUAL, DES-LATE, PRODIGY), n = 4 trials with more than one P2Y12 inhibitor, (ITALIC, DAPT, ARCTIC-Interruption, NIPPON) - PEGASUS-TIMI 54 (ticagrelor) was excluded, did not meet eligibility criteria (only identified RCT to assess the benefits and harms of long-term ticagrelor use, results were summarized and made available as supplement of the original publication) <p>results Comparative Effect of Extended Versus Standard DAPT for the Whole Population (Table 2) DAPT > 12 Months vs. DAPT 6 to 12 Months Relative Risk (95% CI), No. of RCT, No. of Participants</p> <p>All-cause death 1.07 (0.80 to 1.42), n = 7 (n = 25,982)</p> <p>Cardiovascular death 0.98 (0.74 to 1.30), n = 5 (n = 21,561)</p> <p>Non-cardiovascular death</p> | <p>AMSTAR-II high</p> <p>limitations</p> <p>subgroup analyses: small sample size</p> <p><i>Hinweis:</i> supplement leider nicht verfügbar</p> | <p>developing stent thrombosis and de-novo recurrent ischemic events were given as reason for extending the duration of DAPT beyond 12 months</p> <p>discussion: “extending DAPT beyond 12 months may reduce the risk of MI and stent thrombosis, but may also increase the risk of bleeding”</p> <p>“no significant differences in the risk of all-cause or cardiovascular death, stroke, urgent target revascularization, MACCE, or gastrointestinal bleeding”</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - those presenting with ACS - those with diabetes - different age subgroups - those who smoke <p>Methods</p> <ul style="list-style-type: none"> - systematic review, meta-analysis (if possible NMA) - Medline, Embase, Cochrane Library, grey literature - PROSPERO (No. CRD42018082587) - PRISMA, Cochrane Handbook - RCT - adult patients - undergone PCI - receiving DAPT <p>Quality assessment</p> <p>Cochrane Collaboration's risk of bias tool (RoB 2.0)</p> <p>Intervention</p> <p>DAPT after PCI extended duration (more than 12 months)</p> <p>Comperator</p> <p>DAPT for 6 to 12 months</p> <p>DAPT = P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor) + ASS</p> <p>Outcome</p> <p>primary death (cardiovascular, all-cause, non-cardiovascular)</p> <p>secondary</p> | <p>2.15 (1.30 to 3.55), n = 3 (n = 14,666)</p> <p>Myocardial infarction 0.58 (0.48 to 0.70), n = 6 (n = 24,534)</p> <p>Stroke 0.94 (0.70 to 1.25), n = 6 (n = 24,534)</p> <p>Stent thrombosis: definite 0.49 (0.22 to 1.08), n = 5 (n = 20,825)</p> <p>Stent thrombosis: probable or definite 0.38 (0.21 to 0.67), n = 5 (n = 19,489)</p> <p>Urgent revascularization 0.60 (0.24 to 1.54), n = 2 (n = 3,136)</p> <p>MACCE 0.95 (0.76 to 1.19), n = 5 (n = 21,227)</p> <p>Gastrointestinal bleeding 0.89 (0.34 to 2.30), n = 1 (n = 3,773)</p> <p>TIMI major bleeding 1.42 (0.88 to 2.29), n = 4 (n = 9,579)</p> <p>TIMI minor bleeding 0.95 (0.53 to 1.72), n = 2 (n = 3,248)</p> <p>GUSTO moderate bleeding 1.68 (1.22 to 2.30), n = 2 (n = 13,046)</p> <p>GUSTO severe bleeding 1.41 (0.90 to 2.20), n = 2 (n = 13,046)</p> <p>GUSTO moderate or severe bleeding 1.57 (1.17 to 2.11), n = 2 (n = 13,046)</p> | | <p>“one large RCT (DAPT) reported an increased risk of non-cardiovascular death (primarily cancer and trauma deaths) among participants who received extended DAPT (30 months of DAPT); this finding was not replicated in two smaller RCT”</p> <p>dose extendet DAPT:</p> <ul style="list-style-type: none"> - clopidogrel 75 mg daily - prasugrel 10 mg daily - ticagrelor 60 mg twice daily <p>dose first year:</p> <ul style="list-style-type: none"> - clopidogrel 75 mg daily - prasugrel 10 mg daily - ticagrelor 90 mg twice daily <p>(RCT and guideline recommendation; Canadian Cardiovascular Society)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - bleeding (major, minor, gastrointestinal) - urgent target vessel revascularization - major adverse cardiac and cerebrovascular events - myocardial infarction - stroke - stent thrombosis <p>MACCE = major adverse cardiac and cerebrovascular events</p> | <p>BARC Type 3 bleeding 1.29 (0.76 to 2.22), n = 3 (n = 16,353)</p> <p>BARC Type 5 bleeding 1.72 (0.62 to 4.47), n = 3 (n = 16,353)</p> <p>BARC Type 2,3,5 bleeding 0.89 (0.48 to 1.68), n = 1 (n = 1,398)</p> <p>authors noted current guidelines recommendations</p> <ul style="list-style-type: none"> - tailoring the length of DAPT depending on patient characteristics - American College of Cardiology/American Heart Association (ACC/AHA) guidelines: <ul style="list-style-type: none"> o DAPT for six months following PCI for patients with stable coronary artery disease and for 12 months in patients with acute coronary syndrome (ACS) o with the consideration of extended DAPT beyond 12 months if potential thrombotic risk is high and bleeding risk is deemed low o use of the DAPT score to identifying high-risk patients - European Society of Cardiology (ESC) guidelines (2017): <ul style="list-style-type: none"> o one-year minimum duration of DAPT for patients with ACS - Canadian guidelines: <ul style="list-style-type: none"> o individualized approach to selecting DAPT duration, with different recommendations for patients with ACS or non-ACS indications at the time of PCI <p>NICE recommendations recommendation 1:</p> <ul style="list-style-type: none"> - recommends that a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) be reimbursed for use beyond 12 | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>months in combination with ASS in patients who recently underwent PCI with DES insertion</p> <ul style="list-style-type: none"> ○ any decision should be made together with the patient ○ undergoing extended DAPT, consult at least once per year ○ extended DAPT treatment should not exceed three years ○ ticagrelor standard DAPT with 90 mg twice daily ○ ticagrelor extended DAPT with 60 mg twice daily <p>- reasons:</p> <ul style="list-style-type: none"> ○ SR of n = 7 RCT (extended DAPT beyond 12 months vs. standard DAPT (6-12 months)) <ul style="list-style-type: none"> ▪ myocardial infarction (MI) ▪ RR 0.58, 95% [CI], 0.48 to 0.70 ▪ NNT 174 ▪ stent thrombosis ▪ RR 0.38, 95% CI, 0.21 to 0.67 ▪ NNT 348 ▪ compared with ▪ results are mainly driven by clopidogrel because most patients enrolled in the included studies were using this P2Y12 inhibitor ○ SR of n = 7 RCT (extended DAPT beyond 12 months vs. standard DAPT (6-12 months)) <ul style="list-style-type: none"> ▪ Bleeding ▪ GUSTO moderate bleeding ▪ RR 1.68, 95% CI, 1.22 to 2.30 ▪ NNH 156 ▪ GUSTO moderate and severe bleeding ▪ RR 1.57, 95% CI, 1.17 to 2.11 ▪ results also mainly driven by clopidogrel ○ n = 1 large RCT (DAPT) reported a significant increase in non-cardiovascular death (RR 2.15, 95% CI, 1.30 to 3.55) among participants who received DAPT > 12 months | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> ○ duration of included studies extended to a maximum of 48 months, with the largest included study (i.e., the DAPT trial) following patients for up to 30 months <ul style="list-style-type: none"> ▪ extending DAPT beyond three years after an initial 12 months treatment should be undertaken only if the patient is evaluated by a physician with expertise in cardiovascular disease <p>recommendation 2:</p> <ul style="list-style-type: none"> - recommends that selection of which P2Y12 inhibitor is used for extended DAPT be made at the discretion of the treating physician and that this be based on the individual characteristics and risk profile of each patient - reasons: <ul style="list-style-type: none"> ○ insufficient information about comparative clinical effectiveness of individual P2Y12 inhibitors (i.e., clopidogrel, prasugrel, and ticagrelor) <p>included studies:</p> <p>6. Collet JP et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): A randomized trial. <i>Lancet</i>. 2014;384(9954):1577.</p> <p>7. Gilard M et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial. <i>J Am Coll Cardiol</i>. 2015;65(8):777.</p> <p>8. Helft G et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: The OPTIDUAL randomized trial. <i>Eur Heart J</i>. 2016;37(4):365.</p> <p>9. Lee CW et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, controlled trial. <i>Circulation</i>. 2014;129(3):304.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>10. Valgimigli M et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multi-center trial. <i>Circulation</i>. 2012;125(16):2015.</p> <p>11. Mauri L et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>N Engl J Med</i>. 2014;371(23):2155.</p> <p>12. Nakamura M et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. <i>JACC Cardiovasc Interv</i>. 2017;10(12):1189.</p> | | |

Yamamoto et al. 2023/21 – Watanabe et al. 2022 1 Monat DAPT + Clopidogrel Langzeittherapie (RCT, STOPDAPT-2; PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------|
| <p>Yamamoto K. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. <i>JACC Asia</i> 2023; 3(1):31–46. https://www.ncbi.nlm.nih.gov/pubmed/36873770. [63]</p> | <p>BACKGROUND: High bleeding risk (HBR) and complex percutaneous coronary intervention (PCI) are major determinants for dual antiplatelet therapy (DAPT) duration.</p> <p>OBJECTIVES: The aim of this study was to evaluate the effects of HBR and complex PCI on short vs standard DAPT.</p> <p>METHODS: Subgroup analyses were conducted on the basis of Academic Research Consortium-defined HBR and complex PCI in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Verulam's-Eluting Cobalt-Chromium Stent-2) Total Cohort, which randomly compared clopidogrel monotherapy after 1-month DAPT with 12-month DAPT with aspirin and clopidogrel after PCI. The primary endpoint was the composite of cardi-</p> | <p>RESULTS: Regardless of HBR (n = 1,893 [31.6%]) and complex PCI (n = 999 [16.7%]), the risk of 1-month DAPT relative to 12-month DAPT was not significant for the primary endpoint (HBR, 5.01% vs 5.14%; non-HBR, 1.90% vs 2.02%; P (interaction) = 0.95) (complex PCI, 3.15% vs 4.07%; noncomplex PCI, 2.78% vs 2.82%; P (interaction) = 0.48) and for the cardiovascular endpoint (HBR, 4.35% vs 3.52%; and non-HBR, 1.56% vs 1.22%; P (interaction) = 0.90) (complex PCI, 2.53% vs 2.52%; noncomplex PCI, 2.38% vs 1.86%; P (interaction) = 0.53), while it was lower for the bleeding endpoint (HBR, 0.66% vs 2.27%; non-HBR, 0.43% vs 0.85%; P (interaction) = 0.36) (complex PCI, 0.63% vs 1.75%; noncomplex PCI, 0.48% vs 1.22%; P (interaction) = 0.90). The absolute difference in the bleeding between 1- and 12-month DAPT was numerically greater in patients with HBR than in those without HBR (-1.61% vs -0.42%).</p> <p>CONCLUSIONS: The effects of 1-month DAPT relative to 12-month DAPT were consistent regardless of HBR and complex PCI. The absolute benefit of 1-month DAPT over 12-month DAPT in reducing major bleeding was numerically greater in patients with HBR than in those without HBR. Complex PCI might not be an appropriate determinant for DAPT durations after PCI. (Short and Optimal Duration of</p> | <p>Zunächst nicht bewertet und extrahiert (Abstract verfügbar)</p> | <p>STOPDAPT-2</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | ovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) or bleeding (Thrombolysis In Myocardial Infarction [TIMI] major or minor) endpoints at 1 year. | Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 [STOPDAPT-2], NCT02619760; Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 for the Patients With ACS [STOPDAPT-2 ACS], NCT03462498). | | |
| Yamamoto K. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2023; 16(1):19–31. https://www.ncbi.nlm.nih.gov/pub-med/36599584 . [64] | <p>BACKGROUND: Diabetes was reported to be associated with an impaired response to clopidogrel.</p> <p>OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of clopidogrel monotherapy after very short dual antiplatelet therapy (DAPT) in patients with diabetes undergoing percutaneous coronary intervention (PCI). METHODS: A subgroup analysis was conducted on the basis of diabetes in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2) Total Cohort (N = 5,997) (STOPDAPT-2, n = 3,009; STOPDAPT-2 ACS [Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 for the Patients With ACS], n = 2,988), which randomly compared 1-month DAPT followed by clopidogrel monotherapy with 12-month DAPT with aspirin and clopidogrel after cobalt-chromium everolimus-eluting stent implantation. The primary endpoint was a composite of cardiovascular (cardiovascular death, myocardial infarction, definite</p> | <p>RESULTS: There were 2,030 patients with diabetes (33.8%) and 3967 patients without diabetes (66.2%). Regardless of diabetes, the risk of 1-month DAPT relative to 12-month DAPT was not significant for the primary endpoint (diabetes, 3.58% vs 4.12% [HR: 0.87; 95% CI: 0.56-1.37; P = 0.55]; nondiabetes, 2.46% vs 2.49% [HR: 0.99; 95% CI: 0.67-1.48; P = 0.97]; P(interaction) = 0.67) and for the cardiovascular endpoint (diabetes, 3.28% vs 3.05% [HR: 1.10; 95% CI: 0.67-1.81; P = 0.70]; nondiabetes, 1.95% vs 1.43% [HR: 1.38; 95% CI: 0.85-2.25; P = 0.20]; P(interaction) = 0.52), while it was lower for the bleeding endpoint (diabetes, 0.30% vs 1.50% [HR: 0.20; 95% CI: 0.06-0.68; P = 0.01]; nondiabetes, 0.61% vs 1.21% [HR: 0.51; 95% CI: 0.25-1.01; P = 0.054]; P(interaction) = 0.19).</p> <p>CONCLUSIONS: Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT reduced major bleeding events without an increase in cardiovascular events regardless of diabetes, although the findings should be considered as hypothesis generating, especially in patients with acute coronary syndrome, because of the inconclusive result in the STOPDAPT-2 ACS trial. (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 [STOPDAPT-2], NCT02619760; Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2 for the Patients With ACS [STOPDAPT-2 ACS], NCT03462498).</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | stent thrombosis, or stroke) or bleeding (TIMI [Thrombolysis In Myocardial Infarction] major or minor) endpoints at 1 year. | | | |
| <p>Watanabe H. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 2022; 7(4):407–17. https://www.ncbi.nlm.nih.gov/pub-med/35234821. [65]</p> | <p>OBJECTIVE: To test the hypothesis of noninferiority of 1 to 2 months of DAPT compared with 12 months of DAPT for a composite end point of cardiovascular and bleeding events in patients with ACS.</p> <p>DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized clinical trial enrolled 4169 patients with ACS who underwent successful PCI using cobalt-chromium everolimus-eluting stents at 96 centers in Japan from December 2015 through June 2020. These data were analyzed from June to July 2021. INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091).</p> <p>MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular (cardiovascular death, myocardial infarction [MI], any stroke, or definite stent thrombosis) or bleeding (Thrombolysis in MI major or minor bleeding) events at 12 months, with a noninferiority margin of 50% on the hazard ratio (HR) scale. The major</p> | <p>RESULTS: Among 4169 randomized patients, 33 withdrew consent. Of the 4136 included patients, the mean (SD) age was 66.8 (11.9) years, and 856 (21%) were women, 2324 (56%) had ST-segment elevation MI, and 826 (20%) had non-ST-segment elevation MI. A total of 4107 patients (99.3%) completed the 1-year follow-up in June 2021. One to 2 months of DAPT was not noninferior to 12 months of DAPT for the primary end point, which occurred in 65 of 2058 patients (3.2%) in the 1- to 2-month DAPT group and in 58 of 2057 patients (2.8%) in the 12-month DAPT group (absolute difference, 0.37% [95% CI, -0.68% to 1.42%]; HR, 1.14 [95% CI, 0.80-1.62]; P for noninferiority = .06). The major secondary cardiovascular end point occurred in 56 patients (2.8%) in the 1- to 2-month DAPT group and in 38 patients (1.9%) in the 12-month DAPT group (absolute difference, 0.90% [95% CI, -0.02% to 1.82%]; HR, 1.50 [95% CI, 0.99-2.26]). The major secondary bleeding end point occurred in 11 patients (0.5%) in the 1- to 2-month DAPT group and 24 patients (1.2%) in the 12-month DAPT group (absolute difference, -0.63% [95% CI, -1.20% to -0.06%]; HR, 0.46 [95% CI, 0.23-0.94]).</p> <p>CONCLUSIONS AND RELEVANCE: In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months of DAPT for the net clinical benefit with a numerical increase in cardiovascular events despite reduction in bleeding events. The directionally different efficacy and safety outcomes indicate the need for further clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02619760 and NCT03462498.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | secondary end points were cardiovascular and bleeding components of the primary end point. | | | |
| Yamamoto K. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. <i>Circ Cardiovasc Interv</i> 2021; 14(5):e010384. https://www.ncbi.nlm.nih.gov/pub-med/34003662 . [66] | <p>BACKGROUND: Safety and efficacy of clopidogrel monotherapy after very short dual antiplatelet therapy (DAPT) is uncertain in patients undergoing complex percutaneous coronary intervention (PCI).</p> <p>METHODS: We conducted a post hoc subgroup analysis based on the complexity of PCI in the STOPDAPT-2 trial (Short and Optimal Duration of Dual Antiplatelet Therapy-2), which randomly compared 1-month DAPT followed by clopidogrel monotherapy with 12-month DAPT after cobalt-chromium everolimus-eluting stent implantation. Complex PCI was defined as any of the following: 3 vessels treated, ≥3 stents implanted, ≥3 lesions treated, bifurcation with 2 stents, >60 mm total stent lengths, and target of chronic total occlusion. The primary end point was the composite of cardiovascular (cardiovascular death/myocardial infarction/definite stent thrombosis/stroke) and bleeding (TIMI [Thrombolysis in Myocardial Infarction] major/minor) end points. The major secondary end points were the cardiovascular and bleeding end points.</p> | <p>RESULTS: Among the 3009 study patients, there were 509 patients (16.9%) with complex PCI (1-month DAPT: N=245, and 12-month DAPT: N=264) and 2500 patients (83.1%) without complex PCI (1-month DAPT: N=1255, and 12-month DAPT: N=1245). There were no significant interactions between the complexity of PCI and the effects of 1-month DAPT versus 12-month DAPT on the primary end point (complex PCI: 1.67% versus 5.32%, hazard ratio, 0.30 [95% CI, 0.10–0.92], P=0.04, and noncomplex PCI: 2.50% versus 3.35%, hazard ratio, 0.75 [95% CI, 0.47–1.20], P=0.23; Pinteraction=0.14), and on the major secondary cardiovascular end point (complex PCI: 1.67% versus 3.04%, hazard ratio, 0.54 [95% CI, 0.16–1.79], P=0.31, and noncomplex PCI: 2.02% versus 2.39%, hazard ratio, 0.86 [95% CI, 0.50–1.47], P=0.58; Pinteraction=0.49). The cumulative 1-year incidence of the major secondary bleeding end point was significantly lower in the 1-month DAPT group than in the 12-month DAPT group regardless of the complexity of PCI (complex PCI: 0% versus 2.29%, log-rank P=0.02, and noncomplex PCI: 0.48% versus 1.38%, log-rank P=0.02).</p> <p>CONCLUSIONS: The effects of clopidogrel monotherapy after 1-month DAPT relative to 12-month DAPT for the primary and major secondary end points were comparable in complex PCI and noncomplex PCI without significant interactions. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02619760.</p> | | |

Lee et al. 2022 1 Monat DAPT + ASS Langzeittherapie (RCT, Post-hoc-Analyse; PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------|
| <p>Lee Y-J. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: A post hoc analysis of the randomised One-Month DAPT trial. EuroIntervention 2022; 18(6):471–81. https://www.ncbi.nlm.nih.gov/pub-med/35470799. [67]</p> | <p>BACKGROUND: The impact of 1-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy according to clinical presentation has not been elucidated.</p> <p>AIMS: This study aimed to compare the impact of 1-month DAPT followed by aspirin monotherapy after polymer-free drug-coated stent (PF-DCS) implantation (1-month DAPT after PF-DCS) vs 6-12-month DAPT followed by aspirin monotherapy after biodegradable polymer drug-eluting stent (BP-DES) implantation (6-12-month DAPT after BP-DES) according to clinical presentation.</p> <p>METHODS: This is a post hoc analysis of the One-Month DAPT trial. The primary outcome was the composite of major adverse cardiac and cerebrovascular events (MACCE; a composite of cardiac death, non-fatal myocardial infarction, target vessel revascularisation, and stroke) and major bleeding.</p> | <p>RESULTS: Among 1,828 patients with stable coronary artery disease (CAD), 1-month DAPT after PF-DCS resulted in lower rates of the primary outcome than 6-12-month DAPT after BP-DES (3.9% vs 6.5%; hazard ratio [HR] 0.59, 95% confidence interval [CI]: 0.39-0.90; p=0.012). However, among 1,192 patients with acute coronary syndrome (ACS), the rates of the primary outcome were not significantly different between the two therapy groups (5.6% vs 3.6%; HR 1.57, 95% CI: 0.91-2.70; p=0.102) and a significant interaction was observed between therapy and clinical presentation regarding the primary outcome (P(int)=0.005). A significant interaction was observed in MACCE (P(int)=0.016), but not in major bleeding (P(int)=0.276).</p> <p>CONCLUSIONS: In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS. CLINICALTRIALS: gov: NCT02513810.</p> | <p>Zunächst nicht bewertet und extrahiert (Abstract verfügbar)</p> | <p>One-Month DAPT</p> |

Han et al. 2023 verlängerte duale Therapie (Kohortenstudie, ACS, nach PCI, ≥ 12 Monate)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Han J. Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. Glob Heart 2023; 18(1):11. https://www.ncbi.nlm.nih.gov/pub-med/37228657.</p> | <p>Objective to investigate the benefits and risks of applying DAPT for different durations after PCI in acute coronary syndromes (ACS) patients in China and to explore prolonged DAPT with ticagrelor in the real-world</p> | <p>n = 3,205 patients</p> <ul style="list-style-type: none"> - mean age ~ 60 years - male ~ 75% - prior PCI ~ 37% vs. ~ 33 % - prior CABG ~ 3 % vs. ~ 1 % - prior MI ~ 8 % vs. ~ 6 % - prior stroke ~ 8 % vs. ~ 7% | <p>n. a.</p> <p>adjusted by propensity score matching using logistic regression</p> | <p>authors noted that that prolonged DAPT is more common than the 1-year regimen in Chinese ACS patients and that effectiveness and safety of this treatment</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| [68] | <p>Methods</p> <ul style="list-style-type: none"> - single-center prospective cohort study - real-world observation - PHARM-ACS Patient Registration Database (NCT04184583) - Department of Pharmacy, Beijing Anzhen Hospital - ≥18 years old - patients with ACS - diagnosed with STsegment elevation MI (STEMI), non-ST-segment elevation MI (NSTEMI), unstable angina - after PCI - patients discharged between April and Dec 2018 - follow-up at least 18 months - have received DAPT for at least one year - received clopidogrel or ticagrelor + aspirin at discharge - patients with major adverse cardiovascular and cerebrovascular events (MACCE), target vessel revascularization, stent thrombosis, or major bleeding event were excluded - treatment with three or more antiplatelet agents, with anticoagulants or alteration of antiplatelet drugs were excluded | <ul style="list-style-type: none"> - hypertension ~ 61 % vs. ~ 60 % - hyperlipidemia ~ 37 % vs. ~ 36 % - ~ 98 % with statins - ~ 30-35 % 1 or 2 or 3 vessel disease, respectively - median follow-up 572 (IQR 545, 622) days - n = 1,004 (31.33%) patients with DAPT for 1 year - n = 2,201 (68.67%) patients with DAPT > 1 year - median DAPT time 19 (IQR 18, 20) months - n = 1,236 (38.56%) DAPT ticagrelor + ASS - n = 1,969 (61.44%) DAPT clopidogrel + ASS - DAPT > 1-year group with higher proportion of <ul style="list-style-type: none"> o prior PCI 15.24% vs. 18.90%, P = 0.012 o prior CABG 0.50% vs. 1.59%, P = 0.010 o prior MI 5.68% vs. 8.54%, P = 0.005 o diabetes 28.19% vs. 33.35%, P = 0.004 - n = 2,201 (68.67%) DAPT prolonged one year - n = 2,000 patients propensity score-matched <ul style="list-style-type: none"> o mean age ~ 59 years o male ~ 76% <p>results</p> <ul style="list-style-type: none"> - DAPT > 1-year (n = 1000) vs. - DAPT = 1-year patients (n = 1000) <p>MACCE</p> <ul style="list-style-type: none"> - n = 5 (0.50 %) vs. n = 13 (1.30 %) - adjusted HR 0.23 (0.05–1.10), p = 0.065 <p>All cause death</p> <ul style="list-style-type: none"> - n = 2 (0.20 %) vs. n = 7 (0.70 %) - adjusted HR 0.14 (0.02–1.20), p = 0.073 <p>Cardiac death</p> <ul style="list-style-type: none"> - n = 2 (0.20 %) vs. n = 2 (0.20 %) - adjusted HR 0.39 (0.03–4.80), p = 0.465 <p>MI</p> <ul style="list-style-type: none"> - n = 1 (0.10 %) vs. n = 1 (0.10 %) - adjusted HR 1.00 (0.06–16.02), p = 0.999 <p>Stroke</p> <ul style="list-style-type: none"> - n = 2 (0.20 %) vs. n = 5 (0.50 %) - adjusted HR 0.38 (0.07–2.04), p = 0.262 | <p>panel of experts made a judgment of clinical endpoints</p> <p>prasugrel is not a listed medication in China → DAPT consists of clopidogrel or ticagrelor + ASS</p> <p>follow-up every six months (trained staff), follow-up includes telephone, WeChat, clinical visits</p> <p>single-center study (limited generalization)</p> <p>observational study</p> <p>choice of DAPT determined by physician</p> <p>probably patients with low bleeding risk (toleration of 12 months DAPT)</p> | <p>pattern require urgent verification</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Intervention DAPT 1-year</p> <p>Comperator DAPT >1-year</p> <p>DAPT = clopidogrel or ticagrelor + ASS</p> <p>Outcome primary</p> <ul style="list-style-type: none"> - major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, and stroke occurring from 12 months after discharge - significant bleeding event (BARC ≥ 2) <p>secondary</p> <ul style="list-style-type: none"> - all-cause death, - cardiogenic death, - myocardial infarction (MI), - stroke, - target vessel revascularization, - stent thrombosis | <p>Revascularization</p> <ul style="list-style-type: none"> - n = 32 (3.20 %) vs. n = 10 (1.00 %) - HR 3.36 (1.64–6.87), p = 0.001 <p>Stent thrombosis</p> <ul style="list-style-type: none"> - n = 7 (0.69 %) vs. n = 4 (0.40 %) - HR 1.88 (0.54–6.51), p = 0.317 <p>Bleeding BARC ≥ 2</p> <ul style="list-style-type: none"> - n = 16 (1.60 %) vs. n = 24 (2.40 %) - adjusted HR 0.63 (0.32–1.24), p = 0.179 <p>authors interpreted survival analysis of the Kaplan-Meier curve with differences in the cumulative incidence of MACCE (log-rank P = 0.062, power = 0.71), significant bleeding events (log-rank P = 0.25), and revascularization (log-rank P < 0.001)</p> <p>subgroup analysis of MACCE risk data after PSM showed no significant difference in treatment effect between DAPT = 1-year and DAPT > 1-year, even in patients using different P2Y12 receptor inhibitors (P-value for interaction 0.468) (see Table 3)</p> | | |

Zeymer et al. 2023 Status der antithrombotischen Therapie (Kohorte, AF, PCI, Deutschland, u. a. Therapiedauer)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-----------|
| Zeymer U. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibril- | <p>Objective a prospective registry study including consecutive patients with AF undergoing PCI to determine the current</p> | <p>n = 1636 patients in 51 german hospitals (enrolled between 2018 and 2020)</p> <ul style="list-style-type: none"> - mean age 75.5 years - age ≥ 65 years n = 1437 (87.8%) | <p>n. a.</p> <p>limitations observational design (registry)</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| <p>lation undergoing percutaneous coronary intervention in Germany. Herz 2023; 48(2):134–40. https://www.ncbi.nlm.nih.gov/pub-med/35243515. [69]</p> | <p>clinical practice, planned duration of combination therapies after discharge, and in-hospital events</p> <p>Methods</p> <ul style="list-style-type: none"> - “Rivaroxaban in Patients with Atrial Fibrillation Undergoing PCI” (RIVA-PCI) registry - clinicaltrials.gov NCT03315650 - prospective, noninterventional, multicenter observational study - age ≥18 years - patients with nonvalvular AF (known or newly) - undergoing PCI during index hospital stay - follow-up until 14 months after discharge - treatment according to current guidelines - inclusion in the registry is completely independent of the medical treatment - patients at any RCT influencing the antithrombotic therapy were excluded <p>Intervention Rivaroxaban</p> <p>Outcome</p> <ul style="list-style-type: none"> - current use of antithrombotic therapies (before PCI and at discharge) - adherence | <ul style="list-style-type: none"> - age ≥ 75 years n = 1027 (62.8%) - women n = 484 (29.6%) - prior myocardial infarction n = 395 (24.1%) - prior stroke n = 161 (9.8%) - heart failure n = 714 (43.6%) - hypertension n = 1492 (91.2%) - hyperlipidemia n = 1006 (61.5%) - indications for PCI: <ul style="list-style-type: none"> o elective n = 860 (52.6%) o unstable angina n = 289 (17.7%) o non-ST-elevation myocardial infarction (NSTEMI) n = 353 (21.6%) o ST-elevation myocardial infarction (STEMI) n = 134 cases (8.2%) - bleeding events before PCI: <ul style="list-style-type: none"> o n = 37 (2.3%) cases - median CHA2DS2-VASc: 5 (range 1-9) - median HAS-BLED: 2 (range 0-6) - chronic antithrombotic treatment before PCI: <ul style="list-style-type: none"> o n = 209 patients (12.8%) none o n = 214 (13.1%) antiplatelet therapy only o n = 279 (17.1%) VKA o n = 934 (57.1%) NOAC <ul style="list-style-type: none"> ▪ apixaban 372 (22.7%) ▪ edoxaban 124 (7.6%) ▪ rivaroxaban 386 (23.6%) ▪ dabigatran 60 (3.7%) - intravenous anticoagulation: <ul style="list-style-type: none"> o unfractionated heparin n = 1372 (83.9%) o low-molecular-weight heparin n = 160 (9.8%) - drug-eluting stents n = 1615=98.7% <ul style="list-style-type: none"> o n = 1107 (67.7%) one stent o n = 293 (17.9%) two stents o n = 236 (14.4%) three or more stents | <p>possible selection bias</p> | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>- ischemic, embolic, and bleeding events</p> <p>(definitions (stroke, ischemic stroke, hemorrhagic stroke, myocardial infarction etc.) see within the publication)</p> | <p>in hospital:</p> <ul style="list-style-type: none"> - median length of stay after PCI 2 days (range 1-5) <ul style="list-style-type: none"> o 6 months OAC and clopidogrel (most common) o triple or dual therapy for 12 months more often for ACS compared to elective PCI: <ul style="list-style-type: none"> ▪ TT 19.8% vs. 9.1% p< 0.01 ▪ DT 40.1% vs. 23.6% p< 0.001 - death n = 12 (0.7%) - myocardial infarction n = 4 (0.2%) - stroke n = 4 (0.2%) - bleeding n = 46 (2.8%) - recommended duration of combination therapie <ul style="list-style-type: none"> o 1 to 12 months <p>at discharge:</p> <ul style="list-style-type: none"> - n = 1079 (66.0%) dual: OAC and P2Y12 inhibitor - n = 5 (0.3%) dual: OAC and ASS - n = 425 (26.0%) triple therapy - n = 90 (5.5%) dual antiplatelet therapy - n = 37 (2.3%) monotherapy <ul style="list-style-type: none"> o 14 antiplatelet and 23 OAC - n = 700 (42.8%) rivaroxaban - 27.5% apixaban - 11.5% VKA - 6.4% edoxaban - 5.5% dabigatran <ul style="list-style-type: none"> - doses used for the NOACs: - apixaban 2x 5mg (43.2%); 2x 2.5mg (48.6%); other (8.2%) - dabigatran 2x 150mg (22.2%); 2x 110mg (75.6%); other (5.9%) - edoxaban 60mg (48.2%); 30mg (49.1%); other (2.7%) - rivaroxaban 20mg (5.3%); 15mg (86.0%); 10mg, (2.9%); other (5.9%) - Clopidogrel 75mg (n= 1557, 95.2%) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - ASS 100mg (n= 521, 31.8%) - ticagrelor (n= 39, 2.4%) - prasugrel (n= 15, 0.9%) - oral anticoagulants in triple therapy (n= 425) <ul style="list-style-type: none"> o rivaroxaban n = 195, o apixaban n = 110, o VKA n = 65, o dabigatran n = 31, o edoxaban n = 24 - concomitant medication with a proton pump inhibitor n = 760 (46.5%) <p>associations ACS vs. elective PCI (n = 860 vs. n = 776)</p> <ul style="list-style-type: none"> - DAPT only: 7.9% vs. 3.4%, p< 0.001 - triple therapy: 30.4% vs. 22.0%, p< 0.001 - dual therapy: 59.3% vs. 72.6%, p< 0.001 | | |

12.5.4 Zusatzinformation Hintergrundtext (E 7-5; Wirksamkeit und Sicherheit; weitere)

A21-41 (IQWiG) 2023 Clopidogrel, Prasugrel oder Ticagrelor + ASS (Rapid Report; ACS)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>A21-41 Clopidogrel, Prasugrel und Ticagrelor zur Prävention atherothrombotischer Ereignisse bei akutem Koronarsyndrom (22.02.2023) – Rapid Report, https://www.iqwig.de/download/a21-41_clopidogrel-prasugrel-und-ticagrelor-beim-akuten-koronarsyndrom_rapid-report_v1-0.pdf [70]</p> | <p>Fragestellung vergleichende Nutzenbewertung von Clopidogrel, Prasugrel und Ticagrelor, jeweils in Kombination mit Acetylsalicylsäure (ASS) im Anwendungsgebiet Prasugrel-haltiger Arzneimittel, also zur Prävention atherothrombotischer Ereignisse bei erwachsenen Patientinnen und Patienten mit akutem Koronarsyndrom (ACS) mit primärer oder verzö-</p> | <p><i>Hinweis:</i> der Bericht bezieht sich auf eine vergleichende Nutzenbewertung; die Bewertung des Nutzens und Schadens von Clopidogrel, Prasugrel oder Ticagrelor (jeweils + ASS) wurde in anderen Berichten bereits vorgenommen:</p> <ul style="list-style-type: none"> - Patient*innen mit NSTEMI-ACS, akutes Koronarsyndrom ohne ST-Streckenhebung (Abschlussberichte 2009, 2011): <ul style="list-style-type: none"> o insgesamt ein Beleg für einen Nutzen von Clopidogrel + ASS gegenüber einer ASS-Monotherapie o Behandlungszeitraum bis zu 12 Monaten | AMSTAR-II high | <p>eine potentielle NMA konnte nicht durchgeführt werden (Grund: fehlende Daten für die Analyse spezifischer Vergleiche)</p> <p>potentielle Netzwerke vgl. S. 11 im Bericht: A: STEMI + PCI - Clopidogrel + ASS (Brückenkomperator)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>gerter perkutaner Koronarintervention (PCI) hinsichtlich patientenrelevanter Endpunkte</p> <p>Methodik</p> <ul style="list-style-type: none"> - Zielpopulation: Patient*innen mit ACS (d. h. instabiler Angina Pectoris, NSTEMI (Nicht-ST-Streckenhebungsmyokardinfarkt) oder STEMI (ST-Streckenhebungsmyokardinfarkt)) - mit primärer oder verzögerter PCI - gültiger Zulassungsstatus in Deutschland - getrennte Betrachtung von Patientinnen und Patienten mit STEMI + PCI und NSTEMI / IA + PCI - RCT - mind. 3 Monate Studiendauer - systematische Übersichtsarbeiten, HTA Berichte <p>(letzte Suche am 18.10.2021)</p> <p>Intervention Clopidogrel, Prasugrel und Ticagrelor, jeweils in Kombination mit ASS</p> <p>Kontrolle Vergleich untereinander</p> <p>Endpunkte</p> <ul style="list-style-type: none"> - Mortalität - Gesamtmortalität - Morbidität | <ul style="list-style-type: none"> o basierend u. a. auf einem Vorteil bei der Myokardinfarktrate o demgegenüber steht ein Nachteil für Clopidogrel + ASS aufgrund erhöhter Blutungskomplikationen o Vergleich von Prasugrel + ASS gegenüber Clopidogrel + ASS zeigte sich für Patient*innen mit NSTEMI-ACS ein Hinweis auf einen Zusatznutzen u. a. bei nicht tödlichen Schlaganfällen (nur bei Patient*innen ohne Gefäßvorerkrankungen) und nicht tödlichen Myokardinfarkten o demgegenüber steht ein Hinweis auf einen höheren Schaden von Prasugrel + ASS aufgrund häufiger auftretender schwerwiegender Blutungen sowie ein Anhaltspunkt für einen höheren Schaden aufgrund häufiger auftretender Neoplasien o Vergleich von Ticagrelor mit Clopidogrel, jeweils + ASS, zeigte sich für Patient*innen mit NSTEMI-ACS insgesamt ein Beleg für einen beträchtlichen Zusatznutzen von Ticagrelor + ASS im Vergleich zu Clopidogrel + ASS o dieser basierte auf Vorteilen hinsichtlich Gesamtmortalität und kardiovaskulärer Mortalität sowie Anzahl an Myokardinfarkten o es zeigte sich kein höherer oder geringerer Schaden <ul style="list-style-type: none"> - Patient*innen mit STEMI nach primärer PCI (Abschlussberichte 2009, 2011): <ul style="list-style-type: none"> o im Rahmen aller 3 Bewertungen jeweils keine Studien identifiziert, in denen die Wirkstoffkombination (Clopidogrel, Prasugrel oder Ticagrelor, jeweils + | | <ul style="list-style-type: none"> - Prasugrel + ASS - Ticagrelor + ASS <p>Basis: TRITON-TIMI 38 H7T-MC-TACE PLATO PHILO TICAKOREA HEALING AMI Tang 2016 Wu 2018 ISAR-REACT 5</p> <p>B: NSTEMI / IA + PCI)</p> <ul style="list-style-type: none"> - Clopidogrel + ASS - Prasugrel + ASS - Ticagrelor + ASS <p>Basis: TRITON-TIMI 38 H7T-MC-TACE PLATO PHILO Yang 2020 Qui 2020 TICAKOREA ISAR-REACT 5</p> <p>(zu berücksichtigen sind hier u. a. die Zulassung der drei Wirkstoffe sowie Ähnlichkeitsannahmen)</p> <p>Kontext zu internationalen Leitlinien: laut Bericht übereinstimmend bei Patient*innen mit ACS</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> ○ kardiovaskuläre Morbidität ○ zerebrovaskuläre Morbidität ○ gefäßbedingte nicht kardiovaskuläre und nicht zerebrovaskuläre Morbidität - gesundheitsbezogene Lebensqualität - Nebenwirkungen <ul style="list-style-type: none"> ○ schwerwiegende unerwünschte Ereignisse (SUEs) ○ Studienabbrüche wegen unerwünschter Ereignisse (UEs) ○ Blutungen <p><i>Hinweis:</i></p> <ul style="list-style-type: none"> - Clopidogrel ist laut Bericht in Kombination mit ASS für Patient*innen mit medikamentös behandeltem ACS (NSTE-ACS / STEMI) sowie NSTE-ACS nach erfolgter PCI zugelassen (Anmerkung: Information aus einer Fachinformation) Clopidogrel + ASS ist nicht für die Behandlung von Patient*innen mit STEMI nach primärer PCI zugelassen (Brückenkomparatorbewertung im Netzwerk) - Prasugrel ist in Kombination mit ASS nur für Patientinnen und Patienten mit ACS (NSTE-ACS / STEMI) | <p>ASS) mit einer ASS-Monotherapie verglichen wurde</p> <ul style="list-style-type: none"> ○ Clopidogrel + ASS ist nicht für die Behandlung von Patient*innen mit STEMI nach primärer PCI zugelassen ○ Beim Vergleich von Ticagrelor + ASS gegenüber Prasugrel + ASS zeigte sich im Rahmen eines indirekten Vergleichs über den Brückenkomparator Clopidogrel + ASS für Patient*innen mit STEMI nach primärer PCI kein Anhaltspunkt für einen Zusatznutzen <ul style="list-style-type: none"> - Insgesamt zeigt sich, dass insbesondere im Anwendungsgebiet von Prasugrel, also beim ACS nach primärer oder verzögerter PCI, keine Aussagen darüber getroffen werden können, welcher P2Y12-Inhibitor (in Kombination mit ASS) primär zur Behandlung dieser Patient*innen eingesetzt werden sollte - die vorliegende Bewertung beschäftigt sich daher mit der vergleichenden Nutzenbewertung von Clopidogrel, Prasugrel und Ticagrelor im Anwendungsgebiet von Prasugrel <p>n = 0 SR n = 11 relevante Studien identifiziert (gesamt) (Studiencharakteristika der eingeschlossenen Studien sind in Abschnitt A3.2 dargestellt, ab S. 69 im Bericht)</p> <ul style="list-style-type: none"> - Vergleiche (Wirkstoffe, Fragestellungen) <ul style="list-style-type: none"> - Prasugrel + ASS vs. Ticagrelor + ASS: <ul style="list-style-type: none"> ○ n = 1 Studie (ISAR-REACT 5 [21]) mit Teilpopulationen zu STEMI + PCI und NSTEMI / IA + PCI - Prasugrel + ASS vs. Clopidogrel + ASS: <ul style="list-style-type: none"> ○ n = 2 Studien (TRITON-TIMI 38 [22] und H7T-MC-TACE [23]) mit Teilpopulationen zu STEMI + PCI und NSTEMI / IA + PCI | | <p>nach PCI bis zu 12 Monate duale anti-thrombozytäre Therapie (DAPT aus P2Y₁₂-Inhibitor + ASS)</p> <p>Nutzen und Schaden von Clopidogrel, Prasugrel und Ticagrelor (je + ASS) bereits in mehreren Bewertungen vorgenommen</p> <p>Studiendauer: das Risiko für ein Rezidivereignis nach ACS ist im 1. Jahr sehr hoch (9 bis 10 %), wobei die meisten Rezidivereignisse in den ersten 3 Monaten nach ACS auftreten [DEGAM, S2e Leitlinie]. (daher Studien mit Mindestdauer von 3 Monaten eingeschlossen)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>nach erfolgter PCI zugelassen (Anmerkung: Information aus <u>einer</u> Fachinformation)</p> <ul style="list-style-type: none"> - wobei die Behandlung mit Prasugrel bei Patient*innen mit transitorischer ischämischer Attacke (TIA) oder Schlaganfall in der Anamnese kontraindiziert ist - Ticagrelor ist laut Bericht in Kombination mit ASS für die Behandlung von Patientinnen und Patienten mit ACS (NSTE-ACS / STEMI) zugelassen (Anmerkung: Information aus <u>einer</u> Fachinformation) | <ul style="list-style-type: none"> - Ticagrelor + ASS vs. Clopidogrel + ASS: <ul style="list-style-type: none"> o n = 8 Studien <ul style="list-style-type: none"> ▪ STEMI + PCI: HEALING-AMI [24], PHILO (Teilpopulation) [25], PLATO (Teilpopulation) [26], Tang 2016 [27], TITAKOREA (Teilpopulation) [28], Wu 2018 [29] ▪ NSTEMI / IA + PCI: PHILO (Teilpopulation), PLATO (Teilpopulation), Qiu 2020 [30], TICAKOREA (Teilpopulation), Yang 2020 [31] - kleinere Studien, in denen zusätzliche, bisher nicht berücksichtigte Endpunkte (z. B. gesundheitsbezogene Lebensqualität) berichtet werden, wurden nicht identifiziert <p>n = 4/11 herstellergesponsort (PHILO, PLATO, TRITON-TIMI 38 und H7T-MC-TACE) n = 7/11 Prüfer-initiierte Studien (investor-investigated trials)</p> <p>n = 1 laufende Studie, n = 3 Studien mit unklarem Status, n = 2 Studien, abgeschlossen, ohne Ergebnisbericht</p> <p>auf Grund unvollständiger Daten wurden Anfragen zu den 4 herstellergesponsorten Studien sowie für eine prüferinitiierte Studie gestellt:</p> <ul style="list-style-type: none"> - angeforderte Daten zu Teilpopulationen der Studien TRITON-TIMI 38 und H7T-MC-TACE wurden vom Hersteller nicht übermittelt <p>daher war laut dem Bericht eine potentielle NMA (Netzwerkmetaanalyse) nicht möglich</p> <p>das IQWiG schlussfolgerte, dass die Datenbasis für den Vergleich Prasugrel vs. Clopidogrel, jeweils in Kombination mit ASS, sowohl für Patientinnen und Patienten mit STEMI</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>+ PCI als auch für Patientinnen und Patienten mit NSTEMI / IA + PCI unvollständig ist</p> <p>die beiden Studien TRITON-TIMI 38 und H7T-MC-TACE sind die einzige identifizierte Evidenz für den Vergleich von Prasugrel vs. Clopidogrel, jeweils in Kombination mit ASS</p> <p>die Auswertung der verfügbaren limitierten Daten stellt damit keine valide Entscheidungsgrundlage für den G-BA dar explorative Betrachtung der verfügbaren Ergebnisse:</p> <ul style="list-style-type: none"> - für keinen der Wirkstoffe Clopidogrel, Prasugrel und Ticagrelor ist ein eindeutiger Vorteil zu erkennen <p>eingeschlossene Studien</p> <p>21. Schupke S, Neumann FJ, Menichelli M et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019; 381(16): 1524-1534. https://dx.doi.org/10.1056/NEJMoa1908973. (Prasugrel + ASS vs. Ticagrelor + ASS: (ISAR-REACT 5))</p> <p>22. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001-2015. https://dx.doi.org/10.1056/NEJMoa0706482. (Prasugrel + ASS vs. Clopidogrel + ASS: (TRITON-TIMI 38))</p> <p>23. Eli Lilly. A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome [online]. 2011 [Zugriff: 01.06.2022]. URL: https://ClinicalTrials.gov/show/NCT00830960. (Prasugrel + ASS vs. Clopidogrel + ASS: H7T-MC-TACE))</p> <p>24. Park Y, Koh JS, Lee JH et al. Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI). JACC Cardiovasc Interv 2020; 13(19): 2220-2234. https://dx.doi.org/10.1016/j.jcin.2020.08.007.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>(Ticagrelor + ASS vs. Clopidogrel + ASS: (HEAL-ING-AMI))</p> <p>25. Goto S, Huang CH, Park SJ et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. <i>Circ J</i> 2015; 79(11): 2452-2460. https://dx.doi.org/10.1253/circj.CJ-15-0112. (Ticagrelor + ASS vs. Clopidogrel + ASS: (PHILO))</p> <p>26. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med</i> 2009; 361(11): 1045-1057. https://dx.doi.org/10.1056/NEJMoa0904327. (Ticagrelor + ASS vs. Clopidogrel + ASS: (PLATO))</p> <p>27. Tang X, Li R, Jing Q et al. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>J Cardiovasc Pharmacol</i> 2016; 68(2): 115-120. https://dx.doi.org/10.1097/fjc.0000000000000390. (Ticagrelor + ASS vs. Clopidogrel + ASS)</p> <p>28. Park DW, Kwon O, Jang JS et al. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. <i>Circulation</i> 2019; 140(23): 1865-1877. https://dx.doi.org/10.1161/circulationaha.119.041766. (Ticagrelor + ASS vs. Clopidogrel + ASS: (TICAKOREA))</p> <p>29. Wu HB, Tian HP, Wang XC et al. Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. <i>Am J Transl Res</i> 2018; 10(7): 2175-2183. (Ticagrelor + ASS vs. Clopidogrel + ASS)</p> <p>30. Qiu C, Hu J, Zhang X et al. Effects of ticagrelor and clopidogrel on serum homocysteine level and neutrophil-to-</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | lymphocyte ratio in elderly patients with coronary heart disease. Int J Clin Exp Med 2020; 13(10): 7936-7942. (Ticagrelor + ASS vs. Clopidogrel + ASS) 31. Yang B, Zheng C, Yu H et al. Comparison of Efficacy between Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome after Interventional Treatment and Their Effects on IL-6. Iran J Public Health 2020; 49(2): 240-248. (Ticagrelor + ASS vs. Clopidogrel + ASS) | | |

Sachdeva et al. 2023 P2Y12 Hemmer (Datenbankenanalyse; ACS; Clopidogrel, Prasugrel, Ticagrelor; u. a. Charakteristika der Betroffenen)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sachdeva A. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes. J Interv Cardiol 2023; 2023:1147352. https://www.ncbi.nlm.nih.gov/pub-med/37251366 . [71] | <p>Objective to determine the comparative efficacy and safety of the novel P2Y12 inhibitors versus clopidogrel in a large integrated healthcare delivery system, among those presenting with ACS undergoing percutaneous coronary intervention (PCI)</p> <p>Methods</p> <ul style="list-style-type: none"> - Kaiser Permanente Northern California (KPNC) - 21 medical centers, including >250 ambulatory care facilities, pharmacies, and laboratories, providing comprehensive inpatient, emergency department and outpatient care, with nearly all care captured through its electronic health record (EHR) system - patients underwent PCI for ACS - regional cardiac catheterization laboratories of KPNC between | n = 15,479 patients - mean age 66.3 years (SD ± 12.0) - 27.8% female - n = 14408 (93%) clopidogrel - n = 570 (3,6%) ticagrelor - n = 501 (3,2%) prasugrel - clopidogrel group (see Table 1): <ul style="list-style-type: none"> o was older (66.5 vs. 61.3 (ticagrelor) vs. 58.1 (prasugrel) years), o had a higher proportion of female patients (28.0% vs. 22.9% vs. 19.4%), o was more likely to have a significant cardiovascular history such as prior CABG, cerebrovascular disease, and heart failure, o had more comorbidities such as chronic kidney disease (25.2% vs. 15.1% vs. 14.8%) and hypertension (75.2% vs. 63.0% vs. 64.1%) o (all p < 0.05) o had lower haemoglobin and platelet values, (p < 0.001) | n. a. propensity score (PS) matching (hypothesis of prognostic factors), minimal 1:1 match and maximal 1:5 match during the preparation of the manuscript, it was realized that hypertension was inadvertently omitted from the statistical models (both multivariate and propensity matching) for the abstract (important risk factor that should adjusted for) → model was adapted (discordance from protocol) limitations <ul style="list-style-type: none"> - observational study - unmeasured confounding could not be excluded - large sample size for clopidogrel compared with | baseline demographic, laboratory data, procedural data, and medication use after index PCI were extracted, comorbidities (ICD-9 and 10), PRECISE DAPTscore, a validated score for predicting bleeding risk after stent implantation, was calculated for each patient (F. Costa, et al., "PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE- |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>January 1st, 2012, and December 31st, 2018</p> <ul style="list-style-type: none"> - ticagrelor was FDA-approved in 2011 - exclusion criteria were described in detail - index event was assigned as the first qualified hospitalized ACS event during the study period <p>Intervention</p> <ul style="list-style-type: none"> - P2Y₁₂ antagonist within 30-days post index PCI discharge - ticagrelor or prasugrel was compared to clopidogrel <p>Comperator</p> <ul style="list-style-type: none"> - clopidogrel as reference group <p>Outcomes</p> <p>primary allcause mortality, hospitalized myocardial infarction, hospitalized stroke, and hospitalized bleeding events (within the first year after index ACS)</p> <p>note: adherence (MRA > 80%), persistence (gap between refills < 15 days), and switching (more than one P2Y₁₂) of P2Y₁₂ inhibitors were assessed</p> | <ul style="list-style-type: none"> - larger proportion of patients with prasugrel (40.7%) or ticagrelor (49.8%) had STElevation myocardial infarction (STEMI) as their PCI indication vs. clopidogrel (20%) <ul style="list-style-type: none"> o higher proportion of these patients were classified as emergency cases and having cardiogenic shock - Risk score (Precise DAPT score) <ul style="list-style-type: none"> o clopidogrel 27.7 ± 19.3 o ticagrelor 18.4 ± 13.6, p <0.001 o prasugrel 18.7 ± 16.1, p <0.001 - Medication use post PCI <ul style="list-style-type: none"> o ACE inhibitors <ul style="list-style-type: none"> ▪ clopidogrel n = 8872 (61.6) ▪ ticagrelor n = 406 (71.5), p <0.001 ▪ prasugrel n = 351 (70.1), p <0.001 o ARBs <ul style="list-style-type: none"> ▪ clopidogrel n = 3680 (25.5) ▪ ticagrelor n = 139 (24.5), p = 0.57 ▪ prasugrel n = 101 (20.2), p = 0.01 o Oral anticoagulation <ul style="list-style-type: none"> ▪ clopidogrel n = 1541 (10.7) ▪ ticagrelor n = 22 (3.9), p <0.001 ▪ prasugrel n = 30 (6.0), p <0.001 o Beta blockers <ul style="list-style-type: none"> ▪ clopidogrel n = 13532 (93.9) ▪ ticagrelor n = 542 (95.4), p = 0.14 ▪ prasugrel n = 477 (95.2), p = 0.24 o Statins <ul style="list-style-type: none"> ▪ clopidogrel n = 13983 (97.1) ▪ ticagrelor n = 557 (98.1), p = 0.16 ▪ prasugrel n = 490 (97.8), p = 0.33 - clopidogrel use dropped over time from 94.7% of total dispensed in 2012 to 88.2% in 2018 - ticagrelor use increased from 0% to 10.2% - and prasugrel use decreased from 5.3% to 1.5% - (p < 0.001) <p>after propensity score matching</p> | <ul style="list-style-type: none"> - ticagrelor and prasugrel (statistical power) - ASS use was not available | <p>DAPT) score: a pooled analysis of individual-patient datasets from clinical trials," Lancet, vol. 389, pp. 25–34, 2017)</p> <p>authors found after propensity score matching (adjustment) in patients undergoing PCI for ACS, the use of ticagrelor vs. clopidogrel was associated with a lower risk of all-cause mortality, but similar rates for other outcomes; no difference between prasugrel and clopidogrel</p> <p>switch was high to clopidogrel, probably due to higher cost</p> <p>higher proportion of patients on clopidogrel were persistent to treatment (implications for treatment effect and prediction of stent thrombosis)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - n = 1 704 clopidogrel vs. n = 568 ticagrelor - n = 1 503 clopidogrel vs. n = 501 prasugrel <p>Outcomes at 1 year follow-up (evaluation using log-rank test with comparison group of clopidogrel)</p> <p>Mortality</p> <ul style="list-style-type: none"> - clopidogrel n = 622 (4.3%) - ticagrelor n = 12 (2.1%), p=0.01 - prasugrel n = 18 (3.6%), p=0.44 <p>Myocardial infarction</p> <ul style="list-style-type: none"> - clopidogrel n = 817 (5.7%) - ticagrelor n = 31 (5.5%), p=0.80 - prasugrel n = 22 (4.4%), p=0.23 <p>Stroke</p> <ul style="list-style-type: none"> - clopidogrel n = 399 (2.8%) - ticagrelor n = 12 (2.1%), p=0.33 - prasugrel n = 7 (1.4%), p=0.07 <p>Bleeding events</p> <ul style="list-style-type: none"> - clopidogrel n = 519 (3.6%) - ticagrelor n = 17 (3.0%), p=0.43 - prasugrel n = 14 (2.8%), p=0.33 <p>at 1 year follow-up (event rates in propensity score matched population)</p> <p>Mortality</p> <ul style="list-style-type: none"> - clopidogrel n = 47 (2.8%) - ticagrelor n = 12 (2.1%), p=0.41 - clopidogrel n = 37 (2.5%) - prasugrel n = 18 (3.6%), p=0.18 <p>MI</p> <ul style="list-style-type: none"> - clopidogrel n = 75 (4.4%) - ticagrelor n = 31 (5.5%), p=0.31 - clopidogrel n = 42 (2.8%) - prasugrel n = 22 (4.4%), p=0.08 | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Stroke</p> <ul style="list-style-type: none"> - clopidogrel n = 22 (1.3%) - ticagrelor n = 12 (2.1%), p=0.16 <ul style="list-style-type: none"> - clopidogrel n = 22 (1.5%) - prasugrel n = 7 (1.4%), p=0.93 <p>Bleeding events</p> <ul style="list-style-type: none"> - clopidogrel n = 33 (1.9%) - ticagrelor n = 17 (3.0%), p=0.14 <ul style="list-style-type: none"> - clopidogrel n = 33 (2.2%) - prasugrel n = 14 (2.8%), p=0.44 <p>Hazard Ratio (HR) 95% confidence interval (CI)</p> <p>Mortality</p> <p>Ticagrelor vs clopidogrel</p> <p>Unadjusted HR 0.49 (0.27–0.86)</p> <p>Multivariable adjusted HR 0.67 (0.38–1.19)</p> <p>Propensity adjusted HR 0.43 (0.20–0.92)</p> <p>Prasugrel vs clopidogrel</p> <p>Unadjusted HR 0.83 (0.52–1.33)</p> <p>Multivariable adjusted HR 1.54 (0.96–2.48)</p> <p>Propensity adjusted HR 1.42 (0.76–2.68)</p> <p>Myocardial infarction</p> <p>Ticagrelor vs clopidogrel</p> <p>Unadjusted HR 0.96 (0.67–1.37)</p> <p>Multivariable adjusted HR 1.26 (0.87–1.81)</p> <p>Propensity adjusted HR 1.07 (0.68–1.68)</p> <p>Prasugrel vs clopidogrel</p> <p>Unadjusted HR 0.77 (0.51–1.18)</p> <p>Multivariable adjusted HR 1.02 (0.67–1.57)</p> <p>Propensity adjusted HR 1.38 (0.81–2.34)</p> <p>Stroke</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Ticagrelor vs clopidogrel Unadjusted HR 0.75 (0.43–1.34) Multivariable adjusted HR 1.19 (0.67–2.12) Propensity adjusted HR 1.52 (0.72–3.24)</p> <p>Prasugrel vs clopidogrel Unadjusted HR 0.50 (0.24–1.06) Multivariable adjusted HR 0.94 (0.44–2.0) Propensity adjusted HR 0.94 (0.38–2.34)</p> <p>Bleeding events Ticagrelor vs clopidogrel Unadjusted HR 0.82 (0.51–1.34) Multivariable adjusted HR 1.38 (0.85–2.25) Propensity adjusted HR 1.77 (0.94–3.31)</p> <p>Prasugrel vs clopidogrel Unadjusted HR 0.77 (0.45–1.31) Multivariable adjusted HR 1.30 (0.76–2.23) Propensity adjusted HR 1.45 (0.75–2.80)</p> <p>adherence to P2Y12 inhibitor therapy</p> <ul style="list-style-type: none"> - mean PDC <ul style="list-style-type: none"> o clopidogrel 89.3 (SD 22.3), n = 14 408 o ticagrelor 89.4 (SD 21.0), n = 570, p=0.06 o prasugrel 88.1 (SD 22.1), n = 501, p=0.26 - PDC > 80 % <ul style="list-style-type: none"> o clopidogrel n = 11 914 (82,7%) o ticagrelor n = 462 (81,3%), p=0.40 o prasugrel n = 395 (78.8%), p=0.03 - switch <ul style="list-style-type: none"> o clopidogrel n = 289 (2.0%) o ticagrelor n = 109 (19.2%), p>0.001 o prasugrel n = 64 (12.8%), p>0.001 - persistence <ul style="list-style-type: none"> o clopidogrel n = 10671 (74.1%) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> o ticagrelor n = 397 (69.9%), p=0.03 o prasugrel n = 339 (67.7%), p=0.001 | | |

Squizzato et al. 2017 Clopidogrel + ASS vs. ASS (SR)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Squizzato A. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev 2017; 12(12):CD005158. https://www.ncbi.nlm.nih.gov/pub-med/29240976. [72]</p> | <p>Objectives to review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or were at high risk of atherothrombotic disease, but did not have a coronary stent</p> <p>Methods</p> <ul style="list-style-type: none"> - updated the searches of CENTRAL (2017, Issue 6), MEDLINE (Ovid, 1946 to 4 July 2017) and Embase (Ovid, 1947 to 3 July 2017) on 4 July 2017 - also searched ClinicalTrials.gov and the WHO ICTRP portal, handsearched reference lists - RCT comparing over 30 days use of ASS + clopidogrel or ASS alone - people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease | <p>n = 15 trials (n = 33,970 patients), reported in 30 references published between 2001 and 2017 (n = 13 studies in addition to n = 2 studies in the previous version)</p> <ul style="list-style-type: none"> - daily dose of clopidogrel was 75 mg, except for one study at 100 mg - ASS daily doses varied from 70 mg to 325 mg - minimum of six weeks to a maximum of 3.4 years (mean; range 0 to 8.2 years) <p>Outcomes ASS + clopidogrel vs. ASS (placebo)</p> <p>cardiovascular mortality</p> <ul style="list-style-type: none"> - RR 0.98, 95% CI 0.88 to 1.10; participants = 31,903; studies = 7; moderate quality evidence <p>all-cause mortality</p> <ul style="list-style-type: none"> - RR 1.05, 95% CI 0.87 to 1.25; participants = 32,908; studies = 9; low quality evidence <p>fatal and non-fatal myocardial infarction</p> <ul style="list-style-type: none"> - RR 0.78, 95% CI 0.69 to 0.90; participants = 16,175; studies = 6; moderate quality evidence <p>There was a reduction in the risk</p> <p>fatal and non-fatal ischaemic stroke</p> <ul style="list-style-type: none"> - RR 0.73, 95% CI 0.59 to 0.91; participants = 4006; studies = 5; moderate quality evidence <p>risk of major bleeding</p> <ul style="list-style-type: none"> - RR 1.44, 95% CI 1.25 to 1.64; participants = 33,300; studies = 10; moderate quality evidence <p>minor bleeding</p> <ul style="list-style-type: none"> - RR 2.03, 95% CI 1.75 to 2.36; participants = 14,731; studies = 8; moderate quality evidence | <p>AMSTAR-II high</p> <p>risk of bias was low in n = 4 trials (for all key domains, even if some of them were funded by the pharmaceutical industry)</p> <p>other studies had high risk of bias within the domain of blinding or other bias or unclear classifications in some other domains</p> <p>suggestion of publication bias was reported (funnel plot)</p> <p>according to the GRADE system, quality of evidence was generally moderate for all outcomes except all-cause mortality (low quality) and adverse events (very low quality evidence)</p> | <p>authors noted that available evidence demonstrates that the use of clopidogrel plus ASS in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and minor bleeding compared with ASS (quality of evidence was moderate for all outcomes except all-cause mortality (low quality evidence) and adverse events (very low quality evidence))</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - excluded people who had a coronary stent - studies on the optimal duration of clopidogrel plus aspirin therapy in people with coronary drug-eluting stent (DES) or non-DES (or both) were excluded <p>Quality assessment Risk-of-bias, GRADE</p> <p>Intervention ASS + clopidogrel</p> <p>Comperator ASS (+ placebo)</p> <p>no other platelet aggregation inhibitors as co-intervention were accepted</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - cardiovascular mortality, - all-cause mortality, - fatal and non-fatal myocardial infarction, - fatal and non-fatal ischaemic stroke, - adverse events <p>secondary</p> <ul style="list-style-type: none"> - major and minor bleeding <p>post hoc</p> <ul style="list-style-type: none"> - repeated revascularization - saphenous vein graft (SVG) patency - amputation | <p>insufficient data on adverse events for meta-analyses</p> <ul style="list-style-type: none"> - If reported, gastrointestinal disorders and infections were the most commonly reported (17% in the clopidogrel group and 9% in the placebo group) - minor adverse events: immune hypersensitivity, seasonal allergy, haematuria and renal failure for combination <p>overall</p> <p>n = 13 myocardial infarctions and n = 23 ischaemic strokes prevented for every 1000 patients treated with the combination in a median follow-up period of 12 months</p> <p>n = 9 major bleeds and n = 33 minor bleeds would be caused during a median follow-up period of 10.5 and 6 months</p> <p>repeated revascularization in the subgroup of participants undergoing coronary artery bypass grafting</p> <ul style="list-style-type: none"> - RR 0.50, 95% CI 0.09 to 2.72; participants = 413; studies = 2 <p>saphenous vein graft patency after a coronary artery bypass graft surgery</p> <ul style="list-style-type: none"> - RR 1.06, 95% CI 1.01 to 1.12; participants = 662; studies = 3 <p>amputation in the subgroup of participants undergoing a revascularization procedure for peripheral arterial disease</p> <ul style="list-style-type: none"> - RR 0.68, 95% CI 0.44 to 1.05; studies = 2; participants = 931 | | |

12.5.5 Empfehlung 7-6 duale Therapie nach invasiven Verfahren (orale Antikoagulation und Thrombozytenaggregation; in Bezug auf die Therapiedauer)

Montalto et al. 2023 Dauer einer dualen Therapie (SR/MA, nach PCI, Indikation zur Antikoagulation)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Montalto C. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2023; 9(3):220–30. https://www.ncbi.nlm.nih.gov/pub-med/36427063. [73]</p> | <p>Objective to evaluate the impact of DAPT duration after PCI irrespective of OAC type in patients with indication for such treatment</p> <p>Methods</p> <ul style="list-style-type: none"> - SR, MA, NMA - (search between Jan 2000 and Sep 2021) - databases and reference lists - PROSPERO CRD284001 - RCT - lifelong oral anticoagulant therapy (VKA, DOAC), indication of OAC - concomitant DAPT: <ul style="list-style-type: none"> o PCI or ACS (with/without PCI) – DAPT (abbreviated or prolonged) - comparison of abbreviated (< 3 months) vs. prolonged (≥ 3 months) strategy - treatment with short DAPT and DOAC vs. longer DAPT and VKA were excluded (type of OAC influenced the incidence of bleeding): aim to compare the influence of duration | <p>n = 5 RCT (n = 7 665 patients) (WOEST, ISAR-TRIPLE, AUGUSTS, SAFE-A, MASTER-DAPT)</p> <ul style="list-style-type: none"> - n = 3 843 abbreviated DAPT vs. n = 3 822 prolonged DAPT) - undergoing PCI or suffering ACS - concomitant indication of long-term OAC - mean age 72 years - main indication to OAC (AF): 92,2% - ACS 51,1% - DOAC 46,7% <ul style="list-style-type: none"> o apixaban 81,5% - DAPT <ul style="list-style-type: none"> o clopidogrel 79,2% - mean DAPT duration <ul style="list-style-type: none"> o prolonged 6 months (range 3-12 months) o abbreviated 3 months (range peri-procedural/in-hospital – 6 weeks) <p>results abbreviated DAPT vs. prolonged DAPT</p> <p>major bleeding</p> <ul style="list-style-type: none"> - 3.4% vs. 5.1% - RR 0.70 (0.52; 0.95), p = 0.01, n = 5 studies - NNT 58.8 <p>major or clinically relevant bleeding (MCRB)</p> <ul style="list-style-type: none"> - 10.2% vs. 16.3% - RR 0.69 (0.52; 0.91), p = 0.01, n = 5 studies - NNT 16.4 <p>MACE (major cardiovascular events)</p> <ul style="list-style-type: none"> - 7.1 vs. 7.0% - RR 0.96 (0.70; 1.33), p = 0.6, n = 5 studies | <p>AMSTAR-II low</p> <p>(keine Liste der ausgeschlossenen Volltexte mit Ausschlussgrund vorhanden)</p> <p>supplemental material (Word-Dokument)</p> <ul style="list-style-type: none"> - geringes Risk-of-Bias für die eingeschlossenen Studien <p>sensitivity analyses and subgroup analyses were performed</p> <p>network meta-analysis was planned (to compare peri-procedural vs. short vs. prolonged DAPT duration)</p> <p>heterogeneity in clinical endpoint definitions between studies included</p> | <p>graphical abstract available</p> <p>authors noted that OAC is mostly maintained long-term or life-long whereas DAPT duration is a key modifiable factor to balance ischemic and bleeding risk</p> <p>authors main findings:</p> <ul style="list-style-type: none"> - abbreviated DAPT (up to 6 weeks) in patients undergoing PCI or with ACS and concomitant OAC indication is associated with reduction of major bleeding and of major or clinically relevant bleeding vs. prolonged DAPT - abbreviated DAPT was |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> studies with DT with DOAC vs. TT with VKA were excluded <p>Intervention/Comperator</p> <ul style="list-style-type: none"> DAPT on top of OAC two-arm analysis (short vs. standard DAPT) <ul style="list-style-type: none"> abbreviated (≤ 6 weeks) prolonged (≥ 3 months) three-arm analysis (periprocedural vs. short vs. longer DAPT) <ul style="list-style-type: none"> periprocedural short (4-6 weeks) longer (≥ 3 months) <p>(NMA: impact of peri-procedural DAPT vs. longer treatment)</p> <p>Quality assessment Risk-of-Bias (RoB-2), GRADE</p> <p>Outcomes</p> <p>primary</p> <ul style="list-style-type: none"> occurrence of major bleedings composite of major or clinically relevant non-major bleedings (MCRB) <p>safety</p> <ul style="list-style-type: none"> composite of major adverse cardiovascular events (MACE) <p>secondary</p> <ul style="list-style-type: none"> MACE (all-cause deaths) | <p>MACE (major cardiovascular events with cardiovascular mortality instead of all-cause mortality)</p> <ul style="list-style-type: none"> RR 0.95 (0.75–1.2); P = 0.7 (supplement) <p>all-cause death</p> <ul style="list-style-type: none"> RR 0.89 (0.61; 1.31), n = 5 studies <p>cardiovascular death</p> <ul style="list-style-type: none"> RR 0.91 (0.68; 1.2), n = 5 studies <p>myocardial infarction</p> <ul style="list-style-type: none"> 3.1 vs. 2.5% RR 1.15 (0.81–1.60), p = 0.4, n = 5 studies <p>ischaemic stroke</p> <ul style="list-style-type: none"> 0.7 vs. 1.2% RR: 0.64 (0.32–1.26); p = 0.1, n = 5 studies <p>stent thrombosis</p> <ul style="list-style-type: none"> 0.7 vs. 0.5% RR: 1.24 (0.5–3.0); p = 0.6, n = 5 studies <p>results were consistent in the sensitivity and subgroup analysis</p> <p>authors noted for network meta-analysis</p> <ul style="list-style-type: none"> peri-procedural DAPT had the highest probability to prevent <ul style="list-style-type: none"> major or clinically relevant bleeding (97.1%) vs. 2.54% vs. 0.39% major bleeding (92.0%) vs. 6.87% vs. 1.12% MACE (58.4%) vs. 18.4% vs. 23.2% when compared with both short (4–6 weeks) and longer (≥ 3 months) DAPT regimens <p>MCRB, periprocedural DAPT vs. prolonged DAPT</p> <ul style="list-style-type: none"> OR 0.46 (0.25–0.77); high confidence <p>periprocedural DAPT vs. short DAPT</p> <ul style="list-style-type: none"> OR 0.53 (0.22–1.02); moderate confidence | | <p>not associated with an excess cardiac ischemic events</p> <ul style="list-style-type: none"> DAPT limited to peri-procedural/in-hospital period ranked highest to be the best treatment strategy to reduce bleeding events vs. short and prolonged DAPT |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - MACE (cardiovascular mortality) <ul style="list-style-type: none"> o individual definitions | major bleedings periprocedural DAPT vs. prolonged DAPT <ul style="list-style-type: none"> - RR 0.55 (0.29–0.97); high confidence periprocedural DAPT vs. short DAPT <ul style="list-style-type: none"> - RR 0.58 (0.23–1.26); moderate confidence | | |

Smits et al. 2022/2021 (RCT, ACS, nach PCI, hohes Blutungsrisiko, MASTER DAPT)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-------------|
| Smits PC. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. J Am Coll Cardiol 2022; 80(13):1220–37. https://www.ncbi.nlm.nih.gov/pub-med/36137672 . [74] | <p>OBJECTIVES: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction.</p> <p>METHODS: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anti-coagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding.</p> | <p>RESULTS: NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; P(interaction) = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; P(interaction) = 0.72) with abbreviated APT.</p> <p>CONCLUSIONS: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Biore-sorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).</p> | <i>Zunächst nicht bewertet und extrahiert (Abstract verfügbar)</i> | MASTER-DAPT |
| Smits PC. Abbreviated Antiplatelet Therapy in Patients at High Bleeding | <p>BACKGROUND: The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or</p> | <p>RESULTS: Net adverse clinical outcomes or major adverse cardiac and cerebral events did not differ with abbreviated versus nonabbreviated APT regimens in patients with OAC</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| <p>Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> 2021; 144(15):1196–211. https://www.ncbi.nlm.nih.gov/pub-med/34455849. [75]</p> | <p>without oral anticoagulation (OAC) after coronary stenting remains unclear.</p> <p>METHODS: In the investigator-initiated, randomize, open-label MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioreabsorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen), 4579 patients at high bleeding risk were randomized after 1-month dual APT to abbreviated or nonabbreviated APT strategies. Randomization was stratified by concomitant OAC indication. In this subgroup analysis, we report outcomes of populations with or without an OAC indication. In the population with an OAC indication, patients changed immediately to single APT for 5 months (abbreviated regimen) or continued ≥ 2 months of dual APT and single APT thereafter (nonabbreviated regimen). Patients without an OAC indication changed to single APT for 11 months (abbreviated regimen) or continued ≥ 5 months of dual APT and single APT thereafter (nonabbreviated regimen). Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes (composite of all-cause death, myocardial infarction, stroke, and Bleeding Academic Research Consortium 3 or 5 bleeding events); major adverse cardiac and cerebral events (all-cause death, myocardial infarction, and stroke); and</p> | <p>indication (n=1666; hazard ratio [HR], 0.83 [95% CI, 0.60-1.15]; and HR, 0.88 [95% CI, 0.60-1.30], respectively) or without OAC indication (n=2913; HR, 1.01 [95% CI, 0.77-1.33]; or HR, 1.06 [95% CI, 0.79-1.44]; P(interaction)=0.35 and 0.45, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding did not significantly differ in patients with OAC indication (HR, 0.83 [95% CI, 0.62-1.12]) but was lower with abbreviated APT in patients without OAC indication (HR, 0.55 [95% CI, 0.41-0.74]; P(interaction)=0.057). The difference in bleeding in patients without OAC indication was driven mainly by a reduction in Bleeding Academic Research Consortium 2 bleedings (HR, 0.48 [95% CI, 0.33-0.69]; P(interaction)=0.021).</p> <p>CONCLUSIONS: Rates of net adverse clinical outcomes and major adverse cardiac and cerebral events did not differ with abbreviated APT in patients with high bleeding risk with or without an OAC indication and resulted in lower bleeding rates in patients without an OAC indication. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03023020.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. | | | |
| <p>Frigoli E. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. Am Heart J 2019; 209:97–105. https://www.ncbi.nlm.nih.gov/pub-med/30703644. [76]</p> | <p>BACKGROUND: The optimal duration of antiplatelet therapy in high-bleeding risk (HBR) patients with coronary artery disease treated with newer-generation drug-eluting bioresorbable polymer-coated stents remains unclear. DESIGN: MASTER DAPT (clinicaltrials.gov-NCT03023020) is an investigator-initiated, open-label, multicenter, randomized controlled trial comparing an abbreviated versus a standard duration of antiplatelet therapy after bioresorbable polymer-coated Ultimaster (TANSEI) sirolimus-eluting stent implantation in approximately 4,300 HBR patients recruited from ≥100 interventional cardiology centers globally. After a mandatory 30-day dual-antiplatelet therapy (DAPT) run-in phase, patients are randomized to (a) a single antiplatelet regimen until study completion or up to 5 months in patients with clinically indicated oral anticoagulation (experimental 1-month DAPT group) or (b) continue DAPT for at least 5 months in patients without or 2 in patients with concomitant indication to oral anticoagulation, followed by a single antiplatelet regimen (standard antiplatelet regimen). With a final sample size of 4,300 patients, this study is powered to assess the noninferiority of the abbreviated antiplatelet regimen with respect to the net adverse clinical and major adverse cardiac and cerebral events composite end</p> | <p>CONCLUSIONS: The MASTER DAPT study is the first randomized controlled trial aiming at ascertaining the optimal duration of antiplatelet therapy in HBR patients treated with sirolimus-eluting bioresorbable polymer-coated stent implantation.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|-----------|
| | points and if satisfied for the superiority of abbreviated as compared to standard antiplatelet therapy duration in terms of major or clinically relevant nonmajor bleeding. Study end points will be adjudicated by a blinded Clinical Events Committee. | | | |

12.5.6 Zusatzinformation Hintergrundtext (E 7-6; Wirksamkeit und Sicherheit)

Bainey et al. 2020/2018 Rivaroxaban + ASS vs. ASS (RCT, PCI, COMPASS-PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-------------|
| Bainey KR. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> 2020; 141(14):1141–51. https://www.ncbi.nlm.nih.gov/pub-med/32178526 . [77] | <p>BACKGROUND</p> <p>The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, in patients with chronic coronary syndromes or peripheral arterial disease. Whether this remains true in patients with a history of percutaneous coronary intervention (PCI) is unknown.</p> <p>METHODS</p> <p>In a prespecified subgroup analysis from COMPASS, we examined the outcomes of patients with chronic coronary syndrome with or without a previous PCI treated with DPI versus</p> | <p>RESULTS</p> <p>Of the 27 395 patients in COMPASS, 16 560 patients with a chronic coronary syndrome were randomly assigned to DPI or aspirin, and, of these, 9862 (59.6%) had previous PCI (mean age 68.2±7.8, female 19.4%, diabetes mellitus 35.7%, previous myocardial infarction 74.8%, multivessel PCI 38.0%). Average time from PCI to randomization was 5.4 years (SD, 4.4) and follow-up was 1.98 (SD, 0.72) years. Regardless of previous PCI, DPI versus aspirin produced consistent reductions in MACE (PCI: 4.0% versus 5.5%; hazard ratio [HR], 0.74 [95% CI, 0.61-0.88]; no PCI: 4.4% versus 5.7%; HR, 0.76 [95% CI, 0.61-0.94], P-interaction=0.85) and mortality (PCI: 2.5% versus 3.5%; HR, 0.73 [95% CI, 0.58-0.92]; no PCI: 4.1% versus 5.0%; HR, 0.80 [95% CI, 0.64-1.00], P-interaction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI, 1.34-2.21]; no PCI: 2.9% versus 1.8%; HR, 1.58 [95% CI, 1.15-2.17], P-interaction=0.68). In those with previous PCI, DPI compared with aspirin produced consistent (robust) reductions in MACE irrespective of time since previous PCI (as early as 1 year and as far as 10 years; P-interaction=0.65), irrespective of having a previous myocardial infarction (P-interaction=0.64).</p> <p>CONCLUSIONS</p> | Zunächst nicht bewertet und extrahiert (Abstract verfügbar) | COMPASS-PCI |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | aspirin alone. Among patients with a previous PCI, we studied the effects of treatment according to the timing of the previous PCI. | DPI compared with aspirin produced consistent reductions in MACE and mortality but with increased major bleeding with or without previous PCI. Among those with previous PCI 1 year and beyond, the effects on MACE and mortality were consistent irrespective of time since last PCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01776424. | | |
| Anand SS. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> 2018; 391(10117):219–29. https://www.ncbi.nlm.nih.gov/pubmed/29132880 . [78] | <p>BACKGROUND</p> <p>Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.</p> <p>METHODS</p> <p>This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0.90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once</p> | <p>FINDINGS</p> <p>Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0.72, 95% CI 0.57-0.90, p=0.0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0.54 95% CI 0.35-0.82, p=0.0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0.86, 95% CI 0.69-1.08, p=0.19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0.67, 95% CI 0.45-1.00, p=0.05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1.61, 95% CI 1.12-2.31, p=0.0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1.68, 95% CI 1.17-2.40; p=0.0043).</p> <p>INTERPRETATION</p> <p>Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease.</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. | Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with aspirin alone, but reduced major adverse limb events and increased major bleeding. FUNDING Bayer AG. | | |
| Connolly SJ. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117):205–18. https://www.ncbi.nlm.nih.gov/pubmed/29132879 . [79] | BACKGROUND Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease. METHODS In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospitals, clinics, or community centres in 33 countries. This paper reports on patients with coronary artery disease. Eligible patients with coronary artery disease had to have had | FINDINGS Between March 12, 2013, and May 10, 2016, 27 395 patients were enrolled to the COMPASS trial, of whom 24 824 patients had stable coronary artery disease from 558 centres. The combination of rivaroxaban plus aspirin reduced the primary outcome more than aspirin alone (347 [4%] of 8313 vs 460 [6%] of 8261; hazard ratio [HR] 0.74, 95% CI 0.65-0.86, p<0.0001). By comparison, treatment with rivaroxaban alone did not significantly improve the primary outcome when compared with treatment with aspirin alone (411 [5%] of 8250 vs 460 [6%] of 8261; HR 0.89, 95% CI 0.78-1.02, p=0.094). Combined rivaroxaban plus aspirin treatment resulted in more major bleeds than treatment with aspirin alone (263 [3%] of 8313 vs 158 [2%] of 8261; HR 1.66, 95% CI 1.37-2.03, p<0.0001), and similarly, more bleeds were seen in the rivaroxaban alone group than in the aspirin alone group (236 [3%] of 8250 vs 158 [2%] of 8261; HR 1.51, 95% CI 1.23-1.84, p<0.0001). The most common site of major bleeding was gastrointestinal, occurring in 130 [2%] patients who received combined rivaroxaban plus aspirin, in 84 [1%] patients who received rivaroxaban alone, and in 61 [1%] patients who received aspirin alone. Rivaroxaban plus aspirin reduced mortality when compared with aspirin alone (262 [3%] of 8313 vs 339 [4%] of 8261; HR 0.77, 95% CI 0.65-0.90, p=0.0012). | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>a myocardial infarction in the past 20 years, multi-vessel coronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, patients were randomly assigned (1:1:1) to receive rivaroxaban (2.5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day). Randomisation was computer generated. Each treatment group was double dummy, and the patients, investigators, and central study staff were masked to treatment allocation. The primary outcome of the COMPASS trial was the occurrence of myocardial infarction, stroke, or cardiovascular death. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.</p> | <p>INTERPRETATION In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding. There was no significant increase in intracranial bleeding or other critical organ bleeding. There was also a significant net benefit in favour of rivaroxaban plus aspirin and deaths were reduced by 23%. Thus, addition of rivaroxaban to aspirin has the potential to substantially reduce morbidity and mortality from coronary artery disease worldwide.</p> <p>FUNDING Bayer AG.</p> | | |

Greenberg et al. 2019 Rivaroxaban + ASS vs. ASS (RCT, Post hoc Analyse, thromboembolische Ereignisse, HF, CAD, AF, COMMANDER HF)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------|
| <p>Greenberg B. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol 2019; 4(6):515–23. https://www.ncbi.nlm.nih.gov/pub-med/31017637. [80]</p> | <p>OBJECTIVE To examine whether low-dose rivaroxaban was associated with reduced thromboembolic events in patients enrolled in the COMMANDER HF trial.</p> <p>DESIGN, SETTING, AND PARTICIPANTS</p> | <p>RESULTS Of 5022 patients, 3872 (77.1%) were men, and the overall mean (SD) age was 66.4 (10.2) years. Over a median (interquartile range) follow-up of 19.6 (11.7-30.8) months, fewer patients assigned to rivaroxaban compared with placebo had a thromboembolic event including sudden/unwitnessed deaths: 328 (13.1%) vs 390 (15.5%) (hazard ratio, 0.83; 95% CI, 0.72-0.96; P = .01). When sudden/unwitnessed deaths were excluded, the results analyzing thromboembolic</p> | <p><i>Zunächst nicht bewertet und extrahiert (Abstract verfügbar)</i></p> | <p>COMMANDER-HF</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>Post hoc analysis of the COM-MANDER HF multicenter, randomized, double-blind, placebo-controlled trial in patients with CAD and worsening HF. The trial randomized 5022 patients postdischarge from a hospital or outpatient clinic after treatment for worsening HF between September 2013 and October 2017. Patients were required to be receiving standard care for HF and CAD and were excluded for a medical condition requiring anticoagulation or a bleeding history. Patients were randomized in a 1:1 ratio. Analysis was conducted from June 2018 and January 2019.</p> <p>INTERVENTION Patients were randomly assigned to receive 2.5 mg of rivaroxaban given orally twice daily or placebo in addition to their standard therapy.</p> <p>MAIN OUTCOMES AND MEASURES For this post hoc analysis, a thromboembolic composite was defined as either (1) myocardial infarction, ischemic stroke, sudden/unwitnessed death, symptomatic pulmonary embolism, or symptomatic deep venous thrombosis or (2) all of the previous components except sudden/unwitnessed deaths because not all of these are caused by thromboembolic events.</p> | <p>events were similar: 153 (6.1%) vs 190 patients (7.6%) with an event (hazard ratio, 0.80; 95% CI, 0.64-0.98; P = .04).</p> <p>CONCLUSIONS AND RELEVANCE In this study, thromboembolic events occurred frequently in patients with HF, CAD, and sinus rhythm. Rivaroxaban may reduce the risk of thromboembolic events in this population, but these events are not the major cause of morbidity and mortality in patients with recent worsening of HF for which rivaroxaban had no effect. While consistent with other studies, these results require confirmation in prospective randomized clinical trials.</p> <p>TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01877915.</p> | | |

NICE 2019 Rivaroxaban + ASS vs. ASS (HTA, koronare Herzkrankheit oder periphere arterielle Verschlusskrankheit)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>NICE -ER: Single Technology Appraisal Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [ID1397] Committee Papers. 17. Oktober 2019 https://www.nice.org.uk/guidance/ta607/evidence/committee-papers-pdf-6955673437 [81]</p> | <p>Objective main aim was to test the hypothesis that rivaroxaban 2.5mg bd plus aspirin (or rivaroxaban 5mg bd alone) was superior to aspirin in the above population</p> <p>Methods</p> <ul style="list-style-type: none"> - SR of RCT - adults with coronary or peripheral artery disease, excluding people with atrial fibrillation, at high risk of ischaemic events <p>Intervention rivaroxaban + ASS</p> <p>Comperator in stable CAD</p> <ul style="list-style-type: none"> - ASS - ASS in combination with ticagrelor 60 mg twice daily <p>in PAD</p> <ul style="list-style-type: none"> - ASS - Clopidogrel <p>Outcomes</p> <ul style="list-style-type: none"> - non-fatal myocardial infarction (STEMI and NSTEMI) - non-fatal stroke - urgent coronary, cerebrovascular or peripheral revascularisation - bleeding events | <p>rivaroxaban 2 x 2,5 mg / day + ASS vs. ASS n = 1 RCT (COMPASS trial)</p> <ul style="list-style-type: none"> - n = 9152 vs. n = 9126 patients - CAD and peripheral artery disease subgroup <ul style="list-style-type: none"> o n = 1656 vs. n = 1641 - CAD and heart failure subgroup <ul style="list-style-type: none"> o n = 1909 vs. 1912 - CAD and poor renal function subgroup <ul style="list-style-type: none"> o n = 1824 vs. n = 1873 <p>ticagrelor 2 x 60 mg / day + ASS vs. ASS n = 1 RCT (PEGASUS trial) – stable CAD (TA420)</p> <ul style="list-style-type: none"> - indirect treatment comparison (using the Bucher method) of rivaroxaban + ASS vs. ticagrelor + ASS <p>results primary composite of CV death, stroke, or myocardial infarction (COMPASS study)</p> <p>rivaroxaban 2 x 2,5 mg / Tag + ASS vs. ASS</p> <ul style="list-style-type: none"> - incidence: n = 376 (4.1%) vs. n = 496 (5.4%) - incidence rate (per 100 patient-years (95% confidence interval (CI))): <ul style="list-style-type: none"> o 2.18 per 100 PY (1.97-2.41) vs. o 2.88 per 100 PY (2.64-3.15) - HR 0.76 (95% CI 0.66; 0.86), p < 0.001 <p>sougroups CAD and Peripheral artery disease subgroup</p> <ul style="list-style-type: none"> - incidence: n = 94 (5.7%) vs. n = 138 (8.4%) - incidence rate: <ul style="list-style-type: none"> o 3.06 per 100 PY (2.47-3.75) vs. o 4.55 per 100 PY (3.83-5.38) - HR 0.67 (0.52-0.87), p = 0.00262 <p>CAD and heart failure subgroup</p> | <p>AMSTAR-II high</p> <p>ERG (review group) agrees with the company's assessment of the COMPASS RCT finding it to be a well-conducted study which is likely to be at a low risk of bias</p> <p>limitations some data were missing for ticagrelor 2 x 60 mg / day + ASS;</p> <p>there are a couple of clinical issues for the comparison of rivaroxaban 2.5mg bd + ASS and ticagrelor 60mg bd + ASS: heterogeneity regarding inclusion criteria (e. g. PEGASUS recruited patients with prior MI, while in the COMPASS trial the proportion of subjects with a history of MI was 62%); definition for major bleeding differs</p> <p>the are no key clinical issues in the comparison of rivaroxaban + ASS versus ASS</p> | <p>authors noted that coronary artery disease (CAD) or coronary heart disease (CHD) are the most common CVD</p> <p>few advances in anti-thrombotic therapy for secondary prevention of CV events; thrombotic risk is high (not the same for all patients with CAD)</p> <p>ischemic risk determined by patients history and extent of narrowing of coronary arteries</p> <p>patients with CAD have other risk factors such as PAD, heart failure or poor renal function</p> <p>The investigated mechanism of action of rivaroxaban has shown synergistic effects with aspirin in secondary prevention for patients with established cardiovascular disease.</p> <p>Rivaroxaban + aspirin in patients with estab-</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - limb ischemia (including limb amputation) - mortality - adverse effects of treatment - health-related quality of life <p>major bleeding was defined as a composite of:</p> <ul style="list-style-type: none"> - fatal bleeding, and/or - symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, or - bleeding into the surgical site requiring re-operation, and/or - bleeding leading to hospitalisation (with or without an overnight stay) <p>(subgroups:</p> <ul style="list-style-type: none"> - People with coronary artery disease who also have poor renal function - People with coronary artery disease who also have peripheral arterial disease - People who have had a previous myocardial infarction - People who have had multiple myocardial infarctions) <p>authors conducted an economic modelling (ASS vs. ticagrelor 60 mg</p> | <ul style="list-style-type: none"> - incidence: n = 105 (5.5%) vs. n = 151 (7.9%) - incidence rate: <ul style="list-style-type: none"> o 3.12 per 100 PY (2.55-3.78) vs. o 4.60 per 100 PY (3.89-5.39) - HR 0.68 (0.53-0.87), p = 0.002 <p>CAD and poor renal function subgroup</p> <ul style="list-style-type: none"> - incidence: n = 119 (6.5%) vs. n = 165 (8.8%) - incidence rate: <ul style="list-style-type: none"> o 3.42 per 100 PY (2.84-4.10) vs. o 4.71 per 100 PY (4.02-5.48) - HR 0.73 (0.57-0.92), p = 0.007 <p>intervention was superior to control and was stopped early after a mean follow-up of 23 months</p> <p>major bleeding (ISTH criteria, composite) (COMPASS study)</p> <p>rivaroxaban 2 x 2,5 mg / Tag + ASS vs. ASS</p> <ul style="list-style-type: none"> - incidence: n = 288 (3.1%) vs. n = 170 (1.9%) - incidence rate: <ul style="list-style-type: none"> o 1.67 per 100 PY (1.48-1.87) vs. o 0.98 per 100 PY (0.84-1.14) - HR 1.70 (1.40-2.05), p < 0.001 <p>souubgroups</p> <p>CAD and Peripheral artery disease subgroup</p> <ul style="list-style-type: none"> - incidence: n = 52 (3.1%) vs. n = 36 (2.2%) - incidence rate: <ul style="list-style-type: none"> o 1.70 per 100 PY (1.27-2.23) vs. o 1.17 per 100 PY (0.82-1.62) - HR 1.43 (0.93-2.19), p = 0.09819 <p>CAD and heart failure subgroup</p> <ul style="list-style-type: none"> - incidence: n = 49 (2.6%) vs. n = 36 (1.9%) - incidence rate: <ul style="list-style-type: none"> o 1.46 per 100 PY (1.08-1.92) vs. o 1.08 per 100 PY (0.76-1.50) | | <p>lished CAD or symptomatic PAD has been assessed by the EMA via the EU centralised procedure. Marketing authorisation was received on the 23 August 2018.</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | bd + ASS) (SR with single trial PEG-ASUS; NICE TA420) and rivaroxaban 2.5 mg bd + ASS vs. ASS (single trial, COMPASS); no head to head comparison → indirect treatment comparison (using the Bucher method) | <ul style="list-style-type: none"> - HR 1.35 (0.87-2.07), p = 0.17489 CAD and poor renal function subgroup <ul style="list-style-type: none"> - incidence: n = 75 (4.1%) vs. n = 55 (2.9%) - incidence rate: <ul style="list-style-type: none"> o 2.17 per 100 PY (1.71-2.72) vs. o 1.55 per 100 PY (1.16-2.01) - HR 1.41 (1.00-2.00), p = 0.05058 myocardial infarction (COMPASS study) rivaroxaban 2 x 2,5 mg / Tag + ASS vs. ASS <ul style="list-style-type: none"> - incidence: n = 178 (1.9%) vs. n = 205 (2.2%) - incidence rate: <ul style="list-style-type: none"> o 1.02 per 100 PY (0.87-1.18) vs. o 1.18 per 100 PY (1.03-1.36) - HR 0.86 (0.70-1.05), p = 0.14 stroke (COMPASS study) rivaroxaban 2 x 2,5 mg / Tag + ASS vs. ASS <ul style="list-style-type: none"> - incidence: n = 83 (0.9%) vs. n = 142 (1.6%) - incidence rate: <ul style="list-style-type: none"> o 0.47 per 100 PY (0.38-0.59) vs. o 0.82 per 100 PY (0.69-0.96) - HR 0.58 (0.44-0.76), p <0.001 CV death (COMPASS study) rivaroxaban 2 x 2,5 mg / Tag + ASS vs. ASS <ul style="list-style-type: none"> - incidence: n = 160 (1.7%) vs. n = 203 (2.2%) - incidence rate: <ul style="list-style-type: none"> o 0.91 (0.77-1.06) vs. o 1.16 (1.00-1.33) - HR 0.78 (0.64-0.96), p = 0.02 indirect comparison of rivaroxaban + ASS and ticagrelor + ASS in the COMPASS population | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | rivaroxaban + ASS vs. ASS / ticagrelor + ASS vs. ASS HR [95%CI] for comparison rivaroxaban + ASS vs ticagrelor + ASS Stroke/MI/CV death - HR 0.90 [0.75, 1.09] All-cause death - HR 0.92 [0.74, 1.15] CV death - HR 0.94 [0.71, 1.25] Stroke - HR 0.77 [0.53, 1.14] Ischaemic stroke - HR 0.67 [0.44, 1.02] Myocardial Infarction - HR 1.02 [0.79, 1.32] Major adverse limb event (MALE) - HR 0.65 [0.36, 1.18] Amputations - ITC not feasible Acute limb ischaemia (ALI) - HR 0.82 [0.26, 2.60] Venous thromboembolism (VTE) - HR 1.85 [0.06, 54.97] Major bleeding - HR 0.73 [0.50, 1.07] Intracranial bleeding - HR 0.87 [0.40, 1.89] Haemorrhagic stroke (HS) - HR 1.54 [0.44, 5.34] Gastrointestinal bleeding - ITC not feasible Fatal bleeding - HR 1.49 [0.47, 4.69] clinical treatment pathway (NICE recommendation) - recommendations differ during the acute period and long-term management | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - acute: dual therapy, followed by low-dose ASS monotherapy <ul style="list-style-type: none"> o ticagrelor 60 mg twice daily + ASS in patients experienced myocardial infarction 1-2 years earlier <p>(Table 1, page 7) pathways for CAD myocardial infarction (cardiac rehabilitation or further MI), CG172</p> <ul style="list-style-type: none"> - DAPT for up to 12 months (ASS + 2nd antiplatelet), followed by ASS monotherapy (clopidogrel if ASS is contraindicated or if hypersensitive to ASS) <p>stable angina (management), CG126</p> <ul style="list-style-type: none"> - ASS monotherapy <p>acute and long term management unstable angina and NSTEMI (early management), CG94</p> <ul style="list-style-type: none"> - ASS monotherapy (clopidogrel if hypersensitive) <p>ticagrelor 90 mg + ASS (TA236) prasugrel + ASS (TA182) rivaroxaban 2,5 mg twice daily + ASS (TA335)</p> <ul style="list-style-type: none"> - followed by <ul style="list-style-type: none"> o ticagrelor 60 mg twice daily + ASS o rivaroxaban 2,5 mg twice daily + ASS <p>note: Rivaroxaban, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. (restriction see within the publication page 8f)</p> <p>rivaroxaban 2.5 mg twice daily in combination with a daily dose of aspirin 75-100mg</p> <p>duration of treatment determined for each individual patient and should consider the risk for thrombotic events versus the bleeding risks</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Note: Other doses, tablet strengths used in other indications</p> <p>included studies Eikelboom JW et al N Engl J Med. 2017 Oct 5;377(14):1319-1330 Anand SS et al Lancet. 2018 Jan 20;391(10117):219-229</p> | | |

Zhao et al. 2018 Ticagrelor + ASS vs. Ticagrelor vs. ASS (RCT, 1 Jahr nach CABG)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------|
| <p>Zhao Q. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA 2018; 319(16):1677–86. https://www.ncbi.nlm.nih.gov/pub-med/29710164. [82]</p> | <p>OBJECTIVE To compare the effect of ticagrelor + aspirin or ticagrelor alone vs aspirin alone on saphenous vein graft patency 1 year after CABG.</p> <p>DESIGN, SETTING, AND PARTICIPANTS Randomized, multicenter, open-label, clinical trial among 6 tertiary hospitals in China. Eligible patients were aged 18 to 80 years with indications for elective CABG. Patients requiring urgent revascularization, concomitant cardiac surgery, dual antiplatelet or vitamin K antagonist therapy post-CABG, and who were at risk of serious bleeding were excluded. From July 2014 until November 2015, 1256 patients were identified and 500 were enrolled. Follow-up was completed in January 2017.</p> <p>INTERVENTIONS Patients were randomized (1:1:1) to start ticagrelor (90 mg twice daily) + aspirin (100 mg once daily) (n = 168), ticagrelor (90 mg twice</p> | <p>RESULTS Among 500 randomized patients (mean age, 63.6 years; women, 91 [18.2%]), 461 (92.2%) completed the trial. Saphenous vein graft patency rates 1 year post-CABG were 88.7% (432 of 487 vein grafts) with ticagrelor + aspirin; 82.8% (404 of 488 vein grafts) with ticagrelor alone; and 76.5% (371 of 485 vein grafts) with aspirin alone. The difference between ticagrelor + aspirin vs aspirin alone was statistically significant (12.2% [95% CI, 5.2% to 19.2%]; P < .001), whereas the difference between ticagrelor alone vs aspirin alone was not statistically significant (6.3% [95% CI, -1.1% to 13.7%]; P = .10). Five major bleeding episodes occurred during 1 year of follow-up (3 with ticagrelor + aspirin; 2 with ticagrelor alone).</p> <p>CONCLUSIONS AND RELEVANCE Among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone. Further research with more patients is needed to assess comparative bleeding risks.</p> <p>TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02201771.</p> | <p><i>Zunächst nicht bewertet und extrahiert (Abstract verfügbar)</i></p> | <p>(DACAB Studie)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|-----------|
| | <p>daily) (n = 166), or aspirin (100 mg once daily) (n = 166) within 24 hours post-CABG. Neither patients nor treating physicians were blinded to allocation.</p> <p>MAIN OUTCOMES AND MEASURES Primary outcome was saphenous vein graft patency 1 year after CABG (FitzGibbon grade A) adjudicated independently by a committee blinded to allocation. Saphenous vein graft patency was assessed by multislice computed tomographic angiography or coronary angiography.</p> | | | |

12.5.7 Empfehlung 7-7 Tripeltherapie (orale Antikoagulation + 2 Thrombozytenaggregationshemmer; in Bezug auf die Dosierung sowie Therapiedauer)

Shah et al. 2019 kurz- vs. langzeitige Tripeltherapie (SR, Stent, Indikation zur Antikoagulation)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Shah R. Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: A meta-analysis of randomized clinical trials. Coron Artery Dis 2019; 30(2):116–23. https://www.ncbi.nlm.nih.gov/pub-med/30589646. [83]</p> | <p>Objective to conduct a meta-analysis of selected RCT to assess the efficacy and safety of shorter duration (≤ 6 weeks) triple therapy (TT with OAC) vs. longer duration (6-12 months) TT</p> <p>Methods</p> <ul style="list-style-type: none"> - SR of RCT - PRISMA, meta-analyses guidelines - PubMed, ClinicalTrials, Cochrane databases - Cross-referencing | <p>n = 3 RCT (n = 1 883 patients)</p> <ul style="list-style-type: none"> - mean age 70.3 to 73.9 years - duration of TAT (short 4-6weeks, long 6-12 months) - OAC indication AF (69.4-100%) - index event ACS (27.5-50.1%) - index event stable CAD (49.1-72.5%) - clopidogrel (96.5-100%) - prasugrel (0.6-0.9%) - ticagrelor (2.5-2.6%) <p>Results short-term TT vs. long-term TT primary</p> | <p>AMSTAR-II moderate</p> <p>high quality trials based on Cochrane guidelines (low risk of bias)</p> <p>significant heterogeneity was reported, sensitivity analyses did not reveal an impact on summary results</p> <p>type of coronary stent and P2Y12-inhibitor varied across the studies</p> <p>open-label RCT</p> | <p>authors noted that oral anticoagulation (OAC) is indicated additional to DAPT in 5-10% of patients with coronary stents</p> <p>authors concluded that short-term TT after stenting was associated with similar rates of MI, stroke, stent thrombosis, and TIMI major bleeding, but</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> patients undergoing coronary stenting (PCI) including patients with additional indication of OAC (long-term use) <p>Intervention short-term triple therapy (TT), no more than 6 weeks</p> <p>Comperator long-term TT, 6-12 months</p> <p>Quality assessment Cochrane Risk-of-Bias tool</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> major adverse cardiovascular events (MACE), defined as composite of cardiac death, myocardial infarction, stent thrombosis, or stroke <p>secondary</p> <ul style="list-style-type: none"> cardiac mortality all-cause mortality myocardial infarction stroke stent thrombosis <p>safety</p> <ul style="list-style-type: none"> thrombolysis in myocardial infarction (TIMI) major bleeding any bleeding events | <p>MACE</p> <ul style="list-style-type: none"> RRR 31% RR 0.69 (95% CI 0.50; 0.96), p=0.031 <p>(subgroup analyses: short-term vs. 12 months: decreased risk (RR 0.60 (95% CI 0.41; 0.89), p = 0.011), short-term vs. 6 months: no difference (RR 1.01 (95% CI 0.54; 1.88), p = 0.97)</p> <p>secondary cardiac mortality</p> <ul style="list-style-type: none"> RR 0.62 (95% CI 0.43; 0.91), P = 0.014 <p>(subgroup analyses: short-term vs. 12 months: decreased risk (RR 0.62 (95% CI 0.41; 0.92), p = 0.02), short-term vs. 6 months: no difference (RR 0.67 (95% CI 0.27; 1.67), p = 0.39)</p> <p>all-cause mortality</p> <ul style="list-style-type: none"> RR 0.55 (95% CI 0.32; 0.97), p = 0.040 <p>(supplement: sensitivity analysis was nonsignificant, but with strong trend favouring short-term TT)</p> <p>myocardial infarction</p> <ul style="list-style-type: none"> RR 0.64 (95% CI 0.32; 1.30), p = 0.222 <p>(subgroup analyses showed similar results for 6 and 12 months (RR 1.26 (95% CI 0.23; 6.90), p = 0.78; RR 0.56 (95% CI 0.26; 1.21), p = 0.14)</p> <p>stroke</p> <ul style="list-style-type: none"> RR 0.913 (95% CI 0.43; 1.93), p = 0.811 <p>(subgroup analyses showed similar results for 6 and 12 months (RR 1.07 (95% CI 0.33; 3.41), p = 0.90; RR 0.81 (95% CI 0.30; 2.16), p = 0.67)</p> <p>stent thrombosis</p> <ul style="list-style-type: none"> RR 0.64 (95% CI 0.24; 1.72), p = 0.383 | <p>all patients received warfarin, thus findings not be generalized to patients receiving novel OAC (NOAC), but warfarin commonly used worldwide (cost, only anticoagulant effective for patients with mechanical valves)</p> | <p>with decreased rates of MACE, cardiac mortality, all-cause mortality, and any bleeding events</p> <p>subgroup analyses suggested that 6 months TT provided no benefit over short-term TT (≤ 6 weeks) and that prolonged TT beyond 6 months is harmful</p> <p>findings support the current guidelines</p> <p>discussion: combination of oral antiplatelet therapy and OAC significant increase the risk of bleeding (Gibson et al. N Engl J Med 2016)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>(subgroup analysis showed similar results for 6 and 12 months)</p> <p>safety</p> <p>major bleeding</p> <ul style="list-style-type: none"> - RR 1.10 (95% CI 0.70; 1.72), p = 0.664 - (subgroup: short-term vs. 12 months: RR 0.91 (95% CI 0.47; 1.77), p = 0.80, 6 months: RR 1.28 (95% CI 0.70; 2.35), p = 0.412) <p>any bleeding events</p> <ul style="list-style-type: none"> - RR 0.77 (95% CI 0.67; 0.89), p < 0.001 - (subgroup: short-term vs. 12 months: decreased risk (RR 0.60 (95% CI 0.48; 0.75), p < 0.001), 6 months: no difference RR 0.91 (95% CI 0.76; 1.09), p = 0.34)) <p>Included studies</p> <p>Dewilde et al. Lancet 2013 Use of clopidogrel with or without ASS in patients taking oral anticoagulant therapy and undergoing PCI: an open-label RCT (WOEST)</p> <p>Fiedler et al. J Am Coll Cardiol 2015 Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-Triple trial (ISAR-TRIPLE)</p> <p>Gibson et al. N Engl J Med 2016 Prevention of bleeding in patients with atrial fibrillation undergoing PCI. (PIONEER-AF-PCI)</p> <p>Gibson et al. Circulation 2017 Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin-K antagonist treatment strategy. (PIONEER-AF-PCI)</p> | | |

Peterson et al. 2021 duale (Dabigatran + P2Y₁₂) vs. Tripletherapie (Warfarin + P2Y₁₂ + ASS) (RCT, „Landmark“-Analyse, AF, PCI, RE-DUAL PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Peterson BE. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC Cardiovasc Interv 2021; 14(7):768–80. https://www.ncbi.nlm.nih.gov/pub-med/33826497. [84]</p> | <p>Objective to explore the early vs. late benefits and risks of dabigatran dual therapy vs. warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial</p> <p>Methods</p> <ul style="list-style-type: none"> - Landmark analysis of RE-DUAL PCI trial - open-label RCT - patients with nonvalvular atrial fibrillation - undergo PCI - USA (< 80 years), Japan (< 70 years), 3 arms - older patients (≥ 80 or 70 years) received 2 x 110 mg dabigatran, 2 arms - increased risk for bleeding and thrombotic events - 3 arms (1:1:1) <p>Intervention dabigatran 2 x 110 mg / day or dabigatran 2 x 150 mg / day + P2Y₁₂-inhibitor (no ASS)</p> <p>Comperator warfarin + P2Y₁₂-inhibitor + ASS (ASS discontinued after 90 days in patients with DES – drug-eluting</p> | <p>n = 2,725 patients</p> <ul style="list-style-type: none"> - all included in the main 30-days landmark analysis - n = 2,251 (82.6%) undergone stenting with DES <ul style="list-style-type: none"> o included in the secondary 90-days analysis o n = 1,425 with dabigatran DT o n = 826 with warfarin TT o mean time from PCI to randomization 1.5 ± 1.17 days (median 1 day) o median follow-up 12.9 months (IQR 9-18 months) <p>results before 30 days ISTH MBE (International Society on Thrombosis and Hemostasis; major bleeding event(s)/ CRNMBE (clinically relevant nonmajor bleeding event) dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 981 vs. n = 981 patients - n = 40 (4.1%) vs. n = 86 (8.8%) - HR 0.45 (0.31–0.66) p<0.0001 - ARD -4.7 <p>(ARD = absolute risk difference)</p> <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 763 vs. n = 764 - n = 29 (3.8%) vs. n = 61 (8.0%) - HR 0.46 (0.30–0.72) p=0.0006 - ARD -4.2 <p>DTE (death or thromboembolic event) or unplanned revascularisation dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 981 vs. n = 981 patients - n = 28 (2.9%) vs. n = 20 (2.0%) - HR 1.39 (0.79–2.47) p=0.26 - ARD 0.9 | <p>Selection bias randomization: low concealment and unpredictability: low</p> <p>Performance bias blinding of participants and staff: high (open-label)</p> <p>Detection bias blinding of evaluation: unclear (open-label; clinical endpoints were centrally adjudicated by independent committee members who were blinded to treatment assignment)</p> <p>Attrition bias lost to follow-up: low ITT-analysis: low (post hoc analyses, subgroup analyses; all patients enrolled were included in the main 30-day analysis)</p> <p>Reporting bias selective result presentation: low</p> <p>limitations open-label design</p> <p>multiple comparisons that exist with any secondary analysis of a clinical trial; study was not powered for this landmark analysis, nor was this a pre-specified analysis</p> | <p>Landmark analysis to understand whether dabigatran, ASS cessation, or both contribute to lower bleeding rates in DT vs. TT (early time period when ASS was withdrawn from both dabigatran arms)</p> <p>in 2016 RE-DUAL PCI results were first published (DT dabigatran 110 mg and 150 mg + clopidogrel vs. triple therapy with warfarin); significant reduced bleeding risk in DT vs. TT, DT noninferior to TT related to death or thromboembolic events or unplanned revascularisation</p> <p>authors concluded that the first 30 days post-PCI are the most critical, especially for bleeding risk</p> <p>authors concluded that in the early phase of treatment both doses of dabigatran plus a P2Y₁₂ inhibitor resulted in a substantial</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>stents and after 30 days in patients with BMS – bare-metal stents)</p> <p>after discontinuing ASS: DT with P2Y₁₂-inhibitor + warfarin or respective dose of dabigatran for 12 months</p> <p>P2Y₁₂-inhibitor = clopidogrel or ticagrelor</p> <p>Outcomes</p> <p>primary</p> <ul style="list-style-type: none"> - time to the first major or clinically relevant nonmajor (CRNM) bleeding event (definition: ISTH) - composite of time to DTE (myocardial infarction, stroke, or systemic embolism) or unplanned revascularization <p>secondary</p> <ul style="list-style-type: none"> - time to DTE, stent thrombosis, or myocardial infarction <p>Landmark analysis was performed at 30 and 90 days (patients with BMS were not included in the primary 90 days analyses, but in the supplement analyses and the primary 30 days analyses)</p> <p>protocol Cannon CP, Gropper S, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI Trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with</p> | <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 763 vs. n = 764 - n = 12 (1.6%) vs. n = 17 (2.2%) - HR 0.70 (0.33–1.46) p=0.34 - ARD -0.6 <p>net clinical benefit</p> <p>dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 981 vs. n = 981 patients - n = 66 (6.7%) vs. n = 100 (10.2%) - HR 0.65 (0.47–0.88) p=0.0062 - ARD -3.5 <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 763 vs. n = 764 - n = 41 (5.4%) vs. n = 74 (9.7%) - HR 0.54 (0.37–0.79) p=0.0015 - ARD -4.3 <p>after 30 days (14 months average)</p> <p>ISTH MBE (International Society on Thrombosis and Hemostasis; major bleeding event(s)/ CRNMBE (clinically relevant nonmajor bleeding event)</p> <p>dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 912 vs. n = 867 patients - n = 111 (11.9%) vs. n = 178 (20.3%) - HR 0.55 (0.43–0.69) p<0.0001 - ARD -8.4 <p>(ARD = absolute risk difference)</p> <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 721 vs. n = 679 - n = 125 (17.1%) vs. n = 135 (19.6%) - HR 0.82 (0.65–1.05) p=0.12 - ARD -2.5 | | <p>reduction in bleeding risk</p> <p>compared with warfarin TT (early net clinical benefit in both doses dabigatran), without increased numerical thrombotic events in dabigatran 2 x 150 mg during first 30 days:</p> <ul style="list-style-type: none"> - for dabigatran 110 mg (55% reduction in bleeding) - for dabigatran 150 mg (54% reduction in bleeding) - DT group with 2 x 110 mg dabigatran had numerical higher rates of DTE or unplanned revascularization |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol 2016;39:555–64.</p> <p>Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–24.</p> | <p>DTE (death or thromboembolic event) or unplanned revascularisation</p> <p>dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 912 vs. n = 867 patients - n = 121 (12.7%) vs. n = 111 (11.7%) - HR 1.09 (0.84–1.40) p=0.53 - ARD 1 <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 721 vs. n = 679 - n = 78 (10.4%) vs. n = 81 (11.0%) - HR 0.94 (0.69–1.28) p=0.67 - ARD -0.6 <p>net clinical benefit</p> <p>dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total: n = 912 vs. n = 867 patients - n = 196 (21.5%) vs. n = 249 (28.7%) - HR 0.70 (0.58–0.85) p=0.0002 - ARD -7.2 <p>dabigatran 2 x 150 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 721 vs. n = 679 - n = 181 (25.1%) vs. n = 185 (27.2%) - HR 0.88 (0.72–1.08) p=0.22 - ARD -2.1 <p>secondary endpoints show not statistically significant differences</p> <p>at 90 days among patients with DES</p> <p>ISTH MBE (International Society on Thrombosis and Hemostasis; major bleeding event(s)/ CRNMBE (clinically relevant nonmajor bleeding event)</p> <p>dabigatran 2 x 110 mg DAT vs. warfarin TT</p> <ul style="list-style-type: none"> - total n = 804 vs. n = 826 - n = 55 (6.8%) vs. n = 135 (16.3%) - HR: 0.40; 95% CI: 0.29 to 0.54; p < 0.0001 | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | dabigatran 2 x 150 mg DAT vs. warfarin TT <ul style="list-style-type: none"> - total n = 621 vs. n = 638 - n = 56 (9.0%) vs. n = 100 (15.7%) - HR: 0.54; 95% CI: 0.39 to 0.75; p = 0.0003 DTE (death or thromboembolic event) or unplanned revascularisation dabigatran 2 x 110 mg DAT vs. warfarin TT <ul style="list-style-type: none"> - total n = 804 vs. n = 826 - n = 37 (4.6%) vs. n = 30 (3.6%) - HR: 1.26; 95% CI: 0.78 to 2.04; p = 0.34 dabigatran 2 x 150 mg DAT vs. warfarin TT <ul style="list-style-type: none"> - total n = 621 vs. n = 638 - n = 24 (3.9%) vs. n = 25 (3.9%) - HR: 0.97; 95% CI: 0.55 to 1.70; p = 0.92 net clinical benefit dabigatran 2 x 110 mg DAT vs. warfarin TT <ul style="list-style-type: none"> - total n = 804 vs. n = 826 - 10.7% vs. 18.5% - HR: 0.55; 95% CI: 0.42 to 0.72; p < 0.0001 dabigatran 2 x 150 mg DAT vs. warfarin TT <ul style="list-style-type: none"> - total n = 621 vs. n = 638 - 12.2% vs. 18.2%; - HR: 0.64; 95% CI: 0.48 to 0.86; p = 0.0025 | | |

Keineis et al. 2019 NOAC duale vs. Tripletherapie vs. Warfarin Tripletherapie (RCT, AF, PIONEER AF-PCI)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Keineis M. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER | Objective to compare the rate of cardiovascular or bleeding related hospitalizations between rivaroxaban based with VKA based double therapy among | n = 2124 <ul style="list-style-type: none"> - group 1: n = 709 patients - group 2: n = 709 patients - group 3: n = 706 patients | Selection bias randomization: low concealment and unpredictability: | authors noted that PIONEER AF-PCI demonstrated that rivaroxaban + P2Y ₁₂ -inhibitor |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>AF-PCI Trial. Circ Cardiovasc Interv 2019; 12(11):e008160. https://www.ncbi.nlm.nih.gov/pub-med/31707805. [85]</p> | <p>subjects undergoing PCI enrolled in PIONEER AF-PCI trial</p> <p>Methods</p> <ul style="list-style-type: none"> - PIONEER AF-PCI - patients with paroxysmal, persistent, or permanent nonvalvular AF - underwent PCI - n = 2124 patients were randomized to 3 groups: <ul style="list-style-type: none"> o rivaroxaban 15 mg / day + P2Y₁₂-I for 12 months (1) o rivaroxaban 2 x 2,5 mg / day + DAPT for 1, 6 or 12 months(2) o standard: VKA + DAPT for 1, 6 or 12 months (3) - stratification according to prespecified duration of DAPT (1, 6, or 12 months) after prespecified DAPT duration subjects of (2) were switched to rivaroxaban 15 mg + low dose ASS; subjects of (3) were switched to VKA + low dose ASS - exclusion criteria e. g.: history of stroke or TIA, significant gastrointestinal bleeding within 12 months of randomization, creatinine clearance less than 30 mL per minute | <p>study period after the prespecified duration of DAPT (determined by study investigator)</p> <p>n = 906 were prespecified to a 1 or 6 months DAPT duration</p> <ul style="list-style-type: none"> - n = 716 with rivaroxaban and n = 361 with warfarin were included in the analyses (DT) <ul style="list-style-type: none"> o group 1: n = 359 (50.6%) riva + P2Y₁₂ o group 2: n = 357 (50.4%) riva + ASS o group 3: n = 361 (51.1%) VKA + ASS - mean age ~ 71 years - female ~ 25 % - P2Y₁₂: clopidogrel: 95.4 vs. 97 % - patients on rivaroxaban were more likely to have an elective revascularisation an take more often a beta blocker, ACE-inhibitor or ARB, and statins - median follow-up <ul style="list-style-type: none"> o 1 month DAPT: 332.0 days o 6 months DAPT: 183.0 days <p>results</p> <p>hospitalizations (at least one event) (patients)</p> <ul style="list-style-type: none"> - n = 93 (15.2%) patients assigned to NOAC + one antiplatelet agent (SAPT) - n = 65 (22.1%) patients assigned to VKA + SAPT <p>multiple hospitalizations (patients)</p> <ul style="list-style-type: none"> - n = 20 (3.3%) patients assigned to NOAC + one antiplatelet agent (SAPT) - n = 15 (5.1%) patients assigned to VKA + SAPT <p>primary endpoint (rehospitalizations)</p> <ul style="list-style-type: none"> - NOAC + SAPT vs. VKA + SAPT - n = 124 (20.3%) vs. n = 87 (29.6%) - 34.1 events per 100 patient years vs. 50.8 events per 100 patient years - HR 0.65 (95% CI 0.45; 0.93), p = 0.008 - no modification of treatment effect by HAS-BLED or CHA₂DS₂VASc scores | <p>low</p> <p>Performance bias</p> <p>blinding of participants and staff: high (open-label)</p> <p>Detection bias</p> <p>blinding of evaluation: unclear (open-label)</p> <p>Attrition bias</p> <p>lost to follow-up: low</p> <p>ITT-analysis: low (subgroup analyses)</p> <p>Reporting bias</p> <p>selective result presentation: low</p> <p>limitations</p> <p>open-label design</p> <p>sensitivity analyses were performed</p> <p>subgroup analyses; total number of subjects was low (underpowered)</p> <p>assumption that subjects adhere to their treatment regimen (ITT)</p> <p>early period after PCI (high risk period) was not included - analysis does not reflect the acute phase of first weeks after PCI</p> | <p>reduced the risk of re-hospitalization vs. VKA + DAPT in patients with AF undergoing PCI</p> <p>subgroup analysis adds that after discontinuation of one of the 2 antiplatelet agents, rivaroxaban based DT still reduced the rate of bleeding or cardiovascular related rehospitalization vs. VKA based regimen</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <ul style="list-style-type: none"> - all subjects with prespecified duration of 12 months DAPT were excluded <p>Intervention</p> <ul style="list-style-type: none"> - DT with rivaroxaban 15 mg + P2Y12-I (1) - DT with rivaroxaban 15 mg + low dose ASS* <p>Comperator</p> <ul style="list-style-type: none"> - DT with VKA + low dose ASS* <p>(*after prespecified DAPT duration)</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - bleeding and cardiovascular rehospitalizations among subjects on NOAC DT vs. VKA DT <p>analysed was the time after discontinuing/switch</p> <p>design and results published previously: Gibson et al. NEJM 2016 Gibson et al. AM Heart J 2015 (enthalten in Shah et al. 2019 [83])</p> | <ul style="list-style-type: none"> - 1 months DAPT group <ul style="list-style-type: none"> o 69 events vs. 49 events o 39.8 events per 100 patients years vs. 60.6 events per 100 patient years o HR 0.62 (0.37; 1.02), p = 0.010 - 6 months DAPT group <ul style="list-style-type: none"> o 55 events vs. 38 events o 29.0 events per 100 patient years vs. 42.0 events per 100 patients years o HR 0.74 (0.46; 1.17), p = 0.21 - rivaroxaban + P2Y₁₂-inhibitor vs. VKA + ASS <ul style="list-style-type: none"> o HR 0.62 (0.41; 0.93), p < 0.001 o DAPT 1 month: HR 0.44 (0.24; 0.83), p < 0.001 o DAPT 6 months: 34 vs. 38 (numerical) o details on supplement - rivaroxaban + ASS vs. VKA + ASS <ul style="list-style-type: none"> o HR 0.68 (0.44; 1.05), p = 0.026 o DAPT 1 month: 43 vs. 49 (numerical) o DAPT 6 months: 21 vs. 38 (numerical) o details on supplement | | |

12.5.8 Zusatzinformation Hintergrundtext (E 7-7)

Marquis-Gravel et al. 2020 (Vergleich internationaler Leitlinienempfehlungen, CAD)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------|
| Marquis-Gravel G. A Critical Comparison of Canadian and International Guidelines Recommendations | Objective | <p>DAPT duration</p> <ul style="list-style-type: none"> - multiple studies from the early 2010s demonstrated noninferiority of reduced DAPT duration | n. a. | authors noted that antiplatelet therapy for patients with CAD |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>for Antiplatelet Therapy in Coronary Artery Disease. Can J Cardiol 2020; 36(8):1298–307. https://www.ncbi.nlm.nih.gov/pub-med/32553812. [86]</p> | <p>to put Canadian guidelines into perspective via-a-vis international recommendations, major topics:</p> <ul style="list-style-type: none"> - DAPT duration following drug-eluting stent (DES) implantation - DAPT following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) and indication for OAC - DAPT management for noncardiac surgery following PCI with DES <p>Methods</p> <ul style="list-style-type: none"> - Scientific societies from Canada, United States and Europe published updated recommendations for CAD - 2018 Canadian Association of Interventional Cardiology (CCS) published 39 updated recommendations on antiplatelet therapy (management in AF, PCI) - 2016 the American College of Cardiology (ACC/AHA) published a focused update of DAPT duration - 2016 AHA/ACC/Heart Rhythm Society (HRS) published recommendations for AF, ACS - Since 2017 European societies published sequentially 5 different sets of guidelines or consensus documents (DAPT duration, DAPT in patients requiring OAC) - CCS categorized recommendations according to strength and level of evidence | <p>(< 12 months), following PCI (grounded by thrombotic and bleeding events)</p> <ul style="list-style-type: none"> - later studies for superiority showed that continuation of DAPT > 12 months was superior to interrupted DAPT within 12 months, following PCI with DES and in patients with myocardial infarction - multiple meta-analyses for bleeding risk in longer duration of DAPT <ul style="list-style-type: none"> o benefit for patients with MI and technically complex PCI - CCS, ACC/AHA, ESC provide 5, 14 and 24 recommendations on duration of DAPT (with 1-3 to 36 months), Table 1 within the publication - all guidelines agree that the individual approach should balance the likelihood of bleeding and expected thrombotic risk reduction <ul style="list-style-type: none"> o risk factors to weighing (supplement) o prediction models o risk score (validated) – lack of validation contributes to heterogeneous ways of implementation - ACC/AHA and ESC recommend a 6-month duration of DAPT (based on noninferiority trials) - CCS also recommends 6 months DAPT for most patients, but provides the option of continuing up to one year (thrombotic risk) - high-quality of evidence - in patients with high bleeding risk DAPT can be shortened to 3 months (all guidelines) - ESC provides an additional recommendation to 1 month if safety concerns with DAPT (2 large RCT, comparing novel stents with bare-metal in patients with high bleeding risk (no control with other length) (low grade recommendation) - CCS and ESC incorporate PCI complexity features as criteria to consider duration of DAPT beyond 6 months (MA of 6 RCT) – effect modifier | | <p>evolved dramatically over the last decades</p> <p>that dual antiplatelet therapy (DAPT) duration can be tailored to individual ischemic and bleeding risks</p> <p>that strategies to personalize antiplatelet therapy have been developed when concomitant oral anticoagulation (OAC) is indicated</p> <p>the review finds broad agreement across international expert consensus documents on the majority of recommendations (DAPT, TT, perioperative management),</p> <p>unanswered questions: place of ASS in secondary prevention of CAD, ASS-free strategies early after PCI, safe minimal duration of DAPT with newer-generation stents</p> <p>international committee with relevant expertise and representation could be a solution to update more frequently</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>Quality assessment GRADE</p> | <ul style="list-style-type: none"> - all guidelines recommend 12 months DAPT strongly for patients with ACS treated with PCI can be shortened to 6 months in patients at higher bleeding risk (exploration from trials with mixed population, stable angina and ACS) - all guidelines recommend prolonged DAPT >12 months in selected patients with lower bleeding than thrombotic risk (CCS 3 years, ACC/AHA and ESC > 12 months) - after 12 months CCS favours ticagrelor 60 mg twice daily or clopidogrel 75 mg over prasugrel (PEGASUS-TIMI and DAPT trial) - in patients with previous MI, the ESC suggests ticagrelor 60 mg 2x daily over ticagrelor 90 mg 2x daily or prasugrel (PEGASUS-TIMI, and MA) - ESC/EACTS on myocardial revascularization recommends the addition of rivaroxaban 2,5 mg twice daily to ASS and Clopidogrel in patients with ACS, no history of TIA or stroke, at high ischemic risk, and low bleeding risk (low-grade recommendation, based on TIMI trial) - 2019 ESC for CCS: addition of P2Y12-inhibitor or rivaroxaban 2,5 mg twice daily + ASS can be considered in patients at high and moderate ischemic risk and not at high risk of bleeding (long-term secondary prevention) (COMPASS trial) - absence of properly powered head-to-head RCT; expert opinion - future evidence: SMART-DATE (6 month duration), SMART-CHOICE (mono vs- duale therapy), STOPDAPT-2 (short and optimal duration), ISAR-REACT 5 (prasugrel vs. ticagrelor), TROPICAL-ACS (P2Y12-inhibitor de-escalation after discharge), TOPIC (timing) | | <p>and avoiding duplication of resources</p> <p>future directions: AUGUST trial (P2Y12-I + OAC after ACS, PCI), OAC apixaban or VKA + ASS or placebo</p> <p>ENTRUST-AF PCI (DT Edoxaban + P2Y12-I vs. TT with VKA), non-inferiority</p> <p>SAFE A (safety of apixaban + ASS + P2Y12-I)</p> <p>MASTER-DAPT (long term OAC)</p> <p>authors added some information for DAPT management after non-cardiac surgery (see within the publication)</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Antithrombotic therapy in patients with AF undergoing PCI</p> <ul style="list-style-type: none"> - evidence on long-term safety and efficacy of combination of different antiplatelet and OAC regimen - Gibson et al. NEJM 2016 (Rivaroxaban, PIO-NEER-AF-PCI), Cannon et al. NEJM 2017 (Dabigatran, Re-DUAL-PCI), Dewilde et al. Lancet 2013 (Clopidogrel, WOEST), Fiedler et al. J Am Coll Cardiol 2015 (Clopidogrel, ISAR-TRIPLE), Lopes et al. NEJM 2019 (Apixaban, AUGUST), Vranckx et al. Lancet 2019 (Edoxaban, EN-TRUST-AF PCI) - Limitations: <ul style="list-style-type: none"> o lack of statistical power (thrombotic events); o exclusion of patients in higher spectrum of bleeding risks (substantial proportion of the PCI population in clinical practice) o heterogenous guideline recommendations because some guidelines published before study results were published - CCS antiplatelet and AF guidelines provide 6 and 2 recommendations (AF, undergoing PCI) - 2019 AHA/ACC/HRS update provides 5 recommendations (AF and ACS) - ESC guidelines provide 9 recommendations (DAPT following PCI, indication for OAC) - also within the 2018 guideline myocardial revascularization - guidelines recommend (indication for OAC, undergoing PCI) a strategy involving a progressive decrease of antithrombotic intensity across 3 sequential time periods <ul style="list-style-type: none"> o initial period of TT o followed by period of dual pathway (OAC + single antiplatelet agent) o followed by OAC alone (\pm 1 antiplatelet agent) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - variations involved mainly the duration of each treatment phase <p>initial phase:</p> <ul style="list-style-type: none"> - CCS and ESC guidelines: peri-PCI period: TT duration may be extended up to 6 months (trade-off between bleeding and thrombotic risk) - in patients with ACS or undergoing elective PCI with high-risk thrombotic features guidelines allow discontinuation of ASS following the peri-PCI period or continuation of ASS up to 6 months (strong recommendation, moderate quality of evidence) - suggest a dual pathway with clopidogrel + AOC for at least 3 months after DES in absence of high-risk features (weak recommendation, moderate-quality evidence) - in ESC DT (clopidogrel + OAC) can replace the initial TT in patients at higher risk of bleeding than thrombotic risk (based on WOEST, PIONEER-AF-PCI), <i>note</i>: lack of statistical power - AHA/ACC/HRS favour dual pathway (OAC + P2Y12-inhibitor) after discharge following PCI (based on WOEST, RE-DUAL, PIONEER-AF-PCI) (no signals of harm with DT) - For those treated with TT, transition to DT at no longer than 4-6 weeks is considered - all guideline recommend clopidogrel as P2Y12-I - Standard dose ASS is preferred over high dose (81-100 mg/d) - OAC for TT: <ul style="list-style-type: none"> o rivaroxaban 2,4 mg twice daily (PIONEER-AF-PCI), or o warfarin (INR target 2.0-2.5) (CCS guidelines) o NOAC over warfarin, when combination is required (ESC 2019, ESC/EACTS, AHA/ACC/HRS) <p>treatment following the initial phase of TT</p> <ul style="list-style-type: none"> - all guidelines recommend dual pathway (OAC + antiplatelet agent) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - usually clopidogrel is antiplatelet agent of choice for DT in AF after PCI, ESC allow ASS (ISAR-TRI-PLE) - CCS do not recommend specific OAC agent (PIONEER-AF-PCI, RE-DUAL PCI, WOEST), rivaroxaban 15 mg / daily (10 mg in patients with renal dysfunction), dabigatran 110 or 150 mg twice daily, or warfarin - Dabogatran 110 mg twice daily not approved in USA (AHA/ACC/HRS DT with warfarin + clopidogrel or ticagrelor OR DT with dabigatran 2 x 150 mg daily or rivaroxaban 15 mg daily + clopidogrel) - ESC do not favour specific OAC for DT (if rivaroxaban is used: 15 mg daily (PIONEER-AF)) - 2019 ESC (CCS) also recommend dabigatran dose of 110 mg twice daily (over 150 mg twice daily) if bleeding concerns prevail over thrombotic concerns) <p>long-term phase</p> <ul style="list-style-type: none"> - beyond 12 months follow-up after PCI all guidelines recommend OAC alone (generally) - CCS: there is a provision to add a single antiplatelet agent to OAC, according to ischemic and bleeding risk (low-level evidence) | | |

Mishra et al. 2019 antithrombotische Therapie (SR, AF, PCI, u. a. Übersicht Dauer duale und Tripeltherapie)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Mishra A. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. J Cardiovasc Pharmacol 2019; 74(2):82–90. https://www.ncbi.nlm.nih.gov/pub-med/31306367. [87]</p> | <p>Objective to summarize data regarding the safety and efficacy of various antithrombotic regimens in patients with nonvalvular AF in the setting of PCI with DES, BMS and others</p> <p>Methods</p> | <p>n = 76 studies</p> <ul style="list-style-type: none"> - n = 8 guidelines - n = 35 RCT - n = 17 meta-analyses - n = 16 observational studies <p>Results antithrombotic regimen in patients with nonvalvular AF, PCI introduction:</p> | <p>AMSTAR-II critically low</p> <p>(no meta-analysis), no protocol, no list of excluded studies, no Risk-of-Bias assessment and no discussion of the Risk-of-Bias</p> | <p>authors concluded that in most patients with nonvalvular AF who requiring anticoagulation after PCI:</p> <p>30 days of TT followed by DT or DT alone for</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <ul style="list-style-type: none"> - SR: PubMed, Web of Science, Cochrane Library, ClinicalTrials, Google Scholar - RCT, MA, cohort studies, guidelines - ACS, CAD, AF - PCI | <ul style="list-style-type: none"> - ~15 % of patients with AF have a history of MI - ~5-15% will require stenting - ~18-47% have CAD - potential need for future PCI while receiving long-term OAC (oral anticoagulation) therapy - international guidelines agree the duration of TT should be minimized - TT duration depends on ischemic and bleeding risk - after 12 months of PCI, monotherapy with OAC is recommended in low ischemic risk <p>trials comparing DT with TT</p> <ul style="list-style-type: none"> - guidelines recommend the use of TT even for a short period - new RCT suggested that DT ist superior to TT (WOEST, ISAR-TRIPLE, Pioneer-AF, Re-DUAL): <ul style="list-style-type: none"> o WOEST: TT (ASS+clopidogrel+VKA) had higher rates of TIMI bleeding and all-cause mortality vs. DT (clopidogrel + VKA) o ISAR-TRIPLE: no difference in primary endpoint (composite) or TIMI major bleeding o Pioneer-AF: rivaroxaban group experienced less bleeding than VKA group, no differene in MACE or ST o Re-Dual: dabigatran groups had lower rates of bleeding than VKA group, MACE and ST did not differ - cohort studies suggest that the bleeding risk with TT is high, compared with DT, regardless of the regimen - meta-analyses found that the DT group had significant lower rates of thrombolysis in MI, major bleeding, minor bleeding compared to TT, with | | <p>up to 12 months seems appropriate</p> <p>TT can be extended for 3-6 months in ACS patients with intermediate to low bleeding propensity</p> <p>preferred agend should be clopidogrel (limited data for other P2Y12-I for DT and TT)</p> <p>NOAC have emerged as the preferred drug over VKA (in DT and TT combination)</p> <p>limited data suggest that reduced NOAC dose may be efficacious and safe</p> <p>bleeding risk should be considered, possible PPI use</p> <p>for most patients with AF 12 months after PCI, requiring OAC, antiplatelet therapy can be safely discontinued</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>similar rates of all-cause mortality, cardiovascular mortality, MI, ST, stroke</p> <p>NOAC and newer P2Y12-inhibitors (DT and TT), in AF NOAC vs. VKA:</p> <ul style="list-style-type: none"> - full-dose VKA was the OAC of choice in patients with AF - new evidence suggested that NOAC be noninferior or superior to VKA regimen in preventing thromboembolism with similar or better rates of bleeding - (ROCKET-AF, Danish health registry (Lee et al.), McWilliams et al.) <p>newer P2Y12-inhibitors (DT and TT)</p> <ul style="list-style-type: none"> - TRANSLATE-ACS, TRITON-TIMI, n = 2 cohort studies - no high-quality study exists comparing various regimen for TT with newer P2Y12-inhibitors - current guideline do not recommend the use of prasugrel or ticagrelor as part of TT regimen - a DT with prasugrel or ticagrelor may be appropriate for patients with high ischemic/thrombotic risk and low bleeding risk <p>shorter vs. longer DAPT duration, undergoing PCI</p> <ul style="list-style-type: none"> - tradeoff between bleeding and ischemic/ST risk - evidence on optimal standard duration is still lacking - EXCELLENT, OPTIMIZE, ITALIC, SECURITY, ISAR-SAFE, ARTIC, PRODIGY, DES-LATE - SMART-DATE - Benefit of extended DAPT may be stent specific - RESET, PRODIGY, DAPT trial, DAPT-STEMI trial <p>antithrombotic regimen in non-ACS AF patients undergoing PCI</p> <ul style="list-style-type: none"> - antiplatelet therapy after PCI was found to be safer and more effective than OAC | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - decision to give ≥ 12 months DAPT after PCI with first generation DES was based on expert opinion - no RCT for duration of DAPT in non-ACS undergoing PCI - Canadian guidelines recommend 1 (BMS) to 3 (DES) months of DT (VKA or rivaroxaban + clopidogrel) for low risk elective PCI and 1-6 months TT (VKA or rivaroxaban, clopidogrel + ASS), followed by DT through 12 months in high risk elective PCI - European guidelines do not differentiate antithrombotic regimen or duration based on stent type: TT (ASS, clopidogrel, VKA or NOAC) for 1 months followed by DT (clopidogrel or ASS + VKA or NOAC) up to 12 months for low ischemic risk patients - clopidogrel is the recommended P2Y12-inhibitor - CHEST guideline does not differentiate between SIHD and ACS in AF, PCI: 1-6 months of TT (ASS, clopidogrel, VKA or NOAC) in high thrombotic/low bleeding risk, followed by DT (clopidogrel and VKA or NOAC) until 12 months; 12 months DT in high bleeding/low thrombotic risk patients, 1-3 months TT in patients with balanced thrombotic/bleeding risk, followed by up to 12 months DT (similar recommendations for Noth American Expert Document) <p>antithrombotic regimen in elderly ≥ 65 years, need of anticoagulation</p> <ul style="list-style-type: none"> - high risk of MACE and bleeding - most patients are not eligible for higher doses, need reduced doses - TT only for single cases - DAPT may not be an optimal treatment for prevention of thromboembolism in AF - ongoing trials <p>strategies to improve bleeding complications</p> <ul style="list-style-type: none"> - gastrointestinal: proton-pump inhibitor (PPI) | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - interactions should be observed - NOAC preferred over VKA - Clopidogrel preferred to newer P2Y12-inhibitors - Low-dose ASS - Targeting a lower INR | | |

Kwon et al. 2021 Trends im antithrombotischen und antikoagulativen Therapieregime (Kohortenstudie, AF, PCI, Korea)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Kwon S. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Korean Circ J 2021; 51(5):409–22. https://www.ncbi.nlm.nih.gov/pub-med/33764010. [88]</p> | <p>Objective to investigate how periprocedural antithrombotic regimens have been changed since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) among Korean patients with AF undergoing PCI</p> <p>Methods</p> <ul style="list-style-type: none"> - retrospective cross-sectional study - claims database of the Health Insurance Review and Assessment during 2013–2018 - n = 27,594 patients with AF (diagnostic codes of I48.0-48.4 or I48.9) undergoing PCI (procedural codes of M6551, M6552, M6561-6564, M6571, and M6572) - patients with mitral stenosis (I50, I52, and I59) or prosthetic heart valves (Z952-Z954) were excluded <p>Intervention</p> | <p>n = 27,594 patients with AF undergoing PCI (2013-2018)</p> <ul style="list-style-type: none"> - number of patients with AF undergoing PCI: <ul style="list-style-type: none"> o n = 3,913 in 2013 o n = 5,075 in 2018 - number of patients who had coronary stent implantation <ul style="list-style-type: none"> o n = 3,380 (86.4%) in 2013 o n = 4,432 (87.3%) in 2018 - mean age <ul style="list-style-type: none"> o 69.4 years in 2013 o 71.3 years in 2018, (p for trend <0.001) - proportion of females <ul style="list-style-type: none"> o 35.2% in 2013 o 30.7% in 2018, (p for trend <0.001) - prevalence of dyslipidemia, congestive heart failure, and renal and liver diseases <ul style="list-style-type: none"> o increased over the years - prevalence of MI, intracranial hemorrhage, and gastrointestinal bleeding <ul style="list-style-type: none"> o decreased over the years o (p for trend <0.001 in all cases except intracranial hemorrhage [p for trend =0.009] and gastrointestinal bleeding [p for trend =0.004]) - CHA2DS2-VASc and HAS-BLED scores <ul style="list-style-type: none"> o 3.7±1.8 and 3.3±1.1 in 2013 o 4.0±1.9 and 3.5±1.0 in 2018 o (p for trend <0.001 for both scores) - CHA2DS2-VASc scores ≥2 | <p>n. a.</p> <p>limitations may be discrepancy between prescriptions and medications actually consumed</p> <p>lack of detailed clinical information or medical records</p> <p>study focused on the periprocedural period; long-term therapy was not assessed</p> | <p>authors concluded that since introduction of NOAC, the patterns of periprocedural antithrombotic regimens changed rapidly towards mor TAT (triple therapy), specially with NOAC</p> <p>to evaluate the risks of ischemic stroke and bleeding, the CHA2DS2-VASc and HAS-BLED scores were used; high risk: CHA2DS2-VASc score ≥2 or HAS-BLED score ≥3</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>antithrombotic agents:</p> <ul style="list-style-type: none"> - aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban) - (in Korea, NOAC was fully reimbursed after July 2015) <p>Outcomes</p> <ul style="list-style-type: none"> - annual prevalence of PCI and prescriptions of each antithrombotic agent, including antiplatelet agents and oral anticoagulants, within 30 days after PCI | <ul style="list-style-type: none"> o 89.1% in 2013 o 91.5% in 2018 <p>- HAS-BLED scores ≥ 3</p> <ul style="list-style-type: none"> o 80.0% in 2013 o 84.9% in 2018 <p>Temporal trends of antithrombotic regimens among patients with AF undergoing PCI 2013 vs. 2018</p> <ul style="list-style-type: none"> - Patients with AF undergoing PCI <ul style="list-style-type: none"> o n = 3,913 vs. n = 5,075 - Triple therapy (NOAC) <ul style="list-style-type: none"> o n = 39 (1.0%) vs. n = 2,027 (39.9%), p <0.001 - Triple therapy (warfarin) <ul style="list-style-type: none"> o n = 956 (24.4%) vs. n = 308 (6.1%), p <0.001 - Double therapy (NOAC) <ul style="list-style-type: none"> o n = 1 (0.0%) vs. n = 115 (2.3%), p <0.001 - Double therapy (warfarin) <ul style="list-style-type: none"> o n = 25 (0.6%) vs. n = 10 (0.2%), p <0.001 - DAPT <ul style="list-style-type: none"> o n = 2,815 (71.9%) vs. n = 2,525 (49.8%), p <0.001 - SAPT (single antiplatelet therapy) <ul style="list-style-type: none"> o n = 50 (1.3%) vs. n = 58 (1.1%), p = 0.284 - Patients with NOAC-based regimens <ul style="list-style-type: none"> o n = 40 vs. n = 2,142 - Patients with regular-dose NOAC <ul style="list-style-type: none"> o n = 17 (42.5%) vs. n = 398 (18.6%), p <0.001 - Patients with reduced-dose NOAC <ul style="list-style-type: none"> o n = 23 (57.5%) vs. n = 1,744 (81.4%), p <0.001 <p>subgroup analyses patients with high risk of systemic thromboembolism*</p> | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - n = 3,486 vs. n = 4,641 - Triple therapy (NOAC) <ul style="list-style-type: none"> o n = 38 (1.1%) vs. n = 1,904 (41.0%), p<0.001 - Triple therapy (warfarin) <ul style="list-style-type: none"> o n = 870 (25.0%) vs. n = 284 (6,1%), p<0,001 - DAPT <ul style="list-style-type: none"> o n = 2,489 (71.4%) vs. n = 2,254 (48.6%), p<0.001 <p>patients with high risk of bleeding</p> <ul style="list-style-type: none"> - n = 3,132 vs. 4,310 - Triple therapy (NOAC) <ul style="list-style-type: none"> o n = 36 (1.1%) vs. n =1,778 (41.3%), p>0.001 - Triple therapy (warfarin) <ul style="list-style-type: none"> o n = 802 (25,6%) vs. n = 256 (5,9%), p<0,001 - DAPT <ul style="list-style-type: none"> o n = 2,207 (70.5%) vs. n = 2,091 (48.5%), p<0.001 <p>NOAC type 2013 to 2018</p> <ul style="list-style-type: none"> - rivaroxaban and apixaban are the two most preferred NOACs - dabigatran uses 75.6% to 7.9% - apixaban use to 34.3% - edoxaban use to 24.2% <p>for P2Y12 inhibitors, clopidogrel was the most preferred choice (ticagrelor use has been substantially increased)</p> <p>Predictors of favoring triple antithrombotic therapy over dual antiplatelet therapy</p> <ul style="list-style-type: none"> - age ≥75 OR 1.890; 95% CI, 1.576–2.267 (most significant predictor of TAT) - age of 65–74 years, - congestive heart failure, - CHA2DS2-VASc scores ≥2, | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <ul style="list-style-type: none"> - hypertension, - systemic thromboembolic events favoring DAPT over TAT <ul style="list-style-type: none"> - female sex, - peripheral arterial disease, - MI, - dyslipidemia, - renal disease, - intracranial haemorrhage OR, 0.375; 95% CI, 0.170–0.827 (most potent predictor of DAPT) | | |

12.6 Versorgungskoordination

12.6.1 Daten aus dem deutschen Versorgungskontext

Qualitätsbericht 2021 Disease-Management-Programme Nordrhein

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Qualitätsbericht 2021 Disease-Management-Programme Nordrhein www.zi-dmp.de [89] | Die Autor*innen geben an, dass seit 1.5.2003 in Deutschland Verträge zum DMP KHK abgeschlossen werden können; in Nordrhein besteht der Vertrag seit 2004 (drittältestes strukturiertes Versorgungsprogramm) insbesondere die Symptomatik sowie die Lebensqualität der Betroffenen sollen günstig beeinflusst werden; weitere Ziele sind die Reduktion der Sterblichkeit sowie der kardiovaskulären Morbidität | In 2021 255 697 Betroffene im DMP KHK insgesamt (Abnahme um -6 317 im Vergleich zum Vorjahr) Hausärztlich betreut: 98,2% Anzahl der aktiven ärztlichen Teilnehmenden: 5 066 Betroffene mit aktueller Folgedokumentation: 248 368 (97,1%) (Abnahme um -5 851 im Vergleich zum Vorjahr) <ul style="list-style-type: none"> - Hinweis: alle nachfolgenden Darstellungen beziehen sich auf diese Teilgruppe Anteil Frauen: 35,1% Anzahl teilnehmender stationärer Einrichtungen: 61 Anteil der DMP-Betreuten von den Erkrankten: ca. 70% Mittleres Alter: 72,8 Jahre (SD 11,2) Alter ≥ 76 Jahre: 45,3% Mittlere DMP-Teilnahmedauer: 7,8 Jahre (SD 5,2 Jahre) DMP-Teilnahmedauer ≥ 10 Jahre: 35,4% | n. a. | Ausführliche Darstellung der Ziele unter www.zi-dmp.de/dmp-atlas_nrw als Herausforderung beschrieben wird das große Ausmaß an Multimorbidität bei Betroffenen im DMP KHK (Alter und Multimorbidität werde als von großer Bedeutung für die Weiterentwicklung des Programms beschrieben) |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>98,3% der Betreuten weisen mind. eine Begleit- und Folgeerkrankung auf:</p> <ul style="list-style-type: none"> - arterielle Hypertonie (88,5 Prozent) - Fettstoffwechselstörung (78,8 Prozent) - Diabetes mellitus (48,3 Prozent) - bei > einem Viertel: kardiovaskuläre Begleiterkrankung – also ein nicht tödlicher Herzinfarkt oder ein akutes Koronarsyndrom (ACS), eine chronische Herzinsuffizienz, eine arterielle Verschlusskrankheit oder ein nicht tödlicher Schlaganfall <p>Komorbidität</p> <ul style="list-style-type: none"> - keine/andere 24,5% - Diabetes mellitus 20,2% - kardiovaskulär 27,1% - Diabetes + kardiovaskulär 28,2% <p>Komorbidität im Detail (häufig dokumentierte Begleiterkrankung)</p> <ul style="list-style-type: none"> - Arterielle Hypertonie 88,5% - Asthma bronchiale 6,2% - Chronische Herzinsuffizienz 17,5% - COPD 17,2% - Diabetes mellitus 48,3% - Fettstoffwechselstörung 78,8% - Herzinfarkt oder akutes Koronarsyndrom 40,3% - Periphere arterielle Verschlusskrankheit (pAVK) 11,0% - Schlaganfall 5,1% - Multimorbidität (≥ 3 Begleiterkrankungen) 67,5% <p>Blutdruck (mmHg)</p> <ul style="list-style-type: none"> - < 130/85: 33,8% - 130/85 - <140/90: 30,8% - 140/90 - < 160/100: 28,0% - ≥ 160/100: 7,3% <p>LDL-Cholesterin</p> <ul style="list-style-type: none"> - < 70 mg/dl: 22,4% - ≥ 70 und < 100 mg/dl: 39,2% - ≥ 100 und ≤ 135 mg/dl: 25,1% - > 135 mg/dl: 13,3% | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Medikamentöse Therapie</p> <ul style="list-style-type: none"> - Thrombozytenaggregations-Hemmer (TAH): 82,8% - Antikoagulanzen: 11,1% - Betablocker: 77,1% - ACE-Hemmer: 66,4% - Sartane: 9,0% - Diuretika: 30,0% - Statine: 82,2% <p>Einflussfaktoren auf die Verordnungsquoten: Alter und Geschlecht sowie Begleiterkrankungen, z. B.</p> <ul style="list-style-type: none"> - bei Betroffenen mit anamnetisch dokumentiertem Herzinfarkt oder Schlaganfall erhöhte Verordnungshäufigkeit von TAH: 90,7% bzw. 87,2%, Betablockern (84,6% bzw. 79,8%) sowie Statinen (88,0% bzw. 83,8%) - bei Betroffenen mit chronischer Herzinsuffizienz höher Verordnungsquoten von Betablockern (84,2%) sowie ACE-Hemmern (70,3%) <p>Versorgungsqualität der Betroffenen im DMP KHK (zum April 2021: anhand verschiedener Qualitätsziele)</p> <ul style="list-style-type: none"> - die beiden Ziele zum Anteil an geschulten Patientinnen und Patienten sind derzeit noch nicht sinnvoll auswertbar - im aktuellen Berichtsjahr erstmalig Diabetes- und Hypertonieschulungen zusammengefasst - Aussagen zu den Schulungen beziehen sich nun auf einen Zeitraum von zwei Jahren - Betablocker-Verordnung bezieht sich nur noch auf Betroffene mit einem neu aufgetretenen Herzinfarkt - Veränderung hinsichtlich der Statin-Dokumentation (Erfassung, ob aktuell eine niedrige, mittlere oder hohe Statindosis verordnet wird + neues Qualitätsziel hinsichtlich der Frage, ob die Statin-Verordnung leitliniengerecht erfolgt) - weiteres neues Ziel: Anteil an KHK-Patientinnen und -Patienten, die regelmäßig sportliches Training betreiben | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | | <p>Von den derzeit auswertbaren Qualitätszielen mit quantitativer Vorgabe werden die Ziele hinsichtlich der Medikation erreicht und die Quote der Patientinnen und Patienten, denen das Vermeiden von Angina pectoris-Beschwerden gelingt, liegt deutlich über der Zielvorgabe (Abb. 2):</p> <p>Betroffene mit u. a.:</p> <p>Blutdruck < 140/90 mm Hg: 63,9% (140 384 von 219 785) Nicht-rauchen: 84,7% (210 450 von 248 358) TAH verordnet: 82,8% (181 738 von 219 505) Betablocker verordnet nach Herzinfarkt: 85,7% (1 423 von 1 661) Statine verordnet: 82,2% (192 586 von 234 248) Statine leitliniengerecht verordnet: 84,5% (162 735 von 192 586) keine Angina pectoris Beschwerden mehr: 93,9% (233 283 von 248 362) Sportliches Training betreiben: 31,3% (60 368 von 192 879), Limitation: betagtes Patient*innenkollektiv</p> <p>Im Bericht angegeben: langfristige zeitliche Veränderungen der erreichten Zielquoten in den meisten Zielvorgaben stabil</p> <p>z. B. kontinuierlich etwa zwei Drittel der Betroffenen mit arterieller Hypertonie erreichte einen Blutdruck unter 140/90 mmHg; etwas mehr als acht von 10 Betroffene erhielten Thrombozytenaggregationshemmer (TAH); leichter Anstieg bei Statinverordnungen (u. a. durch ausführlichere Dokumentationsvorgaben) sowie bei Betroffenen ohne Angina Pectoris Beschwerden</p> <p>ergänzend angegeben, dass seit 2021 in der KHK-Dokumentation nicht mehr unterschieden wird zwischen der Diabetes- und Hypertonie-Schulung zudem kann seit 2021 erstmals eine KHK-spezifische Schulung veranlasst werden, unabhängig von der Begleiterkrankung (die Zahl der empfohlenen Schulungen hat seitdem zugenommen)</p> | | |

Kirsch et al. 2020 Disease Management Program (guideline-adherence, patients with coronary artery disease after acute myocardial infarction)

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Kirsch et al. Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival. Eur J Health Econ. 2020 Jun;21(4):607-619. doi: 10.1007/s10198-020-01158-z. Epub 2020 Feb 1. https://pubmed.ncbi.nlm.nih.gov/32006188/</p> <p>[90]</p> | <p>Objective to compare guideline-recommended medication, health care expenditures, and survival of patients previously and continuously enrolled and not enrolled in the German DMP for coronary artery disease (CAD) after an AMI, from the perspective of a third-party payer over a follow-up period of 3 years</p> <p>Methods</p> <ul style="list-style-type: none"> - pseudonymized claims data provided by the Allgemeine Ortskrankenkasse Bayern (AOK Bayern), a large regional statutory health insurance fund in the German federal state of Bavaria, covering the years 2008–2014 - patients continuously insured within AOK Bayern - individuals with a hospitalization (main discharge diagnosis of AMI (ICD-10 I21)) between Jan 2009 and Dez 2011 - AMI before 2009 were excluded - AMI after 2011 were excluded to guarantee a 3-year follow-up period - patients were excluded if they died within 30 days after AMI, to avoid a nega- | <p>study population: 15,360 patients</p> <ul style="list-style-type: none"> - 4 100 enrolled and 11 260 not enrolled in the DMP - propensity score matching: 3 870 pairs of patients enrolled and not enrolled in the DMP CAD after AMI - median age 74 years - female: ~34% - smokers: 5-7% - dyslipidemia: 18-19% - atrial hypertonia: 30-32% <p>after matching, only the standardized mean difference of HMG compensations (0.161) were above the threshold of 0.10</p> <p>Results primary (DMP vs. not DMP)</p> <p>PDC</p> <ul style="list-style-type: none"> - PDC rates over the three year follow up after AMI: <ul style="list-style-type: none"> o anti-platelet agents: 76.43% vs. 70.66% o statins: 54.18% vs. 52.13% o ACE-inhibitors: 60.95% vs. 58.92% - PDC rates over the first year after AMI: <ul style="list-style-type: none"> o β-blockers: 61.95% vs. 52.64% o only the difference for β-blockers were rated as statistically significant (<i>supplement Table 2; DOCX-document</i>) <p>Costs (DMP vs. not DMP)</p> <ul style="list-style-type: none"> - adjusted mean health care expenditures per day per person for all three observation years: <ul style="list-style-type: none"> o €58.24 [€53.36;€63.81] vs. o €72.72 [€67.56;€78.38] o p < 0.001 - adjusted mean health care expenditures per day per person for the first observation year: | <p>n. a.</p> <p>note: supplement only available as Word-document</p> <p>Limitations:</p> <p>only data from a large regional statutory health insurance fund in the German federal state of Bavaria (eingeschränkte Übertragbarkeit)</p> <p>“caliper” matching tends to result in estimates of treatment effect with less bias compared to other methods (konservativer Ansatz)</p> <p>long period, 1 year before AMI and a 3-year follow-up period were available (Vorteil gegenüber RCT; versorgungsnaher Analyse)</p> <p>socioeconomic status, which may differ from their individual status (deprivation index as a proxy); e. g. a significant positive impact of height of old-age pensions on enrollment in the DMP (well balanced after matching)</p> <p>treatment choices may be based on selection bias (no RCT); unmeasured confounding</p> <p>(pharmacy-dispensing data were used (PDC), which does not allow definite judgment as to whether</p> | <p>hypothesis: adherence to guideline recommended medication has a protective effect on death in patients after AMI:</p> <ul style="list-style-type: none"> - an extended model was estimated that included the additional covariates of PDC rates for antiplatelet agents, statins, β-blockers, and ACE-inhibitors <p>authors noted that being enrolled in the DMP CAD after AMI is a promising strategy as it is associated with enhanced guideline-recommended medication, lower total health care expenditures and reduced risk of death</p> <p>authors discussed a protective effect of being female on survival and assumed that women after hospital discharge might have a better prognosis;</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>tive overestimation of proportion of days covered (PDC) rates</p> <ul style="list-style-type: none"> patients were excluded as control if they were enrolled in the DMP CAD during the year before AMI or during the 3-year follow-up period <p>propensity score (1:1) matching with caliper method was conducted</p> <p>generalized linear and Cox proportional hazard models were used</p> <p>hierarchical morbidity group (HMG) compensation (control variable)</p> <ul style="list-style-type: none"> related to 80 costly chronic diseases and serious illnesses (1-year follow-up costs of the HMG group from a regression analysis) differentiated comorbidity index HMG groups in the year before index date compensations reflect the predicted costs in the first year after the index date <p>confirmed by the ethics committee of the State Chamber of Physicians of Bavaria, no ethical approval was required for this study</p> <p>Intervention patients enrolled in the Disease Management Program (DMP)</p> | <ul style="list-style-type: none"> €71.18 [€66.55;€76.26] vs. €85.45 [€80.28;€90.84] p < 0.001 <p>Details:</p> <ul style="list-style-type: none"> Health care expenditures year 2 <ul style="list-style-type: none"> N=3337 €24.05 [€21.79;€26.45€] vs. N=3106 €22.98 [€20.69;€25.34] Health care expenditures year 3 <ul style="list-style-type: none"> N=3008 €22.04 [€19.98;€24.53€] vs. N=2684 €19.45 [€17.42;€21.73] Outpatient care all 3 years <ul style="list-style-type: none"> N=3870 €3.06 [€2.38;€3.90€] vs. N=3870 €2.75 [€2.20;€3.48€] Outpatient care year 1 <ul style="list-style-type: none"> N=3870 €2.95 [€2.20;€3.90] vs. N=3870 €2.75 [€2.14;€3.57] Outpatient care year 2 <ul style="list-style-type: none"> N=3337 €2.65 [€1.94;€3.83] vs. N=3106 €2.37 [€1.75;€3.34] Outpatient care year 3 <ul style="list-style-type: none"> N=3008 €3.16 [€2.17;€4.89] vs. N=2684 €2.14 [€1.50;€3.19] p < 0.05 Medication all 3 years <ul style="list-style-type: none"> N=3870 €3.95 [€3.68;€4.23] vs. N=3870 €4.17 [€3.92;€4.45] Medication year 1 <ul style="list-style-type: none"> N=3870 €4.63 [€4.33;€4.92] vs. N=3870 €4.80 [€4.49;€5.15] Medication year 2 <ul style="list-style-type: none"> N=3337 €3.21 [€2.90;€3.56] vs. N=3106 €3.18 [€2.93;€3.47] Medication year 3 <ul style="list-style-type: none"> N=3008 €2.66 [€2.42;€3.01] vs. N= 2684 €2.71 [€2.44;€3.03] Hospitalization all 3 years*** <ul style="list-style-type: none"> N=3870 €48.60 [€44.00;€54.07] vs. N=3870 €61.85 [€56.73;€67.43] p < 0.001 Hospitalization year 1 | <p>patients had actually taken the medication collected at the pharmacy); Vorteil gegenüber Fragebögen: Vollständigkeit der Daten (Rücklaufquote)</p> <p>for all covariates, correlation of Schoenfeld residuals with survived days was examined, and the Kolmogorov–Smirnov supreme test was conducted; additionally sensitivity analyses were performed (Korrekturen für multiples Testen wurden nicht beschrieben)</p> | <p>as well as for angina pectoris, where several other studies available which found a relationship estimating a prognostic value of preinfarction angina pectoris by indicating less extensive infarct size resulting in better short- and long-term survival</p> |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>for coronary artery disease (CAD) after an AMI</p> <p>Comperator patients not enrolled enrolled in the DMP after an AMI</p> <p>Outcomes primary</p> <ul style="list-style-type: none"> - adherence rates (based on proportions of days covered (PDC)) - average overall costs in euro (€) per person per day insured - survival days <p>adherence based on ATC: anatomical therapeutic chemical classification system for: anti-platelet agents (B01A), statins (C10), β-blockers (C07), and angiotensin converting enzyme (ACE) inhibitors (C09A and C09B)</p> <p>PDC (observation period): the total number of days supplied for filled prescriptions, given the number of defined daily doses (DDD) per prescription</p> <p>DDDs supplied by the scientific institute of the AOK ('WIdO') based on a German adaption of the WHO database (if discrepancies were seen, the dosage from the national guidelines was used)</p> | <ul style="list-style-type: none"> o N=3870 €59.92 [€55.32;€64.77] vs. o N=3870 €72.86 [€67.87;€77.97] - Hospitalization year 2 <ul style="list-style-type: none"> o N=3337 €16.46 [€14.65;€18.44] vs. o N=3106 €16.03 [€14.27;€17.85] - Hospitalization year 3 <ul style="list-style-type: none"> o N=3008 €14.99 [€13.37;€16.83] vs. o N=2684 €13.55 [€11.85;€15.28] - Rehabilitation all 3 years <ul style="list-style-type: none"> o N=3870 €1.91 [€1.72;€2.11] vs. o N=3870 €2.39 [€2.16;€2.65] o p < 0.001 - Rehabilitation year 1 <ul style="list-style-type: none"> o N=3870 €3.14 [€2.93;€3.37] vs. o N=3870 €3.52 [€3.27;€3.77] o p < 0.05 - Rehabilitation year 2 <ul style="list-style-type: none"> o N=3337 €0.45 [€0.36;€0.56] vs. o N=3106 €0.35 [€0.28;€0.43] - Rehabilitation year 3 <ul style="list-style-type: none"> o N=3008 €0.35 [€0.27;€0.43] vs. o N=2684 €0.30 [€0.24;€0.37] - Remedies all 3 years <ul style="list-style-type: none"> o N=3870 €1.11 [€1.01;€1.22] vs. o N=3870 €1.46 [€1.34;€1.61] o p < 0.001 - Remedies year 1 <ul style="list-style-type: none"> o N=3870 €1.11 [€1.01;€1.22] vs. o N=3870 €1.49 [€1.35;€1.64] o p < 0.001 - Remedies year 2 <ul style="list-style-type: none"> o N=3337 €0.70 [€0.62;€0.78] vs. o N=3106 €0.90 [€0.80;€1.02] o p < 0.001 - Remedies year 3 <ul style="list-style-type: none"> o N=3008 €0.81 [€0.70;€0.95] vs. o N=2684 €0.80 [€0.70;€0.96] | | |

| Referenz | Charakteristika / Methodik | Ergebnisse | methodische Qualität / Sonstiges | Kommentar |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------|
| | <p>in case of hospitalizations, it was assumed that drugs were supplied by the hospital and thus the number of days that needed to be covered was reduced by the length of hospital stays</p> <p>costs were calculated by summing up every patient's costs by category and year and dividing them by the number of days the patient was insured in that period</p> | <ul style="list-style-type: none"> - authors noted that hospitalization costs far exceeded costs of medication, outpatient care, rehabilitation, and remedies for each observation year - differences mainly driven by higher inpatient expenditures in the first year after AMI - compared to the first year after AMI, in which significantly higher health care expenditures arise in the non-DMP group with regard to hospitalization ($p < 0.001$), rehabilitation ($p < 0.05$) and remedies ($p < 0.001$), in year two only costs for remedies ($p < 0.001$) and in year three only costs for ambulatory care ($p < 0.05$) were significantly different <p>Survival days (DMP vs. not DMP)</p> <ul style="list-style-type: none"> - base case survival analysis (Table 3 and Fig. 2) <ul style="list-style-type: none"> o hazard ratio (HR) 0.757 (95% CI 0.700–0.819) o $p < 0.001$ - authors noted significant confounder: e. g. additional enrollment in DMP COPD and DMP type 2 diabetes; as well as age and congestive heart failure, atrial hypertonia (increased risk of death) | | |

Literatur

1. Porst M, Lippe Ev, Leddin J, et al. The Burden of Disease in Germany at the National and Regional Level-Results in Terms of Disability-Adjusted Life Years (DALY) from the BURDEN 2020 Study. *Dtsch Arztebl Int* 2022; 119(46):785-792. DOI: 10.3238/arztebl.m2022.0314. <http://www.ncbi.nlm.nih.gov/pubmed/36350160>.
2. Robert Koch-Institut (RKI). Ergebnisdatensatz BURDEN 2020 – Krankheitslast in Deutschland und seinen Regionen. 2022 [cited: 2023-10-02]. DOI: 10.5281/zenodo.7323766. <https://www.daly.rki.de/map>.
3. Robert Koch-Institut (RKI). Gesundheitliche Lage der erwachsenen Bevölkerung in Deutschland – Ergebnisse der Studie GEDA 2019/2020-EHIS. *J Health Monit* 2021; 6(3). https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloads/J/JoHM_03_2021_GEDA_2019_2020_EHIS.html.
4. Robert Koch-Institut, editor. Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes. Gemeinsam getragen von RKI und Destatis. Berlin: RKI; 2015. http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtld/gesundheits_in_deutschland_2015.pdf.
5. Wissenschaftliches Institut der AOK (WIdO). Woran erkranken wir in Deutschland? Häufigkeiten ausgewählter Krankheiten unter allen Einwohnern in den Regionen Deutschlands. 2017 [cited: 2023-10-02]. <https://www.krankheitslage-deutschland.de/>.
6. Zentralinstitut der kassenärztlichen Bundesvereinigung (ZI), Zentralinstitut der kassenärztlichen Bundesvereinigung. Versorgungsatlas – Dashboard häufige chronische Krankheiten. Koronare Herzkrankheit. 2021 [cited: 2023-10-02]. <https://www.versorgungsatlas.de/dashboard/#/evaluation/1005>.
7. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Deutsche Gesellschaft für Innere Medizin (DGIM), Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK). S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung. Nr. 15 Evidenzreport [in Erstellung][cited: 2023-05-25]. <https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung>.
8. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Deutsche Gesellschaft für Innere Medizin (DGIM), Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK). S3-Leitlinie Brustschmerz - DEGAM-Leitlinie für die primärärztliche Versorgung [in Erstellung][cited: 2023-05-25]. <https://register.awmf.org/de/leitlinien/detail/053-023#anmeldung>.
9. Harskamp RE, Laeven SC, Himmelreich JC, et al. Chest pain in general practice: A systematic review of prediction rules. *BMJ open* 2019; 9(2):e027081. DOI: 10.21037/jccm.2018.01.10. <http://www.ncbi.nlm.nih.gov/pubmed/30819715>.
10. Juarez-Orozco LE, Saraste A, Capodanno D, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. *Eur Heart J Cardiovasc Imaging* 2019; 20(11):1198–207. DOI: 10.1093/ehjci/jez054. <http://www.ncbi.nlm.nih.gov/pubmed/30982851>.
11. Haase R, Schlattmann P, Gueret P, et al. Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: Meta-analysis of individual patient data. *BMJ (Clinical research ed.)* 2019; 365:11945. DOI: 10.1136/bmj.11945. <http://www.ncbi.nlm.nih.gov/pubmed/31189617>.
12. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Computertomografie-Koronarangiografie mit oder ohne funktionelle Beurteilung zur Diagnose einer chronischen koronaren Herzkrankheit - Vorbericht (vorläufige Nutzenbewertung). Projekt: D22-01. Version 1.0. 2023 [cited: 2023-05-26]. <https://www.iqwig.de/projekte/d22-01.html>.
13. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Computertomografie-Koronarangiografie mit oder ohne funktionelle Beurteilung zur Diagnose einer chronischen koronaren Herzkrankheit. Abschlussbericht. Projekt: D22-01. Version 1.1. 2023 (IQWiG-Berichte; 1570) [cited: 2023-07-03]. <https://www.iqwig.de/projekte/d22-01.html>.
14. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). CT- oder MRT-Diagnostik bei Verdacht auf chronische koronare Herzkrankheit: eine Evidenzkartierung. Arbeitspapier. Auftrag GA20-01. Version 1.0. 2020 (IQWiG-Berichte; 920) [cited: 2023-05-26]. <https://www.iqwig.de/projekte/ga20-01.html>.
15. Rolf A, Schmermund A, Hell MM, et al. Qualitätskriterien für die Erbringung kardialer CT-Leistungen. *Kardiologie* 2023; 17(2):81–94. DOI: 10.1007/s12181-023-00599-z.
16. Sieren MM, Maintz D, Gutberlet M, et al. Status der kardiovaskulären Bildgebung in Deutschland: Strukturierte Datenerhebung auf Basis des nationalen Zertifizierungsprogramms, des ESCR-Registers und einer Umfrage unter Radiologen. *Rofo* 2022; 194(2):181–91. DOI: 10.1055/a-1554-9236. <http://www.ncbi.nlm.nih.gov/pubmed/34384112>.
17. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Behandlungsgespräche. Führt eine gemeinsame Entscheidungsfindung von Arzt und Patient bei der Therapiewahl zu besseren Ergebnissen? Vorläufiger HTA-Bericht. Projekt: HT22-01 Version: 1.0. 2023 (Themen Check Medizin) [cited: 2023-12-13]. <https://www.iqwig.de/sich-einbringen/themencheck-medin/berichte/ht22-01.html>.
18. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. 2023 (NICE Guideline; 181) [cited: 2023-07-03]. <https://www.nice.org.uk/guidance/cg181>.
19. Chehrevar M, Vafa RG, Rahmani M, et al. Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention. *Interv Cardiol* 2022; 17:e20. DOI: 10.15420/icr.2022.13. <http://www.ncbi.nlm.nih.gov/pubmed/36890806>.

20. Hong S-J, Lee Y-J, Lee S-J, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. *JAMA* 2023; 329(13):1078–87. DOI: 10.1001/jama.2023.2487. <http://www.ncbi.nlm.nih.gov/pubmed/36877807>.
21. Kaldal A, Tonstad S, Jortveit J. Long-term hospital-based secondary prevention of coronary artery disease: A randomized controlled trial. *BMC Cardiovasc Disord* 2021; 21(1):600. DOI: 10.1186/s12872-021-02426-3. <http://www.ncbi.nlm.nih.gov/pubmed/34915839>.
22. Ersbøll AK, Kristensen MS, Nybo M, et al. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study. *PLoS one* 2023; 18(5):e0286376. DOI: 10.1371/journal.pone.0286376. <http://www.ncbi.nlm.nih.gov/pubmed/37256879>.
23. Homeniuk R, Stanley F, Gallagher J, et al. Heartwatch: An Irish cardiovascular secondary prevention programme in primary care, a secondary analysis of patient outcomes. *BMJ open* 2023; 13(1):e063811. DOI: 10.1136/bmjopen-2022-063811. <http://www.ncbi.nlm.nih.gov/pubmed/36599635>.
24. Kerneis M, Cosentino F, Ferrari R, et al. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: The ESC-EORP C1CD-LT registry. *Eur J Prev Cardiol* 2022; 29(15):1945–54. DOI: 10.1093/eurjpc/zwac089. <http://www.ncbi.nlm.nih.gov/pubmed/35653582>.
25. Bundesärztekammer (BÄK). Medikamentöse Cholesterinsenkung zur Vorbeugung kardiovaskulärer Ereignisse. Version 1.0. 2023 [cited: 2023-03-24]. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimitteltherapie/LF/PDF/Cholesterinsenkung.pdf.
26. Goldberg AC, Leiter LA, Stroes ES, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA* 2019; 322(18):1780–8. DOI: 10.1161/JAHA.118.010376. <http://www.ncbi.nlm.nih.gov/pubmed/31714986>.
27. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N Engl J Med* 2019; 380(11):1022–32. DOI: 10.1056/NEJMoa1803917. <http://www.ncbi.nlm.nih.gov/pubmed/30865796>.
28. Ballantyne CM, Banach M, Mancini GB, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. *Atherosclerosis* 2018; 277:195–203. DOI: 10.1016/j.atherosclerosis.2018.06.002. <http://www.ncbi.nlm.nih.gov/pubmed/29910030>.
29. Laufs U, Banach M, Mancini GB, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. *J Am Heart Assoc* 2019; 8(7):e011662. DOI: 10.1161/JAHA.118.009778. <http://www.ncbi.nlm.nih.gov/pubmed/30922146>.
30. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol* 2020; 27(6):593–603. DOI: 10.1177/2047487319864671. <http://www.ncbi.nlm.nih.gov/pubmed/31357887>.
31. Bundesärztekammer (BÄK). Medikamentöse Cholesterinsenkung zur Vorbeugung kardiovaskulärer Ereignisse. Version 2.0. 2023 [cited: 2023-07-11]. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimitteltherapie/LF/PDF/Cholesterinsenkung.pdf.
32. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med* 2023; 388(15):1353–64. DOI: 10.1056/NEJMoa2215024. <http://www.ncbi.nlm.nih.gov/pubmed/36876740>.
33. Sayed A, Shazly O, Slipczuk L, et al. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. *Cardiovasc Drugs Ther* 2023:[Epub ahead of print]. DOI: 10.1007/s10557-023-07474-9. <http://www.ncbi.nlm.nih.gov/pubmed/37261676>.
34. Krishna Mohan GV, Chenna VS, Tirumandiyam G, et al. Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials. *Cureus* 2023; 15(5):e38662. DOI: 10.7759/cureus.38662. <http://www.ncbi.nlm.nih.gov/pubmed/37288183>.
35. Lin Y, Parco C, Karathanos A, et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: A systematic review and meta-analysis. *BMJ open* 2022; 12(2):e048893. DOI: 10.1136/bmjopen-2021-048893. <http://www.ncbi.nlm.nih.gov/pubmed/35210334>.
36. Dai L, Zuo Y, You Q, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* 2021; 28(8):825–33. DOI: 10.1177/2047487320930585. <http://www.ncbi.nlm.nih.gov/pubmed/34298558>.
37. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Bempedoinsäure (primäre Hypercholesterinämie und gemischte Dyslipidämie) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung Auftrag A20-92. Version 1.0. 2021 (IQWiG-Berichte; 1033) [cited: 2023-07-05]. <https://www.iqwig.de/projekte/a20-92.html>.
38. National Institute for Health and Care Excellence (NICE). Single Technology Appraisal. Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]. Committee Papers. 2020 [cited: 2023-07-05]. <https://www.nice.org.uk/guidance/ta694/evidence/appraisal-consultation-committee-papers-pdf-9082103581>.
39. National Institute for Health and Care Excellence (NICE). Single Technology Appraisal. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]. Committee Papers. 2021 [cited: 2023-07-05]. <https://www.nice.org.uk/guidance/ta694/evidence/final-appraisal-determination-committee-papers-pdf-9082103582>.

40. Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. *Am Heart J* 2021; 235:104–12. DOI: 10.1016/j.ahj.2020.10.060. <http://www.ncbi.nlm.nih.gov/pubmed/33470195>.
41. Laufs U, Ballantyne CM, Banach M, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. *J Clin Lipidol.* 2022; 16(3):286–97. DOI: 10.1016/j.jacl.2022.03.001. <http://www.ncbi.nlm.nih.gov/pubmed/35346603>.
42. Ballantyne CM, Banach M, Bays HE, et al. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). *Am J Cardiol* 2022; 174:1–11. DOI: 10.1016/j.amjcard.2022.03.020. <http://www.ncbi.nlm.nih.gov/pubmed/35483979>.
43. Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. *Cochrane Database Syst Rev* 2018; 11(11):CD012502. DOI: 10.1002/14651858.CD012502. <http://www.ncbi.nlm.nih.gov/pubmed/30480766>.
44. Schmidt AF, Carter J-PL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *The Cochrane database of systematic reviews* 2020; 10(10):CD011748. DOI: 10.1002/14651858.CD011748.pub3. <http://www.ncbi.nlm.nih.gov/pubmed/33078867>.
45. Meza-Contreras A, Wenczenovicz C, Ruiz-Arellanos K, et al. Statin intolerance management: A systematic review. *Endocrine* 2023; 79(3):430–6. DOI: 10.1007/s12020-022-03263-w. <http://www.ncbi.nlm.nih.gov/pubmed/36459335>.
46. Rostom A, Dube C, Wells GA, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database of Systematic Reviews* 2021; 2021(10):195. DOI: 10.1002/14651858.CD002296. <http://dx.doi.org/10.1002/14651858.CD002296>.
47. Garegnani L, Escobar Liquitay CM, Puga-Tejada M, et al. Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. *Cochrane Database Syst Rev* 2022(5):357. DOI: 10.1002/14651858.CD014585.
48. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. *Lancet Gastroenterol Hepatol* 2018; 3(4):231–41. DOI: 10.1016/S2468-1253(18)30037-2. <http://www.ncbi.nlm.nih.gov/pubmed/29475806>.
49. Mo C, Sun G, Lu M-L, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. *World J Gastroenterol.* 2015; 21(17):5382–92. DOI: 10.3748/wjg.v21.i17.5382. <http://www.ncbi.nlm.nih.gov/pubmed/25954113>.
50. García Rodríguez LA, Martín-Pérez M, Hennekens CH, et al. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. *PloS one* 2016; 11(8):e0160046. DOI: 10.1038/nrcardio.2014.88. <http://www.ncbi.nlm.nih.gov/pubmed/27490468>.
51. Freedberg DE, Kim LS, Yang Y-X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology* 2017; 152(4):706–15. DOI: 10.1053/j.gastro.2017.01.031. <http://www.ncbi.nlm.nih.gov/pubmed/28257716>.
52. Tan BE-X, Wong PY, Baibhav B, et al. Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. *Current problems in cardiology* 2023; 48(8):101174. DOI: 10.1016/j.cpcardiol.2022.101174. <http://www.ncbi.nlm.nih.gov/pubmed/35341798>.
53. Gragnano F, Cao D, Pirondini L, et al. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. *Journal of the American College of Cardiology* 2023; 82(2):89–105. DOI: 10.1016/j.jacc.2023.04.051. <http://www.ncbi.nlm.nih.gov/pubmed/37407118>.
54. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis. *Lancet (London, England)* 2020; 395(10235):1487–95. DOI: 10.1016/S0140-6736(20)30315-9. <http://www.ncbi.nlm.nih.gov/pubmed/32386592>.
55. Yuan J, Xu GM, Ding J. Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. *Advances in therapy* 2019; 36(8):2062–71. DOI: 10.1016/j.ahj.2017.12.002. <http://www.ncbi.nlm.nih.gov/pubmed/31154631>.
56. Kang J, Park KW, Lee H, et al. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study. *Circulation* 2023; 147(2):108–17. DOI: 10.1161/CIRCULATIONAHA.122.062770. <http://www.ncbi.nlm.nih.gov/pubmed/36342475>.
57. Rhee T-M, Bae J-W, Park KW, et al. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. *JAMA cardiology* 2023; 8(6):535–44. DOI: 10.1016/j.jacc.2006.03.038. <http://www.ncbi.nlm.nih.gov/pubmed/37043192>.
58. Koo B-K, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. *Lancet (London, England)* 2021; 397(10293):2487–96. DOI: 10.1016/S0140-6736(21)01063-1. <http://www.ncbi.nlm.nih.gov/pubmed/34010616>.
59. Costa F, Montalto C, Branca M, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials. *European heart journal* 2023; 44(11):954–68. DOI: 10.1093/eurheartj/ehac706. <http://www.ncbi.nlm.nih.gov/pubmed/36477292>.

60. Gelbenegger G, Erari-Canyurt U, Grafeneder J, et al. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A meta-analysis. *Vascular pharmacology* 2021; 138:106858. DOI: 10.1016/j.vph.2021.106858. <http://www.ncbi.nlm.nih.gov/pubmed/33753284>.
61. Canadian Agency for Drugs and Technologies in Health. Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Recommendations. 2019 Mar (CADTH Optimal Use Reports).
62. Canadian Agency for Drugs and Technologies in Health. Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration — Project Protocol. 2018 Feb (CADTH Optimal Use Reports).
63. Yamamoto K, Watanabe H, Morimoto T, et al. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. *JACC. Asia* 2023; 3(1):31–46. DOI: 10.1016/j.jacasi.2022.09.011. <http://www.ncbi.nlm.nih.gov/pubmed/36873770>.
64. Yamamoto K, Watanabe H, Morimoto T, et al. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. *JACC. Cardiovascular interventions* 2023; 16(1):19–31. DOI: 10.1016/j.jcin.2022.09.053. <http://www.ncbi.nlm.nih.gov/pubmed/36599584>.
65. Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. *JAMA cardiology* 2022; 7(4):407–17. DOI: 10.1001/jamacardio.2021.5244. <http://www.ncbi.nlm.nih.gov/pubmed/35234821>.
66. Yamamoto K, Watanabe H, Morimoto T, et al. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. *Circulation. Cardiovascular interventions* 2021; 14(5):e010384. DOI: 10.1161/CIRCINTERVENTIONS.120.010384. <http://www.ncbi.nlm.nih.gov/pubmed/34003662>.
67. Lee Y-J, Cho JY, Yun KH, et al. Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: A post hoc analysis of the randomised One-Month DAPT trial. *EuroIntervention journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology* 2022; 18(6):471–81. DOI: 10.4244/EIJ-D-22-00135. <http://www.ncbi.nlm.nih.gov/pubmed/35470799>.
68. Han J, Zhang Y, Shi X, et al. Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. *Global heart* 2023; 18(1):11. DOI: 10.5334/gh.1185. <http://www.ncbi.nlm.nih.gov/pubmed/37228657>.
69. Zeymer U, Toelg R, Wienbergen H, et al. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. *Herz* 2023; 48(2):134–40. DOI: 10.1007/s00059-022-05099-6. <http://www.ncbi.nlm.nih.gov/pubmed/35243515>.
70. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel, Prasugrel und Ticagrelor beim akuten Koronarsyndrom. Rapid Report. Auftrag A21-41. Version 1.0. 2023 (IQWiG-Berichte; 1504) [cited: 2023-07-04]. <https://www.iqwig.de/projekte/a21-41.html>.
71. Sachdeva A, Mutyala R, Mantri N, et al. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes. *Journal of interventional cardiology* 2023; 2023:1147352. DOI: 10.1016/s0895-4356(97)00040-1. <http://www.ncbi.nlm.nih.gov/pubmed/37251366>.
72. Squizzato A, Bellesini M, Takeda A, et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. *Cochrane Database Syst Rev* 2017; 12(12):CD005158. DOI: 10.1002/14651858.CD005158.pub4. <http://www.ncbi.nlm.nih.gov/pubmed/29240976>.
73. Montalto C, Costa F, Leonardi S, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. *European heart journal. Cardiovascular pharmacotherapy* 2023; 9(3):220–30. DOI: 10.1093/ehjcvp/pvac065. <http://www.ncbi.nlm.nih.gov/pubmed/36427063>.
74. Smits PC, Frigoli E, Vranckx P, et al. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. *J Am Coll Cardiol* 2022; 80(13):1220–37. DOI: 10.1016/j.jacc.2022.07.016. <http://www.ncbi.nlm.nih.gov/pubmed/36137672>.
75. Smits PC, Frigoli E, Tijssen J, et al. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. *Circulation* 2021; 144(15):1196–211. DOI: 10.1161/CIRCULATIONAHA.121.056680. <http://www.ncbi.nlm.nih.gov/pubmed/34455849>.
76. Frigoli E, Smits P, Vranckx P, et al. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. *American heart journal* 2019; 209:97–105. DOI: 10.1016/j.ahj.2018.10.009. <http://www.ncbi.nlm.nih.gov/pubmed/30703644>.
77. Baine KR, Welsh RC, Connolly SJ, et al. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). *Circulation* 2020; 141(14):1141–51. DOI: 10.1161/CIRCULATIONAHA.119.044598. <http://www.ncbi.nlm.nih.gov/pubmed/32178526>.
78. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial. *Lancet (London, England)* 2018; 391(10117):219–29. DOI: 10.1016/S0140-6736(17)32409-1. <http://www.ncbi.nlm.nih.gov/pubmed/29132880>.

79. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: An international, randomised, double-blind, placebo-controlled trial. *Lancet (London, England)* 2018; 391(10117):205–18. DOI: 10.1016/S0140-6736(17)32458-3. <http://www.ncbi.nlm.nih.gov/pubmed/29132879>.
80. Greenberg B, Neaton JD, Anker SD, et al. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. *JAMA cardiology* 2019; 4(6):515–23. DOI: 10.1016/j.jhealun.2010.08.027. <http://www.ncbi.nlm.nih.gov/pubmed/31017637>.
81. National Institute for Health and Care Excellence (NICE). Single Technology Appraisal. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease [ID1397]. Committee Papers. 2019 [cited: 2023-07-04]. <https://www.nice.org.uk/guidance/ta607/evidence/committee-papers-pdf-6955673437>.
82. Zhao Q, Zhu Y, Xu Z, et al. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. *JAMA* 2018; 319(16):1677–86. DOI: 10.1001/jama.2013.281053. <http://www.ncbi.nlm.nih.gov/pubmed/29710164>.
83. Shah R, Khan SA, Khan B, et al. Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: A meta-analysis of randomized clinical trials. *Coronary artery disease* 2019; 30(2):116–23. DOI: 10.1097/MCA.0000000000000690. <http://www.ncbi.nlm.nih.gov/pubmed/30589646>.
84. Peterson BE, Bhatt DL, Gabriel Steg P, et al. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. *JACC. Cardiovascular interventions* 2021; 14(7):768–80. DOI: 10.1016/j.jcin.2021.02.022. <http://www.ncbi.nlm.nih.gov/pubmed/33826497>.
85. Kerneis M, Yee MK, Mehran R, et al. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. *Circulation. Cardiovascular interventions* 2019; 12(11):e008160. DOI: 10.1161/CIRCINTERVENTIONS.119.008160. <http://www.ncbi.nlm.nih.gov/pubmed/31707805>.
86. Marquis-Gravel G, Mehta SR, Valgimigli M, et al. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. *The Canadian journal of cardiology* 2020; 36(8):1298–307. DOI: 10.1016/j.cjca.2019.12.013. <http://www.ncbi.nlm.nih.gov/pubmed/32553812>.
87. Mishra A, Singh M, Acker WW, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. *Journal of cardiovascular pharmacology* 2019; 74(2):82–90. DOI: 10.1097/FJC.0000000000000697. <http://www.ncbi.nlm.nih.gov/pubmed/31306367>.
88. Kwon S, Jung JH, Choi EK, et al. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Korean circulation journal* 2021; 51(5):409–22. DOI: 10.4070/kcj.2020.0407. <http://www.ncbi.nlm.nih.gov/pubmed/33764010>.
89. Kassenärztliche Vereinigung Nordrhein (KVNO). Qualitätsbericht 2021. 2022 [cited: 2023-01-31]. https://www.kvno.de/fileadmin/shared/pdf/online/quali/dmp_qualibericht_2021.pdf.
90. Kirsch F, Becker C, Schramm A, et al. Patients with coronary artery disease after acute myocardial infarction: Effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival. *Eur J Health Econ* 2020; 21(4):607–19. DOI: 10.1007/s00392-018-1216-4. <http://www.ncbi.nlm.nih.gov/pubmed/32006188>.

Versionsnummer: 7.0

Erstveröffentlichung: 02/2006

Überarbeitung von: 08/2024

Nächste Überprüfung geplant: 08/2029

Die AWMF erfasst und publiziert die Leitlinien der Fachgesellschaften mit größtmöglicher Sorgfalt - dennoch kann die AWMF für die Richtigkeit des Inhalts keine Verantwortung übernehmen. **Insbesondere bei Dosierungsangaben sind stets die Angaben der Hersteller zu beachten!**

Autorisiert für elektronische Publikation: AWMF online